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Sean Flynn – Modulating docetaxel encapsulation and release from branched vinyl 
copolymer nanoparticles formed via co-nanoprecipitation 
The acute toxicity and inherent low water solubility of many chemotherapeutics often prevent 
such drugs from achieving the optimal therapeutic effect in a clinical setting. Branched vinyl 
copolymer nanoparticles have been investigated as potential drug delivery vehicles for the 
controlled release of docetaxel, a commercially available hydrophobic anti-cancer drug. 
Branched vinyl copolymer nanoparticles were produced via co-nanoprecipitation; this 
relatively new nanoformulation technique involved the simultaneous nanoprecipitation of high 
molecular weight, hydrophobic branched copolymers with their corresponding amphiphilic 
AB block copolymers, through a rapid manipulation of their solvent environment. This 
approach was used to entrap docetaxel molecules within the hydrophobic cores of branched 
vinyl copolymer nanoparticles during the co-nanoprecipitation process.   
A comprehensive study was undertaken to expand the scope of branching vinyl copolymer 
nanoparticles that can be produced via co-nanoprecipitation, beyond the limited number of 
nanomaterials that have been reported to date. This involved co-nanoprecipitation of a large 
number of hydrophobic and amphiphilic polymers which possessed a wide range of different 
chemical and physical properties. This required the development of an unlikely synthetic 
approach, copper-catalysed reversible-deactivation radical polymerisation in anhydrous 
alcoholic media, for the development of novel hydrophobic polymeric materials.  Fundamental 
studies were conducted to understand the experimental factors which influence nanoparticle 
formation during co-nanoprecipitation and, where possible, these factors were used as leavers 
to influence nanoparticle characteristics.  
Promising branched vinyl copolymer nanoparticle candidates were taken forward to drug 
encapsulation and release studies. This involved the use of radiometric techniques to quantify 
the encapsulation and release of docetaxel from branched vinyl copolymer nanoparticles. 
Docetaxel loadings of up to 25 weight % of the total nanoparticle mass and encapsulation 
efficiencies of up to 97 % were achieved during co-nanoprecipitation. The properties of the 
polymers used to construct branched vinyl copolymer nanoparticles also had a significant 
impact on docetaxel release. The impact of nanoparticle properties, including core polarity and 
viscosity, on the levels of docetaxel entrapment during co-nanoprecipitation and the rate of 
docetaxel release will be presented. The suitability of leading nanoparticle candidates as 
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Over the remainder of the 21st century cancer is expected to become the leading cause of death 
and the largest barrier to increasing life expectancy in every country across the globe.1 In 2015, 
the World Health Organisation (WHO) estimated that cancer was the first or second leading 
cause of death in adults below the age of 70, in 91 of the 172 countries studied; furthermore, 
cancer was in the top four most prevalent causes of death in an additional 22 countries.2 Cancer 
has increasing prevalence in highly economically developed countries which have higher life 
expectancies. The American Cancer Society estimated that 606,880 cancer related deaths 
occurred in 2019;3 in the UK, there were an estimated 363,484 new cancer diagnoses each 
year between 2014 and 2016, with a subsequent 163,000 cancer related deaths reported in 
2016.4 The increased prevalence of cancer in the UK precipitated a coordinated response from 
cancer charities, healthcare professionals and national government which  resulted in the 
launch of a National Cancer Strategy by the Department for Health and Social Care in 2011.5 
This strategy takes a multi-faceted approach by targeting: (1) cancer prevention, by reducing 
risk factors such as unhealthy lifestyles and occupational exposures to harmful substances. 
(2) Early detection, by increasing cancer awareness and screening services and (3) Improving 
the range and efficacy of cancer treatments available by funding fundamental research for the 
development and translation of novel cancer treatments. Whilst preventative strategies may go 
a long way to reduce the number of cancer diagnoses in the future, the versatile and complex 
nature of existing cancers will likely always drive clinical demand for novel therapies which 
can save, or improve the quality of, the lives of cancer patients.   
1.1.1 Conventional Cancer Treatments  
There are a wide range of treatments available to either halt or slow the growth of cancerous 
tumours (Table 1.1). In cases where tumours are concentrated in one area and can be accessed 
without high levels of risk, they can be removed with surgery; this approach can also be used 
to ‘debulk’ tumours in order to increase the effectiveness of other cancer treatments. Whilst 
the acute risk of continued growth or even spreading of tumours often justifies the need for 
surgery, this invasive technique can cause patient discomfort and lead to complications such 
as infection. Radiotherapy is another treatment which can be used against localised cancer 
cells. This involves treating a tumour with a beam of ionising radiation which causes damage 
to the cell DNA and subsequently inhibits cell replication processes, resulting in cell death. A 
key drawback of radiotherapy is that it is non-specific and therefore can also damage 
non-cancerous cells surrounding the tumour causing a range of undesirable side effects. In 
recent years the development of Proton Beam Therapy has provided radiotherapists with the 
ability to deliver doses of ionising radiation over a narrow depth range; this allows specific 




Table 1.1 A general overview of conventional cancer therapies, including the associated: cancer 
forms/ areas treated, advantages, disadvantages and common side effects.   
Treatment Cancer Form Advantages Disadvantages Side Effects 

















Kills cancer cells. Non-specific. Fatigue, hair loss, nausea/ vomiting, 
skin changes, diarrhoea, taste 
changes, headaches, urinary and 
bladder changes, swelling.    
Chemotherapy Wide ranging. Kills cancer cells, 
can prolong 
patient survival.  
Non-specific, toxic, 
strong side effects, 
cumulative impact.  
Anaemia, appetite loss, 
constipation, delirium, diarrhoea, 
fertility issues, hair loss, infection, 
nausea/vomiting, nerve problems, 
inflammation, pain, skin changes, 




system’s ability to 
fight cancer.  
Limited availability, 
limited success.  
Pain, skin changes, flu-like 
symptoms, low/high blood pressure, 
nausea/vomiting, swelling, heart 














cancer cells develop 
drug resistance. 
Drug dependent. Diarrhoea, liver 
problems, fatigue, blood clotting, 
high blood pressure, fatigue, mouth 
sores, nail changes, loss of hair 
colour, skin changes, 
















Low libido, poor body temperature 
regulation, weakened bones, 
diarrhoea, nausea/ vomiting, 
fatigue, mood changes, menstrual 
cycle disruption, vaginal dryness.   















Bleeding, increased risk of 
infection, damage to skin, liver, 
intestines and other organs (graft-
versus-host disease).  
     
Some less common but equally important cancer treatments include immunotherapy, targeted 
therapy, hormone therapy and stem cell treatment. Immunotherapies make use of the body’s 
immune system to identify and subsequently destroy cancerous cells; this can be achieved by 
attaching markers to cancer cells, making it easier for the immune system to identify and 
subsequently destroy them. Alternatively, they can also be used to trigger an immune response, 
this increases the sensitivity of the immune system which also aides the identification of 




on naturally occurring hormones; these are particularly relevant for prostate and breast 
cancers.7 Treatments aim to prevent growth of cancerous cells either by halting hormone 
production or by influencing the way hormones behave in the body. Targeted therapies are a 
form of precision medicine which rely on a detailed understanding of the specific cell biology 
and tumour formation processes which occur in individual forms of cancer. A plethora of 
precision medicine approaches are currently being studied for the treatment of cancer.  
Stem cell transplants are another form of treatment received by cancer patients. Often used to 
offset the detrimental side-effects of cancer therapies, stem cell treatment involves the 
injection of blood stem cells which can promote the production of red blood cells (RBC), white 
blood cells (WBC) and platelets. For example, patients suffering from the side-effects of toxic 
chemotherapeutics often receive stem cell treatment to strengthen their cardiovascular and 
immune systems. Whilst primarily used to aid patient recovery, allogenic stem cell transplants 
have also shown direct impact against cancer via the ‘graft vs. tumour effect’ in which graft 
WBCs, formed by external donor stem cells, attack tumour cells.8 However, graft WBCs have 
also been known to attack healthy tissues therefore causing undesirable patient side-effects. 
Chemotherapy is perhaps the most well-known cancer treatment. It involves the administration 
of anti-cancer drugs, herein referred to as chemotherapeutics, within systemic circulation in 
order to treat, or to suppress the symptoms of, a wide range of cancers. Whilst the specific 
mechanisms of action for individual chemotherapeutics are as varied as the drugs themselves, 
chemotherapeutics are generally cytotoxic to cancer cells and typically induce apoptosis via 
interference in the processes of cell division, which characteristically proceed at higher mitotic 
rates compared with healthy cells. The indiscriminate nature of chemotherapy often results in 
chemotherapeutics being taken up by healthy tissues. Cells containing high mitotic activity, 
such as those in bone marrow, hair follicles and gut epithelium, are particularly sensitive to 
chemotherapy and their uptake of chemotherapeutics cause detrimental side-effects for cancer 
patients.9  
The complex and diverse range of the physiological barriers which chemotherapeutics must 
overcome in order to perform their anti-cancer functions in vivo has significantly hindered the 
translation of many promising therapeutic candidates to a clinical setting.10 This has driven 
clinical demand for novel technological interventions which can increase the efficacy and thus 
economic viability of the next generation of chemotherapy treatments. In recent years this has 
inspired scientists to explore the next generation of cancer based research which includes the 







Nanomedicine is a developing field which has evolved from the significant advances made in 
the area of nanotechnology over the last quarter of a century. It combines nanotechnology with 
the pharmacological and biomedical sciences in order to generate novel solutions for the 
diagnosis, imaging and treatment of existing and emerging global healthcare issues.11 This is 
typically achieved by the construction of nanomaterials, using either top-down or bottom-up 
approaches, with sizes ranging from 1-1000 nm (Figure 1.1). Such materials can be designed 
to possess bespoke chemical and physical properties which enable them to perform precise 
functions when applied within a biological or clinical setting. There are many advantages to 
working at the nanoscale. The small size of nanomaterials can provide them with desirable 
behaviours in vivo; such nanomaterials also possess high surface functionality, compared with 
their bulk materials, as a result of their significantly larger surface-to-volume ratios.   
Nanomedicine utilises a wide range of nanomaterials including: dendrimers, polymer-
conjugates, inorganic nanoparticles as well as a range of polymer and drug-based 
nano-assemblies. These materials are employed across many nanomedicine disciplines, 
including drug delivery, bio-imaging, bio-sensing, blood purification, tissue engineering and 
medical devices.12 Nanomedicine has proven an effective tool in the fight against cancer; in 
particular, is has been used to improve the imaging and treatment of tumours within clinical 
settings.13 Given the vast scope of research covered by nanomedicine and the specific nature 
of this thesis, the focus will be the drug delivery aspect of nanomedicine which will be 
discussed herein. 
 




1.2.1 Enhanced Drug Delivery 
In order to achieve their desired therapeutic effect, chemotherapeutics must be selectively 
taken up by cancer cells at the site of a tumour. This requires such chemotherapeutics to be 
administered and travel to a target site. A key issue with many chemotherapeutics is that they 
exhibit low solubility in biological fluids, are difficult to formulate and creating particles out 
of them can lead to aggregation. In addition, particles are readily cleared from systemic 
circulation via the mononuclear phagocytic system (MPS). This significantly hinders their 
uptake within target cells and thus limits their therapeutic effect.  
In response to the clinical need to overcome such issues, the development of drug nanocarrier 
systems (DNC) has become one of the leading areas of research in nanomedicine. The concept 
of a DNC involves the formation of a stable nanosuspension either containing or solely 
consisting of the pharmacologically active compound. The use of a DNC system enables many 
pharmacological factors, such as the biodistribution and plasma drug concentration, to be 
manipulated in order to produce a desired therapeutic effect. Many formulation strategies have 
been employed in the quest to produce stable nanoparticle dispersions; an overview of some 
of the leading strategies is presented in Figure 1.2. These include lipid based nanocarriers, 
block copolymer self-assemblies, drug-polymer composites and drug nanocrystals.  
 
Figure 1.2 General overview of the diverse range of DNC classes currently being researched in 
nanomedicine. DNC systems consist of a pharmacologically active payload encapsulated within a 
nanocarrier system consisting of: a) Lipids, including solid lipid nanoparticles and liposomes. b) Block 
copolymers, including micelles and vesicles. c) Synthetic polymers and surfactants, such as solid drug 
nanoparticles and nanoprecipitates and d) Drug colloids such as nanocrystals.14,15 
Numerous lipid based DNCs have been developed for the encapsulation of pharmacologically 
active payloads; these include liposomes and solid lipid nanoparticles (SLN).16–19 Liposomes 
have often been referred to as the “gold standard” of lipid-based drug delivery systems. These 
phospholipid based vesicular systems are capable of loading both hydrophilic and hydrophobic 
drugs within their aqueous core and lipophilic bilayer respectively. The fact that they are 
constructed of highly biocompatible lipids means that liposomes are typically 




a clinical setting.20,21 In contrast, SLNs contain a solid hydrophobic core, consisting of lipids, 
stabilised by a range of polymer and small molecule based surfactants. The term lipid is used 
more liberally when discussing SLNs, as a number of hydrophobic compounds have been used 
to construct such nanomaterials, including triglycerides, partial glycerides, fatty acids, waxes, 
and steroids.22 Whilst the static nature of their core provides SLNs with increased stability and 
controlled drug release profiles, it has also been a barrier to achieving high drug loadings 
during SLN formation.23,24 Nonetheless, SLNs still remain the subject of significant amounts 
of nanomedicine research which targets the development of novel cancer treatments.25–27 
The self-assembly of amphiphilic block copolymers offers another synthetic strategy for the 
generation of DNC systems. Amphiphilic block copolymers contain segmented hydrophilic 
and hydrophobic blocks. Micelles and vesicles are formed when amphiphilic block 
copolymers undergo self-assembly in water in order to minimise energetically unfavourable 
hydrophobe-water interactions. The morphology of these materials is dependent on their 
respective block lengths and can be tuned to generate either spherical or cylindrical micelles, 
or vesicles containing a tuneable membrane thickness. It is possible to encapsulate 
hydrophobic drug molecules within either the micelle core or vesicle membrane during the 
self-assembly of such nanostructures. This has led to such materials being studied as DNC 
systems for the encapsulation and release of a range of hydrophobic drug payloads.28 
A wide range of formulation strategies have been used to developed drug-polymer 
nanocomposites which can act as a DNC system in vivo.29 Such strategies typically use 
polymers and surfactants to generate stable aqueous nanosuspensions containing high levels 
of a therapeutic compound. Perhaps the most predominant formulation strategy involves a 
technique known as nanoprecipitation.30 This approach involves displacement of a good 
solvent from a solution of a particle forming substance, typically a polymer, with a miscible 
non-solvent. The process of nanoprecipitation is well studied and this will be discussed in 
more detail in Chapter 3 Section 3.1. Briefly, nanoprecipitation proceeds as a three-stage 
process, involving the nucleation, growth and aggregation of polymers following a rapid 
change to their solvent environment. The relative contributions of these stages dictate 
nanoparticle size, stability and uniformity and, when optimised, can result in the formation of 
highly monodisperse polymer-based nanoparticles of tuneable size. The facile nature of the 
nanoprecipitation process allows the production of nanoparticles to be scaled up with relative 
ease; as a result, many high throughput and continuous production processes have been 
employed for nanoprecipitation based research.30 The incorporation of hydrophobic drugs 
within the nanoprecipitation process has enabled their encapsulation within polymer-based 
nanoparticles and has led to the study of such materials as prospective DNC systems for the 




An alternative drug-polymer composite formulation strategy, which has been used to generate 
solid drug nanoparticles (SDN), is the emulsion template freeze-drying (ETFD) approach.32-35 
SDNs consist of a solid particle core, consisting of an active pharmaceutical ingredient, 
typically a drug, stabilised by a matrix of polymers and surfactants. They are typically 
generated using a three-stage process.36,37 The first stage involves the formation of an 
oil-in-water emulsion. This is achieved via emulsification of an aqueous solution of 
water-soluble polymers and surfactants with a water-immiscible organic solvent, in which the 
hydrophobic drug is dissolved. The drug-loaded emulsion is then rapidly frozen, typically 
under liquid nitrogen, to entrap droplets within a solid emulsion template; both the aqueous 
and non-aqueous phases are then removed by freeze-drying to leave a monolith of water 
soluble polymer, surfactants and the active pharmaceutical payload. This monolith can then 
be dispersed in water to form a colloidally stable aqueous nanodispersion of the active 
pharmaceutical.37 Similar nanomaterials have also been formulated using spray drying based 
techniques.38–41 SDNs have been generated using a range of pharmaceutically active 
compounds, in particular, as DNCs of chemotherapeutics and antiretrovirals for the treatment 
of cancer and the human immunodeficiency virus (HIV).42–44  
The final class of DNC system to be discussed here is drug nanocrystals. These are solid 
crystals of pharmaceutically active drugs with sizes ranging from 1-1000 nm. The main 
advantage of drug nanocrystals is that they solely consist of the active drug and therefore 
theoretically contain optimal drug loadings; however, in practice, surfactants and stabilisers 
are often required in order to prevent further crystallisation/aggregation processes.45 
Nanocrystals can be produced using either top-down or bottom-up based formulation 
strategies. Top-down strategies are typically attrition-based mechanical processes, such as 
high shear homogenisation or wet milling, which employ high levels of stress in order to break 
down large drug crystals into their nanosized equivalents.46 In contrast, bottom-up approaches 
typically involve the building of nanostructures from individual drug molecules. This is often 
achieved via nanocrystallisation of drugs through manipulation of their solvent environment 
and requires the use of surfactants and stabilisers to cap the crystallisation process at the 
nanoscale. Known as combinations approaches, combinations of top-down and bottom-up 
techniques have also been used to generate drug nanocrystals.47 The ability to generate stable 
nanocrystals of pharmaceutically active drugs has attracted significant research interest and as 
a result drug nanocrystals are considered one of the leading DNC systems for clinical 
translation.48,49  
Whilst significant progress has been made towards the design of a range of DNC systems, 
capable of encapsulating high amounts of therapeutically active payloads, many prospective 




application. This has often occurred as a result of DNC systems being unable to overcome a 
range of physiological barriers, such as removal from systemic circulation and selective uptake 
within target tissues, in vivo. As a result, despite the ability to encapsulate high drug loadings, 
some DNC systems have proved ineffective in the delivery of pharmacologically active 
payloads and have thus been unable to produce the desired therapeutic response.50 
1.2.2 Physiological Barriers and Opportunities for DNC Systems 
In order to achieve the desired therapeutic effect, DNCs must deliver their pharmacologically 
active payloads to a desired location, typically a tumour site, in a concentration which exceeds 
the therapeutic dose required. To achieve this, DNCs must overcome a wide range of 
physiological hurdles which include a number of vascular, extracellular and intracellular 
barriers.51–53 It is therefore essential that such barriers are taken into account when designing 
the chemical and structural properties of new DNC systems.54 This has opened up a new field 
of research in the design of biocompatible nanomaterials which can overcome a diverse range 
of physiological barriers in order to carry out specific functions in nanomedicine.55  
Although it is the most common drug delivery route, oral administration presents numerous 
challenges which DNCs must overcome before entering systemic circulation.14,15,56,57 The 
harsh acidic conditions within the gastrointestinal (GI) tract can cause the structural integrity 
of the DNC to become compromised and subsequently enable chemical degradation of the 
pharmacologically active payload.58 In order to enter systemic circulation, DNCs must also 
pass through an epithelial membrane of the small intestine wall. This process is significantly 
hindered by the presence of a layer of mucus, a viscoelastic mucin fibre hydrogel, which sits 
on top of the endothelial membrane.59,60 Mucus layers trap and rapidly clear pathogens and 
foreign particulates to prevent their entry into systemic circulation via absorption through the 
small intestine wall. This has been highlighted as a significant barrier to nanoparticle entry 
into systemic circulation.61–69 As a result, despite the formulation of poorly soluble drugs into 
DNC systems, oral administration can still result in low bioavailability of the active 
pharmacological compounds.70–72 
The physiological barriers associated with oral administration can be avoided via direct 
intravenous (IV) administration of the DNC into systemic circulation. IV administration offers 
the most efficient and reproducible way to deliver DNCs into systemic circulation and 
overcome issues such as low drug bioavailability. Once in the blood stream, DNCs are faced 
with further obstacles, including retaining colloidal stability within the blood, opsonisation 
and subsequent removal via the MPS, as well as other physiological filtration mechanisms 





1.2.2.1 Interactions with Blood Components within Systemic Circulation 
IV administration causes a substantial change to the media in which DNCs are suspended and 
poses a significant risk to the colloidal stability of DNC systems. Blood consists of 
erythrocytes and leukocytes, also known as RBCs and WBCs respectively, along with 
thrombocytes (platelets), suspended in a solution of proteins and low molecular weight solutes 
known as plasma. Minimal interactions occur between DNCs and non-phagocytic species such 
as RBCs and platelets within systemic circulation;73 this is also true for the majority of WBCs 
which require activation before their defence mechanisms take effect.74 However, alternative 
WBC dependent responses have proven effective defence mechanisms against pathogens. For 
example, following exposure to pathogens, neutrocytes can secrete granule proteins and 
chromatin in order to nullify and kill invading pathogens.75 Known as neutrophil extracellular 
traps (NET), such responses have been identified in vivo and have also proven an effective 
defence mechanism for the entrapment of bacteria within septic blood.76,77 Such cellular 
defence mechanisms present complex obstacles for DNC systems and can potentially limit 
their lifetime within systemic circulation. NETs formed by neutrocytes, monocytes and 
macrophages in vitro have proven an effective clearance mechanism for the removal of 
Au-NPs, of varying sizes and shapes.78  
Blood plasma contains a range of proteins which are capable of interacting with foreign species 
such as DNCs. The level of interaction which occurs between plasma proteins and DNCs is 
highly dependent on the physiochemical properties of the DNC; in particular in the particle 
size, shape and surface properties, including charge and chemical functionality.79–81 The extent 
of protein adsorption can significantly impact a nanoparticle’s lifetime within systemic 
circulation as well as its subsequent biodistribution.82,83 Human albumin is the most abundant 
protein found in blood plasma. Responsible for the regulation of osmotic pressure and for the 
transportation of hydrophobic molecules within systemic circulation, albumin interacts with 
DNCs via a number of ionic and hydrophobic interactions.82,83 The coating of albumin on 
nanoparticle surfaces is a dynamic process, in which weakly-bound albumin rapidly undergoes 
reversible adsorption and desorption processes. Albumin can therefore be displaced at the 
surface of DNC systems by proteins that possess higher binding affinities.82,83 As a result, the 
dysopsonic benefits of albumin binding to DNC systems is somewhat limited; for example, 
pre-binding of albumin, to the surface of 50 nm polystyrene-based nanoparticles, showed only 
modest increases in nanoparticle circulation times following IV administration to Wistar rats.84  
Albumin also presents opportunities for DNC systems. Due to its macromolecular structure 
(67 kDa), albumin binding results in a significant increase to the nanoparticle’s hydrodynamic 




such as: small molecules, polymer-drug conjugates, inorganic nanoparticles and block 
copolymer micelles, which are vulnerable to, Rh dependent, glomerular filtration 
mechanisms.85,86 In addition to improved colloidal stability, albumin coating of DNCs have 
also been shown to increase patient tolerance to potent taxane-derived chemotherapeutics, 
which resulted in a 1.71 fold increase in the maximum tolerated dose during human clinical 
trials.85,86 Albumin has a binding affinity for the glycoprotein receptor, GP60, located on the 
surface of the endothelial cells which line the blood vessels surrounding solid tumours. 
Albumin coating of DNCs therefore also provides an additional entry route into the 
interstitium of solid tumours. Interaction between albumin bound nanoparticles and GP60 
results in the activation of caveolin-1 and promotes transcytosis of the intact nanoparticles 
across the cell membrane. Once located within the tumour, albumin-bound nanoparticles 
benefit from a tumour selective targeting process induced by interactions with Secreted Protein 
Acidic Rich in Cysteine (SPARC).87 SPARC is a protein which is released in order to modulate 
interactions between cells and species dissolved/suspended within the extracellular matrix.88 
Whilst not unique to cancer cells,89 high levels of SPARC are commonly associated with 
advanced stages of tumours formed by a range of head and neck, non-small cell lung and breast 
cancers.90–93 Following release into the extracellular matrix, the strong affinity between 
SPARC and albumin leads to the formation of a SPARC-albumin-DNC complex. This 
complex accumulates at the membrane of tumour cells where the reversible albumin-DNC 
binding process facilitates diffusion of the active chemotherapeutic into the intracellular 
compartments of cancer cells promoting selective apoptosis. These albumin-mediated 
transport and cancer targeting mechanisms provide unique opportunities to incorporate 
albumin binding in the design of DNCs systems capable of overcoming the physiological 
barriers associated with the specific targeting of tumours.  
The complement system presents another physiological barrier which can reduce the 
circulation time of DNCs within systemic circulation. The complement system is responsible 
for enhancing the ability of the immune system, using both the adaptive and innate immune 
systems, to clear microbes and damaged cells from an organism.94,95 The complement system 
consists of more than 30 dormant enzyme precursors and membrane-bound proteins which, 
once activated, can trigger a cascade of protein cleavage reactions in a process known as 
complement activation. Activation can be achieved via classical, alternative and lectin binding 
pathways and result in the clearance of pathogens via either i) enhanced pathogen recognition 
by the MPS following opsonisation processes or ii) formation of a membrane attack complex 
which facilitates an uncontrolled influx of intracellular fluids causing the swelling and 
subsequent lysis of pathogens. Whilst an effective defence mechanism against a range of 




by the immune system.96 The complement system therefore offers an additional clearance/ 
destruction pathway which must be avoided by DNCs within systemic circulation.  
High plasma concentrations of proteins involved in the complement system lead to a multitude 
of interactions with circulating DNCs;80,97,98 the binding of such proteins initiates an 
amplification process which promotes further opsonisation and subsequently results in the 
phagocytosis of DNC systems.73 Activation of the complement system by DNCs is highly 
dependent upon the surface properties of the nanocarrier. The adsorption of proteins of the 
complement system is typically promoted by nanoparticles which contain: a significant 
negative or positive surface charges, high levels of hydrophobicity and/or an irregular surface 
topology.99–101 The nature of nanoparticle surface charge has been shown to influence the 
complement activation pathway; negatively charged nanoparticles have been shown to activate 
the complement system via the classical pathway, whereas positively charged species induce 
alternative activation pathways.102 Nanoparticle size, and subsequently the radius of curvature, 
is another factor which influences the extent of absorption of proteins of the complement 
system.103 Larger nanoparticles (Rh > 200 – 800 nm) that possess low curvature allow high 
levels of opsonisation by proteins of the complement system in comparison to their smaller 
analogues. The level of opsonisation therefore decreases with nanoparticle size as the radius 
of curvature increases. However, the extent of nanoparticle removal via complement mediated 
phagocytosis is dependent upon the extent of nanoparticle opsonisation rather than 
nanoparticle size.102 Efforts to reduce the opsonisation and subsequent removal of 
nanoparticles via the complement system involve coating nanoparticles with chemically inert, 
hydrophilic polymers. Such polymers, which will be discussed later in this Chapter, can 
significantly reduce the level of non-specific deposition of proteins of the complement system 
and thus increase the circulation times of PEGylated nanoparticles in vivo.104–108 
In addition to the physiological barriers presented by the binding of albumin and proteins of 
the complement system, nanoparticles also face challenges which arise as a result of the 
adsorption of other plasma proteins. Lipoproteins are assemblies of cholesterol esters, 
phospholipids, triacylglycerides and a range of apolipoproteins which are responsible for the 
transport of lipids within systemic circulation.109,110 Lipoproteins and apolipoproteins can 
interact with DNCs within systemic circulation;109,111 for example, phospholipid exchange 
with lipoproteins can disrupt the colloidal stability of unilamellar vesicles, resulting in the 
premature release of their calcein payload.112 Alternatively, apolipoproteins can displace 
albumin from the surface of circulating nanoparticles;79 this can influence the biodistribution 
of  nanoparticles specifically towards hepatocytes and tissues rich in lipoprotein 
receptors.113-115 Immunoglobulins are large Y-shaped proteins which facilitate the 




systemic circulation their secretion by plasma cells is accelerated during an immunogenic 
response.116,117 Immunoglobulin adsorption onto the surface of DNCs can occur though either 
specific recognition of nanoparticle surface chemistries or via hydrophobic interactions.118 
Such interactions can increase the rate at which nanoparticles are cleared through cooperative 
effects with the complement system.119 Nanoparticle systems may interact with a range of 
other plasma proteins, such as fibronectin, fibrinogen and C-reactive protein.120 Such 
interactions can influence nanoparticle lifetimes in systematic circulation as well as their 
subsequent tissue deposition via combinations of complement activation and 
receptor-mediated internalisation mechanisms.121  
1.2.2.2 Clearance Mechanisms of the Liver, Kidneys and Spleen 
DNCs that can maintain their colloidal stability whilst remaining inert to protein adsorption 
and subsequent clearance mechanisms are able to travel around the body within the vascular 
system. Whilst in systemic circulation they are subjected to many size-dependent filtration 
mechanisms in the liver, kidneys and spleen.122 Nanoformulation of chemotherapeutics within 
DNC systems allows such filtration mechanisms to be by-passed and can therefore can be used 
to increase drug half-lives within systemic circulation.123 
1.2.2.3 Targeted Delivery to Cancer Cells at Tumour Sites 
One challenge facing chemotherapy nanomedicines is the ability to deliver their drug payloads 
specifically to tumour sites. Human tumours are complex and heterogeneous; as a result, 
significant variations arise in the tumour formation processes which occur between patients, 
multiple tumours within the same patient and microenvironments within a single tumour 
site.124–127 As a result, chemotherapy regimens often require optimisation in order to overcome 
the heterogeneous nature of such tumours.128 DNCs must overcome vascular and interstitial 
barriers in order to permeate tumour tissues.129–131  Firstly, they must transude from systemic 
circulation, through a layer of endothelial cells which line the vascular system, in order to 
permeate the micro-environment within a tumour. Despite the complex and heterogeneous 
nature of cancers there are many commonalities in tumour formation processes. These include 
enhanced proliferation and growth rates, impacts on the immune system and the induction of 








Since the 1950s, in vivo studies have shown that small molecule dyes, administered IV into 
animals bearing tumours, are extravasated from systemic circulation and subsequently 
accumulate in tumour tissues.134–136 Further studies have shown that this occurs as a result of 
two key physiological changes which take place during tumour formation: (i) deformation of 
blood vessels’ endothelial membrane at the tumour site, creating so called “leaky vasculature” 
which promotes diffusion into the tumour;137 (ii) impairment of the lymphatic system, typically 
responsible for the clearance of macromolecules, resulting in poor lymphatic drainage from 
tumour tissues.138 These physiological changes form the basis of what is known as the 
enhanced permeability and retention (EPR) effect (Figure 1.4).138 The EPR effect has been 
highlighted as one of the key physiological opportunities for the passive targeting of tumours 
by DNC systems. The EPR effect is particularly relevant for large macromolecules (> 50 kDa) 
and nanoparticles which typically exhibit longer plasma half-lives.139 It typically takes at least 
six hours within systemic circulation before nanoparticle accumulation is observed at a tumour 
site.140 This rules out many small molecule chemotherapeutics which are typically removed 
from systemic circulation shortly following IV administration. It is therefore essential that 
DNC systems, which aim to target tumours using the EPR effect, are able to avoid the wide 
range of clearance mechanisms, including but not limited to those described above. Providing 
they can remain stable and avoid clearance from systemic circulation, nanoparticles are able 
to accumulate within tumours at concentrations significantly higher than that in the plasma 
and with high specificity over non-cancerous tissues.141 This raised the possibility of enhanced 
and specific delivery to tumours and led to the EPR effect being referred to as the “gold 
standard” of new anti-cancer agents.142  
 
Figure 1.4 The enhanced permeability and retention (EPR) effect. Schematic representation of 
the extravasation of nanoparticles through leaky vasculature in endothelial membranes. This facilitates 




Whilst the EPR effect has since been the subject of copious amounts of research, the vast 
majority of in vivo studies have been conducted using tumours transplanted into small animal 
models. The relevance of such studies have been the subject of considerable debate.143–147 
Whilst many have identified the EPR effect as an opportunity for the passive targeting of 
tumours, others have questioned its relevance in the treatment of human cancers within a 
clinical setting.54,148,149 The accumulation of nanoparticles within human tumours via the EPR 
effect has been studied extensively;150–154 however, little is known regarding the variability in 
nanoparticle accumulation in solid tumours, observed between different patients and cancer 
types. The extent of nanoparticle accumulation, via the EPR effect, has been linked to the 
degree of deformation caused to endothelial membranes during angiogenesis. For example, in 
the case of Kaposi’s sarcoma, deformation of the endothelial membrane was sufficient enough 
to allow RBCs (ca. 8 µm) to escape the vascular system.155 In this case, the use of 
nanoformulated doxorubicin proved a more effective therapy than the conventional 
chemotherapy treatment;156 whereas the same formulation proved less effective at permeating 
breast cancer tumours possessing “less leaky” vasculature.157 The heterogeneity of the EPR 
effect has been further demonstrated in recent in vivo studies using larger animal models to 
provide “comparative oncology”. Nanoparticle uptake within tumours was significantly higher 
in dogs with carcinomas (85 % of the sample) (leaky vasculature) compared with dogs with 
sarcomas (25 % of the sample).158–160 Similar effects have been observed in clinical studies.161 
These results demonstrate that the EPR effect only provides therapeutic benefits for a limited 
number of cancers and highlights the need to explore alternative tumour-specific permeation 
mechanisms. 
1.2.2.4 Extra-Cellular Barriers for DNC Systems 
Once located within the micro-environment of a tumour, nanocarriers must undergo cellular 
internalisation in order to have their desired therapeutic effect. This can occur via a number of 
non-targeted and receptor mediated cellular internalisation mechanisms. Such mechanisms are 
outlined in Figure 1.5 and include clathrin-independent endocytosis, clathrin-mediated 
endocytosis, micropinocytosis, caveolin-dependent endocytosis, phagocytosis, and 
receptor-mediated endocytosis. Whilst the biological interactions associated with each 
mechanism remain unique, there are many similarities between each of the cellular 
internalisation mechanisms described above. They all involve interactions between 
nanoparticles and the outer surface of cells, leading to the formation of internalised vesicles 
which vary in their size and internal environment. The cellular internalisation mechanism 
taken is largely dependent on the nanoparticle’s physical and chemical properties, including 






Figure 1.5 An overview of passive cellular internalisation mechanisms. a) Clathrin-independent 
endocytosis, b) Caveolin-dependent endocytosis, c) Phagocytosis, d) Micropinocytosis and 
e) Receptor-mediated endocytosis.  
Clathrin-mediated endocytosis (CME) is a complex endocytic pathway which involves 
intracellular signalling, membrane recycling and nutrient uptake.162 Vesicle formation is 
initiated when complex protein assemblies cause a curvature in a cell membrane, resulting in 
the formation of a spherical, clathrin-coated pit at the surface of a cell.163–170  The vesicle 
formation process is completed when the neck of the clathrin-coated pit is resealed by the 
protein, GTPase, to reform the cell-membrane whilst simultaneously releasing the vesicle into 
the cell cytoplasm.171–173 CME has been highlighted as an effective cellular internalisation 
mechanism for non-targeted nanoparticles with sizes of ~100 nm.171–173 In particular, 
non-targeted nanoparticles possessing positive charges particularly favour CME; this is 
possibly due to electrostatic interactions with the negatively charged cell membrane. Whilst 
little detail is known about the mechanistic detail behind CME, it appears to be the 
predominant cellular internalisation pathway for non-targeted nanoparticles. Alternatively, 
cells which are devoid of clathrin rely on clathrin-independent endocytotic pathways for the 
uptake of nutrients and growth hormones from the extracellular environment.174,175 In 
particular, folic acid is known to be taken up by clathrin-independent endocytosis. Given their 
high proliferation and mitotic rates, cancer cells typically have high demand for folic acid.176 
Nanoparticle functionalisation with folic acid has therefore provided an opportunity to achieve 




Caveolae-dependent endocytosis (CDE) is an important factor in many biological functions 
such as cell signalling, transcytosis and lipid regulation and is thought to play a role in many 
types of disease. CDE involves the formation of an oval shaped invagination, typically < 80 
nm in size. The lines of the invagination are lined with caveolin, a dimeric protein responsible 
for their characteristic oval shapes, which are stabilised by another caveolin protein known as 
Caveolin 2, amongst many others.177–179 The CDE pathway has proven a useful opportunity 
for DNC systems; in particular, Abraxane, a commercially available chemotherapeutic 
nanoformulation has been reported to be taken up in cancer cells via CDE. Furthermore, the 
albumin corona, which possesses a high affinity for the GP60 receptor present in caveolae 
endothelial cells, facilitated the transcytosis of Abraxane into the interstitial tumour 
environment.180 One advantage of this cellular internalisation pathway is the neutral pH within 
caveosomes can facilitate the internalisation of pH-sensitive materials during premature 
triggering responses such as nanocarrier degradation or drug release.180 
Micropinocytosis involves the formation of a large membrane extension from cell surface out 
into the extracellular space. These membrane extensions then collapse back onto the cell 
surface and create a large vesicle (>1 µm) whilst entrapping a large “gulp” of the extra-cellular 
fluid.181 Any particles, dissolved molecules, or nutrients within the engulfed extra-cellular 
fluid are taken into the endocytic vesicle known as a macropinosome. This is a non-specific 
bulk uptake and is not impacted by non-specific interactions or ligand-receptor binding. Given 
the larger size of micropinosomes, in comparison with endosomes and caveosomes, 
micropinocytosis offers a feasible cellular internalisation mechanism for the uptake of larger 
particles which are unable enter cells through either clathrin or caveolae dependent 
endocytosis.182 However this route also offers a portal for many pathogens, including bacteria 
and viruses.183 
Phagocytosis is an endocytic process which facilitates the breakdown of pathogens and cell 
debris via the binding, internalisation and subsequent digestion of large particles which arrive 
at a cell surface.184 A key characteristic of phagocytosis is the large size (>250 nm) of the 
internal vesicles formed, known as phagosomes, which allows the internalisation of larger 
species that typically cannot be taken up via alternative cellular internalisation mechanisms.184 
Phagocytosis can be triggered by specific interactions between cell-surface receptors and 
ligands attached on the surface of a nanoparticles.185–188 Alternatively, nanoparticle 
opsonisation with plasma proteins and the subsequent activation of the complement system 
can also accelerate phagocytosis rates, as described in Section 1.2.2.1.189,190 Whilst the shape 
and size of large particles can influence the extent of phagocytosis,191–193 the sizes required to 
promote particle uptake via this mechanism is typically much greater than those exhibited in 




Alternatively enhanced cellular internalisation can be achieved using active targeting 
strategies such as receptor mediated endocytosis (RME). RME involves the targeting of 
over-expressed receptors specifically located on the surface of cancer cells.194 This is achieved 
by the attachment of ligands, which are complementary to the target cell receptor, to the 
surface of a DNC system in order to promote nanoparticle-receptor interactions thus boosting 
cellular internalisation via RME (Figure 1.6). As a result, it is possible to minimise toxicity to 
non-cancerous cells and thus reduce the undesired side effects associated with the active 
therapeutic compound. This approach has been used for the delivery of small molecule 
therapeutics, DNA, siRNA and miRNA specifically to cancer cells using a wide range of cell 
targeting ligands; such as highly abundant small molecules, peptides, aptamers and 
antibodies.195 
 
Figure 1.6 Graphical representation of the cellular internalisation of nanoparticles via 
receptor-mediated endocytosis. a) Nanoparticles, which containing a cell-targeting ligand, approach the 
cell membrane. b) Specific interactions arise between nanoparticle surface ligands and receptors 
expressed on the cell surface. c) Nanoparticles are engulfed during vesicle formation. d) Internalised 
nanoparticles are directed towards early endosomes.  
Folate receptors are macromolecular glycoproteins which are over-expressed on the surface of 
a wide range of cancers.196 Folic acid is a small molecule (441 g mol-1) water-soluble B vitamin 
with a high affinity for folate receptors. Functionalisation of DNCs with folic acid can facilitate 
the selective delivery of drug payloads to cancer cells which over-express folate receptors.196 
Folate-conjugated DNC systems have demonstrated higher efficacies than their non-targeting 
analogues in both in vitro and in vivo studies.197–200 However, folate receptors are also 
expressed by non-cancerous cells, including epithelial cells in the kidney and activated 
macrophages, which can hinder the selectivity of DNC uptake.201,202  
Transferrin is a macromolecular glycoprotein responsible for the uptake and transport of iron 
across cell membranes and subsequently plays a crucial role in cell growth.203–205 Although it 




significantly higher concentrations on the surface of many cancer cell lines. This has made 
transferrin receptor-mediated endocytosis the target of copious amounts of DNC research; in 
particular this has been achieved via surface functionalisation of a range of DNC systems with 
ligands, such as human transferrin and transferring binding single-chain antibody fragments, 
which are capable of facilitating transferrin-mediated endocytosis.206–212 One barrier to 
targeted delivery of DNC systems via the transferrin-mediated endocytic pathway is the 
“neutralisation” of targeting ligands following the adsorption of plasma proteins within 
biological fluids. Study of the cellular uptake of transferrin-coated silica nanoparticles within 
A549 lung epithelial cells, which over-express transferrin receptors, demonstrated that specific 
cell-targeting is supressed within physiological fluids.213 This reduced cell specificity, in 
comparison to experiments conducted in buffered media, was attributed to neutralisation of 
targeting ligands by interaction with solutes present within the complex biological milieu. The 
inability to differentiate between target and non-target cells would result in DNC accumulation 
within healthy tissues and fail to reduce the toxic side effects of future chemotherapy based 
nanomedicines. This therefore raises questions over the suitability of this strategy within a 
clinical setting. 
The epidermal growth factor receptor (EGFR) is a transmembrane protein capable of cellular 
signalling and is responsible for initiating cell growth and replication functions.214,215 
Epidermal growth factors (EGF) are macromolecular proteins capable of binding to the 
extracellular component of an EGFR. Binding of EGFs to EGFR dimers formed at the cell 
surface, whether via homodimerisation of EGFR or heterodimerisation with another member 
of the ErbB tyrosine kinase family, play an important role in stabilisation of EGFR dimers and 
the ensuing cellular signalling processes which take place following their formation. EGFRs 
are overexpressed on a range of tumours including brain, breast, colorectal, ovarian, pancreatic 
and prostate cancers.214,215 The EGFR therefore offers another opportunity for the specific 
targeting of cancer cells using a DNC system. Again, this can be achieved by attachment of 
ligands, which are capable of EGFR binding, to the surface of a DNC. A wide range of species 
are capable of binding to EGFR and may therefore prove useful in the design of EGFR-targeted 
nanomaterials, these include betacellulin, EGF, epigen, epiregulin, transforming growth 
factor-α and heparin binding EGF-like growth factor.216–222 Ligand functionalised 
nanoparticles are capable of binding to and therefore stabilising EGFR dimers complexes on 
the surface of cancer cells. The formation of the ligand-stabilised EGFR dimer complexes 
initiate cellular signalling processes following which the ligand-EGFR dimer complexes are 
internalised via clathrin-mediated endocytosis.223 A number of DNC systems have been 
developed to target cellular internalisation via EGFR-mediated endocytosis.224,225 This has 




functionalisation of superparamagnetic iron oxide nanoparticles with EGF showed improved 
magnetic resonance imaging properties to their non-targeted analogues.226 Similarly, 
EGF-functionalised gelatin based nanoparticles have shown enhanced targeting of highly 
EGFR expressing A549 cells over HFL1 (low EGFR expression) in vivo; such nanoparticles 
were also able to target tumours using EGFRs in an in vivo tumour-bearing mouse model.227 
Whether achieved via passive or active targeting strategies, ensuring cellular internalisation is 
an essential function of a DNC. The physiological barriers and therefore the role of the DNC 
system are, however, not complete once cellular internalisation has been achieved. Once 
located within a cell, DNC systems are faced with a range of intracellular barriers which they 
must overcome in order to ensure that they achieve their desired therapeutic effect.    
1.2.2.5 Intra-Cellular Barriers for DNC Systems 
DNCs which undergo cellular internalisation via CIM, CIE and receptor-mediated endocytosis 
are held within endosomes. Escape from such endosomes is essential in order to avoid 
lysosomal degradation, facilitated by the high enzyme concentrations and/or the low pH within 
lysosomes. Failure to achieve endosomal escape can also allow exocytosis of the DNC systems 
and thus their therapeutic purposes cannot be realised.228 The maturation of early endosomes 
into late endosomes is accompanied by a significant reduction in pH. DNC systems must 
therefore be resistant to changes in pH in order to maintain their colloidal stability and must 
also avoid premature release of their therapeutic payloads. This observed change in pH has 
been exploited as an opportunity to promote endosomal escape; in particular, by 
functionalisation of nanomaterials with pH responsive moieties which, following a decrease 
in pH, are capable of inducing endosomolysis and thus causing the release of the DNC system 
into the cytosol.229–231 Only once DNC systems are within the cytosol must they release their 
drug payloads in order to have the desired therapeutic effect. Intracellular fluids such as cytosol 
contain high concentrations of glutathione, a thiol-containing amino acid, which can be used 
as a stimulus to trigger drug release from DNC systems.232,233 
DNC systems internalised via caveolin-mediated endocytosis are localised in caveosomes. The 
neutral pH within caveosomes puts less demand on the colloidal stability of internalised DNC 
systems and also minimises enzyme- and acid- promoted hydrolysis reactions. Caveosomes 
therefore present a suitable route for the transport of DNC systems which are chemically active 
or susceptible to hydrolysis. It has been shown that caveosomes can facilitate the transcytosis 
of 15 nm gold nanoparticles across endothelial membranes.234 Alternatively, the cargo held 
within caveosomes can be directed towards the Golgi apparatus and endoplasmic 
reticulum.235,236 This highlights the possibility that the caveolin-mediated endocytic pathway 




membranes, in order to access sub-endothelial tissues and ii) The delivery of targeted 
chemotherapeutics which aim to inhibit the biological functions of the Golgi apparatus and/or 
endoplasmic reticulum. 
1.2.2.6 Clinical Application of DNC Systems for the Treatment of Cancer  
Despite the large number of physiological barriers that must be overcome in order to achieve 
the desired therapeutic effect, many DNC systems have been studied as novel drug delivery 
strategies in the fight against cancer. The main types of materials which have been studied in 
clinical trials and subsequently approved for use as novel nanomedicine cancer therapies 
include lipid based nanomaterials, block copolymer self-assemblies, drug-polymer 
composites, drug nanocrystals and drug-conjugates. A list of DNC systems which are currently 
undergoing pre-clinical and clinical evaluation are presented in Table 1.2. Drug conjugates are 
not relevant to the nature of the research discussed in this thesis; the reader is directed to a 
number of excellent review articles which discuss this topic in more detail.237–239  
Table 1.2 Examples of anti-cancer nanomedicines which are either approved for use or are 
currently undergoing clinical trials. Table adapted from Hare et al.240 and Lu et al.241  
DNC type Drug Product name/company Target Phase Ref. 
      
Liposomes Doxorubicin Myocet™/Teva UK 
 









  Thermodox™/Celsion Primary hepatocellular 
carcinoma 




Phase III 243,244 
  2B3–101/2-BBB Medicines 
BV  











 Daunorubicin DaunoXome™/Galen HIV-related Kaposi's 
sarcoma  
Approved 252–257 





 Irinotecan Onivyde™/ Merrimack 
Pharmaceuticals 
 Approved 258–260 
 
 




Table 1.2 Continued 
DNC type Drug Product name/company Target Phase Ref. 
Polymer 
micelles 









  NK105/NanoCarrier™ Stomach cancer 
Breast cancer 
Phase III 265–269 
  NC-4016/ 
NanoCarrier™ 
Solid tumours  Phase I 265,270 
  Nanoxel™/Samyang 
Biopharmaceuticals 
Advanced breast cancer  Phase I 271–274 
 DACH-platin NC-6004 Nanoplatin™ 
/NanoCarrier™ 
Pancreatic cancer 
Head and neck cancer 
Non-small cell lung 
cancer 










Head and neck cancer 
Non-small cell lung 
cancer subtypes 












Advanced solid tumours Phase I 280,281 
Drug 
nanocrystals 
2-methoxyestradiol Panzem®/EntreMed Solid tumours Phase II 282–286 
Paclitaxel  Paxceed®/Angiotech 
Pharmaceuticals 
Solid Tumours Phase II 287–289 
Thymectacin Theralux®/Celmed 
BioSciences 
Solid Tumours Phase II 290 
 
The majority of DNC systems currently undergoing pre-clinical and clinical development are 
not functionalised with cell-targeting ligands, therefore accumulation within tumour tissue 
relies on the EPR effect. Such DNCs are designed to improve drug efficacy and patient 
tolerability via manipulation of the pharmacokinetics and biodistribution of the active 
chemotherapeutic. Retention of the chemotherapeutic within the DNC system allows the 
maximum plasma concentration of free drug (Cmax) to be reduced. This allows accumulation 




specific and prolonged exposure to therapeutic concentrations of the drug. DNC research is 
therefore focused on manipulation of DNC properties in order to ensure the stability and 
controlled release of their payloads in order to allow them to capitalise on the opportunity 
presented by the EPR effect. One key issue which has arisen during pre-clinical evaluation is 
the release of active payloads from DNC before accumulation within the tumour 
microenvironment takes place. A number of strategies have been employed to address this 
including covalent attachment or controlling drug diffusion through polymer matrices.291–293   
Alternatively, some DNC systems currently undergoing clinical development have adopted 
active targeting strategies.294 Another advantage of using DNC systems for the targeted 
delivery of toxic chemotherapeutic agents, specifically to a tumour site, is the ability to reduce 
the harsh side-effects experienced by patients undergoing chemotherapy regimens. For 
example, pre-clinical evaluation of a AZD-2811 nanoformulation showed that encapsulation 
of the active Aurora-B kinase inhibitor within a drug-polymer composite reduced dose toxicity 
to bone marrow.241 As a result, doses of nanoformulated AZD-2811 could be administered in 
excess of the toxic dose limit typically shown by the unformulated chemotherapeutic. 
Alternatively, unformulated water-insoluble chemotherapeutics often require the use of 
excipients to increase their solubility in biological fluids. Such excipients often exhibit toxicity 
and, as a result, can also limit the dose of a chemotherapeutic which can be safely administered. 
This is demonstrated by the variation in the toxic dose limit observed between different 
paclitaxel nanoformulations. For example, higher doses of paclitaxel can be administered as 
the polymeric micelle-based nanoformulation, Genexol-PM™ compared to the 
excipient-stabilised paclitaxel solution, Taxol™.295 This difference in toxicity has been 
attributed to the presence of the excipient Cremophor™ used to solubilise Paclitaxel in the 
Taxol™.290 Achieving improved safety profiles using chemotherapeutic nanoformulations can 
therefore have significant impacts on the clinical performance and thus the outcome of 
chemotherapy treatments.   
Although the development of chemotherapy based DNC systems has proven successful in the 
treatment of a wide range of cancers, the vast majority of cancer research has focused on a 
small range of nanomaterials and DNC platforms. This has limited chemists’ abilities to 
respond to, and further their understanding of the barriers and opportunities presented by the 
vascular, extracellular and intracellular systems, as well as those which arise during tumour 
formation processes. Future research must utilise nanomaterials that have been specifically 
designed to study and/or exploit the opportunities identified by past research. Advances in the 
field of polymer chemistry has facilitated the generation of precise macromolecular structures 
which can be used to generate functional nanomaterials. Such nanomaterials will be 




1.3 Polymer Chemistry  
The field of polymer chemistry is of significant global importance; from the tyres on the cars 
that we drive to the clothes that we wear, polymers play a significant role in many aspects of 
our daily lives. Polymers can either be synthesised via chain growth or step growth 
polymerisation.296 Briefly, chain growth polymerisations involve addition of individual 
monomers to a growing polymer chain, whereas step growth polymerisations involve 
combination of bifunctional monomers to form a series of dimers, trimers and oligomers which 
eventually combine to form long chain polymers. Until relatively recently, neither approach 
provided good control over the polymerisation processes or the properties of the polymers 
subsequently formed. As a result, chemists’ abilities to design precise nanomaterials with 
pre-determined structures and control over polymer molecular weight was somewhat limited. 
Although such control could be achieved using living polymerisation methods, the limited 
monomer scope and its requirement for stringent polymerisation conditions, such as exclusion 
of moisture, have limited its adaptation by polymer chemists. In contrast, the discovery of 
reversible-deactivation radical polymerisation (RDRP) techniques in the last decade of the 20th 
century has revolutionised the field of polymer chemistry and opened up many new areas of 
polymer research.  
1.3.1 Reversible-Deactivation Radical Polymerisation  
The discovery and development of RDRP techniques has, without doubt, provided the most 
significant advancement in the field of polymer chemistry over the past quarter of a century. 
The aim of RDRP techniques is to facilitate the polymerisation of vinyl monomers whilst 
affording polymer chemists with a degree of control over polymer molecular weight whilst 
minimising the disparity between growing polymer chains. There are two key areas where 
RDRP techniques provide significant advances from the conventional radical polymerisation 
techniques. i) They are pseudo-living processes in which all polymer chains are initiated at the 
same time and continue to grow throughout polymerisation. ii) They suppress undesirable side 
reactions by using the RDRP process to minimise the concentration of active radicals during 
polymerisation. These two factors combined allow a known number of polymer chains to grow 
at equal rates with minimal disparity between polymer chain lengths. This has allowed 
polymers of pre-determined number-average molecular weights (Mn) to be produced 
containing significantly lower dispersity (Đ) values  (Đ = 1.01 - 1.30) than those typically 
obtained for polymers produced using conventional radical polymerisation techniques. 
Since the discovery of RDRP in the mid-1990s a plethora of synthetic techniques have been 
developed; however, nitroxide-mediated radical polymerisation (NMP),297–300 atom transfer 
radical polymerisation (ATRP), single electron transfer living radical polymerisation 




polymerisation remain the four most popular techniques in use today. Whilst the subtle detail 
of each technique differ, they all share the same basic mechanistic principles of a reversible 
deactivation radical process. The RDRP process is based on the dynamic covalent affiliation 
between a labile end-group and the ω-terminus of a polymer chain (Figure 1.7). The chemical 
nature of the labile end-group is dependent upon the RDRP technique employed. In ATRP/ 
SET-LRP labile end-groups typically consist of halides. Alternatively, NMP uses nitroxides 
and RAFT polymerisation is facilitated by a range of thiocarbonyl based end-groups, including 
trithiocarbonates, dithioesters and dithiocarbonates (xanthates).304–306 The specific mechanistic 
detail of individual RDRP techniques will be discussed in detail during the introduction 
sections of the relevant chapters.  
 
Figure 1.7 Schematic general representation of the dynamic equilibrium which forms the basis 
of RDRP techniques. This equilibrium exists between dormant (P-X), where X represents a labile group, 
and active (P*) states in which polymers exist during RDRP. P-X undergoes activation (kact) to form 
P*. P* can undergo propagation with monomer (kp) to increase its degree of polymerisation or a 
termination reaction (kt) to form a “dead” polymer chain.  
The reversible attachment of labile end-groups to polymer chains means that polymer chains 
can exist in two forms during RDRP: i) as a “dormant chain” where a labile end-group is 
covalently attached to the ω-terminus of the polymer chain and ii) as an “active” chain, where 
homolysis of the labile covalent bond results in the formation of an active radical at the 
ω-terminus. The dormant state is chemically inert and is therefore unable to participate in 
chemical reactions such as propagation or chain termination. In contrast, the active state 
contains a reactive radical which is capable of facilitating chain growth via propagation with 
a monomer; this occurs with a rate constant kp. Active radicals are also capable of participating 
in undesirable side reactions such as chain termination, occurring with a rate constant kt, which 
irreversibly cap polymer chains and thus preventing their further growth via propagation. 




states throughout polymerisation; these occur via a series of activation and deactivation 
reactions which proceed with the rate constants kact and kdeact, respectively.  
RDRP processes are extremely effective in preventing undesirable side reactions, such as 
chain termination. Once an active species is generated, it can either undergo propagation with 
monomer, termination with another active radical or, most likely, the reverse deactivation 
process, via recombination with a labile end-group. This ensures that active radicals have short 
lifetimes and the fact that the RDRP equilibrium lies in favour of the dormant species also 
maintains a low concentration of active polymer chains throughout polymerisation. As a result 
polymerisations proceed in a pseudo-living manner and the formation of dead polymer chains, 
via radical-radical combination, is effectively suppressed by the RDRP process. This allows 
the majority of polymer chains to continue to grow unhindered throughout polymerisation.   
Another key advance brought about by the discovery of RDRP is that it provided chemists 
with the ability to target the Mn prior to synthesis. Regardless of the technique employed, the 
labile end-group responsible for facilitating the RDRP process is incorporated into polymer 
chains during the initial stage of polymerisation. This is achieved by addition of a molecule 
capable of facilitating RDRP (the RDRP agent) into polymerisation reactions. The chemical 
functionalities of such RDRP agents are subsequently incorporated at either end of the polymer 
chain. As a result, control over the stoichiometry of the monomer and RDRP agent at the start 
of polymerisation allow desired polymer chain lengths to be targeted with relative ease. RDRP 
techniques also provide the ability to polymerise a wider scope of monomers in comparison to 
traditional living polymerisation techniques. Furthermore, a range of RDRP techniques have 
been developed which allow polymerisations to be conducted under mild conditions including 
in aqueous solution, at ambient temperature and in the presence of oxygen;307–309 such 
advances have only helped to promote the industrial translation of such techniques and have 
increased the commercial viability of materials produced by RDRP.310 
The ability to produce polymers of predetermined molecular weight whilst maintaining low 
dispersity between polymer chains was a huge step forward in the field of polymer chemistry. 
This has subsequently formed the basis of decades of research which has pushed the limits and 
scope of polymer science. The versatility of the RDRP process has since been used to generate 
a variety of novel polymer architectures which were previously unachievable using 







1.3.1.1 Polymer Architecture  
RDRP techniques have permitted the synthesis of a wide range of novel macromolecular 
architectures. Macromolecular architectures can vary in many ways including the number of 
monomer types within a polymer, their distribution within a polymer and the way in which 
polymer chains are arranged within a polymer structure (polymer topology). Some of the most 
studied polymer architectures which can be generated using RDRP include: linear 
homopolymers,311 block copolymers,312  multi-block copolymers,313,314  graft copolymers,315  
star polymers,316  branched polymers and hyper-branched polymers.313,314 An overview of 
these macromolecular architectures is presented in Figure 1.8. 
 
Figure 1.8 Examples of the macromolecular structures which can be generated using RDRP. a) 
Variations in the distribution of monomers in across the (co)polymer backbone. b) The wide range of 
polymer architectures which can be generated as a result of the enhanced control provided by RDRP. 
As described in Section 1.3.2.1, RDRP allows the generation of well-defined polymers with 
controlled molecular weights. In cases where polymerisations are conducted using RDRP 
agents which contain a single functional group capable of facilitating RDRP, chain growth 
occurs in one direction. Perhaps considered the conventional RDRP approach, the architecture 
generated is known as a linear polymer. Where polymerisations contain only one type of 
monomer the resulting polymers generated are known as linear homopolymers. In contrast, 
copolymerisation of more than one monomer type generates a linear copolymer. The 
distribution of comonomers within linear copolymers architectures generated via RDRP can 




of monomer consumption during copolymerisation are reflected by the comonomer 
distribution along each individual chain. As a result, not only do linear copolymers possess 
similar molecular weights, they also contain effectively identical compositional gradients 
along their copolymer backbone. The magnitude of the compositional gradient is highly 
dependent upon the relative reactivities of the two (or more) comonomers being 
polymerised.317 In particular, this gives rise to the generation of statistical, alternating and 
gradient/tapered copolymer architectures that cannot be achieved using conventional radical 
polymerisation techniques.318 
Copolymers in which monomers are compartmentalised into discrete regions along the 
copolymer backbone are known as block copolymers. The synthesis of such materials can be 
achieved via RDRP due to the retention of labile polymer end-groups following 
polymerisation. This allows such polymers to be used as macromolecular RDRP agents 
(macro-RDRP agent) in the polymerisation of a second monomer in a subsequent RDRP 
process. Known as a chain extension, this results in the complete segregation of the two 
monomer types across the block copolymer backbone.319 Furthermore, the ability to target Mn 
also facilitates the creation of block copolymers with control over their respective block 
lengths. The high end-group fidelity which has been shown by many RDRP techniques means 
that multiple chain extensions to be conducted without loss of a polymer’s labile end-group. 
This has allowed the creation of multi-block copolymers with as high as 10 different monomer 
segments across the multi-block copolymer backbone using various RDRP techniques.320 
Alternatively, the synthesis of RDRP agents containing more than one moiety capable of 
facilitating RDRP has enabled the creation of multi-arm star polymers.321 Polymerisation from 
such multifunctional RDRP agents promotes divergent growth in a number of directions 
proportional to the number of labile groups present. For example, the use of a trifunctional 
RDRP agent would promote chain growth in three directions, to form a 3-armed star, whereas 
the use of a hexafunctional RDRP agent would facilitate chain growth in six directions, 
forming a 6-armed star. RDRP therefore enables the construction of star polymers through 
what is known as a core-first approach.322 RDRP also offers the ability to produce stars 
containing different arm lengths by controlling the stoichiometry between monomer and 
RDRP agent. Furthermore, the retention of labile end-groups on the polymer arms has allowed 
chain extension of multi-armed star polymers to generate multi-armed star block 
copolymers.321 
Graft copolymers are another form of segmented copolymer where one monomer typically 
forms the copolymer backbone whilst the other monomer forms randomly distributed branches 




brush-like copolymers. There are three main synthetic approaches used for the generation of 
graft copolymers, these are often referred to as grafting-to, grafting-from and grafting-through 
approaches. The grafting-to approach typically involves a two-stage process. Firstly, a 
polymer backbone is synthesised containing one monomer type; this monomer typically 
contains pendant functional groups which are capable of participating in post-polymerisation 
modification reactions. A second step then involves post-polymerisation modification of the 
polymer backbone via covalent attachment of a second polymer to the pendant functional 
groups of the polymer backbone. This approach can be difficult as the production of a suitable 
polymer backbone typically requires bespoke monomer synthesis and post-polymerisation 
modification reactions must achieve high yields in order to obtain the desired graft copolymer 
architecture.  
Alternatively, the grafting-from approach involves two sequential polymerisation reactions. 
The first reaction, similar to that described in the grafting-to approach, involves the synthesis 
of a polymer backbone containing pendant functional groups. However, in the grafting-from 
approach, these functional groups are in fact RDRP agents which act as “grafting points” from 
which the growth of the second component occurs. The grafting-through approach is perhaps 
the simplest synthetic approach for the generation of graft copolymers. Firstly, polymer chains 
are generated containing an end-group functionality which subsequently can be converted into 
a polymerisable group, to form what is known as a macromonomer. The polymerisation of 
such macromonomers therefore allows the generation of graft copolymers via a grafting 
through approach.323 One advantage of this approach is that many macromonomers are now 
commercially available and this can therefore remove the necessity for macromonomer 
synthesis. RDRP techniques have provided a large degree of control over the graft copolymer 
architecture. The ability to control polymer chain lengths allows the length of both polymer 
backbone and polymer side-chains to be pre-determined prior to synthesis. Furthermore, 
addition of a non-functional comonomer during the synthesis of the copolymer backbone has 
allowed the grafting density of graft copolymers to be controlled.324 
Branched and hyper-branched polymers have attracted significant attention since the discovery 
of RDRP.313 The term branched polymer refers to polymers in which a proportion of the 
pendant groups of the polymer backbone either consist of, or are covalently-linked to,  another 
polymer chain. The control provided by RDRP techniques has facilitated the generation of 
branched and hyper-branched polymer architectures which could not previously be obtained 
using conventional radical polymerisation techniques.325 The key difference between branched 
and hyper-branched polymer architectures has been the topic of considerable debate;325 to 
speak generally, polymer nomenclature is typically assigned based on the prevalence of 




developed to determine the prevalence of branching within a polymer. For example, the degree 
of branching (DB) is a quantitative measure of the number of branch points and terminal units 
in the whole polymer structure. Alternatively, others have reported the branching density 
within polymer structures, which represents the mass of branching units as a function of the 
total mass of the branched polymer.326 Under these assessments, branched polymers typically 
exhibit lower degrees of branching/branching densities than hyper-branched polymers. 
The main synthetic approach used for the generation of branched copolymers involves the 
copolymerisation of monofunctional and bifunctional monomers (BFM) via RDRP. BFMs are 
monomers which contain two functional groups capable of participating in propagation 
reactions; incorporation of each of these groups into separate growing polymer chains 
generates a branch point between the two chains. The resulting branched copolymers therefore 
consist of large numbers of primary chains covalently linked through BFMs which act as 
branch points within the branched macromolecular architecture. A detailed mechanistic insight 
into the formation of branched copolymers via copolymerisation of monofunctional and BFMs 
using RDRP is presented in Chapter 2, Section 2.1.3.2. The development of RDRP has aided 
the prevention of gelation in order to provide statistical incorporation of BFMs across all 
growing polymer chains; thus allowing such copolymerisations to conform to the 
Flory-Stockmayer theory of gelation.327 
Alternatively, hyper-branched polymers contain much higher branching densities. The 
construction of hyper-branched polymer architectures has been greatly advanced by the use of 
RDRP. Self-condensing vinyl polymerisation (SCVP) is an approach which involves the 
polymerisation of inimers to generate hyper-branched polymer architectures.328 Inimers are 
species which contain two chemical moieties capable of undergoing RDRP; these include a 
polymerisable group as well as an RDRP agent functionality. As a result, inimers act as both 
monomers and RDRP agents during SCVP. This allows them to be incorporated into a polymer 
backbone through their polymerisable group, whilst simultaneously grafting-from the polymer 
backbone via their RDRP agent functionality.329 Whilst SCVP has been attempted using 
conventional radical polymerisation with only limited success, the application of RDRP 
techniques to SCVP have resulted in the production of hyper-branched architectures which 
exhibit exceptionally high DB values.330 More recently, the construction of hyper-branched 
polymers has been achieved via homopolymerisation of BFMs using RDRP.331 This approach 
has facilitated the production of densely-packed hyper-branched polymers with comparable 
DB values to those obtained via SCVP. RDRP plays an essential role in controlling polymer 




The wide range of polymer architectures which are now easily accessible to polymer chemists 
is another indication of the advances brought about by the discovery and development of 
RDRP techniques. High tolerance of many chemical functionalities has also allowed the 
production of functional macromolecules.332 Furthermore, the use of a broad range of 
components in the design of complex macromolecules, such as monomers, RDRP agents, 
BFMs and inimers to name a few, allow functionality to be incorporated at specific locations 
on the (co)polymer architectures.  
1.3.1.2 Polymer Functionality  
The use of many different reaction components in RDRP, particularly in the construction of 
complex (co)polymer architectures, has allowed chemists to incorporate functionality into 
polymers with relative ease. The reaction components used in RDRP are dependent upon the 
polymer architecture being targeted; however, the most common functional handles through 
which functionality is incorporated into polymers include α-end-groups, monomers, ω-end-
groups and branch points.333 An overview of these functional handles and their locations within 
various macromolecular architectures is presented in Figure 1.9.   
 
Figure 1.9 Schematic representation of the functional handles through which chemical 
functionality can be incorporated into polymer structures. Demonstration of the specific functional 
handles available for a range of polymer architectures, including: a) Linear homopolymers, b) Block 
copolymers, c) Star polymers, d) Graft copolymers, e) Branched copolymers and f) Hyper-branched 
polymers. Functional handles include: monomer (blue and red), α-end-group/core (purple), 




There are two main approaches through which functionality can be incorporated into 
polymers. Perhaps the easier of the two approaches, chemists can employ reaction components 
which already possess the desired chemical functionality in a RDRP; such functionalities are 
therefore incorporated into the polymer structure during polymerisation. Whilst the production 
of such reaction components can often require complex organic syntheses, this process offers 
a relatively facile approach to incorporate chemical functionality into a polymer.  
Alternatively, a desired chemical functionality can be incorporated through 
post-polymerisation modification. This requires the use of reaction components which contain 
precursor moieties. This approach therefore uses polymers as macromolecular scaffolds 
through which desired chemical functionalities can be incorporated. Whilst this approach 
typically removes the need for complex synthesis of reaction components, its success is highly 
dependent upon the efficiency of the post-polymerisation modification reaction and can often 
require additional purification steps to remove side-products. The use of this approach has 
been accelerated by the discovery of click chemistry.334 This term is given to chemical 
reactions which proceed with exceptionally high yields, do not generate side products and 
typically proceed without the need for a catalyst. This approach, including the areas of post-
polymerisation modifications and click chemistry, lies beyond the scope of the work covered 
in this thesis and will therefore not be discussed herein; however, the reader is directed to a 
number of excellent review articles which discuss these topics in more detail.335–338 
Monomer structure is perhaps the most utilised route through which functionality has been 
incorporated into polymers. Monomers typically make up the majority of the overall polymer 
mass, and therefore have a significant impact on the overall properties of the resulting polymer. 
In particular, monomer chemistry is often used to control macroscopic polymer properties such 
as water solubility and thermal properties such as the glass transition temperature (Tg). For 
example, water-soluble polymers can be produced through selection of water-soluble 
monomers, such as those containing: acidic, cationic, anionic, zwitterionic,339,340 short 
water-soluble polymers such as poly(ethylene glycol) (PEG)323 as well as a range of other polar 
functional groups.341 In contrast, selections of hydrophobic monomers such as those containing 
pendant alkyl, aromatic or lipid-based functional groups generate hydrophobic polymers 
which are insoluble in water.342 A number of bespoke monomers have been generated to 
produce polymers containing precise chemical functionalities which are suited towards a 
chosen application. Known as polymer conjugates, such approaches have seen the production 
of polymers functionalised with drugs, carbohydrates, fluorophores, chromophores, 
deoxynucleic acids (DNA) and amino acids.343–346 The extent to which functional groups are 
incorporated into polymers is often controlled by copolymerisation with a relatively benign 




hydrophilic comonomer N-isoproylacrylamide (NIPAAm) to generate a series of water-
soluble glycopolymers via RDRP.347 
Chemical functionality can be incorporated at polymer end-groups through the use of 
functional RDRP agents. As mentioned above, RDRP agents are incorporated at either end of 
polymer chains during the initial stages of polymerisation. The labile end-group functionality 
of an RDRP agent is located at the ω-end-group, where it facilitates chain growth via the RDRP 
process, whereas the remainder of the RDRP agent forms the polymer’s α-terminus and has 
no influence of the polymerisation process. The design and use of functional RDRP agents 
therefore provides an opportunity to integrate chemical functionality at the α-terminus of a 
polymer chain. This approach has been adopted by chemists using different RDRP techniques 
via the creation and use of functional RDRP agents.348 Functional RDRP agents have been 
used to achieve complex macromolecular architectures using relatively simple polymerisation 
techniques. For example, the use of macro-RDRP agents has allowed the production of AB 
diblock and ABA triblock copolymers in a one pot-synthesis.349 In other cases the use of 
dendron-based RDRP agents has enabled the production of linear-dendritic hybrid, 
dendronised polymers and hyper-branched polydendrons.350 Although a relatively facile way 
to incorporate functionality into polymer structures, the main limitations of this approach are: 
i) the possible complexity associated with the synthesis of functional RDRP agents and ii) that 
polymer end-groups typically only make up a small fraction of the overall polymer mass. 
Despite these limitations, end-group functionalisation has attracted significant attention in 
nanomedicine based polymer research.351 
Polymers generated using RDRP typically retain their labile end-group (RDRP agent) 
functionality at their ω-terminus following polymerisation. These functional groups offer 
another handle through which further functionality can be introduced. In the case of RAFT 
polymerisation, remaining ω-end-groups, which typically consist of dithioester- or 
trithiocarbonate-based compounds, can undergo a selection of removal, transformation or 
functionalisation reactions with relative ease.352 A similar series of reactions have also been 
established for the modification of the alkyl halide ω-end-group, which is typically retained 
by polymers produced using ATRP and SET-LRP techniques.353 Perhaps the most effective 
use of remaining RDRP agent functionalities has been the chain extension with a second 
monomer. In many cases this has done to influence the polymer’s physical properties; for 
example, in the chain extension of hydrophilic polymers with hydrophobic monomers in order 
to generate amphiphilic block copolymers.354–356 In other cases chain extensions have been 
used to incorporate functional monomers at the ω-terminus of a polymer. For example, the 
chain extension of an amphiphilic block copolymer with glyco-monomer to incorporate 




the receptor-mediated endocytosis of the resulting block copolymer micelles formed.357 This 
approach has also been used to generate novel macromolecular architectures;330,358 for 
example, the chain extension of hyper-branched polymers has generated hyp-star materials 
which consist of a hydrophobic hyper-branched polymer core and high numbers of hydrophilic 
linear arms. Such materials have been coined ‘unimolecular micelles’ as they remain as 
individual nanoparticles in aqueous solution possessing a hydrodynamic radius of 
approximately 20 nm. 
Branch points offer another handle through which chemical functionality can be incorporated 
into branched and hyper-branched polymers. Until recently, the vast majority of 
(hyper)branched polymer research had focused on the discovery, understanding and 
development of novel synthetic strategies for the production of such materials.330,359,360 As a 
result, the use of branch points as a means to incorporate chemical functionality was relatively 
under-utilised. However, now that a number of synthetic strategies have been established, this 
area of research is receiving increased interest from polymer researchers. In particular research 
has involved the synthesis of functional BFMs and inimers which can then be incorporated 
into (hyper)branched polymer architectures. Due to the infancy of this research area the 
majority of publications have involved “proof of concept” studies to demonstrate the ability 
to introduce relatively benign chemical functionalities into (hyper)branched polymer 
structures.328 However, more recently the introduction of chemical functionality at polymer 
branch points has yielded (hyper)branched materials with potential future applications. For 
example, the use of a macrocyclic ligands containing BFM, capable of chelating Gd3+ ions, 
facilitated the preparation of branched copolymers for application as MRI contrast agents and 
demonstration of this application in in vivo studies.361 Alternatively, inimers containing labile 
covalent bonds as linker groups between their polymerisable and RDRP agent groups were 
used to produce degradable hyper-branched polymers using RDRP-mediated SCVP.362  
Whilst branch points offer a suitable opportunity to generate functional polymers, their 
importance in the formation of (hyper)branched architectures must not be underestimated. The 
introduction of bulky substituents will increase the size and thus steric hindrance around a 
BFM/inimer and may therefore hinder their ability to participate in branching reactions and 
create the desired polymer architecture. This issue can be circumvented via the introduction of 
precursor functionalities at polymer branch points, which are then able to facilitate the 
introduction of more complex or bulkier functionalities through post-polymerisation 
modification. This was demonstrated by Gao and co-workers, who introduced azide 
functionalities at polymer branch points that subsequently facilitated the attachment of focal 
point alkyne functionalised, third generation dendrimers using a post-polymerisation 




The ability to incorporate chemical functionalities at precise locations on complex 
macromolecular structures has equipped chemists with the ability to influence the chemical 
and physical properties of polymers. Many chemical functionalities allow such polymeric 
materials to respond to changes in their chemical and physical environments. The use of such 
chemical functionalities is therefore useful in the design of responsive materials. This has 
attracted significant interest and has formed the basis of considerable amounts of polymer 
chemistry research. 
1.3.1.3 Stimuli-Responsive Polymers 
The ability to incorporate functionality into macromolecular architectures has enabled the 
creation of polymers capable of responding to a range of external stimuli. Stimulus-responsive 
materials typically rely on labile or dynamic covalent interactions, interactions of polymers 
with their external environment, for example the surrounding solvent, or even changes in their 
internal structures to facilitate such responses.364 Stimulus-responsive materials with the 
capability to respond to a wide range of external stimuli have been produced using RDRP. 
These include pH,365 temperature,366 redox, light,367 the presence of ions, and other chemicals 
ranging from small molecules to gases.368 Whilst the specific chemical changes play a critical 
role in the facilitation of such responses, their mechanistic details are beyond the scope of the 
work covered in this thesis. The reader is directed to a number of review articles which discuss 
these topics in further detail.365,369,370 
Of particular interest here is the impact that such chemical changes can have on the behaviour 
of polymers. The main types of polymer stimulus-responsive behaviour can be characterised 
as follows: i) chemical degradation of macromolecular structures,371 ii) changes in aqueous 
solution behaviour, iii) chemical neutrality/ ionisation and iv) impacts on polymer rigidity/ 





Figure 1.10 Schematic representation of the stimuli-responsive behaviours of polymers which can 
be induced by changes to their chemical and physical environment. These include effects on a) 
Structural integrity b) Aqueous solubility, c) Chemical charge and d) Polymer rigidity/ viscosity.  
RDRP involves polymerisation of vinyl-based monomers and therefore typically generates 
polymers containing non-degradable aliphatic backbones. As a result, degradation of polymer 
backbones has, until recently, been considered to be an impossible task. In recent years, the 
radical ring opening polymerisation of cyclic ketene acetals, in particular the seven-membered 
2-methylene-1,3dioxepane (MDO), has opened the door to the synthesis of degradable 
polymer backbones via radical polymerisation techniques.334,372–380 The radical ring-opening 
of MDO places an ester within the backbone of the ensuing polymer, thus allowing polymer 
degradation via base-catalysed hydrolysis following addition of potassium hydroxide. This 
approach has been used to generate a range of macromolecular architectures containing 
degradable polymer backbones using RDRP.381–385Another approach which has been used to 
place a labile link within a polymer backbone and includes the use of bifunctional RDRP 
agents containing degradable linkers.386–389 The use of a bifunctional RDRP agent places it in 
the centre of the polymer chain. Subsequent cleavage can therefore facilitate polymer 




In the cases of branched and hyper-branched polymers, branch points provide another 
opportunity to incorporate labile linkers into macromolecular architectures. This has been 
achieved by the incorporation of labile groups into BFMs and inimers thus forming weak links 
throughout the resulting hyper(branched) structures.328,390 This has allowed the production of 
(hyper)branched materials whose degradation can be triggered by a range of external stimuli, 
including pH, temperature, UV light and the presence of reducing agents.391–393 It is important 
to note that despite the fact that many of the chemical changes which induce 
stimulus-responsive behaviour are reversible, the reformation of the polymer architectures is 
not. The stimulus-responsive degradation of polymers are therefore typically considered as 
irreversible processes. However, in some cases, polymer architectures can be reformed 
through the reversal of the degradation process. For example, in the case of hyper-branched 
polymers held together by thermo-responsive Diels-Alder linkers, 1H NMR analysis showed 
71 % of polymer branch points had reformed on cooling just 48 hours after thermally-triggered 
polymer degradation.390 
Polymer solution behaviours are highly dependent upon the level of interaction between 
polymers and their surrounding solvent. Chemical and physical changes to polymers, which 
arise as a result of stimulus-responsive behaviours, can therefore have significant impacts on 
polymer solution behaviour; generally speaking, they can either have beneficial or detrimental 
effects. Many polymers possess thermally-responsive behaviour in aqueous solution.394 In 
particular, polymers derived from NIPAAm and PEG-based monomers have been produced 
in order to exploit their lower-critical solution (LCST) behaviour. The term LCST refers to the 
temperature at which a polymer precipitates from solution. This is the result of the Gibbs free 
energy (ΔG) of aqueous mixing passing through zero within a practical temperature range; for 
example poly(NIPAAm) and poly((oligoethylene glycol) methacrylate) have LCSTs of 32 ℃ 
and 90 ℃ respectively.395 The construction of copolymers containing varying compositions of 
monomers that  possess contrasting aqueous solution behaviour has enabled the tuning of 
polymer LCSTs.396 Furthermore, polymer LCST behaviour is also dependent on many other 
conditions, including concentration, molecular weight, polymer architecture and the 
concentration of salts within aqueous solution.397 The phase transition which occurs when an 
aqueous solution of polymer is heated above its LCST can easily be reversed by cooling the 
solution;323,398–403 although in some cases a difference can occur between the transition 
temperature obtained between heating and cooling cycles of aqueous solutions containing 
complex macromolecular architectures.356,404–406  
In other cases, pH-responsive monomers can be used to influence polymer aqueous solution 
behaviour. This typically involves incorporation of ionisable groups into a polymer which can 




has generally been achieved using carboxylic acid and amine based polymers which become 
ionised at high and low pH respectively.407,408 In their neutral forms, such polymers typically 
exhibit low water solubility; however, polymer ionisation has an impact on the nature of 
polymer-solvent interactions, typically via the establishment of cation/anion-hydrogen 
bonding, and thus significantly increases the aqueous solubility of such polymers.409 In other 
cases, quaternisation of tertiary amines groups, typically via alkylation using alkyl halides, has 
been used to generate cationic charges;410 such reactions are typically irreversible and they can 
have a dramatic impact on aqueous solubility. 
Thermo-responsive behaviour can also have a significant impact on the physical properties of 
polymers. In particular, temperature has a significant influence on polymer rigidity or viscosity 
in the bulk. These properties are typically linked to the physical state, degree of entanglement 
and strength of intermolecular forces, acting on polymer chains within the bulk material.411 
Polymers are typically characterised as either semi-crystalline or amorphous materials. Semi-
crystalline polymers have regions in which polymer chains are held in highly ordered 
arrangements, which maximise non-covalent interactions between them, known as crystalline 
regions. Sections of the bulk material which do not adopt such highly ordered arrangements 
are known as amorphous regions. Semi-crystalline polymers have both crystalline and 
amorphous regions and, as a result, are typically brittle solids when below their melting points 
(Tm) and Tg. In contrast, polymers which do not possess crystalline regions are known as 
amorphous. They are held together by chain entanglements and intermolecular forces which 
act between the large macromolecules; however, these forces are typically much weaker than 
those present in the highly ordered structures of semi-crystalline materials.412 Amorphous 
polymers typically exhibit rigid/ “glassy” behaviour when below their Tg, above which they 
become soft and flexible. Although possessing greater chain mobility, polymers still behave 
as rubbery solids above their Tg due to strong intermolecular forces still present between 
polymer chains.413 As a result polymer viscosity typically decreases with temperature as chains 
acquire sufficient energy to overcome the intermolecular forces acting between them. The 
thermal transitions and melt viscosities of polymers are highly dependent upon many polymer 
properties, including molecular weight, monomer type, copolymer composition and polymer 
architecture. Polymer melting and glass transitions are both reversible processes and therefore 
temperature can be used as a stimulus to trigger the hardening/softening of polymers in their 
bulk state.414 The use of polymers which are capable of responding to external stimuli can bring 
an additional dimension to the nanomaterials that they are used to construct. This has particular 
relevance to the field of nanomedicine, and in particular targeted drug delivery, where 
nanoparticles may be required to adapt in order to overcome a particular physiological barrier 




incorporated into the design of DNC systems in order to equip them with the ability to respond 
to the physiological challenges presented by the vascular, extracellular and intracellular 
environments; this may ultimately improve their efficacy in delivering chemotherapeutics 
directly to cancer cells.  
1.4 Synthetic Approaches for the Generation of Polymer-Based Nanoparticles 
The advances made in the field of polymer chemistry has facilitated similar progress in the 
field of nanotechnology. In particular, the ability to control the molecular weight, 
macromolecular architecture and chemical functionality of polymers has allowed the 
construction of nanomaterials from well-defined building blocks. Furthermore, this has 
allowed the chemical and physical properties of such polymers to be translated into 
macroscopic behaviours of the resulting nanomaterials. One area which is of particular interest 
to the development of novel DNC systems is the generation of polymer-based nanoparticles 
via the formulation of synthetic polymers. In general, significant advances have been observed 
in two areas of polymer nanotechnology; these are the formation of amphiphilic block 
copolymer self-assemblies and the formation of polymer-based nanoparticles via 
nanoprecipitation.  
1.4.1 Block Copolymer Self-Assembly  
Amphiphilic block copolymers readily undergo self-assembly in water to avoid high energy 
water-hydrophobe interactions and thus minimise free energy. Incompatibility of one (or 
more) of the copolymer blocks with water typically drive the hydrophobic domains of 
numerous block copolymers together to form core-shell structures, where the core consists of 
hydrophobic domains with the hydrophilic domains facing outwards into the aqueous medium. 
The energetics of self-assembly are also driven by the formation of favourable non-covalent 
interactions between hydrophobic domains within the core of the self-assembly. The 
hydrophobic core-forming block also plays an important role in the formation, and 
stabilisation of block copolymer self-assemblies. Extending from the hydrophobic core, 
hydrophilic domains form a dense hydrated corona which provides steric stabilisation. The 
energetics of block copolymer self-assembly are beyond the scope of this thesis. However, the 
reader is directed to a number of excellent review articles which discuss this topic in 
considerable detail.415,416 
Block copolymer self-assemblies can adopt a number of morphologies, including spherical 
micelles, cylindrical/worm-like micelles and polymersomes. Theoretically, the morphology 
adopted by block copolymer self-assemblies can be related to the free energy per chain, which 
consists of the free energy contributions of the hydrophobic and hydrophilic blocks as well as 




morphology adopted by block copolymer self-assemblies.420–423 In practice, however, a 
simplified approach, known as the packing parameter (P = v/aolc) is often used to explain the 
morphology adopted by block copolymer self-assemblies in aqueous solution.424 This 
approach is presented in Figure 1.11. The packing parameter (P) determines the interfacial 
curvature at the core-corona interface of block copolymer self-assemblies in the state of 
minimum energy and thus dictate the copolymer morphology. The parameter, P, is depends 
on a number of factors, such as the volume ratio of the hydrophobic and hydrophilic domains, 
the extent of core hydration and the conformation adopted by the core forming block.425 As a 
result, block copolymer self-assembly can be directed by careful selection of the relative 
degrees of polymerisation of both the hydrophobic and hydrophilic blocks.  
 
Figure 1.11 The influence of the packing parameter (P) on the morphology of amphiphilic block 
copolymer self-assemblies, where V is the hydrophobic chain volume, a0 is the interfacial area per chain 
and Ic is the hydrophobic chain length. Schematic representation of spherical micelles, cylindrical/work-
like micelles and polymersomes.  Figure adapted from reference426.  
1.4.1.1 In-Situ Nanoparticle Forming Techniques 
Block copolymer nanoparticle research initially involved the post-polymerisation self-
assembly of block copolymers generated using, often complex, multi-step polymer syntheses. 
In recent years research focus has switched towards the in situ generation of self-assembled 
block copolymers nanostructures during RDRP. In particular, this has involved the 
development of two synthetic approaches; polymerisation-induced self-assembly (PISA) and 
emulsion-based RDRP. An overview of these approaches is presented in Figure 1.12. The two 
approaches build on the success of emulsion-RDRP techniques which have been used to 
generate block copolymer nanoparticles via the chain extension of water-soluble macro-RDRP 





Figure 1.12 A general overview of the two predominant synthetic approaches used for the in-situ 
generation of block copolymer nanoparticles using RDRP. (Top) polymerisation-induced self-assembly 
(PISA). (Bottom) RDRP-based emulsion polymerisation.  
PISA is a relatively new phenomenon in which aqueous nanoparticle dispersions are formed 
through the in situ self-assembly of propagating block copolymer chains during aqueous 
RDRP.431 This allowed the preparation of aqueous nanoparticle dispersions at much higher 
concentrations than can be achieved through post-polymerisation processing methods (up to 
50 %).432 There are two critical criteria which must be met in order for an aqueous dispersion 
RDRP to proceed via PISA: i) the polymerisation must involve the chain extension of a water 
soluble polymer; ii) polymerisations are limited to monomers which are themselves 
water-miscible yet subsequently form water-insoluble polymers. Aqueous PISA is therefore 
limited to a small number of water-miscible vinyl monomers and requires the use of RDRP 
techniques to facilitate the chain extension of a soluble polymer.433–440 As a result of using both 
a water-soluble macro-RDRP agent and monomer, chain extensions proceed in an identical 
manner to typical homogeneous polymerisations during the early stages of polymerisation. 
However, once the chain length of the water-insoluble block exceeds the limit at which 
polymer solubility can be maintained, the onset of micellar nucleation occurs. This would 
usually result in the macroscopic phase separation between the aqueous and hydrophobic 
polymer phases; however, the presence of the water-soluble block provides steric stabilisation 
and allows the in situ formation of block copolymer nanoparticles via PISA.441,442 The onset of 
PISA can be observed by a characteristic increase in rate of polymerisation; this is caused by 
a relatively local high monomer concentration which arises due to monomer diffusion into the 
core of block copolymer nanoparticles formed.443 Continued monomer consumption following 
the onset of nucleation facilitates the generation of amphiphilic block copolymers of controlled 
molecular weight. PISA has been used to generate aqueous nanoparticle dispersions containing 
various morphology including spherical and cylindrical micelles as well as polymersomes.444 
Alternatively, emulsion-based RDRP has also been used to generate block copolymer 




copolymer self-assemblies as nanoreactors for the polymerisation of water-immiscible 
monomers in aqueous emulsion. Amphiphilic block copolymers fulfil two roles in this 
synthetic approach, they act as both macro-RDRP agents and polymeric stabilisers during the 
aqueous emulsion polymerisation.450 Preparation of block copolymer nanoparticles using 
emulsion-based RDRP first requires the synthesis of an amphiphilic block copolymer. This is 
typically achieved via preparation of a hydrophilic macro-RDRP agent and subsequent chain 
extension with a hydrophobic monomer; the blocking order employed is of crucial importance 
here in order to ensure that the labile end-group is located at the growing end of the 
hydrophobic block.450 These amphiphilic block copolymers can then undergo self-assembly in 
water to form aqueous block copolymer nanodispersions. The corresponding 
water-immiscible monomer and initiator are added to aqueous nanoparticle dispersions to 
facilitate a second chain extension. Diffusion of the water-immiscible monomer into the 
hydrophobic core causes swelling of block copolymer nanoparticles which therefore act as 
polymerisation nanoreactors during the ensuing emulsion-based RDRP. Once polymerisation 
is complete, the hydrodynamic diameter (DH) of block copolymer nanoparticles are larger than 
that of the self-assembly prior to polymerisation of the third block. The magnitude of the 
change in DH is proportional to the ratio of monomer to macro-RDRP agent at the start of 
polymerisation and therefore allows tuning of the size of block copolymer nanoparticles.451 
Block copolymer self-assemblies offer a robust nanoparticle platform with the potential to act 
as DNC systems in vivo.452 Regardless of the synthetic approach employed, hydrophobic guest 
molecules can easily be encapsulated within the core of block copolymer nanoparticles. In the 
case of the post-polymerisation formulation of amphiphilic block copolymers, hydrophobic 
guest molecules can be encapsulated simply by including them in the self-assembly process.453 
Hydrophobic guest molecules can also been incorporated into block copolymer nanoparticles 
using in situ nanoparticle forming techniques by addition of guest molecules during the various 
polymerisation processes.454–458 However, the encapsulation of hydrophobic drugs by physical 
entrapment through PISA has typically shown low encapsulation efficiencies and drug 
loadings.459 Alternatively, a number of post-polymerisation processing procedures have been 
developed to load hydrophobic drugs into block copolymer nanoparticles. These approaches 
have shown high levels of success, particularly in cases where favourable interactions exists 
between guest molecules and the hydrophobic cores of block copolymer nanoparticles.460–463  
In other cases drugs have been incorporated into block copolymer nanoparticles using prodrug 
monomers, which contain cleavable covalent linkers, during PISA; this has allowed 






1.4.2 Nanoprecipitation  
Nanoprecipitation is an alternative formulation approach which can be used to generate 
aqueous nanoparticle dispersions of synthetic polymers.465 It is an easy and reproducible 
post-polymerisation formulation technique which has been applied to a wide range of 
polymers and has allowed the encapsulation of numerous hydrophobic guest molecules.466 
Nanoprecipitation has therefore attracted significant interest within nanomedicine research.467 
1.4.2.1 The Nanoprecipitation Process  
Preparation of polymer-based nanoparticle dispersions via nanoprecipitation involves the 
rapid mixing of a hydrophobic polymer, dissolved within a water-miscible organic solvent, 
with a large amount of an anti-solvent, typically water. The rapid diffusion of the bad solvent 
into the organic phase triggers a significant change in the solvent environment in which the 
polymer is dissolved. As a result, the polymer concentration within the nanoprecipitation 
medium usually exceeds the thermodynamic solubility limit, creating what is known as a state 
of supersaturation. The extent of supersaturation can be represented by the supersaturation 
ratio (Sr = C/Ceq) which, in the case of polymer nanoprecipitation, is defined as the ratio 
between the polymer concentration in the nanoprecipitation medium (C) and that at the 
thermodynamic equilibrium solubility limit (Ceq).468 When the supersaturation limit is 
exceeded (Sr > 1) polymer chains collapse, in order to minimise high energy interactions with 
surrounding anti-solvent, causing the spontaneous formation of nuclei.   
The formation of polymer nanoparticles via nanoprecipitation can occur through two different 
growth mechanisms. These mechanisms are known as nucleation and diffusion-limited growth 
and diffusion-limited cluster-cluster aggregation (DLCA).469 Schematic representations of the 
nucleation and growth mechanisms which occur during the nanoprecipitation of polymers are 





Figure 1.13 Schematic representation of the nucleation and growth mechanisms by which 
polymeric nanoparticles are formed during nanoprecipitation. a)  The collapse and subsequent 
nucleation of polymer chains to form nuclei which occurs in a state of supersaturation. b) Formation of 
polymeric nanoparticles via a nucleation and diffusion limited growth mechanism. c) Formation of 
polymeric nanoparticles via a diffusion limited cluster-cluster aggregation mechanism.  
The mechanism taken is highly dependent upon the nuclei concentration and by extent the 
degree of supersaturation.470 Low degrees of supersaturation result in the formation of few 
stable nuclei, in such cases nanoparticle growth typically occurs through fusion of solute 
molecules to the surface of polymer nuclei until the amount of polymer within the 
nanoprecipitation medium has decreased to the thermodynamic equilibrium concentration. 
Under these conditions, nanoparticle growth is therefore limited by both the rate of nucleation 
and the rate at which polymer solutes diffuse to the surface of polymer nuclei through the 
nanoprecipitation medium. In contrast, high levels of supersaturation enhance the rate of 
polymer nucleation. High concentrations of polymer nuclei promote nanoparticle growth 
predominantly through random collisions of existing nuclei in a process known as DLCA. The 
probability of collisions between nuclei increase in proportion to the square of the number of 
nuclei present. The DLCA mechanism is therefore favoured under conditions of homogeneous 
nucleation. Collisions generally result in aggregation of the particles as typically soft 
nanoparticles rearrange to form dense structures which typically possess spherical 
morphologies. The growth mechanism has a profound impact on the dispersity of the 
nanoparticle size distribution and the segregation of nucleation and growth stages is considered 
crucial for the generation of monodisperse nanoparticles.471,472 Regardless of the growth 
mechanisms adopted, nanoparticles continue to grow until colloidal stability is achieved or, 




The stabilisation of growing nuclei is essential to generate nanoparticles possessing 
hydrodynamic diameters in the nanometer size range and to also prevent excessive growth 
which will eventually lead to larger unstable aggregates. Nanoparticle stabilisation can be 
provided by either charge or steric stabilisation. Both mechanisms ensure that the repulsive 
forces acting between nanoparticles exceed the attractive Van der Waals forces which seek to 
fuse nanoparticle clusters together to form larger aggregates. Schematic representations of the 
repulsive forces provided by charge and steric stabilisation are presented in Figure 1.14.  
 
Figure 1.14 Schematic representation of nanoparticle stabilisation mechanisms. a) Charge 
repulsion between two nanoparticles possessing cationic charge. b) Steric repulsion between the 
overlapping hydrated shells of nanoparticles stabilised using amphiphilic polymeric stabilisers.  
Charged nanoparticles typically possess a surrounding electrical double layers. This causes 
nanoparticles to repel each other and thus prevent aggregation in a process known as 
electrostatic repulsion. Electrostatic repulsion becomes significant when the electrical double 
layer of two (or more) individual nanoparticles come into contact as nanoparticles approach 
each other. The balance between the electrostatic repulsion pushing nanoparticles apart and 
the attractive Van der Waals forces is explained by the DLVO theory, established by 
Derjaguin, Landau, Verwey, and Overbeek.474,475 In cases where the level of electrostatic 
repulsion is sufficient to overcome Van der Waals attraction, aggregation is avoided and 
nanoparticle dispersions remain stable. In contrast, weak repulsive forces are unable prevent 
nanoparticle aggregation. 
Alternatively, steric stabilisation is provided when nanoparticles contain a solvated shell of 
adsorbed polymer chains that prevent nanoparticle-nanoparticle aggregation through steric 
repulsive forces. Steric repulsion is driven by osmotic pressure as the concentration of polymer 
chains increases in the overlap zone.476 Steric stabilisation can be achieved by conducting 
nanoprecipitation in the presence of suitable stabilisers such as low molecular weight 
surfactants or amphiphilic copolymers. Alternatively, nanoprecipitation of polymers which 
themselves contain hydrophilic moieties do not require addition of such stabiliser molecules. 
It is possible to combine charge and steric stabilisation via nanoprecipitation of polymers 
which possess both amphiphilic and polyelectrolyte properties.477 Both stabilisation 




Nanoparticle growth ceases once repulsive forces between nanoparticle clusters become 
sufficient to outweigh the attractive forces bringing them together. The stabiliser concentration 
can therefore be used to influence the extent of growth through cluster-cluster aggregation and 
thus provide control over nanoparticle size.478 
Nanoprecipitation has been used to generate aqueous nanoparticle dispersions using a wide 
range of synthetic polymers and recent research has focused on tailoring nanoprecipitation 
conditions in order to achieve optimal nucleation, growth and stabilisation mechanisms which 
promote the formation of monodisperse nanoparticles with control over their hydrodynamic 
diameter. The use of bespoke synthetic polymers has also allowed the construction of 
functional nanoparticles possessing specific chemical and physical properties. Furthermore, 
the addition of hydrophobic small molecules during nanoprecipitation has facilitated the 
encapsulation of such guest molecules within nanoparticle cores.479 Nanoprecipitation 
therefore offers an exciting formulation platform for the generation of novel DNC systems for 
the delivery of chemotherapeutics. 
1.5 Smart Nanomaterials via Macromolecular Design 
The ability to generate bespoke polymers, with high levels of control over their chemical 
functionality and macromolecular architecture, combined with the ability to formulate such 
polymers into well-ordered nanomaterials, has enabled such nanomaterials to be designed at a 
molecular level. In recent years this bottom-up approach has facilitated the preparation of new 
nanoparticles equipped with the ability to perform a range of specific functions. In particular, 
such approaches have been used to control both the internal and surface chemistry of a variety 
of nanoparticle types and has also facilitated the preparation of functional materials.   
1.5.1 Tailoring Nanoparticle Chemistry 
The incorporation of specific chemical functionalities during nanoparticle formation has been 
an effective strategy to control the macroscopic properties of the resulting nanoparticles. 
Nanoparticle mechanical properties are an important factor which must be considered when 
selecting nanoparticles for applications in nanomedicine. Nanoparticle rigidity can influence 
its ability to function a DNC system in biological/ physiological environments. In particular, 
it can influence nanoparticle: removal from systemic circulation via biological filtration 
mechanisms, biodistribution, tumour penetration and interaction with cancer cells.480 
Nanoparticle morphology is also an important factor in controlling the outcome of the 
application of nanoparticles within biological and physiological environments. For example, 
Li et al. reported that the extent and mechanism of mannose surface-functionalised 
nanoparticle macrophage uptake was significantly higher for spherical nanoparticles than that 




Rannard and co-workers have used end-group chemistry to influence the surface and core 
chemistry of branched vinyl copolymer nanoparticles.350,481,482 Known as hyper-branched 
polydendrons, the use of dendritic initiators in the preparation of branched copolymers via 
ATRP of hydrophobic monomers has allowed dendron surface functionalities to be 
incorporated at each α-terminus on the resulting branched copolymers. Subsequent 
nanoprecipitation of these materials has produced nanoparticles possessing such dendritic 
functionalities both within the core and on the surface of the nanoparticles. Furthermore, 
co-initiation of dendritic initiators containing different surface functionalities has allowed 
systematic variation of nanoparticle functionality. Manipulation of nanoparticle functionality 
have resulted in tuneable permeation through model gut epithelium, influence over 
nanoparticle core hydrophobicity and selective binding of Au nanoparticles. Alternatively, 
other researchers have conjugated cell-targeting ligands at the end-groups of polymers used in 
nanoparticle formation to promote enhanced nanoparticle cellular internalisation via receptor-
mediated endocytosis.483 
1.5.2 Responsive Nanocarriers  
In contrast to the modulation of drug release through manipulation of nanoparticle core 
chemistry, the use of stimulus-responsive polymers has enabled the design of nanoparticles 
capable of facilitating triggered burst release following application of an external stimulus. 
DNC systems have been designed to respond to a wide range of external stimuli, including 
pH, temperature, redox potential, enzymes, magnetic fields, light and sonication.484 Burst 
release is typically triggered by rapid disassembly of the DNC system caused by the chemical 
changes induced by an external stimulus; this has allowed specific design of DNC systems to 
capitalise on many physiological opportunities presented in vivo. For example, Xu et al. 
demonstrated the ability to trigger the release of hydrophobic payloads from pH-sensitive core 
cross-linked ABC triblock copolymer micelles using reversible imine chemistry.485 The pH 
sensitive cross-links were readily cleaved following a reduction in pH to below 5.5; this DNC 
system is therefore specifically designed to release its encapsulated payload within early 
endosomes shortly after cellular internalisation.486 Alternatively, similar approaches have been 
employed using redox-sensitive disulphide chemistry within cross-linked block copolymer 
micelles; this has allowed such materials to utilise intracellular levels of glutathione to trigger 
burst release of encapsulated payloads within the cell cytoplasm.487 In another approach, 
stimuli-responsive chemical linkers have enabled the cleavage of drugs from nanoparticles 
comprising polymer prodrugs containing labile conjugation chemistries.488 This has been 
demonstrated, for example, by Jin et al. who generated amphiphilic block copolymers 




Self-assembly of these block copolymer conjugates generated spherical micelles capable of 
facilitating the burst release of 5-FU under UV irradiation (254 nm).  
The simultaneous advances in the fields of polymer chemistry and nanotechnology have 
provided chemists with the ability to construct precise nanomaterials whose properties can be 
predetermined prior to synthesis. Researchers must therefore pay considerable attention to the 
materials they use when designing new nanomaterials platforms for application as prospective 
drug nanocarrier systems. Understanding of the chemical and physical properties of such 
materials will not only help achieve improved research outcomes but will also allow a deeper 
understanding of the applications for which such materials have been constructed.    
1.6 Research Aims 
Ultimately, the aim of this research was to develop a novel polymer-based nanoparticle 
platform which can demonstrate controlled encapsulation and release of the hydrophobic 
chemotherapeutic, docetaxel. An important aspect of this work was to ensure that such a 
nanoparticle platform has the potential to be used as a DNC system in vivo.  
The production of such a DNC system required the development of a novel synthetic approach 
for the generation of branched vinyl copolymer nanoparticles, known as 
co-nanoprecipitation.490 In order to expand the scope of co-nanoprecipitation, the generation 
of a library of hydrophobic polymers containing various (co)polymer architectures was 
required. This research aimed to build on previously established RDRP techniques, namely 
copper-catalysed RDRP (Cu-RDRP) of hydrophobic methacrylates in anhydrous alcohols, to 
generate this polymer library. Whilst this may be considered an unusual solvent choice for the 
preparation of hydrophobic (co)polymers, this synthetic approach was selected in order to 
explore the potential of Cu-RDRP in anhydrous alcohols for the generation of complex 
polymer architectures. In particular, this work targeted the preparation of linear 
homopolymers, amphiphilic AB block copolymers and branched statistical copolymers. We 
also aimed to discover the scope and limitations which were expected to arise in what would 
appear a complex and possibly even incompatible synthetic platform.  
The materials generated were used to prepare branched copolymer nanoparticles via 
co-nanoprecipitation. We aimed to extend the scope of materials used in co-nanoprecipitation 
with the desire to influence, or even control, nanoparticle properties through careful selection 
of the polymers from which they are constructed. The functional handles through which the 
chemical and physical properties of AB block and branched copolymers have been controlled 
in this research are presented in Figure 1.15. Co-nanoprecipitation was therefore attempted 
using combinations of polymers possessing different chemical and physical properties. We 




possible were linked to the macroscopic properties and behaviour of the branched copolymer 
nanoparticles formed. The ability to influence nanoparticle core polarity was considered an 
important factor which could influence drug release rates; we therefore explored the ability to 
influence nanoparticle core polarity through selection of the polymers used in 
co-nanoprecipitation. Furthermore, we aimed to demonstrate the encapsulation of hydrophobic 
guest molecules during co-nanoprecipitation and thus highlight the potential of such materials 
to act as DNC systems.  
Promising candidates were then advanced to drug encapsulation studies in order to evaluate 
their ability to incorporate docetaxel, a hydrophobic chemotherapeutic, during 
co-nanoprecipitation. Docetaxel encapsulation experiments were designed to explore the drug 
loading capabilities of co-nanoprecipitation and understand the role that Docetaxel plays in 
the co-nanoprecipitation process. Comparative drug-release and encapsulation efficiency 
experiments were attempted using radiometric analyses. Such experiments were designed to 
develop an understanding of the relationships between the physical properties of branched 
copolymer nanoparticles and the encapsulation efficiency and release rates of docetaxel.  
Efforts were made to control drug release rates through systematic variation in the physical 
and chemical properties of the polymers from which branched copolymer nanoparticles were 
constructed. This was attempted via the generation of statistical copolymers in order to create 
incremental changes in polymer properties through comonomer composition. 
Co-nanoprecipitations, drug encapsulation and release experiments aimed to evaluate the 
impact of such changes on the macroscopic behaviours of branched copolymer nanoparticles. 
Finally, we also looked to exploit the numerous functional handles available to incorporate 
functionality into AB block and branched statistical copolymers in order to manipulate the 
chemical and physical properties of nanoparticles subsequently formed through their 
co-nanoprecipitation. The impact of the introduction of such chemical functionalities on the 





Figure 1.15 Schematic representation of the aims of this research project showing the various 
functional handles at which the properties of nanoparticles, formed via co-nanoprecipitation of AB 
block and branched copolymers, can be modified.   
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2.1.1 Copper-Catalysed Reversible-Deactivation Radical Polymerisation  
Copper (Cu)-catalysed reversible-deactivation radical polymerisation (Cu-RDRP) evolved 
after the development and successful implementation of transition metal complexes as 
catalysts in the atom transfer radical addition (ATRA) of olefins to alkyl halides.1–3 The 
presence of halogen atoms within ATRA adducts demonstrated the ability to abstract the 
halogen atom from the transition metal complex. This raised the possibility of performing 
repetitive additions to an alkyl halide and formed the basis of the key principles which 
underpin Cu-RDRP. In 1994, Sawamoto and co-workers reported the first transition 
metal-catalysed polymerisation of methyl methacrylate (MMA). This was facilitated by a 
ligated ruthenium (II)-based transition metal complex, in combination with an 
aluminium-based Lewis acid, capable of reversible halogen abstraction.4 Within a year, a 
report from Matyjaszewski and Wang demonstrated the first RDRP process facilitated solely 
by a transition metal complex. This Cu-based system utilised 2-2’ bipyridine (bpy) ligands and 
facilitated the Cu-RDRP of methyl acrylate and styrene; such formulations conferred the 
ability to target molecular weight (Mw) and produce polymers of low dispersity (Đ) compared 
with those typically generated using conventional radical polymerisation.5 
Since the discovery of Cu-RDRP, numerous techniques have emerged, including conventional 
atom transfer radical polymerisation (ATRP),5 reverse ATRP,6 simultaneous reverse and 
normally initiated ATRP,7 activators (re)generated by electron transfer ATRP,8,9 initiators for 
continuous activator regeneration ATRP,10 supplemental activators and reducing agents 
(SARA) ATRP,11 electrochemically-mediated ATRP,12 single electron transfer(degenerative 
transfer)-living radical polymerisation (SET-LRP),13 photoinitiated ATRP14 and photoinitiated 
SET-LRP.15,16 These techniques enable chemists to generate a range of functional polymers 
with precise control over Mw, chain lengths and architectures. The complex nature of each of 
these techniques goes beyond the scope of the work covered in this thesis. Therefore the reader 
is directed to an excellent review article which discusses each of these processes in more 
detail.17 As the work in this Chapter utilises experimental procedures consistent with those 
described for conventional ATRP mediated by a [Cu(bpy)2]Cl catalytic system, this Cu-RDRP 








2.1.2 Conventional Copper-Catalysed Atom Transfer Radical Polymerisation 
Conventional Cu-catalysed ATRP utilises a reversible redox process, between ligated CuI and 
CuII complexes, to suppress the concentration of active radicals during polymerisation. In 
doing so, it is possible to significantly reduce the prevalence of undesirable side reactions, 
such as chain termination or chain transfer, which are commonly associated with conventional 
free radical polymerisation (FRP). Alkyl halides are typically employed as initiators in ATRP. 
In contrast to FRP, where radicals are constantly generated throughout polymerisation via 
thermal decomposition of an initiator, ATRP involves rapid homogeneous initiation. Halogen 
abstraction by the [Cu(bpy)2]Cl activator initially leads to a high radical concentration. The 
majority of radicals generated undergo rapid deactivation, facilitated by the newly-formed 
[Cu(bpy)2Br]Cl deactivating species, to regenerate the alkyl-halide. However, a small fraction 
of radical species are terminated via radical-radical combination. This leaves a residual amount 
of the deactivating species and allows the ATRP equilibrium to be established.  
The conventional ATRP process facilitated by [Cu(bpy)2]Cl/ [Cu(bpy)2Br]Cl catalytic system 
is represented in Scheme 2.1. Activation of a dormant polymer chain (Pn-Br) occurs following 
halogen abstraction by [Cu(bpy)2]Cl. This activation proceeds with a rate constant kact, 
resulting in the generation of an active polymer species (Pn•) and the subsequent oxidised 
halogenated [Cu(bpy)2Br]Cl complex. The most likely fate of the active polymer radical is to 
undergo deactivation (rate kdeact) by re-abstraction of the halogen atom from the 
[Cu(bpy)2Br]Cl complex, which itself undergoes a one-electron reduction, to regenerate a 
dormant polymer chain and the [Cu(bpy)2]Cl complex respectively. However, the polymer 
radicals can undergo chain growth via propagation with free monomer (M, rate constant kp). 
Alternatively, a polymer radical could also undergo termination with another polymer radical 
(Pm•); this can occur either by combination with another radical species (rate constant ktc) or 
through termination by disproportionation (rate constant ktd).  
 
 
Scheme 2.1 Mechanism of conventional Cu-catalysed ATRP facilitated by CuCl/bpy as described 




The dynamic ATRP equilibrium ensures that the concentration of active radical species 
remains both low and constant throughout polymerisation; this effectively prevents 
undesirable side reactions legitimising the assumption that the contribution of termination is 
negligible during ATRP. A fast equilibrium approximation, which is essential for the 
production of polymers of low Đ, can therefore be used to derive the apparent rate law for 
Cu-catalysed ATRP (Equation 2.1).  







 )            Equation 2.1 
The derived raw law for Cu-catalysed ATRP as reported by Matyjaszewski and co-workers.18 
Rp = observed propagation rate, kp = propagation rate constant, [M] = monomer concentration, 
[P*] = radical concentration, Keq = ATRP equilibrium constant = kact/kdeact (see Scheme 2.1), 
[I]0 = initiator concentration at t0, [CuI] = activator concentration and [X-CuII] = deactivator 
concentration where X = halogen atom.  Kinetic studies of the ATRP of styrenes,19 acrylates,20 
and methacrylates21,22 have shown that the Rp is first order with respect to the concentration of 
monomer, initiator and the Cu-complex. These observations are consistent with the derived 
rate law and are typically demonstrated by a linear evolution in monomer conversion with time 
when plotted using semi logarithmic co-ordinates (Figure 2.1a, red solid line). This also 
demonstrates the efficacy of the ATRP process in maintaining a constant [P·] throughout 
polymerisation. Deviations from this behaviour can occur in cases where termination or 
self-initiation are prevalent during ATRP. 
 
During ATRP, the evolution of Mn with monomer conversion is similar to those described for 
“living” polymerisation processes. The rapid, homogeneous initiation process ensures that all 
initiating moieties grow at the same time; this typically causes a linear increase in Mn with 
monomer conversion (Figure 2.1b, purple solid line). Increases in Mn are typically 
accompanied by a reduction in Đ as the ATRP proceeds (Figure 2.1b, green dashed line). In 
the early stages of polymerisation, the mass acquired following monomer addition, during 
activation/deactivation cycles, makes up a large proportion of the polymer Mn. As a result, 
relatively large discrepancies arise between the Mn of growing polymer chains and thus larger 
Đ values are obtained at low monomer conversion. As the reaction progresses, polymer chains 
become more uniform and propagation has a smaller impact on the Mn of larger polymer 
chains. This is particularly relevant in the ATRP of acrylic monomers which possess large kp 
values. The relatively uniform chain growth process provides the ability to target Mn simply 
by manipulation of the molar ratio of monomer to initiator at the start of polymerisation, 
similar to the case and benefits of traditional ionic “living” polymerisation; this has allowed 
chemists to controllably produce linear homopolymers, copolymers and polymers of various 





Figure 2.1 Graphical representations of the rate of monomer consumption and the evolution of 
the Mn distribution during Cu-RDRP. (a) Typical plots obtained for monomer conversion (dashed blue 
line) and ln([M]0/[M]) (solid red line) vs. time. (b) The typical evolutions observed in the number 
average Mn (Mn, solid purple line) and polymer dispersity (Đ, dashed green line) with monomer 
conversion.  
2.1.3 Varying Polymer Architecture Using Cu-RDRP  
The degree of control exhibited over the polymerisation has allowed a wide range of polymer 
and copolymer architectures to be generated using Cu-RDRP. This has facilitated the 
generation of functional nanomaterials containing precise chemical structures with unique 
macroscopic behaviour; which has often made Cu-RDRP the synthetic tool of choice for the 
creation of bespoke (co)polymers for applications within fields such as bioengineering, 
medicine and nanotechnology.24–29 Whilst any of the extensive list of (co)polymer 
architectures outlined in Chapter 1, Section 1.3.1.1, can be achieved using a well-controlled 
Cu-RDRP processes, the work in this thesis focuses on the generation of AB block copolymers 
and branched statistical copolymers. As a result, these copolymer architectures shall be 
discussed in more detail below. Should the reader be interested in the generation of alternative 
polymer architectures using Cu-RDRP, they are directed to an excellent review article which 
discusses this topic in detail.29 
2.1.3.1 Block Copolymers 
As discussed in Chapter 1, Section 1.3.1.1, the term ‘block copolymer’ refers to a copolymer 
in which comonomers are compartmentalised into discrete regions within a copolymer chain. 
The pseudo-living nature of Cu-RDRP along with its high end-group fidelity has made it a 
popular synthetic tool for the generation of block copolymers. As well as the ability to 
polymerise a broader range of monomer functionalities, Cu-RDRP offers a significant 
advantage over traditional “living” polymerisation techniques in that reactive end-group 
functionalities can be isolated and reinitiated with relative ease. There are two predominant 
synthetic routes used to generate block copolymers via Cu-RDRP. Both approaches involve 
growth from a polymeric species, often termed a macro-initiator. The key difference between 





Figure 2.2 The predominant synthetic strategies used to generate block copolymers using 
Cu-RDRP. (a) Preparation of a macro-initiator via polymer end-group modification and subsequent 
growth of a secondary block using Cu-RDRP. (b) Utilising high end-group fidelity to generate a block 
copolymer via chain extension of a polymer, with a second monomer, using Cu-RDRP. 
One approach involves the preparation of a macro-initiator via end-group modification of a 
polymer chain, usually generated in a separate polymerisation process, in order to equip it with 
a functional group capable of initiating Cu-RDRP. This enables such polymers to facilitate the 
growth of a second polymer block via Cu-RDRP (Figure 2.2a). One advantage of this approach 
is that it allows the combination of Cu-RDRP with polymer segments prepared using 
alternative polymerisation techniques. For example, this has allowed the preparation of 
macro-initiators from polymers prepared using step-growth, co-ordination, anionic and 
cationic vinyl polymerisation, ring-opening polymerisation, FRP and alternative RDRP 
techniques.30–37 This approach has also been used to generate biopolymer conjugates via 
polymerisation from macro-initiators containing naturally-occurring polymers including 
polysaccharides, peptides, proteins and nucleic acids, using Cu-RDRP.38 Furthermore, it can 
be adapted to generate ABA triblock copolymers using α,ω – homo bifunctional 
macro-initiators which facilitate chain growth in two directions.39–42 The success of this 
approach relies heavily on the efficiency of the end-group modification. A low-efficiency 
end-group modification, which fails to equip all polymer chains with an initiating group, 
renders such chains incapable of facilitating Cu-RDRP. The presence of such “dead chains” 
can have drastic implications on the Mn targeting capabilities of subsequent polymerisations 
and can also require additional purification steps, such as dialysis, to remove unreacted 
polymer chains. End-group modification is therefore limited to either a small number of highly 





Alternatively, polymers generated using Cu-RDRP that have retained their end-group 
functionality can also act as macro-initiators. Such macro-initiators can be used in a 
subsequent polymerisation of a second monomer, typically referred to as a chain extension, to 
generate block copolymers using Cu-RDRP (Figure 2.2b). Two crucial requirements for the 
synthesis of well-defined block copolymers are preservation of end-group functionality and 
an efficient (re)initiation/ cross-propagation process. Significant reductions in end-group 
fidelity have often been reported during ATRP at ≥ 60 % monomer conversion.43,44 This has 
been attributed to the prevalence of undesirable side reactions including transfer to ligand and 
bimolecular termination reactions.43 For example, analysis of the end-group fidelity during the 
ATRP of styrene at 90 °C showed that only 48 % of growing chains remained active at 92 % 
monomer conversion.44 This significantly restricts the possibility of producing block 
copolymers using conventional ATRP and often requires polymerisations to be stopped at low 
monomer conversion in order to retain the active end-group responsible for facilitating the 
Cu-RDRP process. The development of alternative Cu-RDRP techniques include SET-LRP 
and SARA ATRP, which employ significantly lower amounts of the activating species in order 
to suppress the concentration of active radicals, have enabled the production of macro-
initiators which retain quantitative end-group fidelity, even at high monomer conversions.45,46 
This  has permitted the production of block and multi-block copolymers with precise control 
over the order, number, length and functionality of the component blocks.45,47 
In general, when producing block copolymers using any RDRP technique, efficient 
re-initiation is essential to ensure that all macro-initiators undergo chain extension. The re-
initiation efficiency is highly dependent on the monomer class of both the macro-initiator and 
the monomer selected for chain extension. It is therefore essential to follow a block order based 
on the reactivity of active chain-ends derived from each monomer. In Cu-RDRP, values of Keq 
can be used to gauge macro-initiator end-group activity; this is typically dictated by a 
combination of electronic and steric effects and follows the order acrylonitrile > methacrylates 
> styrene ~ acrylates > acrylamides.48 This typically hinders the chain extension of a 
macro-initiator with a monomer possessing higher activity. However, Cu-RDRP provides the 
unique ability to modify terminal alkylhalide end-group functionality via a halogen exchange 
reaction; this has allowed the efficient chain extension of relatively low activity acrylate-based 
macro-initiators with more active methacrylate monomers.49,50 This unique ability to overcome 







2.1.3.2 Branched Statistical Copolymers 
The formation of branched copolymers via statistical Cu-catalysed reversible-deactivation 
radical copolymerisation (Cu-RDRcP) of monofunctional and bifunctional monomers 
(BFM) evolved logically from the ‘Strathclyde Approach’51–53 following its discovery shortly 
after the first reports of reversible deactivation radical copolymerisation (RDRcP) techniques 
emerged; as a result this techniques has often been coined ‘A modified Strathclyde Approach’. 
The first synthesis of a branched polymer via copolymerisation of monofunctional and BFMs 
using RDRcP occurred in 2004 when Sherrington and co-workers reported the 
copolymerisation of MMA and ethylene glycol dimethacrylate (EGDMA) using both ATRP 
and group transfer polymerisation.54 Since then, numerous branched copolymers have been 
reported using a variety of RDRP techniques, including ATRP,55 RAFT,56 nitroxide-mediated 
radical polymerisation57 and reversible complexation mediated copolymerisation58 as well as 
other polymerisation techniques such as ring-opening metathesis polymerisation (ROMP)59 
and the palladium-catalysed polymerisation of alkynes.60 
The control afforded by RDRP techniques allows key features of the branched polymer 
architecture to be pre-determined prior to synthesis. RDRP techniques provide control over 
the number of repeat units per primary chain simply by increasing the concentration of 
monomer to initiator at the start of polymerisation ([M]0/[I]0). This has allowed the production 
of branched polymers containing from 10 to > 100 repeat units per primary chain. The 
combination of multiple primary chains result in the formation of high molecular weight 
branched polymers, with Mw > 100 kg mol-1 often reported;61,62 these are significantly higher 
than those obtained for branched polymers produced via the “Strathclyde Approach”. The 
extent of branching is dictated by the average number of BFMs incorporated per primary chain 
during copolymerisation and is dependent upon the relative concentrations of BFM and 
initiator at the start of polymerisation ([B]0/[I]0). Li and Armes studied the influence of [B]0/[I]0 
on the molecular weight distributions of branched polymers isolated from the 
copolymerisation of 2-hydroxypropyl methacrylate (HPMA) and a disulphide-based 
dimethacrylate (DSDMA) using ATRP.55 Increased Mw were observed as [B]0/[I]0 was 
increased from 0.00 – 0.95, due to a greater fraction of polymer chains which partake in 
branching reactions. Formation of an insoluble gel network occurred during copolymerisation 
where [B]0/[I]0 exceeded 1.00; this supported conclusions made by Wang and Zhu who 
conducted a similar ATRP study on the statistical copolymerisation of MMA and EGDMA.63 
Numerous groups have studied the critical [B]0/[I]0 ratio at which insoluble gel networks 
become unavoidable, commonly known as the theoretical gel point. This has been assessed 
both theoretically and experimentally and indicate that, as in the Strathclyde route, gelation 




Significant research effort has focused on developing understanding of the branching process 
which occurs during statistical copolymerisation of monofunctional and BFMs. Bannister et 
al. studied the copolymerisation of HPMA and EGDMA using ATRP and identified that the 
copolymerisation proceeded in three stages (Figure 2.3).  
 
Figure 2.3 The evolution of branching during statistical RDRcP of monofunctional and 
bifunctional monomers. a) The stages of copolymerisation identified by Bannister et al. during the 
copolymerisation of HPMA and EGDMA by ATRP. b) Comparative illustrations of the evolution of 
Mw during linear homopolymerisation of monofunctional monomers (dashed red lines) and statistical 
copolymerisations of monofunctional and bifunctional monomers (dashed blue lines).  
The initial stages of the copolymerisation of HPMA and EGDMA mimicked that of an ATRP 
conducted in the absence of EGDMA. Stage one involved activation and subsequent 
propagation of initiating moieties to form oligomers. During stage two, monofunctional and 
BFMs were statistically incorporated into propagating polymer chains, to produce low 
dispersity primary chains containing a pendant methacrylate group. The consumption of the 
pendant group was suppressed at low monomer conversion due to its low concentration 
relative to unreacted monomer. Consequently, during the early stages of polymerisation, the 
evolution of Mn with monomer conversion was in good agreement with that observed for a 
polymerisation conducted in the absence of a BFM. The polymerisation entered stage three as 




obtained from linear polymerisations at similar monomer conversions. This occurred due to 
the presence of higher Mw species formed through coupling of primary chains via 
intermolecular branching reactions. Branching reactions became dominant at high monomer 
conversion (> 95 %) due to an increased relative concentration of the pendant vinyl group. As 
monomer conversion exceeded 95 % the polymerisation changed from a chain-growth to a 
pseudo-step-growth mechanism. This was evident from the exponential increase observed in 
both Mw and dispersity with monomer conversion which occurred due to statistical coupling 
of high Mw materials (Figure 2.3b).  
The conclusions drawn by Bannister et al. were reinforced by a number of publications which 
reported the copolymerisation of a range of monofunctional and BFMs including 
methacrylates, acrylates, acrylamides and vinyl ethers using a range of RDRP techniques. 
Rosselgong and Armes later studied the copolymerisation of MMA and DSDMA using both 
ATRP and RAFT.66 In this report it was demonstrated that the evolution of branching remained 
independent of the RDRP technique employed and provided further support of the statistical 
branching mechanism proposed previously. The use of DSDMA facilitated the reductive 
cleavage of all branch points by treatment of such branched copolymers with tributyl 
phosphine. Size exclusion chromatography (SEC) analysis before and after branch point 
cleavage revealed that branched polymers consisted of low dispersity primary chains, which 
resembled those produced from the polymerisation of MMA in the absence of DSDMA. This 
also demonstrated that the branching process has no detrimental effect on the control afforded 
by RDRP techniques. 
Another crucial factor which influences the extent of branching during copolymerisation of 
monofunctional and BFMs is the concentration at which polymerisations are conducted. 
Armes and co-workers noted that soluble branched polymers could be obtained above the 
theoretical gel point ([B]0/[I]0 > 1.00) when polymerisations were conducted at low 
concentrations, even at exceptionally high monomer conversions (> 99 %).56 The absence of 
gelation was attributed to a change in pendent methacrylate group consumption during 
polymerisation. Pendant methacrylate groups can be consumed either via intermolecular 





Figure 2.4 Impact of concentration on the nature of pendent methacrylate group consumption 
during copolymerisation. Illustration of the highly branched and lowly branched/ cyclised copolymer 
architectures generated during copolymerisations conducted at high (left) and low concentrations (right) 
respectively.  
Intermolecular branching occurs when a propagating radical reacts with a pendent 
methacrylate group of another polymer chain, generating a branch point between the two 
primary chains. Intramolecular cyclisation occurs when both the reacting propagating radical 
and pendent methacrylate group belong to the same primary polymer chain, subsequently 
forming a cyclic structure within the polymer backbone. The ratio between intermolecular 
branching and intramolecular cyclisation has been studied theoretically and using both 1H and 
13C nuclear magnetic resonance (NMR) spectroscopy.67–69  
Rosselgong and Armes studied the statistical copolymerisation of MMA and DSDMA at 
various monomer concentrations using both ATRP and RAFT.66 This work demonstrated that 
the extent of intramolecular cyclisation was highly dependent on the monomer concentration 
at which polymerisations were conducted. Intermolecular branching was favoured at high 
concentration due to increased proximity of polymer chains with their neighbours in solution. 
Consequently, intramolecular cyclisation was suppressed and intermolecular branching 
dominated consumption of pendant methacrylate groups. As a result, high Mw polymers with 
broad molecular weight distributions were obtained. In contrast, for polymerisations 
conducted at low monomer concentrations, consumption of pendent vinyl groups occurred 
predominantly by intramolecular cyclisation, resulting in low Mw, lightly branched and cyclic 
copolymer architectures. Consumption of pendent vinyl groups via intramolecular cyclisation 
increases the number of BFMs that can be tolerated within primary chains without any 
gelation. Soluble branched polymers containing an average of 5.00 DSDMA groups per 
primary chain were obtained from the RAFT copolymerisation of MMA and DSDMA 
conducted at 10 weight percent (wt %) solids content. Macroscopic gelation, however, was 
observed when polymerisations were attempted using as low as 1.60 and 0.95 equivalents of 
DSDMA per primary chain at 30 and 50 wt % solid contents respectively. These findings were 
supported in a publication by Zhu and co-workers.70 In another publication, Rosselgong et al. 




polymerisations at high monomer concentrations, which resulted in “near-ideal” branching 
behaviour.71 Matyjaszewski and co-workers conducted a similar study which showed that 
intermolecular branching reactions can be completely suppressed when Cu-RDRcP is 
conducted under extreme dilution.72 
2.1.4 RDRP of Hydrophobic Monomers in Polar Solvents 
In recent years, there has been increasing interest in the RDRP of monomers within reaction 
media typically considered to be a poor solvent for the resulting polymer; many strategies have 
been developed to overcome polymer-solvent incompatibility. Percec and co-workers have 
demonstrated the ability to conduct SET-LRP of hydrophobic monomers in biphasic reaction 
mixtures to generate linear homopolymers of low dispersity with considerable control over 
Mn.73–78 The biphasic nature of the solvent systems employed provided control over the levels 
of Cu(I) disproportionation, using a polar solvent phase, whilst maintaining polymer solubility 
within a water-immiscible  non-polar phase. Additionally, polymerisation-induced 
self-assembly (PISA) has become established over recent years, facilitating the formation of 
amphiphilic block copolymers in solvents which are incompatible with one copolymer block 
segment;79  growth of a solvent-incompatible second block drives the self-assembly of 
propagating polymer chains to form well-defined, sterically-stabilised block copolymer 
nanoparticles of varying size and morphology.80–84 Whilst the majority of publications in this 
area rely on RAFT to facilitate RDRP, a wide range of research has been reported using PISA 
facilitated by Cu-RDRP processes. Alternatively, Gao and co-workers have used emulsion 
polymerisation to generate high Mw hyperbranched polymers via self-condensing vinyl 
polymerisation of water-immiscible acrylic and methacrylic inimers in aqueous emulsion.85,86 
Compartmentalisation of inimers within emulsion droplets has proved an effective technique 
to promote the formation of materials with higher Mw and greater degrees of branching than 
were produced in solution.87 
Rannard and co-workers have previously reported the highly controlled nature of the 
Cu-RDRP of n-butyl methacrylate (nBMA) at elevated temperature in anhydrous methanol 
(MeOH; generally considered a poor solvent for the resulting polymer), to give p(nBMA) of 
controlled Mn and low dispersities (Đ = 1.03 - 1.10).88 These enhanced levels of control were 
attributed to two factors: a previously unreported upper critical solution temperature (UCST) 
and the impact of unreacted monomer on the solvent environment. Combined, these factors 
promoted p(nBMA) solubility in anhydrous MeOH at elevated temperatures and allowed 
polymerisations to remain as homogeneous mixtures throughout polymerisation. This 
technique has been used to generate a range of p(nBMA) architectures, including linear 
homopolymers, AB block copolymers, ABA triblock copolymers, branched statistical 




2.1.5 Chapter Aims   
The synthesis of amphiphilic block copolymers was explored to develop a library of polymers 
which to study the generation of branched vinyl polymer nanoparticles via a 
co-nanoprecipitation strategy. This requires a robust RDRP process to be established which 
can facilitate the generation of well-defined linear homopolymers, amphiphilic block 
copolymers and branched statistical copolymers (Figure 2.5). Given its previous success, 
Cu-RDRP in anhydrous alcohols was selected. Specifically, this chapter aims to broaden the 
scope of hydrophobic monomers undergoing successful polymerisation via Cu-RDRP in 
anhydrous alcohol solvents to create a platform for later nanoparticle studies. In addition to 
those previously reported, methyl methacrylate (MMA), ethyl methacrylate (EMA), tert-butyl 
methacrylate (tBMA), n-hexyl methacrylate (nHMA), cyclohexyl methacrylate (CHMA), 
benzyl methacrylate (BzMA), 2-ethylhexyl methacrylate (EHMA), lauryl methacrylate 
(LMA) and stearyl methacrylate (SMA) were selected for polymerisation. Given the proposed 
role of unreacted monomer in the solvation of polymer chains, detailed studies were conducted 
in order to understand the impact of monomer on the solution properties of various 
polymerisation mixtures. Pyrene fluorescence emission spectroscopy was utilised to assess the 
relative polarity of homogeneous alcohol polymerisation mixtures across a range of 
methacrylate monomers and relate this to the controlled nature of Cu-RDRP in anhydrous 
MeOH or isopropyl alcohol (IPA) during linear polymerisations. 
 
Figure 2.5 (a) Structural representation of hydrophobic methacrylate monomers chosen 
for Cu-RDRP in alcoholic media. (b) Schematic representation of polymer architectures targeted 
including: (i) linear homopolymers, (ii) amphiphilic block copolymers and (iii) branched 
statistical copolymers.  
The generation of amphiphilic block copolymers was attempted via polymerisation from a 
macro-initiator with a range of hydrophobic monomers using Cu-RDRP. The statistical 




selected to generate high Mw branched copolymers via Cu-RDRcP. This work aims to explore 
the possibility of creating branched statistical copolymers of hydrophobic monomers in 
anhydrous alcohols typically considered to be poor solvents for their resulting homopolymers. 
Triple-detection SEC analyses were utilised to evaluate the levels of branching which take 
place during copolymerisation. A number of reaction parameters were also studied to 
determine the key factors which govern the extent of branching occurring during Cu-RDRcP 
of hydrophobic methacrylates with a BFM in anhydrous alcohols. 
2.2  Expanding the Scope of Cu-RDRP in Alcoholic Media 
The success of the Cu-RDRP of nBMA in anhydrous MeOH has largely been attributed to the 
co-solvation of growing p(nBMA) chains by unreacted monomer. Whilst the control offered 
by this polymerisation technique combined with its facile synthetic and purification 
procedures has facilitated a substantial amount of research, little is yet known about the extent 
to which nBMA modifies reaction mixtures during polymerisation. With this in mind, along 
with the desire to expand the scope of this polymerisation process, a number of scoping studies 
were conducted to assess the impact of methacrylate monomers on the solution properties of 
polymerisation reaction mixtures.  
2.2.1 Feasibility Studies  
In order to increase the scope of hydrophobic methacrylate monomers which have been 
reported as polymerising in anhydrous MeOH, miscibility experiments were conducted; 
monomer concentrations similar to those used during Cu-RDRP were used. It was observed 
that MMA, HPMA, EMA, nBMA, tBMA, nHMA, CHMA, BzMA, EHMA and LMA all 
formed homogeneous methanolic solutions at a concentration of 50 wt % w.r.t. monomer, at 
both ambient and elevated temperatures (60 ℃). When added to anhydrous MeOH, SMA 
remained an insoluble white powder at temperatures below its melting point (Tm = 18 – 20 ℃) 
and formed a clear biphasic mixture when heated to 60 ℃ (Appendix, Figure A2.1). To 
facilitate the homogeneous polymerisation of SMA an alternative solvent, IPA, was selected 
due to its lower polarity index of 3.9 compared with 5.1 for MeOH.91 On addition of SMA to 
anhydrous IPA at ambient temperature, rapid dissolution was observed and the mixture 
remained homogenous upon heating to 60 ℃. Subsequent studies showed that IPA was a good 
solvent for all methacrylate monomers selected at a solvent concentration of 50 wt %.  
The monomer co-solvency effect relies on the low polarity of methacrylate monomers to 
decrease the overall polarity of polymerisation mixtures, allowing retention of solubility of 
growing chains during polymerisation. Given the varied hydrophobicity of the monomers 
chosen for this study, it was expected that the extent of monomer co-solvency would vary 




monomers in alcoholic media. To evaluate the extent of monomer co-solvency in different 
monomer - alcohol mixtures, monomer polarities were quantified using fluorescence emission 
spectroscopy (Appendix Table A2.1). This was achieved by analysing the fluorescence 
emission of pyrene, in particular the relative intensities of the first (373 nm, I1) and third 
(385 nm, I3) vibrational bands, whilst dissolved in hydrophobic methacrylate monomers as 
well as for all miscible monomer – alcohol mixtures. This method is commonly used for the 
quantification of the polarity of organic solvents, with experimental I1/I3 ratios typically 
varying from 1.87 in protic solvents such as water to 0.58 in non-polar organic solvents such 
as hexane.92 Experimental I1/I3 ratios obtained for pyrene (10 nM) dissolved in neat monomer 
showed that monomer polarity decreased in the order of HPMA (1.48), MMA (1.44), EMA 
(1.39), BzMA (1.39), nBMA (1.30), CHMA (1.27), tBMA (1.27), nHMA (1.23), EHMA 
(1.17), LMA (1.17), SMA (0.95) (Figure 2.6a (green bars) and bi). A general decrease in 
experimental I1/I3 ratios was observed from MMA to SMA, as the mass fraction of the 
lipophilic monomer side chain increased. Polar groups also had a significant impact on 
monomer polarity. The presence of the hydroxyl group in HPMA resulted in an I1/I3 higher 
than those obtained for MMA and EMA, which contain smaller lipophilic side chain weight 
fractions.  
Experiments were conducted to understand the extent of monomer co-solvency upon the 
polarity of monomer – MeOH mixtures. An I1/I3 ratio of 1.53 was obtained for pyrene 
dissolved in anhydrous MeOH. A series of solutions were prepared containing pyrene 
dissolved in monomer – MeOH mixtures (50 wt %). Analysis of solution polarities gave I1/I3 
ratios of 1.49, 1.49, 1.48, 1.46, 1.42, 1.41, 1.39, 1.37, 1.33 and 1.24 for methanolic solutions 
containing HPMA, MMA, EMA, BzMA, nBMA, tBMA, CHMA, nHMA, EHMA and LMA 
respectively (Figure 2.6a). Analyses were conducted using a range of common organic 
solvents. This showed that in cases where little difference was observed between monomer 
polarity and that of pure MeOH, the co-solvency effect had little impact on the polarity of 
polymerisation mixtures. This was particularly relevant for HPMA, MMA and EMA where 
monomer – MeOH mixtures showed comparable I1/I3 ratios to those obtained for pure MeOH. 
In contrast, monomer – MeOH mixtures containing less polar monomers saw a significant 
decrease in solution polarity, with the biggest impacts observed for LMA, EHMA and nHMA. 
It was not possible to measure the polarity of a SMA-MeOH mixture due to the bi-phasic 






Figure 2.6.  Evaluation of monomer polarity by fluorescence emission spectroscopy of pyrene in 
various monomer/ monomer-solvent environments. (a) Obtained I1/I3 ratios of pyrene dissolved in: 
MeOH (red dotted line), THF (grey dotted lines), ethanol (cyan dotted line), IPA (blue dotted line), 
toluene (orange dotted line), diethyl ether (purple dotted line), methacrylic monomers (green bars), 
methacrylic monomer-IPA mixtures (blue bars) and methacrylic monomer-MeOH mixtures (red bars). 
(b) Overlaid fluorescence emission spectra, normalised with respect to the emission at 373 nm (I1), 
obtained for pyrene dissolved in: (i) methacrylic monomers (ii) methacrylic monomer-MeOH mixtures 




To understand how the monomer co-solvency effect varies between different 
monomer-alcohol systems, a series of monomer – IPA solutions were also prepared containing 
pyrene (10 nM). The polarities of monomer – IPA solutions were also quantified by analysing 
the I1/I3 ratio of pyrene using fluorescence emission spectroscopy, and revealed values of 1.38, 
1.37, 1.37, 1.35, 1.32, 1.29, 1.29, 1.27, 1.22, 1.15 and 1.06, for monomer – IPA solutions 
containing: MMA, EMA, HPMA, BzMA, nBMA, tBMA, CHMA, nHMA, EHMA, LMA and 
SMA respectively. In this study, the I1/I3 ratio for pyrene (10 nM) in pure IPA was recorded 
as 1.21. In contrast to the monomer – MeOH systems, solutions containing more polar 
monomers had lower I1/I3 ratios relative to that of the pure monomer as a result of the presence 
of IPA; whereas less polar monomers saw an increase in solution polarity on mixing with IPA. 
In all cases, I1/I3 ratios obtained for monomer – IPA solutions were 0.09 – 0.12 lower than 
those obtained for the same monomer – MeOH solutions. This consistent decrease confirmed 
that solution polarity could also be manipulated by exchanging MeOH for a less polar alcohol.  
These results identified a variety of monomer – alcohol mixtures which form homogeneous 
solutions under typical Cu-RDRP conditions. Fluorescence emission spectroscopy proved a 
useful tool for quantification of both monomer and solution polarities and demonstrated that 
solution polarity is dependent on the nature of the methacrylate monomer chosen and thus 
highlighted the feasibility of extending the monomer co-solvency effect to a wider range of 
hydrophobic methacrylate monomers. 
2.2.2 Linear Polymerisation of Hydrophobic Methacrylates in Anhydrous Alcohols 
Linear polymerisations of hydrophobic methacrylates were conducted using Cu-RDRP in 
anhydrous MeOH and anhydrous IPA.  Polymerisations were attempted using all of the 
hydrophobic monomers used in the monomer-alcohol miscibility and polarity studies 
discussed above. Firstly, this required the synthesis of a hydrophobic Cu-RDRP initiator which 
was soluble in both MeOH and IPA.  
2.2.2.1 Synthesis of an Initiator for Cu-RDRP, Benzyl 2-Bromoisobutyrate  
Benzyl 2-bromoisobutyrate (BzBiB) was selected as the initiator for Cu-RDRP polymerisation 
of hydrophobic methacrylates in anhydrous alcohols as it allowed quantification of the 
composition of polymerisation mixtures and the number average degree of polymerisation 
(DPn) of the polymers subsequently formed. BzBiB was synthesised by esterification of benzyl 
alcohol with α-bromo isobutyrylbromide under an inert dry nitrogen atmosphere in the 
presence of triethyl amine (TEA) and 4-(dimethylamino)pyridine (DMAP), in anhydrous 





Scheme 2.2 Synthesis of benzyl 2-bromoisobutyrate (BzBiB). 
The reaction was initiated by dropwise addition of a concentrated α-bromo isobutyrylbromide/ 
THF solution to a cooled solution of benzyl alcohol, DMAP and TEA in THF. The addition 
was completed using an ice bath in order to remove heat generated by the exothermic reaction. 
Once the addition was complete, the reaction was allowed to proceed at ambient temperature. 
After a total of 24 hours the reaction was quenched by addition of deionised H2O, dried in 
vacuo and the product isolated in 81 % yield using silica gel column chromatography. The 
product was characterised using 1H and 13C NMR spectroscopy (Figures 2.7 and 2.8). The 
formation of the ester linkage was indicated by the chemical shift at ~170 ppm, characteristic 
of a carbonyl environment, in the 13C NMR spectrum; this was supported by a absorption band 
at ~1750 cm-1 in the Fourier transform infrared (FTIR) spectrum.  
 
  








Figure 2.8 13C NMR spectrum (100 MHz, CDCl3) of benzyl 2-bromoisobutyrate (BzBiB). 
2.2.2.2  Cu-RDRP of Hydrophobic Methacrylates in Anhydrous Methanol 
Homopolymerisations of hydrophobic methacrylate monomers were conducted using 
Cu-RDRP at 60 ℃ in anhydrous MeOH employing a Cu(I)Cl/ 2,2 – bipyridine (bpy) catalytic 
system (Scheme 2.3). Polymerisations targeted a DPn of 60 monomer units, using an initial 
molar ratio of monomer: initiator: CuCl: bpy ([M]0: [I]0: [Cu]0: [bpy]0) of 60:1:1:2, at a MeOH 
concentration of 50 wt %. Polymerisations were allowed to proceed for 18 hours. Methanolic 
polymerisations were conducted using: MMA, EMA, nBMA, nHMA, CHMA, BzMA, EHMA 
and LMA. The polymerisations of SMA and tBMA were not attempted due to 
monomer-solvent immiscibility and previously reported unsuccessful polymerisations 
respectively.90 
 
Scheme 2.3 Cu-RDRP of hydrophobic methacrylate monomers in anhydrous MeOH. 
During initial stages of polymerisation all reactions appeared to proceed under controlled 
conditions, showing characteristic dark brown opaque homogeneous solutions commonly 
associated with Cu-RDRP. The polymerisations of MMA, EMA and nBMA remained as 
homogeneous solutions throughout the 18 hour polymerisation period until precipitation was 
observed upon cooling below 60 °C. The polymerisation of nHMA showed phase separation 




brown viscous polymer phase beneath a non-viscous, opaque dark brown liquid. Similar 
observations were made during the polymerisation of CHMA where the polymer phase formed 
an opaque brown solid, likely due to the glass transition temperature (Tg) of p(CHMA) 
exceeding the temperature of the reaction mixture. Conversely, BzMA, EHMA and LMA 
formed biphasic reaction mixtures within 3 hours of initiation. The contrasting homogeneities 
observed during polymerisation likely occurred due to combinations of monomer co-solvency 
and previously reported upper critical solution temperature (UCST) behaviour in MeOH.93–95 
In cases where polymers display UCST behaviour in MeOH, polymers remained solvated at 
elevated temperature despite the minimal monomer co-solvency effect at high conversion 
(Figure 2.9 bi). In contrast, whilst polymers which do not possess UCST behaviour in MeOH 
remain solvated during the early stages of polymerisation, depletion of the monomer 
concentration during polymerisation resulted in the onset of phase separation, as a diminished 
monomer co-solvency effect was no longer able to solvate growing polymer chains (Figure 
2.9 bii).  
 
Figure 2.9 Comparison of polymerisation mixture homogeneity during Cu-RDRP of 
hydrophobic methacrylates in MeOH. (a) Photographs of exemplary (i) homogeneous (p(nBMA)) and 
(ii) biphasic (p(EHMA)) reaction mixtures after 18 hours. (b) Schematic representation of proposed 
co-solvency effects in (i) homogeneous and (ii) biphasic reaction mixtures. 
After 18 hours polymerisations were terminated by exposure to air. This caused rapid 
poisoning of the [Cu(I)(bpy)2]Cl catalytic system, which was evident from a change in the 
colour of the polymerisation from an opaque dark brown to a transparent green solution due 
to the change in oxidation state of the Cu. Biphasic reaction mixtures were diluted with CDCl3 
until a homogeneous solution was formed. Polymers were then purified via a two-stage 
process: 1) The catalytic system was removed by passing the diluted reaction mixture through 
a neutral alumina column using either CHCl3 or THF as the mobile phase, 2) Unreacted 




were concentrated in vacuo and precipitated three times using cold MeOH or cold petroleum 
ether, depending on the nature of the polymer (see Chapter 6, Section 6.3.1.8). Polymers were 
then dried in vacuo at 40 ℃ for 48 hours to ensure complete solvent removal.  
Selection of the BzBiB initiator allowed characterisation of polymerisation mixtures and 
purified polymers by 1H NMR spectroscopy (see Chapter 6, Section 6.3.1.7). Analysis of 
polymerisation mixtures prior to initiation permitted determination of the ratio of monomer to 
initiator at the start of polymerisation ([M]0 /[I]0) and quantification of monomer conversion 
(conv.) once polymerisations were complete; this subsequently allowed estimation of the 
theoretical number-average molecular weight (Mn theory). 1H NMR analysis of purified 
polymers was also used to determine the purity, DPn and subsequently the number-average 
molecular weight (Mn(NMR)) of purified polymers (Table 2.1). Analysis showed that all 
polymerisations had achieved high monomer conversion (92 - > 99 %) after 18 hours. This 
was somewhat surprising, especially in the polymerisations of nHMA, CHMA, BzMA, 
EHMA and LMA, given the observed phase separation which had occurred during 
polymerisation. 
Table 2.1 Cu-RDRP of hydrophobic methacrylates in anhydrous methanol at 60 ℃. 
aCalculated by 1H NMR spectroscopy (CDCl3, 400 MHz) of polymerisation mixture at t = 0.  
 bCalculated by 1H NMR 
spectroscopy of polymerisation mixture at t = final. cMn theory = (([M]0/[I]0 x Mr(monomer)) x conv.) + Mr(Initiator))   
dCalculated by 1H NMR spectroscopy of the purified polymer: Mn = (DPn x  Mr(monomer)) + Mr(initiator).
 eCalculated by TD-
SEC (triple detection size exclusion chromatography) using THF/TEA mobile phase (98/2 v/v %) at 35 °C using a flow rate of 1 
mL min-1. *Characterisation of p(BzMA)60 by 
1H NMR spectroscopy was not possible due to overlap between initiator and 
monomer resonances. 
With the exception of p(LMA), 1H NMR analysis of purified polymers showed good 
agreement between experimental and theoretical number-average molecular weights, with 
initiation efficiencies typically varying from 84 – 92 %. However, the methanolic Cu-RDRP 
of LMA demonstrated poor Mw targeting capability, with a significant discrepancy between 
the theoretical and experimental molecular weights obtained by 1H NMR spectroscopy. The 
















p(MMA)67 60 99 6 300 67 7 000 90 11 000 9 800 1.12 
p(EMA)64 60 97 6 900 64 7 600 91 10 800 8 900 1.21 
p(nBMA)74 62 99 9 100 74 10 800 84 13 000 11 600 1.12 
p(nHMA)67 60 >99 10 500 67 11 700 90 15 800 13 600 1.16 
p(CHMA)66 60 97 10 000 66 11 400 88 15 600 13 100 1.19 
p(BzMA) * 60 97 10 500 -* -* -* 17 000 13 700 1.24 
p(EHMA)65 60 99 12 000 65 13 100 92 18 400 14 500 1.26 




removal of unreacted monomers, free ligand and initiator residues were confirmed by the 
absence of such resonances in the 1H NMR spectra of the polymers after their precipitation.  
Polymers were also characterised using triple-detection size exclusion chromatography in 
THF/TEA (98 / 2 v/v %) which showed mono-modal chromatograms for all polymers, again 
with the exception of p(LMA). Polymers possessed narrow molecular weight distributions 
(Ð = 1.12 – 1.26) characteristic of those typically obtained by Cu-RDRP (Figure 2.10). In 
contrast, the TD-SEC (triple detection size exclusion chromatography) chromatogram 
obtained for p(LMA) contained a broad molecular weight distribution (Ð = 1.59) and showed 
a low molecular weight shoulder likely due to termination of growing chains during 
polymerisation (Figure 2.10 (h)). It is possible that the occurrence of phase separation may 
have isolated some growing polymer chains during the early stages of polymerisation, leading 
to an increase in the dispersity of the p(LMA) sample obtained via the Cu-RDRP of LMA at 
60 ℃ in anhydrous MeOH.   
 
Figure 2.10 Refractive index (RI, red solid lines) and right-angle light scattering (RALS, blue 
dotted lines) chromatograms obtained by TD-SEC of polymers generated via Cu-RDRP at 60 ℃ in 
methanol. (a) p(MMA), (b) p(EMA), (c) p(nBMA), (d) p(nHMA), (e) p(BzMA), (f) p(CHMA), 
(g) p(EHMA), (h) p(LMA).  
To summarise, Cu-RDRPs of MMA, EMA, nBMA, nHMA, CHMA, BzMA and EHMA in 




route for the generation of linear homopolymers with the ability to target Mn whilst 
maintaining a low dispersity. This is somewhat surprising given that polymerisations were 
conducted in a solvent typically considered to be an anti-solvent for the resultant polymers. 
Polymerisation homogeneity was highly monomer dependent as the polymerisations of MMA, 
EMA and nBMA remained homogeneous throughout polymerisation, whilst phase separation 
occurred during the polymerisations of nHMA, CHMA, BzMA and EHMA. In contrast, the 
Cu-RDRP of LMA lacked the control typically associated with an RDRP process and was 
therefore considered an unsuitable approach for the synthesis of p(LMA). Further studies are 
required to understand the impact of polymerisation induced phase separation on Cu-RDRP. 
2.2.2.3 Kinetics Studies of the Cu-RDRP of nHMA in Anhydrous Methanol 
As the role of phase separation during polymerisation remained unclear, kinetic studies were 
conducted in order to determine the impact of phase separation on the rate of formation and 
molecular weight distribution of polymer chains within a biphasic polymerisation. The 
Cu-RDRP of nHMA in anhydrous MeOH was selected as a model biphasic reaction mixture 
and their synthesis was conducted at a [M]0:[I]0:[Cu]0:[bpy]0 molar ratio of 60:1:1:2 and a 
MeOH concentration of 50 wt % (Scheme 2.4).  
 
Scheme 2.4 Cu-RDRP of nHMA in anhydrous methanol at 60 ℃. 
The onset of phase separation made it difficult to obtain homogeneous aliquots of the reaction 
mixture using traditional methods of sampling of the reaction throughout polymerisation. To 
combat this, an experiment was designed to conduct the Cu-RDRP of nHMA in parallel 
reaction flasks, allowing for the isolation of heterogeneous samples at various time points 
throughout the polymerisation. To achieve this, a large scale Cu-RDRP of nHMA (25.0 g) was 
initiated and large aliquots (ca. 2 mL) were immediately transferred into separate reaction 
flasks under N2. The reaction flasks were sealed and placed in an oil bath at 60 ℃. Reaction 
flasks were removed at set time intervals and quenched by deactivation of the catalytic system 
using rapid cooling, dilution and exposure to oxygen. Reaction mixtures remained 
homogeneous during the early stages of polymerisation however, after 7 hours the onset of 




reaction mixture containing a dark brown, non-viscous solvent phase resting above a dark 
brown, viscous polymer layer.  
The use of parallel reaction flasks allowed kinetic sampling of polymerisation beyond the 
onset of phase separation. Biphasic samples were diluted with CDCl3, in order to re-dissolve 
the polymer phase whilst simultaneously ensuring deactivation of the catalytic system, 
allowing determination of monomer conversion by 1H NMR spectroscopy. Samples were then 
purified by passing the diluted solutions over neutral alumina to remove the catalytic system 
and subsequently precipitating into cold MeOH. Analysis of data obtained by 1H NMR showed 
that the polymerisation had achieved near-quantitative monomer conversion after 18 hours 
(>99 %).  
Kinetic plots were constructed using 1H NMR data obtained throughout the polymerisation 
(Figure 2.11). Analysis of monomer conversion vs. time indicated that the polymerisation 
obeyed first order kinetics with respect to nHMA; this was confirmed when a linear plot was 
obtained following replotting of kinetic data in accordance with the first order integrated rate 
law. A plot of ln([M]0/[M]) vs. time demonstrated that the Cu-RDRP of nHMA in anhydrous 
MeOH proceeded with an apparent propagation rate constant of 5.34 x 10-3 min-1 at 60 ℃. The 
fact that first order kinetics were obeyed throughout polymerisation demonstrated a constant 
radical concentration thus indicating that undesirable side reactions, such as termination, are 
negligible throughout this polymerisation. The final homogeneous sample of the 
polymerisation was obtained after 7 hours, shortly before the onset of phase separation, at 
which point the polymerisation had achieved 92 % monomer conversion. Beyond this point, 
the onset of phase separation had little effect on the rate of polymerisation which is somewhat 
surprising given the decreased mobility of growing chains.    
 
Figure 2.11 Monitoring of the Cu-RDRP of nHMA in anhydrous MeOH at 60 ℃ using 1H NMR 




The use of parallel reaction flasks allowed isolation of purified samples of p(nHMA) during 
polymerisation and allowed the evolution of the p(nHMA) molecular weight distribution to be 
studied using TD-SEC (Figure 2.12). A general increase in Mw was observed (Figure 2.12a), 
indicated by polymer elution at shorter retention volumes as the polymerisation proceeded. A 
plot of both Mn(TD-SEC) and Mn(NMR) vs. monomer conversion demonstrated linear increases in 
Mn with monomer conversion which is typical of a well-controlled RDRP (Figure 2.12b). The 
Mn obtained were slightly higher than expected for each of the given time points, likely due to 
termination of active radical species during establishment of the ATRP equilibrium; initiator 
efficiencies of 80 and 81 % were determined by TD-SEC and 1H NMR spectroscopy 
respectively. Further analysis of the evolution of the molecular weight distribution throughout 
polymerisation showed a characteristic reducation in Ɖ with monomer conversion. Ɖ 
decreased from 1.36 to 1.18 as monomer conversion increased from 19 to >99 %.  
 
Figure 2.12 Analysis of the evolution of the molecular weight distribution during the Cu-RDRP 
of nHMA in anhydrous MeOH using TD-SEC. a) Overlaid RI traces for samples of p(nHMA) obtained 





Analysis of the molecular weight distribution throughout polymerisation further substantiates 
the controlled nature of the Cu-RDRP of nHMA in anhydrous MeOH at 60 °C. Perhaps what 
is most surprising is the negligible impact that polymerisation-induced phase separation has 
on both the rate of polymerisation and the evolution of the molecular weight distribution. It is 
likely that any negative impact is diminished due to its occurrence during the latter stages of 
polymerisation (~ 90 % monomer conversion). As a result, growing chains have little 
opportunity to deviate from the trajectory taken during polymerisation under homogeneous 
conditions. It is also likely that residual monomer is soluble and can therefore partition into 
the polymer phase. It is also important to mention that the dark brown colour observed is 
highly indicative that both [Cu(bpy)2]+ and [Cu(bpy)2]2+ species are present within the polymer 
phase formed; it is therefore possible that the RDRP process can continue unhindered 
following the onset of polymerisation-induced phase separation.  
Although biphasic polymerisations of nHMA, CHMA, and EHMA resulted in the formation 
of linear homopolymers with predetermined Mn whilst maintaining low dispersity between 
polymer chains, the polymerisation of LMA did not exhibit such control. Whilst the kinetic 
studies described above provide a detailed insight into the Cu-RDRP of nHMA at 60 °C in 
anhydrous MeOH, further studies are required to determine the impact of the onset of 
polymerisation-induced phase separation during the Cu-RDRP of other hydrophobic 
methacrylate monomers. It is possible that, in cases where phase separation occurs during the 
early stages of polymerisation, it allows significant deviation of the fate of propagating chains 
from that which would have occurred under a homogeneous, well-controlled RDRP process. 
In cases such as this, polymerisations may require an alternative solvent environment which 
could delay, or even prevent polymerisation-induced phase separation.  
2.2.2.4 Cu-RDRP of Hydrophobic Methacrylates in Isopropyl Alcohol 
In an attempt to delay or perhaps even prevent the onset of phase separation, a number of Cu-
RDRP syntheses were conducted in anhydrous IPA for a subset of hydrophobic methacrylate 
monomers (Scheme 2.5). It was expected that conducting polymerisations within a less polar 
polymerisation mixture would provide a better solvent environment for hydrophobic 
propagating chains. Linear homopolymerisations of MMA, tBMA, CHMA, LMA and SMA 
were conducted at a total solids concentration of 50 wt % in anhydrous IPA, targeting a DPn 
of 60 monomer units. MMA, CHMA and LMA were selected due to their contrasting phase 
behaviour during Cu-RDRP in anhydrous MeOH, representing successful homogeneous, 
successful biphasic and unsuccessful biphasic polymerisations respectively. Polymerisations 




reported unsuccessful polymerisation and monomer - MeOH immiscibility, were also 
attempted in anhydrous IPA.  
 
Scheme 2.5 Cu-RDRP of hydrophobic methacrylate monomers in anhydrous IPA. 
All polymerisations and subsequent purification processes were conducted in accordance with 
those used for the generation of linear homopolymers via methanolic Cu-RDRP, described 
above. As was observed during Cu-RDRP in anhydrous MeOH, reaction mixtures showed 
varied phase behaviours during polymerisation. The polymerisations of MMA and tBMA 
remained homogeneous whilst, although they may have initially appeared homogeneous, 
phase separation occurred during polymerisations of CHMA, LMA and SMA within 3 hours 
of initiation. Despite these contrasting phase behaviours, 1H NMR analysis of reaction 
mixtures after 18 hours showed that all polymerisations had achieved high monomer 
conversion (88->99 %). Polymers were purified via flash column chromatography over neutral 
alumina, subsequently precipitated into a suitable anti-solvent, and then dried in vacuo at 40 ℃ 
for 48 hours, facilitating characterisation using 1H NMR spectroscopy and TD-SEC (Table 
2.2).  
Table 2.2 Cu-RDRP of hydrophobic methacrylates in anhydrous IPA at 60 ℃. 
 aCalculated by 1H NMR spectroscopy of polymerisation mixture at t = 0.   bCalculated by 1H NMR spectroscopy of polymerisation 
mixture at t = final.     cMn Theory = (([M]0/[I]0 x Mr(monomer)) x conv.) + Mr(Initiator))   
d Calculated by 1H NMR spectroscopy 
of the purified polymer: Mn = (DPn x  Mr(monomer)) + Mr(initiator). 
eCalculated by TD-SEC using THF/TEA mobile phase (98/2 
v/v %) at 35 °C using a flow rate of 1 mL min-1.  
 1H NMR  TD-SEC (THF/TEA)e 















p(MMA)70 60 >99 6 300 70 7 300 86 11 200 55 000 1.16 
p(tBMA)59 60 88 7 800 59 8 700 91 14 300 10 000 1.43 
p(CHMA)68 60 99 10 300 68 11 700 88 16 400 13 000 1.26 
p(LMA)66 60 97 15 100 66 17 000 89 24 400 17 800 1.37 




End-group analyses were conducted using 1H NMR spectroscopy and showed good agreement 
between theoretical and experimental number-average molecular weights. Initiation 
efficiencies ranged from 86 - 91 %, highlighting a strong Mw targeting capability of Cu-RDRP 
in anhydrous IPA. Molecular weight distributions were obtained using TD-SEC and displayed 
monomodal molecular weight distributions for all polymers with number-average molecular 
weights obtained by TD-SEC showing consistent agreement with those determined by 1H 
NMR spectroscopy (Table 2.2). The absence of a low molecular weight shoulder in any of the 
RI chromatograms, as had been observed for p(LMA) obtained from Cu-RDRP in anhydrous 
MeOH, also indicated minimal chain termination during the early stages of polymerisation.  
Despite the Mn targeting capabilities shown, some polymers generated using Cu-RDRP in 
anhydrous IPA contained broad molecular weight distributions. The Đ values of 1.43, 1.37 
and 1.53 obtained for p(tBMA), p(LMA) and p(SMA) respectively were higher than those 
typically expected of a well-controlled RDRP process (Đ ≤ 1.30). This implies that in these 
cases, although Cu-RDRP in anhydrous IPA provides control over the DPn of the polymers 
formed, the RDRP process is less effective in preventing undesirable side reactions, such as 
chain termination and/or chain transfer, than is typically experienced during Cu-RDRP in 
anhydrous MeOH. Many factors determine the level of control within Cu-RDRP, not least 
factors including monomer type, catalyst solubility and reaction homogeneity. It is therefore 
not sensible to directly compare the polymerisation of one monomer in anhydrous IPA with 
that of another monomer in anhydrous MeOH. For this reason, in order to understand the 
impact of exchanging the alcohol in which Cu-RDRP is conducted, direct comparisons 
between such polymerisations is required.  
2.2.2.5 Comparison of Cu-RDRP in Anhydrous MeOH and Anhydrous IPA 
The anhydrous MeOH and anhydrous IPA polymerisations of MMA, CHMA and LMA were 
compared due to their varying phase behaviours under these conditions (Figure 2.13). Analysis 
of the refractive index and right-angle light scattering chromatograms obtained by TD-SEC 
showed that the change in solvent had minimal impact on the overall polymer molecular 
weight distribution for p(MMA) and p(CHMA). Although a slight broadening was observed 
in both the RI and RALS chromatograms, accompanied by increased Đ values, for MMA and 
CHMA polymers obtained from anhydrous IPA polymerisations. It is important to note that 
whether conducted in anhydrous MeOH or anhydrous IPA, polymerisations of MMA and 
CHMA proceeded as homogeneous and biphasic polymerisations respectively, therefore it 
appeared that reaction mixture homogeneity had little impact on the control exhibited during 
Cu-RDRP. The slight broadening of the molecular weight distribution on switching from 




and had been attributed to the polymer conformation within a poor solvent environment.88 
Whilst this hypothesis can reasonably be applied to the polymerisations described here, it is 
also likely that a change in the reaction solvent would impact the RDRP equilibrium and thus 
affect the levels of control exhibited during polymerisation. 
 
Figure 2.13 Molecular weight distributions of a) p(MMA), b) p(CHMA) and c) p(LMA) 
generated by Cu-RDRP in MeOH (red lines) and IPA (blue dotted lines). (i) Refractive index and (ii) 
right angle light scattering chromatograms obtained by TD-SEC in THF/TEA (92/2 v/v %) at a flow 
rate of 1 mL min-1. 
In contrast, considerable differences were observed between the molecular weight 
distributions of p(LMA) obtained by polymerisations in the different solvents (Figure 2.13, ci 
+ ii). The polymerisation of LMA in MeOH yielded a polymer containing a broad molecular 
weight distribution (Đ = 1.59) with very low initiator efficiencies (IE(TD-SEC) = 55 %). 
Furthermore, the presence of a low molecular weight shoulder in the RI chromatogram (Figure 
2.13ci - red line) demonstrated a lack of control during the polymerisation of LMA in 
anhydrous MeOH and suggests a level of termination during the early stages of 
polymerisation, possibly due to the onset of phase separation. Anhydrous IPA provided an 
improved environment for LMA polymerisation under these conditions (IE(TD-SEC) = 89 %) and 
examination of the RI chromatogram (Figure 2.13ci - blue dotted line) did not show the low 
molecular weight shoulder observed in MeOH reactions. It is possible that switching to a less 
polar reaction mixture may delay the point at which polymerisation-induced phase separation 




The level of control observed in polymerisations varied significantly between monomers. Đ 
values obtained by TD-SEC showed a moderate negative correlation with the polymerisation 
mixture polarities obtained using fluorescence emission spectroscopy, described in Section 
2.2.1 (Figure 2.14). The contrast in reaction mixture polarity within MMA/MeOH and 
SMA/IPA polymerisations (ΔI1/I3 = 0.43) was comparable to that measured between MeOH 
and diethyl ether (ΔI1/I3 = 0.44). It is therefore highly likely that the monomer-controlled 
reaction mixture polarity induces variations in the solubility of the CuCl/bpy catalytic system 
thus limiting the ability of the RDRP process to prevent undesirable side reactions. Despite 
these negative implications, the Đ values obtained for p(LMA) and p(SMA) only just fall 
outside the scope of what is typically considered acceptable for a well-controlled RDRP 
process. This demonstrates that Cu-RDRP in anhydrous alcohols is a suitable synthetic route 
for the generation of linear homopolymers of targeted Mn and low to moderate Đ, for all of the 
monomers selected for study.  
Figure 2.14 Graphical representation of the relationship between polymerisation mixture polarity, 
measured using fluorescence emission spectroscopy (as described in Section 2.2.1), and the Đ values 
obtained by TD-SEC analysis of polymers generated in THF/TEA (92/2 v/v %) at a flow rate of 
1 mL min-1.  
2.3 Amphiphilic AB Block Copolymers via Cu-RDRP in Alcoholic Media 
The discovery of suitable conditions for the polymerisation of all hydrophobic monomers 
targeted in this study provided a platform for the generation of additional polymer 
architectures using Cu-RDRP in anhydrous alcohols. The preparation of AB diblock 
copolymers was initially targeted due to the similarity in the polymerisation methods used to 
generate linear homopolymers; the only difference being that Cu-RDRP would be conducted 
using a polymer based macro-initiator, rather than BzBiB (Scheme 2.6). This approach 
consisted of two stages; firstly, a poly(ethylene glycol) (PEG) macro-initiator (PEG45-Br) was 
synthesised via end-group modification of a methoxy-terminated poly(ethylene glycol) 




PEG45-Br with a range of hydrophobic methacrylate monomers using Cu-RDRP in anhydrous 
alcohols to generate amphiphilic AB diblock copolymers which consisted of a hydrophilic 
PEG block covalently bonded to a hydrophobic methacrylic block.  
 
Scheme 2.6 Schematic representation of the proposed synthetic approach for the generation of 
amphiphilic block copolymers via polymerisation from a PEG macro-initiator using Cu-RDRP in 
anhydrous alcohols.  
2.3.1 Synthesis of a Poly(ethylene glycol) Macro-initiator  
The preparation of PEG based macro-initiators for use in Cu-RDRP has been widely 
reported.61,89,96 Synthesis typically involves esterification between a PEG-OH and an acid 
bromide containing an alkyl bromide initiating moiety. The reaction is widely used not only 
due to the facile synthesis and purification procedures but also as a result of the wide range of 
acid bromides and methoxy-functional PEGs that are commercially available. The preparation 
of a PEG based initiator was achieved via esterification of PEG-OH, containing a Mn = 2000 
g mol-1 with α-bromoisobutyryl bromide in DCM (Scheme 2.7). A DPn of 45 monomer units 
was confirmed by end-group analysis of the starting material using 1H NMR spectroscopy, 
giving a Mn(NMR) = 2130 g mol-1. The reaction was initiated by dropwise addition of a 
concentrated α-bromoisobutyrylbromide / DCM solution to a cooled DCM solution containing 
PEG45-OH, DMAP and TEA. The addition was completed using an ice bath in order to remove 
heat generated by the exothermic reaction. Once the addition was complete the reaction was 
allowed to proceed at ambient temperature. After 24 hours the reaction was quenched by 
addition of deionised H2O; the reaction mixture was then filtered and passed over a basic 
alumina flash column. The polymer was then purified by precipitation from DCM into cold 
petroleum ether (3 times). 
 
 
Scheme 2.7 Synthesis of a PEG45-Br macro-initiator via esterification of PEG45-OH with 




The PEG45-Br macro-initiator was characterised using a number of analytical techniques. The 
end-group modification was confirmed by 1H NMR analysis (Figure 2.15); in particular, by 
the appearance of a chemical shift for the methylene protons (h) at 1.96 ppm, this was 
accompanied by a downfield shift in the terminal ethylene protons (g) to 4.35ppm as a result 
of functionalisation with an α-bromoisobutyrate group at the ω-terminus. Comparison of the 
relative intensities of methyl (a) and isobutyryl (h) groups, located at the α- and ω- terminus 
respectively, indicated that > 99 % of hydroxyl end-groups had undergone functionalisation. 
Comparison between the relative intensity of chemical shifts attributed to PEG repeat units 
(b-f) with respect to polymer end-groups (h and a) reaffirmed a DPn of 45 monomer units, 
confirming a slight increase in Mn(NMR) to 2162 g mol-1 following end-group modification. The 
success of the reaction was further supported by 13C NMR analysis, which showed new 
chemical shifts at 30, 57 and 174 ppm attributed to the methyl, quaternary and carbonyl 
carbons of the α-bromoisobutyryl group (Appendix, Figure A2.2). TD-SEC analysis 
demonstrated negligible difference in the molecular weight distributions of PEG45-OH and 
PEG45-Br; this confirmed that the structural integrity of the macro-initiator had not been 
compromised during either the end-group modification or the purification process that ensued. 
Thus a suitable PEG-based macro-initiator had been prepared for the generation of amphiphilic 









2.3.2 Polymerisation from PEG45-Br via Cu-RDRP in Anhydrous Alcohols  
Polymerisations from PEG45-Br were conducted using Cu-RDRP in anhydrous alcohols in a 
similar manner to those used to generate linear homopolymers, described in section 2.2.2.2. A 
DPn = 120 monomer units was targeted by ensuring a [M]0/[I]0 ratio of 120/1 at the start of 
polymerisation. Reactions were therefore allowed to proceed for 48 hours at 60 ℃ in order to 
achieve this higher targeted DPn. The anhydrous alcohol-monomer pairings were decided 
based on the success of their linear homopolymerisations; polymerisations of MMA, EMA, 
nBMA, nHMA, CHMA, BzMA and EHMA were conducted in anhydrous MeOH whilst 
tBMA, LMA and SMA were polymerised using anhydrous IPA as the reaction solvent. 
Polymerisations were conducted at high solids (> 50 wt %) in order to maximise the impact of 
monomer co-solvency during polymerisation and to attempt to delay any onset of 
polymerisation-induced phase separation. 
 
Scheme 2.8 Polymerisation from a PEG45-Br macro-initiator with various hydrophobic 
methacrylate monomers via Cu-RDRP in anhydrous alcohols.  
Interestingly, the phase behaviours observed during polymerisation were identical to those 
exhibited in the generation of linear homopolymers. Polymerisations of MMA, EMA, nBMA 
and tBMA remained homogeneous throughout polymerisation whereas biphasic reaction 
mixtures formed during polymerisations with: nHMA, CHMA, BzMA, EHMA, LMA and 
SMA. This was somewhat surprising as it had been expected that α-terminus functionalisation 
with an alcohol-soluble PEG chain may prevent phase separation due to increased polymer 
solubility in anhydrous alcohol or that it may even drive block copolymer self-assembly in-
situ, forcing polymerisations to proceed via a polymerisation-induced self-assembly (PISA) 
process. 
Regardless of polymerisation mixture homogeneity, 1H NMR analysis showed that all 
polymerisations achieved high monomer conversion (≥ 94 %) after 48 hours. Polymerisations 
were then terminated through a combination of rapid cooling, dilution with THF/CDCl3 
(monomer dependent, see Chapter 7, Section 6.3.1.7) and deactivation of the copper catalyst 
via exposure to oxygen. The deactivated catalytic system was removed by passing polymer 
solutions over a neutral alumina flash column and the polymers were purified by precipitation 
(three times) from THF into a selected anti-solvent. Finally, residual solvent was removed in 
vacuo at 45 ℃ for 48 hours to give the purified amphiphilic AB block copolymers. Purified 




Table 2.3 Polymerisations from PEG45-Br via Cu-RDRP of hydrophobic methacrylates at 60 ℃ 
using anhydrous alcohol solvents.  
aCalculated by 1H NMR spectroscopy of polymerisation mixture at t = 0.   bCalculated by 1H NMR spectroscopy of polymerisation 
mixture at t = final.     cMn Theory = (([M]0/[I]0 x Mr(monomer)) x conv.) + Mn(Initiator))   
dCalculated by 1H NMR spectroscopy 
of the purified polymer: Mn = (DPn x  Mr(monomer)) + Mn(initiator).
 eCalculated by TD-SEC using THF/TEA mobile phase (98/2 
v/v %) at 35 °C using a flow rate of 1 mL min-1.  
The Mn(NMR) values obtained agreed with Mn theory values calculated based on monomer 
conversion. Calculated initiation efficiencies were in excess of 93 % which demonstrates that, 
despite the contrasting phase behaviours between monomer-alcohol pairings, a range of 
amphiphilic AB block copolymers can be generated with excellent control over Mw, using Cu-
RDRP in anhydrous alcohols. This was supported when Mn values obtained by TD-SEC agreed 
with those obtained by 1H NMR spectroscopy. The success of polymerisations from PEG45-
Br was supported when RI chromatograms obtained for each of the AB block copolymers were 
overlaid with that of the PEG45-Br macro-initiator from which they were constructed (Figure 
2.16). In all cases, monomodal Mw distributions were obtained showing elution of AB block 
copolymers at lower retention volumes relative to those of the PEG45-Br macro-initiator, 
confirming the absence of macro-initiator residues in the purified samples.  
Analysis of molecular weight distributions showed that all polymerisations conducted in 
anhydrous MeOH produced high Mn AB block copolymers with low Đ  values (Đ = 1.08 – 
1.21); this demonstrated a highly effective RDRP process capable of minimising undesirable 
side reactions. Whilst the Đ values obtained for AB block copolymers were lower than those 
obtained for their linear homopolymers generated under identical conditions, the variation in 
DPn targeted prohibits comparison between the level of control achieved for these 
polymerisations. Furthermore, the use of a PEG45-Br macroinitiator would further mask the 















PEG45-Br - - - 45 2 150 - - - - 
PEG45-b-p(MMA)122 120 98 13 900 122 14 400 MeOH 19 800 17 700 1.12 
PEG45-b-p(EMA)125 120 96 15 300 125 16 400 MeOH 21 500 17 700 1.21 
PEG45-b-p(nBMA)125 120 98 18 900 125 19 900 MeOH 24 200 22 500 1.08 
PEG45-b-p(tBMA)122 120 94 18 200 122 19 500 IPA 25 300 18 400 1.38 
PEG45-b-p(nHMA)117 120 96 21 800 117 22 100 MeOH 29 300 25 700 1.14 
PEG45-b-
p(CHMA)123 
120 95 21 300 123 22 300 MeOH 29 200 25 200 1.16 
PEG45-b-p(BzMA)123 120 >99 23 300 123 23 800 MeOH 28 600 24 900 1.15 
PEG45-b-p(EHMA)115 117 >99 25 400 115 25 000 MeOH 31 000 26 600 1.17 
PEG45-b-p(LMA)121 120 >99 32 700 121 32 700 IPA 46 700 33 200 1.41 




impact of small discrepancies between polymer chain lengths on the overall dispersity of the 
AB block copolymer. Polymerisations conducted in anhydrous IPA produced polymers with 
Đ values just outside what is typically expected of a well-controlled RDRP process 
(Đ = 1.38-1.46). This reaffirms the hypothesis that the benefits of manipulating reaction 
mixture polarity, in order to suppress polymerisation-induced phase separation, are partially 
offset by a slight loss of control over the RDRP process which likely arises due to decreased 
catalyst solubility within the reaction media. However, these results demonstrate that the use 
of Cu-RDRP in anhydrous alcohols can easily generate amphiphilic AB block copolymers 
with good control over the molecular weight distribution.  
 
Figure 2.16 TD-SEC analysis of amphiphilic AB block copolymers generated via polymerisation 
from a PEG45-Br macro initiator with hydrophobic methacrylate monomers using Cu-RDRP. Overlaid 
TD-SEC chromatograms showing molecular weight distributions of PEG45-Br macro-initiator (black, 
a-j) with a) PEG45-b-p(MMA) (cyan), b) PEG45-b-p(EMA) (red), c) PEG45-b-p(nBMA) (green), 
d) PEG45-b-p(tBMA) (orange), e) PEG45-b-p(nHMA) (gold), f) PEG45-b-p(CHMA) (teal), 
g) PEG45-b-p(BzMA) (dark red), h) PEG45-b-p(EHMA) (pink), i) PEG45-b-p(LMA) (dark grey), 




2.4 Branched Statistical Copolymers via Cu-RDRP in Anhydrous Alcohols  
Having established the viability of the Cu-RDRP of a range of hydrophobic 
methacrylate monomers in anhydrous alcohols, the synthesis of branched statistical 
copolymer architectures was investigated for each of the most successful monomer-
alcohol combinations. 
2.4.1 Statistical Copolymerisations of Hydrophobic Methacrylates with EGDMA via 
Cu-RDRcP in Anhydrous Alcohols 
Cu-catalysed reversible-deactivation radical copolymerisations (Cu-RDRcP) were 
conducted in an identical manner to those described previously (Section 2.2.2.2) for the 
generation of linear homopolymers. As previously, a DPn of 60 monomer units was 
targeted by ensuring a molar ratio of monomer to initiator of 60:1 prior to initiation 
([M]0/[I]0 = 60); in addition, small amounts of the BFM, EGDMA, were added to 
generate branch points between the primary polymer chains (Scheme 2.9). BzBiB was 
selected as the initiator in order to allow 1H NMR analysis of polymerisations as well 
as for characterisation of the branched statistical copolymers formed.   
 
Scheme 2.9 Synthesis of branched statistical copolymers via statistical copolymerisation of 
hydrophobic methacrylate monomers with EGDMA by Cu-RDRcP using anhydrous alcohol solvents. 
The formation of a 3D gelled network was avoided by ensuring that the nominal molar 
ratio of EGDMA to initiator did not exceed unity ([B]0/[I]0 ≤ 1.00). A series of 
copolymerisations were conducted for each of the monomer-alcohol combinations 
using [B]0/[I]0 ratios varying from 0.59 to 0.97, as determined by 1H NMR spectroscopy 
of the crude reaction mixtures (Chapter 6, Section 6.3.1.8). Polymerisations were 
allowed to proceed for 24 hours during which the phase behaviour observed for all 
monomer-alcohol systems was identical to their corresponding linear 
homopolymerisations described above. Analysis of polymerisation mixtures after 24 
hours showed that all polymerisations had achieved high monomer conversion 




formation of high molecular weight branched copolymers using this approach. Following 
removal of the CuCl/bpy catalytic system via column chromatography and subsequent 
purification by multiple precipitations into a suitable anti-solvent (see Chapter 6, 
Section 6.3.1.7), branched copolymers were characterised using 1H NMR spectroscopy 
to determine DPn and Mn(NMR) of the constituent primary chains within the complex 
branched copolymer architectures. Primary chain Mn(NMR) values (Table 2.4 and 2.5) 
obtained in this way showed good agreement with Mn(NMR) values obtained for their 
corresponding linear homologues generated in the absence of EGDMA (Section 2.2), 
indicating that the presence of EGDMA had negligible impact on primary chain 
formation during branching copolymerisations of hydrophobic methacrylate monomers 
with EGDMA via alcoholic Cu-RDRP. 
The initiation efficiencies observed for branching copolymerisations were comparable 
to those observed during analogous linear homopolymerisations. Initiation efficiency 
was therefore also expected to impact the molar equivalents of the BFM, EGDMA, per 
propagating primary chain during copolymerisation. In order to estimate the actual ratio 
of BFM to initiator within branching copolymerisations, herein described as 
‘experimental [B]0/[I]0’, nominal [B]0/[I]0 values obtained by 1H NMR analysis of the 
polymerisation mixture at t0 were modified in accordance with Equation 2.2. This 
provided accurate understanding of the actual composition of polymerisation mixtures 
(Table 2.4 and 2.5) as well as the number-average equivalents of EGDMA per primary 
chain within the final branched statistical copolymers. Taking one statistical 
copolymerisation of nBMA and EGDMA as an example (Table 2.4), analysis of the 
reaction mixture prior to initiation revealed a nominal [B]0/[I]0 value of 0.94; under 
identical conditions, the linear homopolymerisation of nBMA proceeded with an 
initiator efficiency of 84 %. Using these values, an experimental [B]0/[I]0 value of 1.12 
was obtained, indicating incorporation of 1.12 EGDMA units per primary chain during 
copolymerisation. Analysis of the purified branched copolymer by 1H NMR showed a 
primary chain DPn of 73 nBMA units; the structure of this branched copolymer can 
therefore be expressed as p(nBMA73-co-EGDMA1.12). This nomenclature has been used 
throughout this work to express the composition of branched statistical copolymers 




Table 2.4  Branched copolymers generated by Cu-RDRP of hydrophobic methacrylate monomers and EGDMA in anhydrous methanol. 



















p(MMA67-co-EGDMA0.89) 60 0.80 0.89 Gelation Observed 
p(MMA67-co-EGDMA1.00) 61 0.90 1.00 Gelation Observed 
p(EMA66-co-EGDMA0.89) 59 0.81 0.89 99 7 000 7 800  179.3 30.0 5.97 0.384 
p(EMA68-co-EGDMA0.93) 61 0.85 0.93 99 7 200 8 000  398.6 35.0 11.80 0.385 
p(EMA67-co-EGDMA0.99) 59 0.90 0.99 99 7 000 7 900  538.2 44.4 17.43 0.386 
p(EMA67-co-EGDMA1.04) 60 0.95 1.04 99 7 100 7 900  1 485 51.6 31.78 0.415 
p(nBMA70-co-EGDMA0.95) 61 0.80 0.95 99 8 900 10 200  242.2 33.4 7.25 0.393 
p(nBMA73-co-EGDMA1.01) 63 0.85 1.01 > 99 9 200 10 600  387.5 35.0 11.07 0.394 
p(nBMA72-co-EGDMA1.07) 63 0.90 1.07 99 9 200 10 500  673.3 44.4 15.16 0.392 
p(nBMA73-co-EGDMA1.12) 62 0.94 1.12 > 99 9 100 10 600  798.0 51.6 15.46 0.396 
p(nHMA65-co-EGDMA0.87) 60 0.78 0.87 > 99 10 500 11 300  282.6 29.5 9.58 0.383 
p(nHMA67-co-EGDMA0.94) 62 0.85 0.94 > 99 10 800 11 700  530.2 41.7 12.70 0.391 
p(nHMA65-co-EGDMA0.98) 60 0.88 0.98 > 99 10 400 11 300  591.1 40.9 14.45 0.389 
p(nHMA68-co-EGDMA1.03) 60 0.93 1.03 > 99 10 500 11 800  981.1 50.6 19.39 0.384 
p(BzMA78-co-EGDMA0.91)* 60 0.70 0.91* > 99 10 800 -*  303.5 31.4 9.66 0.390 
p(BzMA78-co-EGDMA1.04)* 60 0.80 1.04* Gelation Observed 
p(BzMA78-co-EGDMA1.17)* 60 0.90 1.17* Gelation Observed 
p(EHMA68-co-EGDMA0.82) 62 0.75 0.82 > 99 12 600 13 700  246.2 42.1 5.84 0.390 
p(EHMA65-co-EGDMA0.89) 60 0.82 0.89 > 99 12 200 13 100  313.1 31.5 9.94 0.392 
p(EHMA68-co-EGDMA0.93) 63 0.86 0.93 > 99 12 800 13 700  879.7 52.0 16.93 0.398 
p(EHMA70-co-EGDMA1.05) 64 0.97 1.05 Gelation Observed 
p(LMA87-co-EGDMA1.01) 60 0.70 1.01 Gelation Observed 
p(LMA87-co-EGDMA1.16) 60 0.80 1.16 Gelation Observed 
p(LMA88-co-EGDMA1.30) 61 0.90 1.30 Gelation Observed 
aCalculated by 1H NMR spectroscopy of polymerisation mixture at t = 0.   bCalculated by 1H NMR spectroscopy of polymerisation mixture at tf.     cMn(Theory) = (([M]0/[I]0 x Mr(monomer)) x conv.) + Mr(Initiator))   dCalculated 
by 1H NMR spectroscopy of the purified polymer: Mn (PC) = (DPn x  Mr(monomer)) + Mr(initiator). eCalculated by TD-SEC using THF/TEA mobile phase (98/2 v/v %) at 35 °C using a flow rate of 1 mL min-1. * Characterisation 









Table 2.5  Branched copolymers generated by Cu-RDRP of hydrophobic methacrylate monomers and EGDMA in anhydrous IPA. 



















p(MMA64-co-EGDMA0.83) 56 0.71 0.83 >99 5 900 6 700  352.6 24.8 14.20 0.347 
p(MMA70-co-EGDMA0.94) 62 0.81 0.94 >99 6 500 7 300  1 758 50.1 35.08 0.382 
p(MMA70-co-EGDMA1.05) 60 0.90 1.05 Gelation Observed 
p(MMA70-co-EGDMA1.10) 60 0.95 1.10 Gelation Observed 
p(tBMA68-co-EGDMA0.77) 61 0.70 0.77 >99 8 900 9 900  66.5 31.8 2.09 0.471 
p(tBMA65-co-EGDMA0.93) 60 0.85 0.93 98 8 800 9 500  94.1 29.4 3.20 0.431 
p(tBMA69-co-EGDMA1.02) 63 0.93 1.02 97 9 200 10 100  150.7 64.0 2.35 0.432 
p(tBMA67-co-EGDMA1.05) 60 0.96 1.05 98 8 800 9 800  163.2 45.3 3.60 0.422 
p(CHMA65-co-EGDMA0.67) 59 0.59 0.67 > 99 10 200 11 200  45.5 17.3 2.34 0.415 
p(CHMA68-co-EGDMA0.91) 60 0.80 0.91 > 99 10 400 11 700  102.9 23.5 4.38 0.403 
p(CHMA69-co-EGDMA1.03) 60 0.91 1.03 > 99 10 400 11 900  227.1 33.5 6.70 0.391 
p(CHMA69-co-EGDMA1.06) 60 0.93 1.06 > 99 10 400 11 900  273.2 35.6 7.68 0.398 
p(LMA72-co-EGDMA0.88) 66 0.78 0.88 > 99 17 000 18 600  96.1 32.2 2.98 0.423 
p(LMA65-co-EGDMA0.96) 60 0.85 0.96 > 99 15 500 16 800  111.1 33.4 3.32 0.407 
p(LMA64-co-EGDMA1.01) 59 0.90 1.01 > 99 15 300 16 500  147.1 30.2 4.86 0.402 
p(LMA70-co-EGDMA1.04) 64 0.93 1.04 > 99 16 500 18 100  294.4 54.0 5.46 0.386 
p(SMA72-co-EGDMA0.89) 64 0.80 0.89 > 99 21 900 24 700  186.0 43.5 4.27 0.404 
p(SMA73-co-EGDMA0.96) 65 0.85 0.94 > 99 22 200 24 900  208.0 39.6 5.24 0.399 
p(SMA68-co-EGDMA1.00) 62 0.90 1.00 > 99 21 200 23 300  362.6 43.1 8.83 0.376 
p(SMA65-co-EGDMA1.06) 60 0.95 1.06 > 99 20 600 22 300  352.4 53.1 6.63 0.392 
aCalculated by 1H NMR spectroscopy of polymerisation mixture at t = 0.   bCalculated by 1H NMR spectroscopy of polymerisation mixture at tf.     cMn(Theory) = (([M]0/[I]0 x Mr(monomer)) x conv.) + Mr(Initiator))   dCalculated 
by 1H NMR spectroscopy of the purified polymer: Mn (PC) = (DPn x  Mr(monomer)) + Mr(initiator). eCalculated by TD-SEC using THF/TEA mobile phase (98/2 v/v %) at 35 °C using a flow rate of 1 mL min-1. * Characterisation of 














            Equation 2.2 
Calculation of the experimental ratio of BFM to initiator at the start of polymerisation, 
accounting for the impact of initiator efficiency. [B]0 / [I]0 represents the relative 
concentration of EGDMA to BzBiB as determined by 1H NMR analysis of the reaction 
mixture prior to initiation. IE(NMR) represents the initiation efficiency, represented as a 
decimal, obtained by 1H NMR spectroscopy from the analogous linear 
homopolymerisation (Appendix, Figure A2.3).  
The formation of branched copolymer architectures was confirmed by TD-SEC. In all 
cases, both the Mw and Mn values obtained by TD-SEC (Mw up to 1,758 kg mol-1 and Mn 
up to 52.0 kg mol-1) were significantly higher than those of their linear homologues, 
despite agreement between DPn values obtained by 1H NMR spectroscopy. This clearly 
indicated the formation of branched copolymers consisting of multiple primary chains 
which closely resemble the linear homopolymers described above.  
TD-SEC chromatograms of branched copolymers also gave broad molecular weight 
distributions (Đ = 2.09 – 35.08), indicating the deviation from conventional linear 
polymer synthesis and the considerable range of species present within the copolymer 
samples created by the statistical branching process. Overlay of the RI and RALS 
chromatograms obtained by TD-SEC show these differences clearly (Figure 2.17 and 
Appendix, Figure A2.4). The presence of high molecular weight species was evident 
from the difference between the respective chromatograms. A comparison of the RI 
chromatogram overlays also shows very close correlation of linear homopolymers and 
the low molecular weight fractions of the corresponding branched statistical copolymers, 
indicating the presence of the component linear homopolymer primary chains within 
the branched copolymer distributions, as has been previously reported.97 This is 
supported by the Mn(NMR) calculations and would suggest a near-identical number of 
primary chains are created in both polymerisations and that they propagate to near-
identical chain lengths; Mw and dispersity differences are, therefore, simply due to the 
number and distribution of conjoined chains. The presence of some linear primary 
chains is the result of the statistical nature of intermolecular branching and is an intrinsic 
feature of such branching copolymerisations, either due to the lack of EGDMA 
incorporation within all chains or consumption of incorporated EGDMA functionality 





Figure 2.17 Comparison of linear and branched copolymer architectures by TD-SEC. 
Overlaid RI (solid lines) and RALS (dashed lines) chromatograms obtained for linear 
homopolymer, p(nBMA)74, (red lines) and branched statistical copolymer, 
p(nBMA73-co-EGDMA1.12) (blue lines). 
 
Further TD-SEC analyses were conducted in order to compare the molecular weight 
distributions of linear homopolymers and branched statistical copolymers. Plots of 
cumulative weight fraction (cum. ωf) vs. Mw can be easily obtained using TD-SEC. 
Overlaid plots obtained for the branched statistical copolymer, 
p(nBMA73-co-EGDMA1.12), and its corresponding linear homopolymers, p(nBMA)74, 
reiterated the formation of high molecular weight copolymers during Cu-RDRcP 
(Figure 2.18a). In the case of the p(nBMA)74 the top half of the cum. ωf is occupied by 
species with absolute Mw ≥ 12 500 g mol-1; in contrast, analysis of p(nBMA73-co-
EGDMA1.12) showed that the top half of the cum. ωf consisted of branched copolymers 
with absolute Mw in excess of 105 200 g mol-1. 
 
Figure 2.18 Understanding the extent of branching within (co)polymer molecular weight 
distributions obtained using TD-SEC. a) Plots of cum. ωf vs. molecular weight and b) cum. ωf 
vs. number of primary chains per macromolecule obtained by TD-SEC of a linear homopolymer, 





Given that 1H NMR analyses and RI TD-SEC chromatograms suggested that branched 
copolymers consisted of primary chains identical to those generated in the absence of 
EGDMA, it was possible to probe the extent of branching across the molecular weight 
distribution. This required modification of cum. ωf  vs. Mw plots to account for the 
Mn(TD-SEC) of the primary chains from which branched copolymers are constructed. This 
was achieved using Mn(TD-SEC) values obtained for the equivalent linear homopolymer 
generated under identical polymerisation conditions. This allowed the construction of 
plots of cum. ωf vs. the number of primary chains per macromolecule within the 
molecular weight distribution. As can be seen in Figure 2.18b, the plot obtained for 
p(nBMA)74 showed a dramatic increase in cum. ωf with 98 % of the branched 
copolymer mass consisting of species theoretically containing < 2.00 primary chains 
per polymer chain; this was expected for a polymer generated in the absence of a BFM 
capable of facilitating inter-chain branching reactions. In contrast, the plot obtained for 
p(nBMA73-co-EGDMA1.12) showed a broader range of species contributing to the 
copolymer mass. Analysis showed that cum. ωf values of 0.25, 0.50 and 0.75 were 
occupied by species containing > 2.59, > 9.00 and > 47.31 primary chains per 
macromolecule respectively. In stark contrast to linear homopolymers, this highlighted 
high levels of branching achieved by some species within the molecular weight 
distribution, and indicates that the top 10 % of the p(nBMA73-co-EGDMA1.12) 
molecular weight distribution consisted of branched copolymers containing no fewer 
than 195 primary chains.  
Whilst plots of cum. ωf vs. number of primary chains per macromolecule demonstrated 
the extent of branching within copolymer samples, they also highlighted the statistical 
nature of the branching process which occurs during polymerisation. This was evident 
by the decreasing gradients observed in both plots obtained for 
p(nBMA73-co-EGDMA1.12) as Mw / number of primary chains per macromolecule 
increased. This indicated that, despite highly branched species having considerably 
larger absolute Mw, the contribution of branched copolymers to the total sample mass 
decreased as the Mw / number of primary chains per macromolecule increased. This 
suggested a decrease in the number of species present at each incremental increase in 
absolute Mw; this was confirmed via number distribution analysis of the species present 
within the p(nBMA73-co-EGDMA1.12) molecular weight distribution; specifically, plots 
were obtained for normalised mol fraction and cumulative mol fraction vs. number of 
primary chains per macromolecule (Figure 2.19). These plots showed the number of 





This is an intrinsic feature of branched copolymers generated via copolymerisation of 
monofunctional and BFMs and arises as a result of the statistical uptake of BFMs across 
primary chains.98 Failure to incorporate a BFM precludes primary chains from partaking 
in branching reactions and results in the presence of unbranched primary chains within 
the final molecular weight distribution. Whilst primary chains that incorporate a single 
BFM unit are capable of facilitating branching reactions, they can only partake in a 
maximum of one branching reaction. Therefore, in cases where this pendant vinyl group 
is consumed through an intermolecular branching reaction, such chains form the 
terminal units of branched statistical copolymers and suppress further growth via 
intermolecular branching. In contrast, primary chains which incorporate ≥ 2 BFMs per 
primary chain can facilitate multiple branching reactions and, providing that pendant 
vinyl groups are not consumed via intramolecular cyclisation, act as branch points 
within the branched copolymer architecture. The statistical copolymerisation of nBMA 
and EGDMA was conducted using an experimental [B]0/[I]0 of 1.12, it is therefore  
likely that the statistical nature of BFM uptake will produce high numbers of primary 
chains containing only 1 EGDMA unit. The probability of  incorporating one of these 
primary chains during the ensuing statistical branching process increases dramatically 
with the number of primary chains per macromolecule and explains why the number of 




Figure 2.19 Analysis of the number distribution of species present within 
p(nBMA73-co-EGDMA1.12). Plots of mol fraction (solid blue) and cumulative mol fraction 




2.4.2 Mark-Houwink-Sakurada Analysis of Branched Statistical Copolymers 
and Linear Homologues 
The formation of branched copolymer architectures was also studied using comparative 
Mark-Houwink-Sakurada (MHS) analysis on both branched statistical copolymers and 
linear homologues which resemble the primary chains from which they are constructed. 
The MHS relationship describes the association between the absolute molecular weight 
of a polymer and the intrinsic viscosity, [η], of the solution formed when it is dissolved 
within a suitable organic solvent. The relationship between these two properties is 
described by the MHS equation (Equation 2.3) and is intrinsically linked to the 
topological structure of the polymer in solution. 
 
[𝜂] = 𝐾𝑀𝛼            Equation 2.3 
 
The MHS equation which describes the relationship between the intrinsic viscosity, [η], 
and absolute molecular weight, M, of a polymer; where K and α are known as MHS 
parameters which are dependent on the nature of polymer-solvent interaction. The [η] 
of a polymer solution typically increases with absolute Mw due to increased 
polymer-solvent interactions. However the degree of polymer-solvent interaction, and 
thus the relationship between [η] and M, is highly influenced by the topological 
structure of the polymer in solution (Figure 2.20). Linear polymers typically adopt a 
random coil conformation in solution. This relatively expanded state allows significant 
levels of polymer-solvent interaction; as a result, the [η] of a linear polymer solution 
shows increased sensitivity higher molecular weight species. In contrast, branched and 
hyper-branched polymers typically form spherical, shape-persistent structures in 
solution with higher density than linear random coils in solution, which reduce the level 
of polymer-solvent interaction and thus decrease the sensitivity of the [η] of branched 
polymer solutions to increases in absolute molecular weight (M).99  
The MHS exponent, α, indicates the topological structure of a polymer in solution. 
TD-SEC allows measurement of the intrinsic viscosity of a polymer-eluent solution 
across the whole of the molecular weight distribution; this facilitates determination of 
the MHS exponent by construction of the MHS plot of log[η] vs. log M. For 
hyperbranched and branched polymers, the MHS exponent, α, typically varies between 
0.2 and 0.5 depending on the degree of branching within the branched polymer 
architecture. In contrast, relatively expanded linear polymers typically give MHS 
exponents between 0.5 and 1.0.99 MHS analysis therefore offers a useful 






Figure 2.20 Schematic representation of the random coil and densely packed sphere 
conformations adopted by a linear homopolymers and a branched statistical copolymers in 
solution along with expected values.  
 
 
To further validate claims that branched copolymer architectures were generated during 
Cu-RDRcP of hydrophobic methacrylates with EGDMA, MHS plots were constructed 
for all branched statistical copolymers as well as for the linear homopolymers generated 
under identical conditions but in the absence of EGDMA. In all cases, overlaid MHS 
plots obtained for branched statistical copolymers highlighted considerable differences 
between the topology of branched statistical copolymers in comparison with their linear 
homologues. MHS exponents described above were calculated by taking averaged 
gradients across the whole of the molecular weight distribution. Linear homopolymers 
gave α values ranging from 0.544 to 0.694, which are representative of linear polymers 
behaving as random coils within a theta solvent. In contrast, α values obtained for 
branched statistical copolymers were significantly lower, ranging from 0.378-0.471; 
these differences could be seen clearly when comparable MHS plots were overlaid 
(Figure 2.21a, and Appendix, Figure A2.5). This confirmed the formation of the 
branched copolymer architectures during all statistical copolymerisations and 
highlighted the significant role that the addition of small amounts of EGDMA plays in 






Figure 2.21 MHS analysis of linear homopolymers and branched statistical copolymers 
generated via Cu-RDRP in anhydrous MeOH. a) Overlaid MHS plots obtained by TD-SEC for 
linear homopolymer, p(nBMA)74, and branched statistical copolymer, 
p(nBMA73-co-EGDMA1.12). b) Deconvolution of the MHS plot obtained for 
p(nBMA73-co-EGDMA1.12), highlighting the architectural contrast between two distinct regions 
within the molecular weight distribution.   
A detailed assessment of the MHS plots obtained for the branched statistical 
copolymers showed that, in all cases, the relationship between [η] and M varied across 
the molecular weight distribution (Appendix, Figure A2.6). This is demonstrated in the 
MHS analysis of p(nBMA73-co-EGDMA1.12) shown in Figure 2.21a. For low molecular 
weight species (M up to 12 000 g mol-1), [η] showed a high sensitivity to increases in 
M. This section of the MHS plot obtained for p(nBMA73-co-EGDMA1.12) was 
comparable to that observed for its linear homologue, p(nBMA)74. At higher M, a 
significant change was observed in the MHS plot as increases in polymer M had a 
smaller impact on [η]. This M dependant variation in the MHS relationship indicated 
that the molecular weight distribution of p(nBMA73-co-EGDMA1.12) consisted of a 
complex mixture of polymer topologies.  
The complex nature of the p(nBMA73-co-EGDMA1.12) molecular weight distribution 
was studied further via deconvolution of the MHS plot using intersectional analysis 
(Figure 2.21b). This allowed calculation of MHS exponents for each the two distinct 
regions within the molecular weight distribution, giving α values of 0.778 and 0.399 
for low and high Mw regions respectively. The value obtained for low M species was 
comparable to that of p(nBMA)74 (0.690) and supported the conclusion that the low M 
fraction of branched copolymer molecular weight distributions consist of unbranched 
linear chains similar to those generated in the absence of EGDMA. In contrast, the α 
value obtained for the high M species was typical of branched polymers which adopt a 
densely packed spherical conformation in solution and confirmed the architectural 
transformation which occurs following linking of primary chains via intermolecular 




complex molecular weight distribution obtained for p(nBMA73-co-EGDMA1.12); 
allowing it to be divided into two distinct regions; a ‘linear region’ which consists of 
linear unbranched primary chains of low Mw and a ‘branched region’ containing high 
Mw species which consist of multiple co-joined primary chains. The deconvolution 
method was used to demonstrate the ‘linear’ and ‘branched’ regions within the 
molecular weight distributions of all branched statistical copolymers described above 
(Appendix, Figure A2.6).  
The range of TD-SEC techniques described above permit detailed analysis of the 
complex nature of the molecular weight distributions of branched statistical copolymers 
generated via Cu-RDRcP in anhydrous alcohols. Such techniques therefore offered an 
effective characterisation tool to understand if and how a range of factors, such as 
copolymerisation concentration, experimental [B]0/[I]0 ratio and polymerisation 
mixture homogeneity, impact the levels of branching that occurs during statistical 
copolymerisations of hydrophobic methacrylates and EGDMA. 
2.4.3 Understanding the Factors Affecting Branching During Cu-RDRcP 
Having established a range of characterisation techniques capable of highlighting 
differences between materials containing complex molecular weight distributions, 
detailed analyses of branched statistical copolymers were conducted in order to identify 
the key factors which influence the level of branching during RDRcP in anhydrous 
alcohols. It is well established that the molar ratio of branching comonomer to initiator 
has a significant impact on the level of branching which occurs during RDRcP of 
monofunctional and BFMs.66,71 This was studied for all hydrophobic monomers/alcohol 
pairings by conducting copolymerisations at increasing nominal [B]0/[I]0 ratios and 
subsequent comparison of copolymer compositions and molecular weight distributions. 
In all cases, a significant impact on the molecular weight distributions was observed by 
TD-SEC (Appendix, Figure A2.7), with Mw, Ð and the weight fraction of primary chains 
incorporated via branching reactions all increasing with [B]0/[I]0 (Tables 2.4 and 2.5). 
This can be seen in Figure 2.22, which shows overlaid a) RI and b) RALS 
chromatograms obtained by TD-SEC of p(nBMA-co-EGDMA) copolymers generated 
at various experimental [B]0/[I]0 molar ratios. In both cases, chromatograms showed 
increases in the concentration and size of the species detected at lower elution volumes 
as the experimental [B]0/[I]0 ratios was increased from 0.95 to 1.12. These increases 
were accompanied by increases in Mw, Mn and Đ from 242.2 kg mol-1, 33.4 kg mol-1 and 
7.25 to 798.0 kg mol-1, 51.6 kg mol-1 and 15.46 respectively. This demonstrates the 
significant impact that increases in the experimental [B]0/[I]0 ratio has on the generation 





Figure 2.22 The impact of experimental [B]0/[I]0 ratio on the molecular weight distributions 
of p(nBMA-co-EGDMA) branched statistical copolymers. Overlaid a) RI and b) RALS 
chromatograms obtained by TD-SEC of p(nBMA73-co-EGDMA1.12) (red lines), 
p(nBMA72-co-EGDMA1.07) (blue lines), p(nBMA72-co-EGDMA1.01) (green lines) and 
p(nBMA70-co-EGDMA0.95) (purple lines).  
Further TD-SEC analyses were conducted to understand how changes in the 
experimental [B]0/[I]0 ratio impacted branching reactions during copolymerisation. A 
logical explanation for the observed increases in Mw is that increases in the experimental 
[B]0/[I]0 ratio will strongly influence the statistical distribution of BFMs across primary 
chains during propagation. Specifically, this would likely reduce the fraction of primary 
chains unable to participate in branching reactions, due to failure to incorporate BFM 
units during propagation; it is also possible that this would increase the number of 
primary chains containing ≥ 2 BFM units which are therefore capable of forming branch 
points, rather than terminal units, within the resulting branched copolymer 
architectures. This was demonstrated by comparison of the MHS plots obtained from 
the ‘branched regions’ of p(nBMA-co-EGDMA) molecular weight distributions 
(Figure 2.23a). Calculation of the MHS exponents showed little difference in the α 
values, This indicated that, regardless of experimental [B]0/[I]0 ratio, there was little 
difference in the topology of the branched copolymers. Polymer topology is 
intrinsically linked, and is commonly associated, to the degree of branching of 
hyperbranched polymers; these data suggest that increases in the experimental [B]0/[I]0 
ratio at which copolymerisations were conducted had minimal impact on the degree of 
branching of statistical copolymers towards the high molecular weight end of the 
molecular weight distribution. It appears that the impact of these increases in the 
experimental [B]0/[I]0 ratio disproportionately fell on chains at the lower end of the 
molecular weight distribution. This was supported by analysis of the cum. ω f  of 
unbranched linear chains within p(nBMA-co-EGDMA) branched copolymers, which 





Figure 2.23 TD-SEC analysis on the impact of experimental [B]0/[I]0 ratio on the molecular 
weight distribution of p(nBMA-co-EGDMA) branched statistical copolymers. Overlaid a) MHS 
plots and b) Plots of cum. ωf vs. number of primary chains per macromolecule obtained for: 
p(nBMA73-co-EGDMA1.12) (red lines), p(nBMA72-co-EGDMA1.07) (blue lines), 
p(nBMA72-co-EGDMA1.01) (green lines) and p(nBMA70-co-EGDMA0.95) (purple lines). 
To support this hypothesis, plots of cum ωf vs. number of primary chains per 
macromolecule were constructed for each of the p(nBMA-co-EGDMA) branched 
statistical copolymers generated at varied experimental [B]0/[I]0 ratios (Figure 2.23b). 
This showed that in copolymers generated at lower experimental [B]0/[I]0 ratios, 
unbranched linear chains and lightly branched copolymers made more significant 
contributions to the overall sample mass than was the case for branched copolymers 
generated at higher experimental [B]0/[I]0 ratios. For example, the lower quartile of the 
p(nBMA70-co-EGDMA0.95) sample mass consisted of species containing ≤ 2 primary 
chains; in contrast, the lower quartile of the mass of a p(nBMA73-co-EGDMA1.12) 
sample consisted of species containing up to 3 primary chains per macromolecule. This 
trend was reiterated at the high end of the molecular weight distribution as the upper 
quartile of p(nBMA70-co-EGDMA0.95) and p(nBMA73-co-EGDMA1.12) sample masses 
consisted of species consisting of ≥ 20 and 46 primary chains respectively.  
The analyses outlined above reaffirmed the widely reported observations that the 
contributions of high Mw branched copolymers to the overall sample mass increased 
with experimental [B]0/[I]0 ratio. It must be noted, however, that despite the significant 
increases in Mw, MHS analysis on the branched copolymer molecular weight 
distributions provide evidence that increases in the experimental [B]0/[I]0 ratio have 
little impact on the degree of branching within high molecular weight species. Increases 
in Mw can therefore be attributed to increases in the extent of branching, rather than the 
degree of branching, achieved during copolymerisation. The extent of branching refers 
to the fraction of the primary chains, generated during Cu-RDRcP, which are 




Alternatively, the degree of branching refers to the ratio between the average numbers 
of branching and terminal units to linear units within a branched copolymer sample.100 
Variation in the extent of branching observed occurs as a result of changes in the 
statistical distribution of EGDMA across propagating primary chains thus increasing 
the fraction of primary chains which can participate in branching reactions.  
2.4.4 Comparison of Branching Observed Between Monomer-Solvent Systems 
Branching copolymerisations utilising experimental [B]0/[I]0 ratios > 1.00 are expected 
to form insoluble crosslinked gels. Whilst 1H NMR analysis of the branching 
copolymerisations described above gave nominal [B]0/[I]0 ratios ≤ 0.97, the varying 
initiation efficiencies observed during linear homopolymerisations indicated 
experimental [B]0/[I]0 ratios in excess of the theoretical gel point. Surprisingly, in many 
cases the formation of a gel network was avoided, and soluble branched polymers were 
obtained from branching copolymerisations conducted at experimental [B]0/[I]0 ratios 
in excess of the theoretical gel point. The high monomer conversions recorded, and the 
absence of unreacted methacrylate groups observed during analysis of purified 
polymers by 1H NMR spectroscopy, indicated that gel formation was not suppressed 
due to incomplete polymerisation of pendant methacrylate groups. It is therefore 
probable that in copolymerisations with experimental [B]0/[I]0 >1.00, gelation was 
avoided due to the consumption of a fraction of pendant methacrylate vinyl groups 
(from EGDMA incorporation) via intramolecular cyclisation.  
Increases in experimental [B]0/[I]0 ratio impacted the Mw of the resulting branched 
statistical copolymers differently for specific monomer-solvent systems. For example, 
in the copolymerisation of EMA and EGDMA in anhydrous MeOH, an increase in the 
experimental [B]0/[I]0 ratio from 0.89 – 1.04 resulted in an increase in Mw from 179 – 
1,485 kg mol-1, whereas in the copolymerisation of SMA with EGDMA in anhydrous 
IPA, similar increases in the experimental [B]0/[I]0 ratio resulted in only modest 
increases in the Mw of the resultant branched copolymers from 186 - 352 kg mol-1.  
Comparisons between the Mw of branched copolymers with Mn values obtained for their 
linear equivalents (Mw(Br)/Mn(L)) provides an indication of the weight-average number 
of chains that are conjoined during copolymerisation. Figure 2.24 demonstrates the 
impact that experimental [B]0/[I]0 ratios have on the extent of branching; Mw(Br)/Mn(L) 
generally increased with experimental [B]0/[I]0 in the branching copolymerisations of 
EGDMA with MMA, EMA, nBMA, nHMA and EHMA. In branching 
copolymerisations of the MMA-IPA and EHMA-MeOH systems, large increases in the 




polymerisations were attempted at experimental [B]0/[I]0 ratios of 1.00 and 1.05 
respectively. A similar trend was observed in branched copolymers obtained from 
copolymerisation of EMA with EGDMA in MeOH; a sudden increase in Mw(Br)/Mn(L) 
occurred as experimental [B]0/[I]0 ratios were increased from 0.99 to 1.04, indicating 
that the latter copolymerisation is approaching the experimental gel point.  
Surprisingly, sudden increases in the extent of branching were not observed in the 
copolymerisations of nBMA and nHMA with EGDMA in MeOH despite being 
conducted at experimental [B]0/[I]0 ratios of 1.12 and 1.03 respectively. This indicates 
that these reactions would likely tolerate experimental [B]0/[I]0 ratios greater than those 
reported here before the onset of gelation. In contrast to the monomer-MeOH systems 
described above, the relationship between the experimental [B]0/[I]0 ratio and the level 
of branching observed was significantly lower for copolymerisations of EGDMA with 
tBMA, CHMA, LMA or SMA. The copolymerisation of CHMA/EGDMA was studied 
across a wide range of experimental [B]0/[I]0 ratios ranging from 0.67 to 1.06 which 
gave increased Mw(Br)/Mn(L) from 2.77 to 16.66 chains. Much smaller differences in 
the extent of branching were recorded for the LMA/EGDMA and SMA/EGDMA 
systems. Copolymerisations of LMA with EGDMA at experimental [B]0/[I]0 ratios 
ranging from 0.88 to 1.04 resulted in an increase in the observed Mw(Br)/Mn(L) from 
3.94 to 12.07 chains. Similar increases were observed in the SMA/EGDMA 
copolymerisation where Mw(Br)/Mn(L) increased from 5.24 to 9.93 chains as 
experimental [B]0/[I]0 ratios were raised from 0.89 to 1.06.  
 
Figure 2.24 Understanding the extent of branching that occurred during Cu-RDRcP. Plots 
showing the variation observed in Mw(Br)/Mn(L) with increasing experimental [B]0/[I]0 ratio for 





This disparity in the extent of branching observed between monomer-alcohol systems 
was surprising. As other factors, such as failure to achieve high monomer conversion, 
had been ruled out, this indicated that the contrasting levels of branching may be due 
to variations in the nature of pendant vinyl group consumption; in particular, the relative 
contributions of intermolecular branching and intramolecular cyclisation which take 
place during copolymerisation. Characterisation of branched copolymers by 1H NMR 
spectroscopy highlighted the samples which contained comparable monomer 
compositions and which should also, theoretically, contain identical branched 
copolymer architectures. These samples were selected for further TD-SEC analysis in 
order to understand the extent to which the level of branching varied between monomer-
alcohol systems.  
Analysis of the cum. ωf versus absolute M, for the highest Mw branched copolymers 
obtained from each of the monomer-alcohol systems, were conducted to account for the 
Mn of the primary chains from which each macromolecule is constructed (Figure 2.25). 
This analysis unveiled the impact of varying the repeat unit mass, and therefore 
structure, on the resulting Mw (as judged by TD-SEC analysis), and provided an insight 
into the mass contributions of each branched species within the molecular weight 
distribution of each sample. The extent of branching observed in the samples studied 
followed the order of p(EMA67-co-EGDMA1.04) > p(MMA70-co-EGDMA0.94) > 
p(nBMA73-co-EGDMA1.12) ≈ p(nHMA68-co-EGDMA1.03) > 
p(EHMA68-co-EGDMA0.93) >> p(CHMA69-co-EGDMA1.06) > 
p(BzMA78-co-EGDMA0.91) > p(LMA70-co-EGDMA1.04) > p(tBMA67-co-EGDMA1.05) 
> p(SMA65-co-EGDMA1.06). This supports the trends seen in the Mw(Br)/Mn(L) analyses 
described above. This trend was reaffirmed when similar analyses were conducted 
using the cumulative mole fraction (Appendix, Figure A2.8). It must be stated however 
that some the samples studied were generated using differing experimental [B]0/[I]0 
ratios. Therefore the ordering identified is only relevant to the samples described here 





Figure 2.25 TD-SEC analyses comparing the levels of branching achieved during 
Cu-RDRcP within various monomer-alcohol systems. Plots showing the Cum. ωf vs. number of 
primary chains per macromolecule for the highest Mw branched statistical copolymers obtained 
from each of the monomer-solvent systems.  
In order to understand the extent to which the levels of branching varied between 
monomer-solvent systems, the cum. ωf vs. number of primary chains per 
macromolecule plots of p(EMA67-co-EGDMA1.04) and p(SMA65-co-EGDMA1.06) were 
directly compared. Whilst these materials possessed the highest Mw (prepared by 
copolymerisation of EMA and SMA with EGDMA in MeOH and IPA respectively) 
and also contained comparable chain lengths and EGDMA contents as determined by 
1H NMR, they exhibited the highest and lowest levels of branching of all the monomer-
solvent systems studied. TD-SEC analysis showed that the lowest 25 % of the 
cumulative weight fraction (ωf = 0.25) was made up of branched copolymers containing 
no more than 4 and 2 primary chains in p(EMA67-co-EGDMA1.04) and 
p(SMA65-co-EGDMA1.06) respectively. In contrast, the same analysis showed that 75 % 
of the weight fraction (ωf = 0.75) was made up of polymer chains containing up to 104 
and 15 chains respectively. The upper quartile of the p(EMA66-co-EGDMA1.04) 
molecular weight distribution therefore has > 7-fold higher number of conjoined chains  





Figure 2.26 Direct comparison of the levels of branching observed in 
p(EMA67-co-EGDMA1.04) and p(SMA65-co-EGDMA1.06) by TD-SEC. Overlaid plots of cum ωf 
vs. number of primary chains per macromolecule, accompanied by schematic representation of 
the branched copolymer architectures occupying the upper and lower quartiles of the 
p(EMA67-co-EGDMA1.04) (red) and p(SMA65-co-EGDMA1.06) (dark blue) sample masses.  
The differences in the levels of branching observed between monomer-solvent systems 
can be explained by three key differences which arise, and most likely influence, 
branching reactions during copolymerisations targeting the same solids content and the 
same primary chain DPn. Most strikingly, the active chain-end concentration, within 
the MMA to SMA copolymerisation series, decreases significantly when seeking to 
achieve constant solids content and identical chain length. The monomer Mr increase 
across the series can also be considered as a vinyl group weight fraction within the 
monomers as decreasing from 85 wt % to 25 wt % which necessitates a subsequent 
reduction in initiator concentration to target a fixed DPn (Figure 2.27 and Appendix, 
Table A2.2). A normalised active chain-end concentration factor can be calculated for 
each branching copolymerisation studied. Across the extremes of the copolymerisations 
reported here, active chain-end concentrations for an MMA/EGDMA branched 
copolymerisation are 3.38-fold higher than the equivalent SMA/EGDMA reaction. 
Similar concentration factors arise when copolymerisations are conducted at lower 
solids contents. Based on theoretical calculations, Figure 2.27 (solid black line) shows 
the dependence of the relative [I]0 on the solids content at which statistical 
copolymerisations of MMA and EGDMA are conducted (Appendix, Table A2.3). The 
impact of copolymerisation concentration on the prevalence of intramolecular 
cyclisation is well known and can likely explain the relatively low levels of branching 
observed in the copolymerisations of LMA and SMA with EGDMA, compared with 






Figure 2.27 The inherent concentration factors which arise during branching copolymerisations. 
Graphical representations of the change in relative [I]0 which accompany variations in monomer side 
chain mass in copolymerisations targeting a fixed DPn, conducted at a constant total solids content (50 
wt %, dashed black line); and the percent solids content at which MMA/EGDMA copolymerisations 
are conducted (solid black line). Dashed coloured lines show the reduction required, in the concentration 
at which a MMA/EGDMA copolymerisation is conducted, in order to produce a concentration 
equivalent to those experienced by each of the monomer-solvent systems. 
Additionally, the variation in steric hindrance created by the methacrylate side-chain 
must also be considered. As the pendent group increases in size, the side-chains will 
ultimately exceed the length of the pendant methacrylate groups resulting from 
EGDMA incorporation (Figure 2.28a). Molecular modelling studies were conducted 
using Spartan’18™ software in order to understand the extent of steric hindrance 
around pendant methacrylate groups during copolymerisation. To achieve this, 
representative oligomers (DPn = 10), derived from each of the hydrophobic 
methacrylate monomers used in this study, were constructed containing one EGDMA 
unit per primary chain; this allowed measurement of the distances that both pendant 
methacrylate groups and monomer side-chains protrude from the polymer backbone 
(Appendix, Figure A2.9). As expected, increases in the size of monomer side chains 
resulted in increased protrusion from the polymer backbone. However, despite 
significant differences in the size of the comonomer side-chain, little difference was 
observed in the protrusion distance of the EGDMA pendant methacrylate group, which 
gave an average protrusion distance of 0.889 nm from the polymer backbone. In 
contrast, repeat unit side-chains of MMA and LMA protruded distances of 0.427 nm 
and 1.619 nm respectively (Appendix A2.9, and Table A2.4). These simulations 




increases with the size of the monomer side-chain. However, it is unclear whether this 
would actually promote consumption of pendant methacrylate groups via 
intramolecular cyclisation over intermolecular branching reactions.101 Whilst further 
studies may be required to determine the relative contributions of intermolecular 
branching and intramolecular cyclisation, increased steric hindrance remains one 
possible explanation for the variation in the levels of branching observed between 
monomer-solvent systems.  
Finally, the varying solvent environment within these polymerisations, and the impact 
on the phase behaviour of the branched copolymers during propagation, may also be 
important. This may be highly specific to the copolymerisations discussed above. 
However, it has previously been hypothesised that for polymerisations where monomer 
consumption progressively leads to a bad solvent environment within the reaction 
mixture, the formation of densely-coiled structures is likely.88 In the branching 
copolymerisations described here, it is likely that the conformations of the propagating 
primary chains within highly branched structures and the lightly branched fraction 
across the copolymerising monomer series differ significantly (Figure 2.28).  
Branching copolymerisations of MMA with EGDMA gave homogeneous reactions 
mixtures, even after cooling, indicating that branched copolymers remained 
well-solvated throughout polymerisation. In contrast, nBMA/EGDMA branching 
copolymerisations remained homogeneous until these reaction mixtures were allowed 
to cool and nHMA/EGDMA copolymerisations remained homogenous until high 
monomer conversion. It is reasonable to envisage that, in relatively poor solvent 
environments, branched copolymers adopt more densely-packed conformations, 
reducing the availability of pendent methacrylate groups and reducing the overlap 
between neighbouring chains in solution. This would also hinder intermolecular 
branching. Several of the monomer/EGDMA copolymerisations studied formed 
biphasic reaction mixtures during copolymerisation, giving highly viscous polymer-
rich phases. It is likely that such phase behaviour, and assumed associated 
conformational changes, negatively impact the creation of intermolecular branch 
points. This is supported by the high levels of branching observed for MMA/EGDMA 
and EMA/EGDMA systems in contrast to the lower levels of branching observed for 
the nBMA/EGDMA and nHMA/EGDMA systems. The lowest extent of branching 
were observed in copolymerisations of CHMA, LMA or SMA with EGDMA, which 
form biphasic reaction mixtures in the early stages of polymerisation with subsequent 





Figure 2.28 Factors affecting branching in the copolymerisation of hydrophobic methacrylates 
with EGDMA via Cu-RDRP in alcohols. (a) Schematic representation of the steric hindrance around 
pendant methacrylate groups in the presence of monomers containing i) short and ii) long alkyl side 
chains. (b) Schematic representation of proposed primary chain conformations in different solvent 
environments. i) collapsed polymer chains within a bad solvent environment and ii) expanded polymer 
chains within a good solvent environment. 
2.5 Conclusions 
This work aimed to expand the scope of Cu-RDRP of hydrophobic methacrylate 
monomers in alcoholic solvents and explore the viability of the synthesis of a range of 
linear homopolymer, AB block copolymer and branched statistical copolymer 
architectures using this unconventional approach. One attraction of RDRP reactions is 
the ability to conduct controlled polymerisations at high solids, leading to final polymer 
solutions of > 50 wt %. However, it is clear that monomer selection has the potential to 
impact the initial solvent environment. Monomer depletion during propagation, and 
formation of polymer, may lead to a transition from a “good” solvent environment to a 
“poor” solvent condition, as exploited by the so-called polymerization-induced 
self-assembly (PISA) reactions.79 Equally, varying solvent/monomer mixture polarity 
may also impact the solubility of the catalytic systems employed and alterations of the 
reversible-deactivation equilibrium during different stages of polymerisation. These 
effects are readily overlooked within reactions where medium is a good solvent for all 
reagents and products. In the generation of linear homopolymers and AB block 
copolymers, reaction homogeneity is not a critical parameter and low degrees of phase 
separation do not appear to have a significant impact on the achievement of high 
conversions or low Ð values. Further work to determine catalyst solubility within 
different monomer-solvent mixtures as well as kinetic monitoring of Cu-RDRP of other 
hydrophobic monomers in alcoholic media, is required to further understand the impact 




The ability to conduct Cu-RDRP in anhydrous MeOH and IPA for a range of 
hydrophobic monomers from MMA to SMA, including cyclic aromatic/aliphatic and 
branched alkyl side chains, is remarkable. The low dispersity and Mn targeting to give 
linear homopolymers is highly interesting with value potentially in more 
environmentally favourable solvent systems being employed on large scales. 
Additionally, incorporation of EGDMA at low comonomer concentrations was not 
unduly impacted and offers a readily available route to the formation of branched vinyl 
polymers. To the best of the authors’ knowledge, the work described here is the first 
report on the preparation of branched statistical copolymers containing either nHMA, 
CHMA, BzMA, EHMA, LMA or SMA using Cu-RDRP in alcoholic media. Again, 
further studies are required to optimise branching copolymerisations of this type under 
these conditions, but it may be possible to overcome poor branching efficiencies 
through simple changes to experimental design, including incremental increases to the 
[B]0/[I]0 ratios beyond those studied here to establish the experimental gel point, 
varying the chemistry and chain length of the BFM used (to overcome inter-chain steric 
issues) and variation in solids content and subsequent initial solvent environment.  
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Expanding the Scope of Co-nanoprecipitation: 
Preparation of Novel Branched Vinyl Copolymer 














The production of polymer based nanoparticles is of considerable interest as it provides the 
opportunity to generate nanomaterials which typically possess different and often 
unobtainable physical and chemical properties to those of their bulk materials.1–5 The 
preparation and utilisation of polymeric nanoparticles has therefore attracted significant 
scientific research interest in recent years.6,7 Nanoprecipitation is one technique which has 
been used to generate nanoparticles using a wide range of polymeric materials.8 The concept 
of nanoprecipitation, including an overview of the mechanisms of nanoparticle formation and 
colloidal stabilisation, was discussed in detail during Chapter 1, Section 1.4.2.1. In particular, 
research has focused on the optimisation of the nanoprecipitation process in order to generate 
polymeric nanoparticles which contain low dispersity whilst maintaining control over their 
hydrodynamic diameters.9 
Nanoprecipitation of hydrophobic polymers has been used to generate aqueous polymer based 
nanoparticle dispersions. In the absence of steric or electrostatic stabilisation mechanisms, the 
inherent increase in interfacial surface area which accompanies a reduction in particle size 
make hydrophobic based polymeric nanoparticles unstable and prone to aggregation and 
sedimentation.10 This is often overcome by using polymers which generate electrostatic charge 
at the nanoparticle surface and prevent particle-particle aggregation via electrostatic repulsion. 
However, such electrostatic stabilisation can be masked in the presence of electrolytes and the 
particles are prone to aggregation via flocculation even at low concentrations of salt.11 
Numerous alternative approaches have been made to stabilise hydrophobic polymer-based 
nanoparticles. These typically include surface modification of nanoparticles with amphiphilic 
copolymers and non-ionic surfactants.12–19 The adsorption of such species at the nanoparticle 
surface provide nanoparticles with a degree of steric stabilisation and can delay or even 
completely prevent nanoparticle aggregation. 
3.1.1 Co-nanoprecipitation  
The synthesis of complex macromolecular architectures using RDRP has facilitated the 
production of novel nanoprecipitation based nanoformulation techniques.20,21 In 2015, 
Rannard and co-workers reported the preparation of sterically stabilised branched vinyl 
copolymer nanoparticles via the simultaneous nanoprecipitation of high molecular weight, 
hydrophobic branched copolymers with their corresponding PEG-based amphiphilic block 
copolymers.22 This approach was coined ‘co-nanoprecipitation’ and facilitated the production 
of highly monodisperse p(HPMA) based nanoparticles with intensity-average hydrodynamic 
diameters ranging from 72 – 293 nm. The use of PEG-based amphiphilic block copolymers in 
co-nanoprecipitation equipped the resulting hybrid nanoparticles with the steric stabilisation 




The formation of branched vinyl copolymer nanoparticles via co-nanoprecipitation is 
presented in Figure 3.1. Briefly, amphiphilic AB block and branched copolymers, molecularly 
dissolved within a mutual good solvent are rapidly added to water, which is a bad solvent for 
the hydrophobic component of each copolymer. The rapid diffusion of water causes a state of 
supersaturation within the co-nanoprecipitation medium and drives nanoparticle formation via 
a diffusion-limited cluster-cluster aggregation (DLCA) growth mechanism. The 
co-nanoprecipitation process is reliant upon the simultaneous nucleation of amphiphilic block 
copolymers; this is achieved by ensuring that both hydrophobic components of the copolymers 
are derived from the same monomer, i.e. co-nanoprecipitation of PEG45-b-p(HPMA)120 with 
p(HPMA50-co-EGDMA0.90). Ford et al. demonstrated that nanoparticle formation occurred 
immediately after copolymer addition and gave stable aqueous nanoparticle dispersions 
following solvent removal via evaporation.22 
 
Figure 3.1 The formation of branched vinyl copolymer nanoparticles via co-nanoprecipitation as 
described by Rannard and co-workers.22 a) Hydrophobic branched and amphiphilic AB block 
copolymers, dissolved within a good solvent, are rapidly added to water. b) Immediate nanoparticle 
formation via co-nanoprecipitation giving swollen p(HPMA) based within the nanoprecipitation media. 
c) Solvent removal via evaporation to give a sterically-stabilised aqueous branched vinyl copolymer 
nanoparticle dispersion.  
The main advantage of the co-nanoprecipitation process is that, in the case of p(HPMA) based 
copolymers, it utilises the varied polymer architectures employed to generate optimal polymer 
nucleation and nanoparticle stabilisation during co-nanoprecipitation. p(HPMA) is considered 
a moderately hydrophobic polymer; as a result, the nanoprecipitation  (p(HPMA-co-EGDMA) 
based copolymers typically show architecture-dependent nucleation.23–25 Co-nanoprecipitation 
therefore relies on high molecular weight branched copolymers to drive nucleation during 
co-nanoprecipitation whilst utilising the hydrophilic domains of amphiphilic AB block 
copolymers to provide the resulting nanoparticles with steric stabilisation.  
Co-nanoprecipitation allows the final composition of branched vinyl copolymer nanoparticles 




copolymer/good solvent solution. This allows the nanoparticle composition and therefore the 
level of steric stabilisation to be determined prior to synthesis. Furthermore, the capping of 
nanoparticle growth via a steric stabilisation mechanism allows multiple co-nanoprecipitations 
to be conducted without impact on the hydrodynamic diameters of the branched vinyl 
copolymer nanoparticles within the aqueous nanoparticle dispersion.22  
3.1.2 Chapter Aims   
The primary aim of the work depicted in this Chapter is to expand the scope and understanding 
of nanoparticle formation via co-nanoprecipitation. This was attempted through the individual 
nanoprecipitations and co-nanoprecipitations of a selection of the vast library of polymers 
generated in Chapter 2, and to build on the successful co-nanoprecipitations of p(HPMA) 
based copolymers previously reported. Here, the first report of the preparation and 
characterisation of branched vinyl copolymer nanoparticles consisting of a variety of 
hydrophobic methacrylate copolymers is presented.  
The factors which influence nanoparticle formation via co-nanoprecipitation were studied; this 
was achieved through the manipulation of polymers used and experimental conditions in 
which co-nanoprecipitations are conducted, see Figure 3.2a.  
 
Figure 3.2 Schematic representation of the aims of the work conducted in Chapter 3. a) The 
preparation of branched vinyl copolymer nanoparticles via co-nanoprecipitation of various amphiphilic 
AB block and hydrophobic branched copolymers. b) Studying polymer and experimental factors which 
influence nanoparticle formation during co-nanoprecipitation and c) Encapsulation of hydrophobic 
guest molecule (pyrene) within the core of branched vinyl copolymer nanoparticles via 
co-nanoprecipitation. 
In particular, the importance of the architecture, composition, and concentration of the 
copolymers used in nanoparticle formation during the co-nanoprecipitation process will be 




A series of studies will also be presented which correlate the physical properties of 
nanoparticles, including composition, size and surface charge, to the chemical and physical of 
the copolymers from which they are constructed.  
The suitability of branched vinyl copolymer nanoparticles as prospective drug nanocarriers 
(DNCs) for the delivery of hydrophobic chemotherapeutics are evaluated. Preliminary studies 
were conducted to understand whether hydrophobic molecules could be encapsulated within 
the core of branched vinyl copolymer nanoparticles during the co-nanoprecipitation process. 
This was attempted via the addition of a small amount of hydrophobic pyrene into the solutions 
from which copolymers were co-nanoprecipitated, Figure 3.2c. Selection of pyrene as the 
hydrophobic guest molecule allowed the core polarity of branched vinyl copolymer 
nanoparticles constructed from various hydrophobic polymers to be assessed by fluorescence 
spectroscopy.  
Finally this work aimed to explore whether branched vinyl copolymer nanoparticles formed 
via co-nanoprecipitation are suitable for application within biological environments. In 
particular, the stability of such nanomaterials to factors which may be experienced following 
IV administration, such as substantial dilution and the presence of high salt concentrations, 
were assessed.  
3.2 Selection of Polymers for use in (Co)nanoprecipitation Studies 
A selection of polymers from Chapter 2 were chosen to study the impact of the following 
polymer characteristics on their performance within the (co)nanoprecipitation processes: 
i) polymer functionality, i.e. the pendant group of the polymer methacrylic repeat unit, 
ii) polymer architecture in particular to draw comparisons between linear and branched 
equivalents and iii) polymer amphiphilicity and its role in nanoparticle stabilisation. Selections 
of the linear homopolymers, amphiphilic block copolymers and the highest Mw branched 
statistical copolymers presented in Chapter 2 were used. An overview of the polymers selected 
for nanoprecipitation and co-nanoprecipitation studies is presented in Figure 3.3 and full 
characterisation of the polymers used in this Chapter is provided in Chapter 2, Tables 2.1 - 
2.4. In addition to the polymers generated in Chapter 2, a p(HPMA)-based linear 
homopolymer, amphiphilic branched copolymer and branched statistical copolymers were 
prepared via methanolic Cu-RDRP. Full characterisation of these materials is presented in 





Figure 3.3 Schematic representation of the library of polymers used in nanoprecipitation and 
co-nanoprecipitation studies in this Chapter. Specifically, the variations in polymer architecture and 





3.3 Nanoprecipitation Studies 
The preparation of polymer nanoparticles via a co-nanoprecipitation process provides 
additional complexity to traditional nanoprecipitation approaches which typically involve a 
sole component. In particular, understanding the role of individual polymer components in the 
co-nanoprecipitation process , or proving their presence within final nanoparticles can often 
be difficult. In an effort to evaluate the potential role that hydrophobic polymers may play 
within co-nanoprecipitation, all individual components were systematically studied as the sole 
components in nanoprecipitations. 
3.3.1 Preliminary Nanoprecipitation Studies  
Preliminary nanoprecipitation studies were conducted using all 33 of the polymers identified 
in Figure 3.3. It was desirable to generate a uniform nanoprecipitation process for all polymers 
which would therefore allow the individual polymers to be isolated. To achieve this, polymer 
solubility studies were conducted to find a common good solvent for all polymers. Solvent 
selection is of critical importance to the success of a nanoprecipitation. Organic solvents must 
be water-miscible in order to allow rapid mixing between good and bad solvents and thus 
create the state of supersaturation required to induce polymer nucleation. Whilst not a 
prerequisite it is also desirable if organic solvents are volatile to allow their removal under 
mild conditions post-nanoprecipitation. Following consideration of these criteria, acetone, 
MeOH, ethanol (EtOH), IPA and THF were considered suitable organic solvents. However; 
following the many cases of polymerisation-induced phase separation observed during Cu-
RDRP in anhydrous alcohols reported in Chapter 2, MeOH, EtOH and IPA were disgarded at 
this point. Polymer solubility studies were therefore conducted using acetone and THF. This 
involved the attempted preparation of polymer solutions at a concentration of 10 mg mL-1 
under constant agitation over a time period of 48 hours; the homogeneity of polymer solutions 
were inspected both visually and by passing them through a 0.25 µm PTFE filter. In all cases, 
polymers showed full solubility in THF whereas all p(LMA) and p(SMA) based polymers 
were insoluble in acetone at a concentration of 10 mg mL-1. As a result, THF was selected as 
the good solvent for all aqueous nanoprecipitations and co-nanoprecipitations conducted 
throughout this research.   
The design of the nanoprecipitation process is also of crucial importance. In particular, the 
initial concentration of polymer dissolved in good solvent ([P]0), the volume ratio of good 
solvent to bad solvent, also known as the dilution ratio (DR = VDI H2O / VTHF) and consequently 
the final polymer concentration in water ([P]f) must all be taken into consideration. In order to 
ensure a uniform process, all nanoprecipitations were conducted using 1 mL of a starting 
solution comprising a [P]0 of 5 mg mL-1 in THF into 5 mL of deionised (DI) H2O. These 




and subsequent nanoparticle formation of a number of polymers containing similar structures 
and functionalities to the ones described here.24–28 A general overview of the nanoprecipitation 
process employed is presented in Figure 3.4. Briefly, 1 mL of a THF solution the polymer was 
rapidly injected into 5 mL of DI H2O under magnetic stirring using a Gilson® manual air 
displacement pipette; nanoprecipitations were left under magnetic stirring at ambient 
temperature for 48 hours to facilitate solvent removal via evaporation to give an aqueous 
nanoparticle dispersion at a [P]f of 1 mg mL-1.  
 
Figure 3.4 Schematic representation of the process by which the nanoprecipitation all 33 
polymers was attempted. Firstly, 1mL of a THF solution containing either: a) linear homopolymer, 
b) AB block copolymer or c) branched copolymer ([P]0 = 5 mg mL-1) were added to 5 mL of DI H2O 
causing rapid nanoprecipitation. THF was removed via evaporation over 48 hours leaving an aqueous 
nanoparticle dispersion at a [P]f of 1 mg mL-1. 
With the exception of p(HPMA)65 and p(HPMA63-co-EGDMA0.90), nanoprecipitations of 
linear and branched copolymers resulted in the immediate formation of a turbid mixture. After 
48 hours, visual inspection of the attempted nanoprecipitations of linear homopolymers and 
branched copolymers, with the exception of p(HPMA63-co-EGDMA0.90), indicated that 
nanoprecipitation had not been successful. This was evident by macroscopic polymer 
precipitation and subsequent sedimentation within the glass vials (Figure 3.5). In contrast, 
p(HPMA63-co-EGDMA0.90) formed a turbid, aqueous nanoparticle dispersion with no 
evidence of polymer sedimentation. The success of the nanoprecipitation of 
p(HPMA63-co-EGDMA0.90) was somewhat unsurprising given the prior reports of the 
formation of branched p(HPMA-co-EGDMA) based nanoparticles in the literature.23,24 The 
size distribution of p(HPMA63-co-EGDMA0.90) nanoparticles was assessed using dynamic 
light scattering (DLS). Analysis showed intensity-derived hydrodynamic diameter (Dz) of 
81 nm and a polydispersity index (PDI) of 0.041. The success of the nanoprecipitation of 
branched copolymers consisting of p(HPMA) has been attributed to the high surface charge of 
the nanoparticles formed. Whilst the explanation for this apparent charge stabilisation remains 




generated here, - 34.7 mV, should provide a moderate level of charge stabilisation.24 What 
perhaps was also unsurprising was the failure of the other predominantly lipophilic groups to 
provide any stabilisation for aqueous nanoparticle dispersions. However, this may seem less 
surprising when considering the relative polarity of repeat units containing short aliphatic or 
even aromatic groups such as those found in MMA and BzMA respectively.  
 
Figure 3.5 Visual observations of nanoprecipitation experiments conducted using a) linear 
homopolymers, b) branched statistical copolymers and c) amphiphilic AB block copolymers, 48 hours 
after polymer addition. (left to right) p(MMA), p(EMA), p(HPMA), p(nBMA), p(tBMA), p(nHMA), 
p(CHMA), p(BzMA), p(EHMA), p(LMA), p(SMA). 
In contrast to nanoprecipitations consisting mainly of linear homopolymers and branched 
copolymers, all nanoprecipitations of amphiphilic block copolymers remained turbid and 
translucent immediately following polymer addition. However, the nanoprecipitation of 
PEG45-b-p(CHMA)123, PEG45-b-p(BzMA)123 and PEG45-b-p(SMA)122 formed macroscopic 
precipitates following solvent evaporation. These nanoprecipitations were repeated at a [P]0 
of 0.5 mg mL-1, which resulted in the formation of stable PEG45-b-p(CHMA)123 nanoparticles. 
The remaining AB block copolymers formed turbid nanoparticle dispersions with no evidence 
of sedimentation (Figure 3.5c). The aqueous nanoparticle dispersions obtained from all 






Table 3.1 Characterisation of polymeric nanoparticles generated through successful 










Branched p(HPMA63-co-EGDMA0.90) 81 65 0.041 486034 -34.7 
AB Block 
PEG45-b-p(MMA)120 97 45 0.239 221229 -* 
PEG45-b-p(EMA)120 99 49 0.313 227997 -* 
PEG45-b-p(HPMA)120 121 98 0.035 253390 -11.9 
PEG45-b-p(nBMA)120 78 58 0.079 395842 -12.0 
PEG45-b-p(tBMA)120 74 50 0.104 218123 -12.0 
PEG45-b-p(nHMA)120 77 58 0.066 379431 -3.4 
PEG45-b-p(EHMA)120 85 63 0.067 516357 -11.6 
PEG45-b-p(LMA)120 93 76 0.026 732780 -1.6 
aObtained using DLS analysis of aqueous nanoparticle dispersions at a concentration of 1 mg mL-1. bObtained via measurement 
of the electrophoretic mobility in 0.01M KCl aqueous nanoparticle dispersions. *Sample unstable, reliable zeta potential data 
could not be obtained. 
Nanoparticle hydrodynamic diameters (Dz = 74 - 124 nm) were broadly comparable to 
number-average hydrodynamic diameters (Dn =  45 - 105 nm) throughout this series of 
materials. No trends were observed between nanoparticle size and the chemical nature of the 
methacrylate monomers from which AB block copolymers were constructed. With the 
exception of PEG45-b-p(MMA)122 and PEG45-b-p(CHMA)123 based nanoparticles, all aqueous 
nanoparticle dispersions had narrow size distributions (PDI ≤ 0.100), which is indicative of 
homogeneous nucleation and rapid growth during the nanoprecipitation process. In all cases 
the zeta potentials obtained were generally low (-1.6 to -12.0 mV) which indicated that 
nanoparticle stability is not maintained by electrostatic stabilisation and thus is likely provided 
through steric stabilisation conferred by the hydrated PEG coronas of individual nanoparticles.   
Interestingly there were varying levels of success observed during nanoprecipitation of 
copolymers which varied in monomer functionality and architecture. In all cases, the sole 
nanoprecipitation of linear homopolymers failed to generate stable nanoparticles. This may 
appear somewhat surprising in the case of p(HPMA)65 whose corresponding branched 
copolymer generated monodisperse electrostatically stabilised nanoparticles. However, the 
role of high molecular weight p(HPMA-co-EGDMA) copolymers in promoting rapid 
homogeneous nucleation during co-nanoprecipitation has been reported previously.23 In all 
other cases the failed nanoprecipitations were less surprising; the absence of groups capable 
of providing either electrostatic of steric stabilisation inevitably resulted in polymer 
aggregation due to uncontrolled growth during the nanoprecipitation process. This explanation 
can also be applied to the failed sole nanoprecipitations of all branched copolymers, with the 
exception of p(HPMA65-co-EGDMA0.90). In contrast, the sole nanoprecipitation of 




majority of polymers. It was assumed that the presence of the PEG block provided 
nanoparticles with steric stabilisation which could prevent nanoparticle-nanoparticle 
aggregation. This is supported by the relatively low zeta potentials obtained which would 
typically be considered insufficient to prevent such aggregation. The failed nanoprecipitations 
of PEG45-b-p(BzMA)123 and PEG45-b-p(SMA)122 were surprising. In the case of 
PEG45-b-p(SMA)122 it is possible that nanoparticle instability could be attributed to the 
relatively low weight fraction of PEG45 hydrophilic block. However, this hypothesis does not 
explain the failed nanoprecipitation of PEG45-b-p(BzMA)123, for which the hydrophilic PEG45 
block has a higher weight fraction than that of PEG45-b-p(EHMA)115 and PEG45-b-(p(LMA)122 
(which both produced stable aqueous nanoparticle dispersions).  
It was evident from these experiments that stable aqueous nanoparticle dispersions could not 
be prepared via individual nanoprecipitation of all of the linear homopolymers or the vast 
majority of the branched copolymers studied here. The preparation of stable aqueous 
nanoparticle dispersions would therefore require the addition of a second component capable 
of conferring colloidal stabilisation. The success of nanoprecipitation with AB block 
copolymers demonstrated that these materials are capable of generating nanoparticles alone, 
which possess steric stabilisation and can therefore prevent nanoparticle-nanoparticle 
aggregation. Further studies therefore focused on generating stable aqueous nanoparticle 
dispersions via co-nanoprecipitation of linear homopolymers and branched copolymers with 
their corresponding amphiphilic block copolymers. 
3.4 Co-nanoprecipitation Studies 
Despite the failure of a significant number of nanoprecipitations described above, 
co-nanoprecipitation studies were conducted using combinations of all 33 polymers identified 
in Section 3.2. This approach was taken to understand whether materials which were unable 
to form stable nanoparticles unilaterally through nanoprecipitation, could be incorporated into 
stable aqueous nanoparticle dispersions via co-nanoprecipitation with another polymer. 
Co-nanoprecipitations were attempted using three (co)polymer combinations: i) linear 
homopolymers and branched copolymers, ii) linear homopolymers and AB block copolymers 
and iii) branched copolymers and AB block copolymers. An overview of the 
co-nanoprecipitation process is presented in Figure 3.6. Co-nanoprecipitations were attempted 
using compatible (co)polymers; for example, in the case of the co-nanoprecipitation of 
p(HPMA) based branched and AB block copolymers, p(HPMA63-co-EGDMA0.90) was 
co-nanoprecipitated with PEG45-b-p(HPMA)124. The combinations of (co)polymer 
architectures were selected to provide further confirmation of the importance of hydrophilic 






Figure 3.6 Schematic representation of the process by which co-nanoprecipitations of all 33 
polymers combinations were attempted. Firstly, 1mL of a THF solution containing combinations of: 
a) linear homopolymer/branched copolymer, b) linear homopolymer/AB block copolymer or c) AB 
block copolymer/ branched copolymer were added to DI H2O causing rapid nanoprecipitation. THF was 
subsequently removed via evaporation over 48 hours leaving an aqueous nanoparticle dispersion.  
3.4.1 Initial Co-nanoprecipitation Studies  
Initial co-nanoprecipitations were conducted via the addition of 1 mL of a polymer-THF 
solution at a [P]0 of 5 mg mL-1 to 5 mL of DI H2O (DR = 5). In all cases polymer-THF solutions 
consisted of equal weight fractions of the two (co)polymers being co-nanoprecipitated 
(ωi = 0.50) and co-nanoprecipitations were left under magnetic stirring for 48 hours to 
facilitate solvent removal via evaporation.   
Unsurprisingly, with the exception of the p(HPMA) based (co)polymers, all 
co-nanoprecipitations of linear homopolymers with branched copolymers were unsuccessful 
and resulted in macroscopic aggregation shortly after polymer addition (Figure 3.7a). Similar 
to the sole nanoprecipitations of linear homopolymers and branched copolymers, the absence 
of groups capable of providing electrostatic and/or steric stabilisation likely resulted in failure 
to prevent nanoparticle-nanoparticle aggregation processes during co-nanoprecipitation. In 
contrast, the co-nanoprecipitation of p(HPMA)65 and p(HPMA63-co-EGDMA0.90) generated a 
colloidally stable near-monodisperse aqueous nanoparticle dispersion. Analysis of the 
nanoparticle size distribution by DLS showed that nanoparticles possessed near identical Dz, 
Dn and PDI values to those generated during the sole nanoprecipitation of p(HPMA63-co-
EGDMA0.90), see Table 3.2. Once again, significant negative zeta potential (= -17.5 mV) 
suggested a moderate degree of electrostatic stabilisation. When considering the composition 
of branched copolymer molecular weight distributions, which were discussed in Chapter 2 
Section 2.4, it is reasonable to suggest that the sole nanoprecipitation of 
p(HPMA63-co-EGDMA0.90) could itself be considered a co-nanoprecipitation of branched 




distributions obtained were therefore anticipated. At this point, it was decided to abandon 
further co-nanoprecipitations of solely hydrophobic linear homopolymers and branched 
copolymers; this approach was not used throughout the remainder of the work discussed in 
this thesis.   


























Linear/ AB block 
MMA* 112 84 0.105 182717 -* 
EMA* 99 69 0.126 342583 -* 
HPMA 100 79 0.063 404430 -17.4 
nBMA 97 72 0.086 587237 -11.7 
tBMA 78 54 0.121 269339 -21.3 
nHMA 109 94 0.011 1107125 -3.68 
CHMA Aggregation 
CHMA* 79 62 0.108 55927 -* 
BzMA Aggregation 
EHMA 110 97 0.010 1086538 -1.56 
LMA 122 106 0.014 1135586 -1.73 
SMA Aggregation 
AB block/ Branched  
MMA* 113 83 0.108 180289 -12.8 
EMA* 100 71 0.111 260780 -* 
HPMA 84 67 0.043 370713 -17.5 
nBMA 94 68 0.086 635687 -10.7 
tBMA 77 53 0.099 273918 -13.3 
nHMA 109 94 0.014 909072 -3.38 
CHMA   Aggregation   
CHMA* 53 41 0.120 47157 -* 
BzMA Aggregation 
EHMA 107 91 0.021 890243 -2.04 
LMA 127 112 0.007 1077041 -1.56 
SMA Aggregation 
aObtained using DLS analysis of aqueous nanoparticle dispersions at a concentration of 1 mg mL-1. bObtained via measurement 
of the electrophoretic mobility within 0.01M KCl aqueous nanoparticle dispersions. *Sedimentation observed. Aqueous 






In contrast, co-nanoprecipitations of hydrophobic linear homopolymers and amphiphilic AB 
block copolymers initially proved more successful, in all cases, nanoprecipitations remained 
turbid and translucent shortly after polymer addition. However, as was observed following the 
sole nanoprecipitations of amphiphilic AB block copolymers, p(CHMA), p(BzMA) and 
p(SMA) based co-nanoprecipitations did not remain colloidally stable following THF 
evaporation (Figure 3.7b). These results were not surprising given the corresponding 
amphiphilic block copolymers were unable to provide sufficient steric stabilisation to prevent 
nanoparticle aggregation when nanoprecipitated under identical conditions. Again, these 
nanoprecipitations were repeated at a decreased [P]0 of 0.5 mg mL-1 which produced a stable 
p(CHMA) based aqueous nanodispersion. In addition to this, p(MMA) based 
co-nanoprecipitations showed small amounts of sedimentation. As a result, DLS analyses were 
conducted after passing the p(MMA) aqueous nanoparticle dispersion through a 0.25 µm 
PTFE filter. Turbid and translucent aqueous nanoparticle dispersions were obtained from 
co-nanoprecipitations of p(EMA), p(HPMA), p(nBMA), p(tBMA), p(nHMA), p(EHMA) and 
p(LMA) based linear homopolymers and amphiphilic AB block copolymers. Similar results 
were observed from co-nanoprecipitations of branched copolymers and AB block copolymers 
(Figure 3.7c); the only clear difference being the presence of small amounts of sedimentation 
in the p(EMA) based co-nanoprecipitation. p(EMA) nanoparticles were therefore passed 
through a 0.25 µm PTFE filter prior to DLS analysis. The p(EMA) co-nanoprecipitations were 
therefore repeated at a decreased [P]0 of 0.5 mg mL-1 but this made little difference to 
nanoparticle stability. 
 
Figure 3.7 Visual observations of conanoprecipitation experiments conducted using 
combinations of a) linear homopolymers and branched copolymers, b) amphiphilic AB block 
copolymers and linear homopolymers, and c) amphiphillic AB block copolymers and branched 
copolymers, 48 hours after polymer addition. (left to right) p(MMA), p(EMA), p(HPMA), p(nBMA), 




Aqueous nanoparticle dispersions from co-nanoprecipitations were assessed via DLS and zeta 
potential analyses (Table 3.2). Co-nanoprecipitations generally created nanoparticles which 
possessed slightly larger hydrodynamic diameters compared to those produced by the sole 
nanoprecipitation of the corresponding amphiphilic AB block copolymer. For example, 
p(nBMA), p(nHMA), p(EHMA) and p(LMA) based co-nanoprecipitations of branched 
copolymers and amphiphilic AB block copolymers generated nanoparticles containing Dz 
values of 97, 109, 107 and 127 nm respectively, whereas nanoparticles generated via the 
analogous sole nanoprecipitations of the corresponding AB block copolymers gave Dz values 
of 78, 77, 85 and 93 nm respectively.  
Similar increases in hydrodynamic diameters were observed for nanoparticles generated 
through co-nanoprecipitation of linear homopolymers with amphiphilic AB block copolymers. 
This can be explained by considering the role that each component plays during the 
co-nanoprecipitation process. As identified in Section 3.3, amphiphilic AB block copolymers 
are the only components capable of providing sufficient levels of steric stabilisation capable 
of preventing nanoparticle-nanoparticle aggregation. The role of amphiphilic AB block 
copolymers during co-nanoprecipitation must therefore be to stabilise the hydrophobic 
(co)polymers with which they are co-nanoprecipitated. This was supported by the low zeta 
potentials demonstrated through measurement of the electrophoretic mobility of aqueous 
nanoparticle dispersions. Initial co-nanoprecipitations were conducted using an amphiphilic 
AB block copolymer ωi of 0.50. As a result, only half the number of stabilising AB block 
copolymer chains are present during co-nanoprecipitation; this lower number of chains are 
now required to stabilise hydrophobic domains which were not present during individual 
nanoprecipitations. It is therefore likely that the reduction in the amphiphilic AB block 
copolymer concentration during co-nanoprecipitation was responsible for the larger 
hydrodynamic diameters. Further investigation of this hypothesis is provided later in this 
chapter (Section 3.4.3.1).   
What may appear to contradict this hypothesis are the results obtained from 
co-nanoprecipitations of p(HPMA) based nanoparticles. Nanoparticles generated via all forms 
of p(HPMA) based co-nanoprecipitations possessed lower hydrodynamic diameters than those 
obtained from the sole nanoprecipitation of PEG45-b-p(HPMA)124. In addition, significant 
variations were observed in the hydrodynamic diameters of nanoparticles generated via 
co-nanoprecipitations of different (co)polymer architectures. This contrasting behaviour can 
be explained by the chemical structure of both the p(HPMA) repeat unit and the architectures 
of the (co)polymers being nanoprecipitated. As demonstrated using pyrene fluorescence 
emission spectroscopy in Chapter 2 (Section 2.2.1), HPMA was the most polar methacrylate 




based (co)polymers can therefore be considered the most polar – or least hydrophobic – 
(co)polymers used in this study.  
It is well known that polymer hydrophobicity is a crucial parameter which governs the extent 
of supersaturation and thus the nucleation rate observed during nanoprecipitation.19 The 
nucleation rate controls the number and therefore the size of the nanoparticles subsequently 
formed. It is therefore likely that the relatively low hydrophobicity of p(HPMA) based 
(co)polymers may influence nucleation during (co)nanoprecipitation. As a result, this could 
explain the architecture-dependent hydrodynamic diameters observed, which have also been 
reported previously.23   
Given the aqueous solubility of its PEG block, it is likely that PEG45-b-p(HPMA)124 would 
express the lowest level of supersaturation within the (co)nanoprecipitation medium (5:1 v/v 
DI H2O: THF) of all the p(HPMA) polymers studied. It is also possible that this would have 
hindered the nucleation process during the sole nanoprecipitation of PEG45-b-p(HPMA)124 
and, as a result, generated aqueous nanoparticle dispersions possessing larger hydrodynamic 
diameters (Dz = 125 nm). In contrast, nanoparticles generated via co-nanoprecipitations of 
PEG45-b-p(HPMA)124 with hydrophobic domains of either linear homopolymers or branched 
copolymers, which do not possess hydrophilic PEG domains, exhibited smaller hydrodynamic 
diameters. It is possible that this may have occurred as a result of such hydrophobic domains 
driving the nucleation process during co-nanoprecipitation due to increased levels of 
supersaturation within the co-nanoprecipitation medium. Interestingly, smaller hydrodynamic 
diameters were observed for nanoparticles generated by co-nanoprecipitation of 
PEG45-b-p(HPMA)124 with p(HPMA63-co-EGDMA0.90) (Dz = 84 nm) than were obtained for 
nanoparticles produced via co-nanoprecipitation with p(HPMA)65  
(Dz = 100 nm). Furthermore, the size distribution of nanoparticles generated in the sole 
nanoprecipitation of p(HPMA63-co-EGDMA0.90) (Dz = 81 nm) was practically identical to that 
of nanoparticles formed during its co-nanoprecipitation with PEG45-b-p(HPMA)124. These 
results demonstrate the importance of the architecture of the hydrophobic domain in the 
co-nanoprecipitation of p(HPMA) based (co)polymers which is consistent with the previous 
reports.23,24 These results therefore suggest that nanoparticles are formed via an 
architecture-dependent nucleation process which occurs as a result of the relatively low levels 
of supersaturation which exist due to the moderate hydrophobicity of p(HPMA) based 
(co)polymers. 
Conversely, in all other cases, DLS analyses showed practically identical hydrodynamic 
diameters for nanoparticles generated via co-nanoprecipitations of amphiphilic AB block 




all polymers, with the exception of p(HPMA), co-nanoprecipitation proceeds via an 
architecture-independent nucleation process. It is likely that this is the result of greater degrees 
of supersaturation within the co-nanoprecipitation medium due to the increased 
hydrophobicity of polymers constructed from lower polarity monomers. 
Nanoparticles generated via co-nanoprecipitation of amphiphilic block and branched 
copolymers were assessed using scanning electron microscopy (SEM). The physical properties 
of the polymers made imaging of nanoparticles difficult. Polymers containing long aliphatic 
side chains typically exhibit low Tg values. As a result, nanoparticles constructed of low Tg 
polymers were unable to retain their independent particle structure during the drying process 
therefore making such dried samples unrepresentative of nanoparticle morphology and 
rendering them unsuitable for SEM imaging (Appendix, Figure A3.2). Alternatively, higher 
Tg polymers maintained their original nanoparticle morphology during the drying process and, 
as a result, suitable images could be obtained for p(HPMA), p(nBMA), p(tBMA) and 
p(CHMA) based nanoparticles (Figure 3.8). SEM images showed that, in all cases, branched 
vinyl polymer nanoparticles possessed spherical morphologies and were able to maintain their 
structural integrity even at high concentration.  
 
Figure 3.8 Scanning electron microscopy images of branched vinyl polymer nanoparticles 
generated via co-nanoprecipitation of AB block and branched copolymers consisting of: a) p(HPMA), 




These experiments demonstrated many examples where stable aqueous nanoparticle 
dispersions can be generated via co-nanoprecipitation of both hydrophobic linear 
homopolymers and branched copolymers with amphiphilic block copolymers. In particular, 
the preparation of near-monodisperse p(MMA), p(HPMA), p(nBMA), p(tBMA), p(nHMA), 
p(CHMA), p(EHMA) and p(LMA) based aqueous nanoparticle dispersions could be achieved 
containing polymeric components which could not individually form stable aqueous 
nanoparticle dispersions in the absence of amphiphilic AB block copolymers. It was not 
possible to generate stable p(BzMA) or p(SMA) based nanoparticles under any circumstances 
therefore these materials were not studied further throughout the remainder of this work. 
Moreover, p(EMA), p(MMA) and p(CHMA) nanoparticles all required co-nanoprecipitation 
from a decreased [P]0 of 0.5 mg mL-1. Nevertheless, these materials still showed signs of 
polymer sedimentation over time, which is indicative of colloidal instability.  
Whilst the ability to generate stable aqueous nanoparticle dispersions is a pre-requisite for the 
development of a novel DNC system, there is no guarantee that the formation of such desirable 
nanomaterials would be produced in the presence of a chemotherapeutic compound. Further 
studies were therefore required to determine (i) whether small molecules could be 
encapsulated using branched vinyl polymer nanoparticles during the co-nanoprecipitation 
process and (ii) to understand their impact, if any, on the co-nanoprecipitation process.  
3.4.2  Encapsulation of a Hydrophobic Molecule during Co-nanoprecipitation   
The preparation of a polymer-based DNC system must include a strategy to encapsulate 
hydrophobic drug molecules within the core of the DNC. A series of model drug encapsulation 
experiments were therefore conducted in order to determine whether it was possible to 
encapsulate a hydrophobic guest molecule within the core of branched vinyl copolymer 
nanoparticles. 
3.4.2.1 Impact of a Guest Molecule on the (Co)nanoprecipitation process  
Encapsulation experiments were conducted using pyrene as a small hydrophobic guest 
molecule. This was achieved by adding pyrene to the copolymer-THF solutions from which 
co-nanoprecipitations were typically attempted (Figure 3.9). It was expected that during this 
co-nanoprecipitation of an amphiphilic block copolymer, a hydrophobic branched copolymer 
and pyrene, the hydrophobic nature of pyrene would cause it to become entrapped and thus 
encapsulated within the core of branched vinyl copolymer nanoparticles during the 
nanoprecipitation process. These experiments aimed to answer two key questions: i) could a 
hydrophobic model drug, i.e. pyrene, be encapsulated without hindering the 
co-nanoprecipitation process and ii) could the environment-dependent fluorescence emission 





Figure 3.9 Schematic representation of the encapsulation of pyrene during co-nanoprecipitation.  
Co-nanoprecipitations of amphiphilic block copolymers, hydrophobic branched copolymers 
and pyrene were conducted in a similar manner to those of the successful 
co-nanoprecipitations described above. Co-nanoprecipitations were conducted from a 
THF-solution containing a [P]0 of 5 mg mL-1 which contained equal mass fractions of AB 
block and branched copolymers; in addition, a model drug loading of 1 weight percent (wt %) 
with respect to the total polymer mass was targeted by also ensuring a pyrene concentration of 
0.05 mg mL-1 within the initial THF solution. Nanoprecipitations were conducted by addition 
of 1 mL of the polymer/ pyrene solution to 5 mL of DI H2O (DR = 5). Following the improved 
co-nanoprecipitations observed at lower [P]0 in THF co-nanoprecipitations of p(MMA), 
p(CHMA) and p(tBMA) based polymers were conducted from a [P]0 of 0.5 mg mL-1 whilst 
maintaining a DR = 5 to give an aqueous nanoparticle dispersion of [P]f = 0.1 mg mL-1.  
In all cases, nanoprecipitations remained turbid/translucent after polymer addition and 
aqueous nanoparticle dispersions were obtained following THF removal via evaporation over 
48 hours without macrophase separation. Nanoparticle size distributions were obtained using 
DLS. In all cases, the size distributions obtained largely resembled those produced via 
co-nanoprecipitation in the absence of pyrene (Figure 3.6); as a result, the Dz, Dn and PDI 
values were broadly comparable to the unloaded aqueous nanoparticle dispersions (Table 3.3). 
This indicated that the presence of small amounts of pyrene had little impact on the 







Table 3.3 Analysis of branched vinyl copolymer nanoparticles obtained from 
co-nanoprecipitations of amphiphilic block copolymers, hydrophobic branched copolymers and pyrene.   








p(MMA70-co-EGDMA0.94)* PEG45-b-p(MMA)122* 159 100 0.180 726635 
p(HPMA63-co-EGDMA0.90) PEG45-b-p(HPMA)124 87 69 0.044 232057 
p(nBMA73-co-EGDMA1.12) PEG45-b-p(nBMA)125 91 64 0.083 393311 
p(tBMA67-co-EGDMA1.05)* PEG45-b-p(tBMA)122* 85 60 0.098 12096 
p(nHMA68-co-EGDMA1.03) PEG45-b-p(nHMA)127 115 95 0.022 468489 
p(CHMA69-co-EGDMA1.06)* PEG45-b-p(CHMA)123* 55 43 0.049 27924 
p(EHMA68-co-EGDMA0.93) PEG45-b-p(EHMA)115 102 85 0.005 787508 
p(LMA70-co-EGDMA1.04) PEG45-b-p(LMA)121 133 114 0.009 595910 
aData obtained using DLS. bData obtained using zeta potential measurement. *Co-nanoprecipitations conducted from a [P]0 of 
0.5 mg mL-1 in THF to a [P]f of 0.1 mg mL
-1 in DI H2O.  
The similarities between nanoparticles generated via co-nanoprecipitation with and without 
the presence of pyrene gave a strong indication that pyrene encapsulation was successful 
during all co-nanoprecipitations. In all co-nanoprecipitations, the resulting pyrene 
concentration within aqueous nanoparticle dispersions (4.94 x10-3 or 4.94 x10-4 mol dm-3) were 
in excess of the aqueous saturation concentration of pyrene (6.67 x10-7 mol dm-3).29 The 
combination of this low aqueous solubility with the absence of sedimentation/ aggregation 
during DLS analyses indicate that pyrene was encapsulated within branched vinyl copolymer 
nanoparticles during co-nanoprecipitation.    
Analysis of aqueous nanoparticle dispersions therefore confirmed that low loadings (1 wt %) 
of pyrene had little/negligible impact on nanoparticle formation during the 
co-nanoprecipitation process. The ability to generate colloidally stable, near-monodisperse 
nanoparticles in the presence of hydrophobic small molecules is a promising sign for the 
generation of DNC systems via co-nanoprecipitation of amphiphilic AB block and branched 
copolymers. However, it is important to state that these results only indicate rather than 
confirm the encapsulation of pyrene during co-nanoprecipitation. Further studies were 







Figure 3.10 Overlaid nanoparticle size distributions obtained by DLS analysis of unloaded 
(dashed lines) and pyrene loaded (solid lines) aqueous nanoparticle dispersions prepared by 
co-nanoprecipitation of: a) p(HPMA), b) p(nBMA), c) p(nHMA), d)  p(EHMA) and e) p(LMA).   
3.4.2.2 Evaluation of Nanoparticle Core Polarity using Fluorescence Emission Spectroscopy   
The selection of pyrene as a hydrophobic guest molecule during co-nanoprecipitation allowed 
confirmation of encapsulation using fluorescence emission spectroscopy. This was achieved 
through analysis of the fine structure of the fluorescence emission of pyrene, in particular the 
relative intensities of the first and third vibrational bands (I1/I3). Pyrene has often been used as 




measure the relative polarities of organic solvents and to determine the critical micelle 
concentration of aqueous surfactant and block copolymer self-assembly processes.30–32 In all 
cases, the fluorescence emissions of aqueous nanoparticle dispersions, obtained following 
excitation at λ = 335 nm, showed that the encapsulation of pyrene during co-nanoprecipitation 
had been successful. This was evident by the significantly lower I1/I3 ratios obtained from 
pyrene encapsulated in branched vinyl polymer nanoparticles (I1/I3 = 1.50 – 0.95) in 
comparison to that of pyrene dissolved in DI H2O (I1/I3 = 1.80, Table 3.4). These results 
demonstrate that pyrene is located within an environment of considerably lower polarity 
following co-nanoprecipitation which is consistent with its encapsulation during 
co-nanoprecipitation.   
Table 3.4 Polarity and hydrophobicity data obtained using molecular modelling calculations 
and pyrene emission spectroscopy. 







p(MMA70-co-EGDMA0.94) PEG45-b-p(MMA)122 0.99 1.44 1.39 
p(HPMA63-co-EGDMA0.90) PEG45-b-p(HPMA)124 0.79 1.48 1.60 
p(nBMA73-co-EGDMA1.12) PEG45-b-p(nBMA)125 2.23 1.30 1.20 
p(tBMA67-co-EGDMA1.05) PEG45-b-p(tBMA)122 1.86 1.25 1.24 
p(nHMA68-co-EGDMA1.03) PEG45-b-p(nHMA)127 3.07 1.23 1.10 
p(CHMA69-co-EGDMA1.06) PEG45-b-p(CHMA)123 2.54 1.27 1.18 
p(EHMA68-co-EGDMA0.93) PEG45-b-p(EHMA)115 3.88 1.17 1.05 
p(LMA70-co-EGDMA1.04) PEG45-b-p(LMA)121 5.77 1.16 1.00 
aObtained via QSAR calculations using Spartan’18 molecular modelling software. bObtained using fluorescence emission 
spectroscopy of pyrene dissolved in neat monomer. cObtained using fluorescence emission spectroscopy of aqueous nanoparticle 
dispersions following attempted encapsulation of pyrene during co-nanoprecipitation.  
Pyrene encapsulation was further corroborated by the strong correlations observed between 
the I1/I3 ratios obtained from the fluorescence emission spectroscopy of encapsulated pyrene 
and the chemical structure of the polymers used in co-nanoprecipitation (Figure 3.11). A 
strong correlation was observed between the I1/I3 ratios obtained for encapsulated pyrene and 
those obtained for pyrene dissolved within the neat monomer from which the branched and 
AB block copolymers used during co-nanoprecipitation were constructed (Figure 3.11, a). 
These data support the encapsulation of pyrene during co-nanoprecipitation, but also raise two 
important points. Firstly, the high dependence of the pyrene fluorescence emission on 
monomer chemistry suggests that pyrene is in fact encapsulated within the nanoparticle core 
rather than adsorbed to the surface or even trapped within the hydrated corona of the 
nanoparticle. In the event that pyrene is located on the surface or even within the external 
hydrated corona of branched copolymer nanoparticles, a much weaker correlation between the 
polarity of the external environment of pyrene and that of the nanoparticle’s hydrophobic 




of the nanoparticle core is highly dependent upon the chemical structure of the comonomers 
from which polymers are constructed. This demonstrates that, in the cases presented here, 
nanoparticle internal polarity is dominated by the low-polarity hydrophobic domains rather 
than the PEG-based hydrophilic domains. 
 
Figure 3.11 Graphical representations of the relationships between nanoparticle internal polarity 
and the chemical properties of the comonomers from which the polymers used during co-
nanoprecipitation are constructed. a) A plot of the I1/I3 ratios of encapsulated pyrene vs. pyrene 
dissolved within neat monomer. b) A plot of the I1/I3 ratios of encapsulated pyrene vs. CLogP values 
for the comonomers from which nanoparticles are constructed.  
Similar analyses were also made taking into account the hydrophobicity of the comonomers 
from which amphiphilic AB block and branched copolymers were constructed. Monomer 
hydrophobicity was measured according to their calculated water-octanol partition coefficients 
(CLogP) obtained using Spartan ’18 molecular modelling software. (Table 3.4). As expected, 
CLogP values increased with increasing lipophilicity of the methacrylate monomer 




vinyl polymer nanoparticles against the CLogP of the monomer from which nanoparticles 
were constructed also showed a strong correlation. A general reduction in the polarity within 
the core of branched copolymer nanoparticles was observed with increasing CLogP. However, 
unlike the relationship observed between I1/I3 ratios described above, the relationship between 
the I1/I3 and CLogP values obtained was non-linear.  
Changes in monomer CLogP appeared to have a more significant impact on nanoparticle core 
polarity at low CLogP values. For example, an increase in the size of the aliphatic chain length 
from 1 to 4 carbons, p(MMA) to p(nBMA), lowers the I1/I3 ratio of encapsulated pyrene from 
1.39 to 1.20 (-0.19). A similar increase from 8 to 12 carbons, for p(EHMA) to p(LMA), caused 
a much smaller reduction from 1.05 to 1.00 (-0.05). Whilst this may initially seem surprising, 
these results are explained by the relative weight fractions of the aliphatic side chains. 
Increases to the aliphatic chain length constitute a higher weight fraction of the overall repeat 
unit mass in monomers containing low relative molecular mass. For example, the weight 
fraction of the aliphatic side chain increases from 0.15 to 0.40 with MMA to nBMA (+ 25 %). 
In contrast, a more modest increase in the weight fraction of the aliphatic side chain, from 0.57 
to 0.67, is observed between EHMA and LMA (+ 9 %). This is supported by the strong 
correlation observed between encapsulated I1/I3 ratios and the weight fraction of the aliphatic 
side chain (R2 = 0.95, Appendix, Figure A3.3).  
Encapsulation of pyrene within branched vinyl polymer nanoparticles during 
co-nanoprecipitation was confirmed using fluorescence emission spectroscopy. The selection 
of pyrene provided a useful tool to probe the internal polarity of branched vinyl polymer 
nanoparticles; this allowed relationships between the specific chemical nature of polymers and 
the macroscopic properties of the resulting nanoparticles to be established. Pyrene 
encapsulation therefore offers a useful tool to study the internal structure of branched vinyl 
polymer nanoparticles and may prove useful in developing further understanding of the factors 
which influence the co-nanoprecipitation process. 
3.4.3 Factors Affecting Co-nanoprecipitation  
Given the expansion of the range of (co)polymers used to generate branched vinyl copolymer 
nanoparticles, further studies were conducted to acquire a deeper understanding of the factors 
which influence the co-nanoprecipitation processes. In particular, the impact of the 
composition of branched and AB block copolymers in the initial THF solution as well as the 
total mass of polymer being co-nanoprecipitated were studied in order to understand their 
significance within the co-nanoprecipitation process. At this point, the co-nanoprecipitations 
of p(HPMA), p(nBMA), p(nHMA), p(EHMA) and p(LMA) based copolymers were studied 




3.4.3.1 Nanoparticle Composition 
In the studies described above, co-nanoprecipitations have been conducted using equivalent 
weight fractions of the two constituent copolymers. Given the likely contrasting roles of 
branched and AB block copolymers during the co-nanoprecipitation process, it was expected 
that manipulation of the weight fractions of the copolymers within the initial THF solution 
would impact the properties of the resulting branched vinyl copolymer nanoparticles. A range 
of co-nanoprecipitations were therefore performed to develop an understanding of the 
importance of the composition of the initial THF solution on the physical properties of the 
branched vinyl copolymer nanoparticles formed; in particular, the impact on nanoparticle 
stability, size and internal polarity. A general overview of how nanoparticle compositions were 
varied during these studies is presented in Figure 3.12. 
 
Figure 3.12 Schematic representation of the approach used to vary nanoparticle composition 
through co-nanoprecipitation. Demonstration of the manipulation of initial THF solutions, containing 
branched: AB block copolymer weight fractions of a) 1.0:0.0, b) 0.5:0.5, c) 0.0:1.0. 
Co-nanoprecipitations were conducted using standard conditions; this included the addition of 
1 mL of a copolymer-THF solution ([P]0 = 5 mg mL-1) to a fixed volume of DI H2O (5 mL). 
THF removal via evaporation over 48 hours at ambient temperature gave aqueous nanoparticle 
dispersions at a [P]f of 1 mg mL-1. In addition, low loadings of pyrene were encapsulated 
during the co-nanoprecipitation process in order to allow evaluation of nanoparticle internal 
polarity using fluorescence emission spectroscopy. It was expected that this would allow the 
impact of AB block: branched copolymer ratio on the internal polarity within branched vinyl 
copolymer nanoparticles to be understood. Pyrene at 1 wt% with respect to the total polymer 
mass was incorporated into the initial THF solution. In all cases, co-nanoprecipitations were 
conducted using AB block: branched copolymer weight fractions systematically varying from 




of AB block and branched copolymers, copolymer weight fractions were  not representative 
of the actual molar ratio of AB block to branched copolymers. Nonetheless, systematic 
variation of the copolymer weight fractions used inherently varied the molar ratio of AB 
block:branched copolymers in the initial THF solution and within the resulting branched vinyl 
copolymer nanoparticles.  
In line with what was observed during the sole nanoprecipitations of branched copolymers in 
Section 3.3, co-nanoprecipitations containing low weight fractions of the amphiphilic AB 
block copolymer resulted in macroscopic aggregation immediately after the addition of the 
copolymer-THF solution. This was generally observed for co-nanoprecipitations conducted 
using AB block copolymer weight fractions ≤ 20 %. The AB block copolymer weight fraction 
at which nanoprecipitations failed was dependent upon the methacrylic repeat unit of the 
copolymers. For example, all co-nanoprecipitations of PEG45-b-p(HPMA)124 and 
p(HPMA65-co-EGDMA0.90) were successful regardless of the AB block copolymer weight 
fraction used whereas p(nBMA), p(nHMA), p(EHMA) and p(LMA) based 
co-nanoprecipitations failed at AB block copolymer weight fractions of: 0.1, 0.1, 0.2 and 0.2 
respectively. Regardless of the chemical nature of the copolymers used, stable aqueous 
nanoparticle dispersions were obtained from all co-nanoprecipitations conducted at AB block 
copolymer weight fractions ≥ 0.3.  
The size distributions, hydrodynamic diameters and PDIs of aqueous nanoparticle dispersions 
were obtained using DLS analysis at a concentration of 1 mg mL-1 (Table 3.5). In the cases 
where macroscopic aggregation had occurred, where possible aqueous nanoparticle 
dispersions were passed through a 1 µm fibreglass filter to allow DLS analysis of any 
polymeric nanoparticles which remained in suspension after 48 hours.  
In all cases, DLS analyses of aqueous nanoparticle dispersions generated from successful 
co-nanoprecipitations showed monomodal size distributions consisting of highly 
monodisperse nanoparticles with intensity-average hydrodynamic diameters ranging from 
64 to 124 nm. Interestingly trends were observed between the hydrodynamic diameters of 
branched vinyl copolymer nanoparticles and the weight fraction of branched copolymer 
employed in co-nanoprecipitation (Figure 3.13). The nature of the relationship between 
branched copolymer weight fraction and the hydrodynamic diameters of branched copolymer 








Table 3.5 Size and internal polarity analyses of branched vinyl copolymer nanoparticles 

















1.0 0.0 121 98 0.035 -11.9 1.39 
0.9 0.1 106 81 0.070 -11.0 1.45 
0.8 0.2 103 68 0.114 -11.6 1.48 
0.7 0.3 81 56 0.090 -13.0 1.52 
0.6 0.4 69 53 0.064 -17.0 1.60 
0.5 0.5 68 51 0.063 -17.5 1.60 
0.4 0.6 67 49 0.068 -20.8 1.63 
0.3 0.7 67 48 0.082 -23.8 1.65 
0.2 0.8 65 45 0.090 -27.0 1.64 
0.1 0.9 65 43 0.110 -27.4 1.65 
0.0 1.0 64 41 0.109 -34.5 1.68 
p(nBMA) 
1.0 0.0 66 44 0.121 -12.0 1.28 
0.9 0.1 69 46 0.109 -12.9 1.26 
0.8 0.2 74 50 0.109 -11.2 1.26 
0.7 0.3 81 57 0.095 -11.4 1.25 
0.6 0.4 85 64 0.076 -12.0 1.24 
0.5 0.5 92 74 0.047 -11.7 1.23 
0.4 0.6 104 85 0.040 -11.0 1.22 
0.3 0.7 129 114 0.007 -10.3 1.21 
0.2 0.8 140 125 0.022 -11.2 1.20 
0.1* 0.9 166 153 0.012 - 1.30 
0.0* 1.0 191 167 0.105 - 1.19 
p(nHMA) 
1.0 0.0 81 65 0.043 -3.44 1.19 
0.9 0.1 82 66 0.031 -3.64 1.18 
0.8 0.2 83 68 0.019 -3.24 0.17 
0.7 0.3 88 73 0.027 -3.87 1.17 
0.6 0.4 95 79 0.013 -3.53 1.16 
0.5 0.5 105 90 0.006 -3.87 1.16 
0.4 0.6 124 109 0.015 -3.80 1.14 
0.3 0.7 136 121 0.022 -3.85 1.14 
0.2 0.8 157 144 0.012 -3.85 1.20 
0.1* 0.9 182 171 0.016 - 1.14 
0.0* 1.0 229 197 0.114 - 1.13 
p(EHMA) 
1.0 0.0 88 73 0.020 -11.6 1.10 
0.9 0.1 95 79 0.006 -9.03 1.11 
0.8 0.2 98 82 0.011 -10.1 1.09 
0.7 0.3 104 89 0.012 -10.7 1.10 
0.6 0.4 119 103 0.009 -8.62 1.07 
0.5 0.5 134 119 0.012 -9.84 1.05 
0.4 0.6 138 123 0.022 -10.9 1.09 
0.3 0.7 165 151 0.031 -10.3 1.06 
0.2* 0.8 Complete aggregation - 1.08 
0.1* 0.9 Complete aggregation - 1.02 
0.0* 1.0 Complete aggregation - 1.03 
p(LMA) 
1.0 0.0 96 78 0.024 -1.64 1.00 
0.9 0.1 99 82 0.020 -1.79 0.99 
0.8 0.2 102 84 0.011 -2.40 0.98 
0.7 0.3 112 94 0.010 -2.04 1.01 
0.6 0.4 122 103 0.047 -2.60 0.96 
0.5 0.5 131 109 0.029 -2.56 0.98 
0.4 0.6 134 114 0.047 -2.50 0.99 
0.3 0.7 137 115 0.029 -2.70 0.96 
0.2* 0.8 143 123 0.049 - 0.94 
0.1* 0.9 169 149 0.019 - 0.96 
0.0* 1.0 284 232 0.175 - 0.93 
aMeasured using DLS analysis at a concentration of 1 mg mL-1. bObtained from fluorescence emission spectroscopy of aqueous 
nanoparticle dispersions at a concentration of 1 mg mL-1 (λex = 335 nm). *Macroscopic aggregation observed. Samples passed 





Figure 3.13 Graphical representation of the impact of the branched copolymer weight fraction on 
the intensity-average (closed circles) and number-average (open squares) hydrodynamic diameters as 
well as the PDI (open triangles) of branched vinyl copolymer nanoparticles generated via 
co-nanoprecipitation of: a) p(HPMA), b) p(nBMA), c) p(nHMA), d) p(EHMA) and e) p(LMA). The 
branched copolymer weight fraction at which sedimentation occurred is highlighted in red.  
DLS analyses showed two contrasting relationships between the branched copolymer weight 
fraction and hydrodynamic diameter. The most common relationship showed a strong increase 
in both intensity-average and number-average hydrodynamic diameters with the increasing 
weight fraction of branched copolymer; this behaviour was observed for the 
co nanoprecipitations of p(nBMA), p(nHMA), p(EHMA), p(LMA) based copolymers. 
Interestingly, these relationships did not show linear increases in hydrodynamic diameter. 
Increases in the branched copolymer weight fraction from 0.0 to 0.5 typically had a relatively 




large increases in nanoparticle size until nanoprecipitations failed. For example, for the 
co-nanoprecipitation of PEG45-b-p(nHMA)123 and p(nHMA68-co-EGDMA1.03), increases in 
the branched copolymer weight fraction from 0.0 to 0.5 resulted in an increase in the intensity-
average hydrodynamic diameter from 81 – 105 nm (ΔDz = +24 nm) whereas further increases 
in the branched copolymer weight fraction to 0.8 saw the hydrodynamic diameter increase to 
157 nm (ΔDz = +52 nm) and finally the appearance of sediment at a branched copolymer 
weight fraction of 0.9.  
The reduction in AB block copolymer weight fraction, which accompanies increasing 
branched copolymer weight fractions, can explain this as fewer AB block copolymer chains 
were available to stabilise the increasing mass of hydrophobic branched copolymer. As a 
result, nanoparticle growth continues until a sufficient level of steric stabilisation is provided 
by the hydrophilic domains of AB block copolymers, which prevent further nanoparticle-
nanoparticle aggregation. It is likely that, in cases where low weight fractions of amphiphilic 
AB block copolymers were used, nanoparticles underwent longer growth periods owing to 
relatively low levels of steric stabilisation . In cases where exceptionally low levels of steric 
stabilisation were provided (AB block copolymer ωi ≤ 0.2), nanoparticles could not achieve 
colloidal stability which resulted in macroscopic precipitation. These results emphasise the 
importance of AB block copolymers in nanoparticle stabilisation during co-nanoprecipitation. 
In stark contrast to the co-nanoprecipitations described above, nanoparticles generated via 
co-nanoprecipitation of p(HPMA) based copolymers exhibited a reduction in hydrodynamic 
diameter as the weight fraction of the branched copolymer was increased. Increases in the 
weight fraction of p(HPMA63-co-EGDMA0.90) had the most significant impact as it was raised 
from 0.0 to 0.4. This was accompanied by a reduction in intensity-average hydrodynamic 
diameter from 121 to 69 nm (ΔDz = 52 nm). Further increases up to and including the sole 
nanoprecipitation of p(HPMA63-co-EGDMA0.90), from ωi = 0.4 to 1.0, had little impact on the 
size of nanoparticles formed (Dz = 64 nm, ΔDz = 5 nm). These results may appear counter-
intuitive given the role of amphiphilic AB block copolymers in the stabilisation of p(nBMA), 
p(nHMA), p(EHMA), p(LMA) based nanoparticles described above. However, there are two 
logical explanations for the trend observed in the hydrodynamic diameters of nanoparticles 
formed during p(HPMA) based co-nanoprecipitations. As demonstrated in Section 3.4.1, the 
high molecular weight branched copolymers play an important role in driving the nucleation 
process which occurs during p(HPMA) based co-nanoprecipitations. The results acquired here 
reiterate this hypothesis and suggest that it may be a reason for the variation observed in 
nanoparticle size. It is possible that nucleation is significantly hindered as a result of low 
amounts, or even the absence, of high molecular weight branched copolymers responsible for 




stable nuclei capable of further growth would be formed, consequently leading to the 
generation of larger nanoparticles. Increases in the branched copolymer weight fraction 
therefore increased the proportion of stable nuclei forming high molecular weight branched 
copolymers within the initial THF solution. As a result, the hydrodynamic diameters of 
nanoparticles generated decreased as the weight fraction of branched copolymer increased. 
Alternatively, the degree of electrostatic stabilisation provided by p(HPMA) could also be a 
contributing factor to the final hydrodynamic diameters of the p(HPMA) nanoparticles formed. 
When nanoprecipitating p(HPMA63-co-EGDMA0.90) in the absence of additional material, 
electrostatic stabilisation prevented nanoparticle-nanoparticle aggregation both during and 
after nanoprecipitation. In contrast, the low zeta potentials obtained for nanoparticles 
generated using low branched copolymer weight fractions suggest that such 
co-nanoprecipitations are reliant on the steric stabilisation provided by the hydrophilic 
domains of PEG45-b-p(nHMA)123 to cap nanoparticle growth. The impact of the branched 
copolymer weight fraction on nanoparticle stability is likely due to the relative contributions 
of electrostatic and steric to nanoparticle stabilisation during co-nanoprecipitation. It is 
therefore likely that the steric stabilisation mechanism is dominant at low branched copolymer 
weight fractions due to low amounts of p(HPMA63-co-EGDMA0.90); this suggestion is 
supported by the relatively low zeta potentials obtained for nanoparticles containing branched 
copolymer weight fractions ≤ 0.40. Whilst further increases in the branched copolymer weight 
fraction had little impact on nanoparticle size, significant increases were observed in the zeta 
potential of nanoparticles, which increased from -17.1 to -27 mV as the branched copolymer 
weight fraction was increased from 0.4 to 0.6. This indicated that at branched copolymer 
weight fractions ≥ 0.4, electrostatic stabilisation may become the predominant growth capping 
mechanism during co-nanoprecipitation. 
These results highlight the differing roles played by branched and AB block copolymers 
containing varied repeat unit functionalities during co-nanoprecipitation. In all cases, the 
components play important roles in both the nucleation and growth stages of 
co-nanoprecipitation. The co-nanoprecipitation of highly hydrophobic copolymers which are 
incapable of providing electrostatic stabilisation is less complex as the increased 
hydrophobicity of such materials generally drive rapid nucleation, regardless of copolymer 
architecture. Amphiphilic AB block copolymers were the sole component responsible for 
arresting nanoparticle growth, therefore nanoparticle hydrodynamic diameters were dependent 





In contrast, the co-nanoprecipitation of p(HPMA) based copolymers was more complex as it 
combined the architecture-dependent factors of copolymer nucleation and nanoparticle 
stabilisation. The relatively moderate hydrophobicity of p(HPMA) based copolymers resulted 
in an architecture-dependent nucleation process where high molecular weight branched 
copolymers were responsible for driving nucleation during co-nanoprecipitation. As a result, 
nanoparticle size depends on the composition of AB block and branched copolymers within 
the initial THF solution. Furthermore, competition between steric and electrostatic growth 
capping mechanisms appeared to be an important factor in the relationship between 
nanoparticle hydrodynamic diameter and branched copolymer composition. Based on the 
fundamental studies conducted and data produced here it would be difficult to correlate the 
relative contributions of nucleation and stabilisation mechanisms to the hydrodynamic 
diameter of p(HPMA) based nanoparticles. However, these studies clearly demonstrate that 
these factors should be considered when manipulating the branched copolymer weight fraction 
of p(HPMA) based copolymers for co-nanoprecipitation formulations.  
Aqueous nanoparticle dispersions were assessed using fluorescence emission spectroscopy of 
pyrene encapsulated during co-nanoprecipitation (λex = 335 nm). Assessment of the internal 
polarity within the core of branched vinyl copolymer nanoparticles should provide information 
on the impact of nanoparticle composition on core polarity. Similar studies had been conducted 
previously to demonstrate that reduction of the branched copolymer weight fraction from 1.0 
to 0.5 had little impact on the internal polarity within the core of p(HPMA) based branched 
vinyl copolymer nanoparticles.22 The authors suggested that AB block copolymers were solely 
located on the surface of branched vinyl copolymer nanoparticles rather than within their 
cores. It was hoped that similar analyses would provide information on the location of AB 
block copolymers within p(nBMA), p(nHMA), p(EHMA) and p(LMA) nanoparticles of 
varied copolymer composition. 
Analysis of pyrene fluorescence emission spectra again showed two conflicting trends 
between nanoparticle internal polarity and the weight fraction of branched copolymer 
employed in co-nanoprecipitation (Figure 3.14). In the case of p(HPMA), I1/I3 ratios increased 
from 1.39 to 1.60 as branched copolymer weight fractions were increased from 0.0 to 0.4. 
Further increases in branched copolymer weight fraction above 0.4 had relatively little impact 
on internal polarity with nanoparticles consisting solely of p(HPMA63-co-EGDMA0.90) having 
an I1/I3 ratio of 1.68. The lack of a relationship between internal polarity and nanoparticle 
compositions at branched copolymer weight fractions ≥ 0.5 was consistent with data 
previously reported.22 However, the additional data points obtained from nanoparticles 
containing branched copolymer composition between 0.0 and 0.4, along with the general 




work provide a new perspective on the location of PEG45-b-p(HPMA)124 within branched vinyl 
copolymer nanoparticles. These results can be explained by considering two factors: i) the 
relative polarities of PEG and p(HPMA) and ii) the stabilisation mechanism by which 
nanoparticle growth is arrested during co-nanoprecipitation.  
Whilst it may appear counter-intuitive, the chemical functionality present on p(HPMA) repeat 
units, which provides a moderate level of electrostatic stabilisation for 
p(HPMA63-co-EGDMA0.90) based nanoparticles, will likely bring an associated polarity to the 
core of any p(HPMA) based branched vinyl copolymer nanoparticles. In contrast, whilst 
considered a relatively polar and hydrophilic polymer, PEG is known for its chemical 
neutrality. It is therefore possible that the relatively high composition of PEG in nanoparticles 
generated using low branched copolymer weight fractions influences the nanoparticle core 
polarity. Increases in the branched copolymer weight fraction significantly increase the 
nanoparticle internal polarity; it is possible that this occurred as a result of the inherent 
reduction in the chemically neutral PEG composition which accompany any increases in the 
branched copolymer weight fraction. The levelling of nanoparticle polarity at branched 
copolymer compositions > 0.5 may have arisen due to vastly diminished PEG compositions 
having negligible impact on nanoparticle core polarity. Whilst a possibility, quantification of 
the relative polarities of pure PEG and p(HPMA) would need to be conducted and validated. 
Alternatively, the mechanism by which nanoparticle growth is arrested during 
co-nanoprecipitation must also be considered. The larger hydrodynamic diameters and low 
zeta potentials obtained for nanoparticles produced at low branched copolymer weight 
fractions were attributed to a steric stabilisation mechanism to halt nanoparticle growth. It is 
possible that combinations of varied nucleation rates between branched and AB block 
copolymers and a reliance on steric stabilisation could result in a disproportionate absence of 
PEG45-b-p(HPMA)124 within the core of branched vinyl copolymer nanoparticles.  
Furthermore, the increased nanoparticle size and the presence of a PEG corona may reduce 
the interaction between pyrene, encapsulated near or at the surface of branched copolymer 
nanoparticles, and surrounding water molecules. This would likely reduce the polarity of the 
environment in which pyrene is located. In contrast, the potential switch to an electrostatic 
growth capping mechanism resulted in a significant reduction in nanoparticle hydrodynamic 
diameter. It is therefore possible that due to the increased nanoparticle surface area and a 
reduced PEG corona, encapsulated pyrene molecules may have increased exposure to 
surrounding water molecules. At this point it is not possible to categorically state whether 
PEG45-b-p(HPMA)124 is located within the core of branched vinyl copolymer nanoparticles 




The trends observed between branched copolymer composition and nanoparticle internal 
polarity appeared more straightforward in cases where there was a stark contrast between the 
polarities of the hydrophilic PEG and the hydrophobic methacrylic domains. This was the case 
for p(nBMA), p(nHMA), p(EHMA) and p(LMA) based co-nanoprecipitations. In all cases, 
modest reductions were observed in nanoparticle internal polarity as the weight fraction of 
branched copolymer was increased. This can be explained simply by considering the inherent 
decrease in the concentration of PEG chains located within branched vinyl copolymer 
nanoparticles as the branched copolymer weight fraction is increased. For example, the 
concentration of PEG within PEG45-b-p(nBMA)125 and p(nBMA73-co-EGDMA1.12) 
copolymers are 11 and 0 wt % respectively. Systematic increases in the proportion of 
p(nBMA73-co-EGDMA1.12) within initial THF solutions would therefore reduce the overall 
composition of PEG within the ensuing branched vinyl copolymer nanoparticles. The fact that 
these trends were observed for p(nBMA), p(nHMA), p(EHMA) and p(LMA) suggested that, 
in all cases, amphiphilic AB block copolymers are entrapped within the nanoparticle cores 
during the co-nanoprecipitation process. This may not be considered a surprise given that, 
again in all cases, amphiphilic AB block copolymers had exhibited effective nucleation during 
their individual nanoprecipitations, discussed in Section 2.3.  
The relatively small impact of the branched copolymer weight fraction on nanoparticle internal 
polarity was initially surprising. For example, in the cases of p(nHMA) based 
co-nanoprecipitations, I1/I3 ratios decreased from 1.19 to 1.13 as the branched copolymer 
weight fraction was increased from 0.0 to 1.0. This can be explained by the low composition 
of PEG within branched vinyl copolymer nanoparticles regardless of the branched copolymer 
weight fraction employed. For example, PEG45-b-p(nBMA)125, PEG45-b-p(nHMA)127, 
PEG45-b-p(EHMA)115 and PEG45-b-p(LMA)122 based copolymers have PEG compositions of 
11, 9, 9 and 7 wt % respectively. Systematic variation of branched copolymer weight fractions 
during co-nanoprecipitation thus only incorporated a maximum of 11 wt % of the polar 
hydrophilic PEG domains within the core of branched vinyl copolymer nanoparticle core.  It 
was concluded that such small variations in the composition of the PEG domain produced only 





Figure 3.14 Graphical representation of the impact of the branched copolymer weight fraction on 
the internal polarity of branched vinyl copolymer nanoparticles generated via co-nanoprecipitation of: 
a) p(HPMA), b) p(nBMA), c) p(nHMA), d) p(EHMA) and e) p(LMA). 
3.4.3.2 Impact of Initial Polymer Concentration on Co-nanoprecipitation  
Polymer concentration was varied to study how this parameter affected the size of the 
nanoparticles. Co-nanoprecipitations conducted previously had produced nanoparticles with 
intensity-average hydrodynamic diameters ranging between 50 and 150 nm, depending on the 
chemical nature of the copolymers used in co-nanoprecipitation. It was hoped therefore that 




be tuned between 10 and 100 nm, which lead to enhanced drug delivery efficiencies in vivo.33 
Nanoparticle hydrodynamic diameters have been shown to increase with polymer 
concentration present within the water-miscible solvent used as the organic phase during 
nanoprecipitation.34 Experiments were designed to investigate whether nanoparticle size could 
be influenced via manipulation of the total copolymer concentration in the good solvent (THF) 
prior to co-nanoprecipitation. 
Given the strong influence that the branched:AB block copolymer ratio had on nanoparticle 
formation during co-nanoprecipitation, discussed in Section 3.4.3.1, all co-nanoprecipitations 
were conducted using equivalent weight fractions of the constituent copolymers employed in 
co-nanoprecipitation (ωi (branched) = ωi (AB block) = 0.50). As the hydrodynamic diameters 
being targeted were typically smaller than those achieved previously, co-nanoprecipitations 
were conducted using initial copolymer concentrations in THF that were less than or equal to 
those used previously ([P]0 = ≤ 5.00 mg mL-1). A constant DR of bad:good solvent was used 
to generate uniform supersaturation conditions in all co-nanoprecipitations (DR = VDI H2O/VTHF 
= 5). Co-nanoprecipitations were conducted using THF solutions of p(HPMA), p(nBMA), 
p(nHMA), p(EHMA) and p(LMA) based copolymers containing incrementally decreasing [P]0 
ranging from 5.0 to 0.5 mg mL-1. An overview of how co-nanoprecipitations were conducted 
is presented in Figure 3.15.  
 
Figure 3.15 Schematic representation of the manipulation of copolymer concentration within the 
good solvent to conduct co-nanoprecipitations at: a) low, b) moderate or c) high concentration.  
In all cases, co-nanoprecipitations formed uniform turbid/translucent mixtures immediately 
after polymer addition and remained as such following solvent removal via evaporation over 
48 hours to give aqueous nanoparticle dispersions of varied [P]f in DI H2O. Aqueous 
nanoparticle dispersions were assessed using DLS from which nanoparticle average 
hydrodynamic diameters, PDIs and DCRs were obtained. Nanoparticle concentrations and 




Table 3.5 The impact of polymer concentration on the size distribution of branched vinyl 















5.000 1.000 76 61 0.030 181444 
4.950 0.990 70 56 0.050 165177 
4.875 0.975 70 56 0.027 163481 
4.750 0.950 75 61 0.024 201323 
4.500 0.900 72 58 0.031 185776 
4.250 0.850 73 58 0.037 160381 
4.000 0.800 73 53 0.024 148879 
3.750 0.750 70 54 0.041 117829 
3.500 0.700 68 55 0.033 116873 
3.000 0.600 70 54 0.034 103683 
2.500 0.500 68 54 0.041 99219 
2.000 0.400 68 54 0.056 81094 
1.500 0.300 66 51 0.075 59235 
1.000 0.200 60 49 0.133 34437 
0.500 0.100 65 52 0.153 36659 
p(nBMA) 
5.000 1.000 107 88 0.019 517987 
4.950 0.990 109 87 0.044 736903 
4.875 0.975 106 86 0.024 478355 
4.750 0.950 104 86 0.022 485867 
4.500 0.900 102 86 0.007 450092 
4.250 0.850 104 84 0.042 464043 
4.000 0.800 103 86 0.011 442725 
3.750 0.750 102 84 0.027 421286 
3.500 0.700 104 85 0.035 402378 
3.000 0.600 101 82 0.027 349793 
2.500 0.500 97 80 0.016 296201 
2.000 0.400 97 79 0.021 265633 
1.500 0.300 98 80 0.022 226652 
1.000 0.200 93 76 0.002 91193 
0.500 0.100 77 61 0.040 24253 
p(nHMA) 
5.000 1.000 106 87 0.033 495260 
4.950 0.990 109 89 0.024 521259 
4.875 0.975 108 89 0.024 484709 
4.750 0.950 106 88 0.019 473906 
4.500 0.900 107 87 0.023 474977 
4.250 0.850 106 88 0.017 439352 
4.000 0.800 104 86 0.023 419232 
3.750 0.750 109 91 0.024 387608 
3.500 0.700 105 87 0.013 380172 
3.000 0.600 100 83 0.010 318753 
2.500 0.500 98 82 0.013 284270 
2.000 0.400 94 76 0.020 245017 
1.500 0.300 98 82 0.015 213560 
1.000 0.200 92 75 0.025 76897 
0.500 0.100 73 52 0.103 21989 
p(EHMA) 
5.000 1.000 109 88 0.031 512757 
4.950 0.990 103 85 0.016 513437 
4.875 0.975 106 88 0.012 525057 
4.750 0.950 107 88 0.015 476623 
4.500 0.900 104 85 0.021 451986 
4.250 0.850 103 85 0.031 436791 
4.000 0.800 101 83 0.020 393764 
3.750 0.750 100 83 0.021 378286 
3.500 0.700 96 77 0.048 310307 
3.000 0.600 101 85 0.025 349695 
2.500 0.500 92 73 0.048 206871 
2.000 0.400 93 77 0.013 215279 
1.500 0.300 83 66 0.050 78607 
1.000 0.200 74 49 0.139 33271 




Table 3.5 (cont.) The impact of polymer concentration on the size distribution of branched vinyl 
















5.000 1.000 140 119 0.021 819851 
4.950 0.990 128 107 0.010 589548 
4.875 0.975 140 120 0.018 579082 
4.750 0.950 140 120 0.013 591223 
4.500 0.900 111 92 0.022 557191 
4.250 0.850 140 120 0.010 547231 
4.000 0.800 144 123 0.029 763449 
3.750 0.750 136 117 0.018 551351 
3.500 0.700 129 107 0.031 551402 
3.000 0.600 121 101 0.023 498301 
2.500 0.500 117 99 0.010 419086 
2.000 0.400 102 74 0.033 295089 
1.500 0.300 88 72 0.019 120926 
1.000 0.200 87 71 0.013 79987 
0.500 0.100 94 76 0.034 48672 
aPolymer concentration in THF prior to co-nanoprecipitation. bNanoparticle concentration in DI H2O following solvent 
evaporation. cDetermined by DLS of aqueous nanoparticle dispersions at [P]f. 
In the vast majority of cases, highly monodisperse aqueous nanoparticle dispersions were 
obtained. All series of co-nanoprecipitations showed small decreases in nanoparticle 
hydrodynamic diameters as [P]0 was decreased. The extent to which nanoparticle 
hydrodynamic diameters varied was dependent upon the chemical nature of the hydrophobic 
domains of the copolymers used in co-nanoprecipitation. For example, in the case of p(HPMA) 
based co-nanoprecipitations, intensity-average hydrodynamic diameters decreased from 76 to 
65 nm as the concentration at which co-nanoprecipitations were conducted was reduced from 
5.0 to 0.5 mg mL-1 and number-average diameters decreased from 61 to 52 nm. This 
represented a 15 % decrease in the intensity-average diameter of p(HPMA) based 
nanoparticles. In contrast, nanoparticles generated through p(LMA) based 
co-nanoprecipitations saw a decrease in the intensity-average diameters from 140 to 94 nm 
which represented a 33 % decrease over the same reduction in [P]0. Relatively consistent 
changes in nanoparticle hydrodynamic diameters were observed for nanoparticles generated 
through co-nanoprecipitation of p(nBMA), p(nHMA) and p(EHMA) based copolymers which 






Figure 3.16 DLS analyses of branched vinyl copolymer nanoparticles. a) The impact of [P]0 on 
nanoparticle PDI (open triangles), intensity- (closed circles) and number- (closed squares) diameters 
and b) The relationship between [P]f and derived count rates obtained from aqueous nanoparticle 




The small changes observed in hydrodynamic diameter indicate that variation in the 
concentration at which co-nanoprecipitations were conducted did have an impact on 
nanoparticle size. It is likely that this occurred as a result of decreased nucleation and growth 
rates during co-nanoprecipitation due to suppressed polymers and nuclei concentrations within 
the THF/DI H2O mixture. The data obtained by DLS provided some evidence of decreased 
nucleation and growth rates. Increased PDI values were obtained at low [P]0 in p(HPMA) 
p(nHMA) and p(EHMA) based co-nanoprecipitations. Increases in PDI are typically 
associated with slow nucleation processes; this occurs due to lower levels of supersaturation 
within the good/bad solvent mixtures and typically results in the continuous formation of 
nuclei throughout the, albeit short, co-nanoprecipitation process. Nuclei formed at different 
stages of the co-nanoprecipitation have varied opportunities for nanoparticle growth and, as a 
result, larger disparities are observed in nanoparticle size. This was particularly evident in 
p(HPMA) based co-nanoprecipitations where, due to the relatively high polarity of the 
p(HPMA) repeat unit, the lowest levels of supersaturation would be expected.  
The general increase observed in nanoparticle hydrodynamic diameters with [P]0 could be 
attributed to lower rates of nanoparticle growth during co-nanoprecipitation. Given the high 
hydrophobicity of the copolymers used in co-nanoprecipitation and the low PDI values 
observed, it is likely that co-nanoprecipitations proceed via DLCA. Decreased concentrations 
of polymers within the initial THF/DI H2O mixture likely decreased the number of nuclei 
(clusters) formed which in turn suppress the rate of nanoparticle growth via cluster-cluster 
aggregation. Slower growth rates would have provided opportunity for the stabilisation of 
nanoparticles via adsorption of stabiliser molecules which may nucleate at slow rates, thus 
allowing nanoparticle growth to be capped at a smaller size.   
Interestingly, in all cases, nanoparticle hydrodynamic diameters appeared to level off at higher 
[P]0. For example, negligible increases were observed in the hydrodynamic diameters of 
nanoparticles generated in p(nHMA) based co-nanoprecipitations as [P]0 was increased from 
of 3.5 and 5.0 mg mL-1 (Dz = 105 and 106 nm). Whilst they may appear to contradict the 
hypotheses of decreased nucleation and growth rates described above, these results indicate 
that arrest of nanoparticle growth by the steric stabilisation provided by amphiphilic block 
copolymers proceeded independently of the nucleation and growth rates which occurred 
during co-nanoprecipitation. Whilst changes to [P]0 did have an impact, changes in 
nanoparticle diameter were somewhat modest. It is possible that this occurred due to the 
limited [P]0 ranges studied; however, the range of [P]0 which could be studied was limited by 
the concentration limitations of DLS analysis. Nonetheless, the size analyses presented here 
demonstrate that, even under extreme dilution, stable branched vinyl copolymer nanoparticles 




Plots of [P]f vs. derived count rate (DCR) were also constructed (Figure 3.16bi-v). In all cases, 
increases were observed in the DCRs obtained during DLS analyses of aqueous nanoparticle 
dispersions with [P]f ; DCRs can be indicative of changes in nanoparticle size or concentration 
and can also indicate simultaneous increases in both nanoparticle size and concentration. This 
was not surprising given the nature of this study ([P]f ~ [P]0), which produced aqueous 
nanoparticle dispersions at varying [P]f in DI H2O. Nonetheless, given the limited changes in 
the hydrodynamic diameters obtained for nanoparticles generated across the concentration 
range specified, the strong relationships observed in plots of [P]f vs. DCR suggested that 
increases in observed DCRs were largely a result of higher nanoparticle concentrations rather 
than increases in nanoparticle size. 
Small changes were observed in nanoparticle hydrodynamic diameters. However, these results 
demonstrate that the initial concentration at which co-nanoprecipitations were conducted was 
not an effective tool in controlling nanoparticle size over a wide range. The small decreases 
observed in the hydrodynamic diameters came with the associated cost of a lower polymer 
concentration within the final aqueous nanoparticle dispersion. This would be problematic for 
the use of such nanomaterials as prospective DNC systems as decreased aqueous nanoparticle 
dispersions would inherently increase the required therapeutic dose. For this reason, 
manipulation of the AB block:branched copolymer ratio offers a more practical alternative to 
vary the size of nanoparticles generated via co-nanoprecipitation. However, these results 
indicate that the [P]0 at which co-nanoprecipitations are conducted could be increased above 
5 mg mL-1 with minimal impact on nanoparticle size. This could allow the preparation of 
branched vinyl copolymer nanoparticles at higher concentrations which would decrease the 
volume of future drug-loaded aqueous nanoparticle dispersions required to achieve clinically 
relevant chemotherapeutic plasma concentrations. A preliminary study was conducted 
focussed on increased concentration which demonstrated that individual nanoprecipitations of 
p(HPMA63-co-EGDMA0.90) could be conducted at [P]0 up to 100 mg mL-1 in THF whilst still 
producing monodisperse nanoparticles with an intensity-average diameter of 145 nm 
(Appendix, Figure A3.4). Alternatively, as discussed in Section 3.1.2, multiple 
co-nanoprecipitations offer another route to increasing nanoparticle concentration. Whilst 
multiple co-nanoprecipitations have not been attempted here, the steric stabilisation growth 
capping mechanism suggested by the results obtained within this study indicate that multiple 
co-nanoprecipitations should be possible for these novel p(nBMA), p(nHMA), p(EHMA) or 






3.4.4 Nanoparticle Stability  
Given the desired application of branched vinyl copolymer nanoparticles as DNC systems, it 
was important to subject nanoparticles to conditions similar to those encountered in vivo. In 
particular, it was essential to assess the stability of branched vinyl copolymer nanoparticles to 
dilution and also to the presence of salt. Studies were therefore designed to subject branched 
vinyl copolymer nanoparticles to biologically relevant conditions and determine whether such 
nanomaterials were able to maintain their structural integrity.  
The nanoparticles used in stability studies were prepared via co-nanoprecipitation of a fixed 
total polymer mass consisting of equal weight fractions of amphiphilic AB block and 
hydrophobic branched copolymers. Co-nanoprecipitations were conducted from THF into DI 
H2O using a fixed dilution ratio (VH2O/VTHF = 5). THF removal occurred over 48 hours at 
ambient temperature to give p(HPMA), p(nBMA), p(nHMA), p(EHMA) and p(LMA) aqueous 
nanoparticle dispersions at a [P]f of 1 mg mL-1. 
3.4.4.1 Nanoparticle Stability to Dilution 
The ability to maintain their structural integrity following high dilution is a pre-requisite for 
polymer-based nanoparticles as prospective applications for DNC systems. Stability to 
dilution is essential in preventing the burst release of encapsulated drug payloads shortly after 
IV administration into systemic circulation. The stability of branched vinyl copolymer 
nanoparticles to dilution was assessed via serial dilution of aqueous nanoparticle dispersions 
([P]H2O = 1 mg mL-1) over a 1000 fold dilution factor (DF). Aqueous nanoparticle dispersions 
were diluted and gently agitated (roller mixer) for 24 hours, in order to allow equilibration 
and/or sedimentation processes to occur, following which, nanoparticles were assessed using 
DLS (Appendix, Table A3.2).  
In all cases, there was no evidence of polymer sedimentation as a result of dilution. DLS 
analyses showed negligible changes in the hydrodynamic diameters and PDI values obtained 
for all aqueous nanoparticle dispersions over a 1000-fold dilution. Plots of nanoparticle 
hydrodynamic diameters and PDI vs. [P]H2O were constructed to demonstrate the consistency 
in nanoparticle properties, despite the significant reduction in nanoparticle concentration 
(Figure 3.17). In all cases, DCR values showed linear increases with [P]f. The absence of any 
change in hydrodynamic diameter combined with the linear relationships observed between 
DCR and [P]H2O therefore demonstrated that branched vinyl copolymer nanoparticles 
consisting of p(HPMA), p(nBMA), p(nHMA), p(EHMA) and p(LMA) based copolymers 





Figure 3.17 Graphical representation of nanoparticle stability to dilution. a) Plots of Dz (closed 
circles), Dn (open squares) and PDI (open triangles) vs. obtained for i) p(HPMA), ii) p(nBMA), 
iii) p(nHMA), iv) p(EHMA) and e) p(LMA) based branched vinyl copolymer nanoparticles. b) Plots of 
DCR vs. [P]H2O. 
Nanoparticle stability to dilution indicated that high molecular weight amphiphilic block 
copolymers, which confer stability via steric stabilisation, are kinetically frozen within the 
nanoparticle structure, presenting PEG chains at the surface of branched vinyl copolymer 
nanoparticles. It is likely that this is due to the high energy cost associated with the 
energetically unfavourable interactions of the highly hydrophobic domains of the amphiphilic 
block copolymer with the aqueous phase. The ability to maintain structural integrity whilst 
under extreme dilution is a promising sign for the use of branched vinyl copolymer 
nanoparticles as DNCs in vivo. Furthermore, these results indicate that, should these 
nanoparticles be loaded with hydrophobic chemotherapeutics, drug release rates would be 




gradient-induced rapid disassembly of the DNC system. Branched vinyl copolymer 
nanoparticles may therefore be able to offer controlled drug release of encapsulated payloads. 
3.4.4.2 Nanoparticle Stability to Salt  
Another factor which any DNC system would encounter during both in vitro and in vivo 
pharmacological evaluations is dilution in buffered media. The presence of metal ions in 
solution is particularly problematic for DNC systems whose colloidal stability is reliant on 
electrostatic repulsion-based stabilisation mechanisms. Given the steric stabilisation provided 
by the hydrophilic PEG domains of amphiphilic block copolymers it was expected that 
branched vinyl copolymer nanoparticles would remain stable in the presence of salt. Studies 
were therefore required to determine the resistance of branched vinyl copolymer nanoparticles 
to the addition of salt.  
Nanoparticle stability to salt was assessed via dilution of aqueous nanoparticle dispersions in 
various concentrations of NaCl ranging from 0.01 – 1.00 mol dm-3. Aqueous nanoparticle 
dispersions ([P]H2O = 1 mg mL-1) were diluted in aqueous salt solutions (DR = 2) and gently 
agitated (roller mixer) for 24 hours.  
The size distributions of aqueous nanoparticle dispersions were then obtained by DLS 
(Figure 3.18, Table 3.6). In all cases, aqueous nanoparticle dispersions showed stability to the 
addition of low concentrations of NaCl (≤ 0.05 mol dm-3). Aqueous nanoparticle dispersions 
remained colloidally stable with no sign of sedimentation. In contrast, NaCl concentrations 
>0.05 mol dm-3 induced small amounts of polymer sedimentation for p(nHMA) and p(EHMA) 
based nanoparticles, therefore reliable DLS analyses could not be obtained. DLS analyses of 
nanoparticles exposed to <0.05 mol dm-3 NaCl solution showed monomodal size distributions 
for all aqueous nanoparticle dispersions analyses. Combined with the low PDI values obtained, 
this indicated that nanoparticles remained stable. These results reiterated the importance of the 
PEG shell in providing nanoparticles with the steric stabilisation as the predominant source of 
nanoparticle stability. This was reinforced by a comparative study of branched vinyl 
copolymer nanoparticles formed from the sole nanoprecipitation of p(HPMA64-co-
EGDMA0.90). With the absence of the PEG-based amphiphilic AB block copolymers such 
nanoparticles are solely reliant on electrostatic repulsions to maintain colloidal stability. As a 
result, nanoparticle aggregation and sedimentation occurred immediately following the 





Figure 3.18 The impact of NaCl on the stability of branched vinyl copolymer nanoparticles. 
Overlaid DLS traces obtained for: a) p(HPMA), b) p(nBMA), c) p(nHMA), d) p(EHMA) and 
e) p(LMA). DLS analyses conducted on aqueous nanoparticle dispersions at [NaCl] of: 0.00 (black), 
0.01 (red), 0.10 (green) and 1.00 (blue) mol dm-3.  
Interestingly, the addition of salt had a varied impact on the hydrodynamic diameters of 
branched copolymer nanoparticles. For example, little difference was observed in the sizes of 
p(nBMA) and p(LMA) based nanoparticles when the NaCl concentration was increased from 
0.0 to 0.5 mol dm-3; such nanoparticles saw increases in their intensity-average diameters from 
82 – 86 nm and 143 – 172 nm over this concentration range. Alternatively, in the cases of 
p(HPMA), p(nHMA) and p(EHMA), nanoparticle size generally increased with the 
concentration of salt. The extent to which hydrodynamic diameters increased, however, varied 
between nanoparticles. For example, p(HPMA) based nanoparticles saw an increase in the 
intensity-average diameter from 64 to 104 nm as the concentration of NaCl increased from 0.0 
to 0.05 mol dm-3, whereas p(EHMA) nanoparticles saw an increase in the intensity-average 
diameter from 76 to 877 nm over the same concentration range.  
These results may appear surprising as the addition of salt typically decreases hydrodynamic 
diameters obtained by DLS as the presence of electrolytes suppress the electrical double layer 
which surround nanoparticles. However, given the low surface charge due to the apparent 
neutrality of the PEG shell, it is possible that this may have little impact on branched vinyl 
copolymer nanoparticles. On the contrary, increases in the concentration of salt may result in 
non-covalent interactions between the, hydrogen/cation binding PEG shell of branched vinyl 
copolymer nanoparticles and the sodium cations within the aqueous nanoparticle dispersion. 
It is also likely that the addition of moderate concentrations of salt would increase the viscosity 




suppress nanoparticle translational coefficients and would therefore artificially inflate the 
increases observed in nanoparticle hydrodynamic diameters. Despite the increase in 
hydrodynamic diameter, the retention of monomodal size distributions and low PDIs indicate 
that branched vinyl copolymer nanoparticles maintain their structural integrity at moderate 
concentrations of NaCl.  
 Table 3.6 Visual and DLS analyses of the stability of aqueous nanoparticle dispersions to 





Sedimentationa Dz (nm)b Dn (nm)b PDI b 
p(HPMA) 
0.000 N 64 50 0.049 
0.005 N 83 67 0.029 
0.050 N 104 76 0.077 
0.500 N 134 97 0.102 
p(nBMA) 
0.000 N 82 59 0.083 
0.005 N 83 62 0.075 
0.050 N 83 62 0.079 
0.500 N 86 65 0.075 
p(nHMA) 
0.000 N 89 73 0.013 
0.005 N 225 205 0.044 
0.050 N 220 160 0.187 
0.500 N - - - 
p(EHMA) 
0.000 N 76 59 0.055 
0.005 N 167 141 0.056 
0.050 N 877 779 0.107 
0.500 Y - - - 
p(LMA) 
0.000 N 143 122 0.008 
0.005 N 156 137 0.022 
0.050 N 160 141 0.034 
0.500 N 172 154 0.028 
aSedimentation inspected visually. Y = Sedimentation observed and N = No sedimentation observed. bObtained by DLS. *Reliable 
DLS data could not be obtained due to polymer sedimentation.  
These studies demonstrate that in all cases aqueous nanoparticle dispersions remained stable 
to the addition of low concentrations of NaCl. p(HPMA), p(nBMA) and p(LMA) based 
nanoparticles demonstrated colloidal stability at NaCl concentrations up to 0.500 mol dm-3 
which is in excess of that typically present within systemic circulation (0.150 mol dm-3); it is 
therefore reasonable to suggest that these materials would be expected to maintain their 
colloidal stability in the presence of salt concentrations present within systemic circulation. In 
contrast, p(nHMA) and p(EHMA) showed colloidal stability at concentrations up to 
0.05 mol dm-3 in this study. A more detailed study would therefore be required to determine 




understand whether they can maintain their colloidal stability under biologically-relevant 
concentrations of NaCl. The presence of salt, however, is not the only factor which could 
impact nanoparticle stability in vivo. Further studies would therefore be required to show the 
level of interaction between branched vinyl copolymer nanoparticles and many of the 
biological proteins within the blood stream.   
3.5 Conclusions 
This work aimed to expand the scope of branched vinyl copolymer nanoparticles that can be 
produced via co-nanoprecipitation and explore the factors which influence nanoparticle 
formation during the co-nanoprecipitation process. In that sense, this was achieved, as 
demonstrated, by the formation of p(nBMA), p(nHMA), p(EHMA) and p(LMA) based 
nanoparticles via co-nanoprecipitation. One attraction of this nanoformulation approach is that 
it allows the incorporation of polymeric materials which themselves are incapable of forming 
stable aqueous nanoparticle dispersions. However, as shown during these studies, successful 
nanoparticle formation is highly dependent upon the chemical nature of the polymers used; for 
example, the preparation of stable aqueous nanoparticle dispersions using p(MMA), p(EMA), 
p(tBMA), p(CHMA), p(BzMA) and p(SMA) based copolymers could not be achieved using 
these methods. Interestingly, all (co)polymers which failed to form stable nanoparticles via 
(co)nanoprecipitation possessed a Tg above room temperature. It is therefore possible that glass 
transition temperature is a crucial polymer property that govern successful nanoprecipitation. 
Furthermore, it is possible that (co)nanoprecipitations at elevated temperature may yield better 
results.   
The use of increasingly hydrophobic (co)polymers helped shed light on the role of individual 
polymeric components, as well as other parameters which influence the co-nanoprecipitation 
process. The use of copolymers with compatible hydrophobic domains appears to ensure 
comparable nucleation rates. As a result, hydrophobic components undergo architecture-
independent nucleation processes; this allowed the previously unreported preparation of stable 
aqueous nanoparticle dispersions consisting of hydrophobic linear homopolymers and their 
corresponding amphiphilic block copolymers via co-nanoprecipitation. Furthermore, the 
entrapment of amphiphilic block copolymers within the core of branched vinyl copolymer 
nanoparticles during nanoparticle growth was confirmed for the first time.  
The ability to encapsulate hydrophobic guest molecules during co-nanoprecipitation highlights 
this approach for the loading of hydrophobic chemotherapeutics within branched vinyl 
copolymer nanoparticles. The fluorescence emission of pyrene proved a useful tool for 
assessing encapsulation and allowed the internal environments of branched vinyl copolymer 




excessive dilution over prolonged time periods. This indicates that the release of encapsulated 
payloads should be governed by the rate of diffusion through the nanoparticle core rather than 
by DNC disassembly and offers a promising prospect for sustained release of such 
hydrophobic payloads. Furthermore, stability to moderate concentrations of salt indicate that 
such nanoparticles may be capable of retaining colloidal stability within buffered and 
biological media.  
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4.1.1 Docetaxel Anticancer Chemotherapeutic Drug 
Chemotherapy remains the most prevalent therapy for the treatment of a wide range of cancers. 
Significant research efforts have focused on platinum based chemotherapy treatments.1 
However, in recent years, there has been considerable interest in the development and 
application of non-metallic chemotherapy treatments. This has led to the discovery and 
development of a number of organic chemotherapeutics, including doxorubicin, daunorubicin, 
fluorouracil, SN38 and taxanes.2 Docetaxel is one such chemotherapeutic which has received 
considerable interest since its discovery by Denis and co-workers in 1988.3,4 Docetaxel is a 
member of the family of taxanes which are naturally occurring diterpenes generated by plants 
of the genus Taxus (yews).4 The most common member of the taxane family is Paclitaxel; a 
naturally occurring product originally sourced from the bark of Pacific yew (Taxus brevifolia). 
The extraction of paclitaxel was, however, a labour-intensive, destructive and ecologically 
unsustainable process. Increased demand for paclitaxel, which arose following its successful 
clinical application as a chemotherapeutic, led to the species of Pacific yew at one point being 
considered “on the brink of extinction”.5 As a result, the need for highly efficient yet 
ecologically sustainable synthetic routes to taxanes was at the centre of organic chemistry 
research during the final two decades of the 20th century.  
Numerous attempts were made to develop pure synthetic routes for the preparation of 
paclitaxel; however, such syntheses could not provide sufficient yields to be considered 
practically and thus commercially viable.6,7 In the early 1980s, an ecologically sustainable 
synthetic route for the preparation of paclitaxel was developed (Figure 4.1).8–10 This involved 
the isolation of large quantities of the naturally occurring precursor, 10-deacetylbaccatin-III, 
from the needles of Taxus baccata (European yew). The precursor was used for the preparation 
of paclitaxel, and later for the discovery of docetaxel in a process known as a semi-synthesis. 
Semi–syntheses are synthetic routes in which one, or more, of the compounds used are derived 
from natural sources. This is a commercially advantageous approach as the use of naturally 
occurring, complex and often high molecular weight building blocks can remove many of the 
synthetic and purification steps required for the production of a desired compound. 
Furthermore, the ability to isolate large qualities of 10-deacetylbaccatin-III allowed the 
targeting of other novel taxanes possessing chemical structures with high similarity to that of 
paclitaxel. It was this approach which led to the discovery of docetaxel, which is now one of 
the most commonly used non-platinum based chemotherapeutics for the treatment of breast, 





Figure 4.1 Schematic representation of the semi-synthesis of the taxanes paclitaxel and 
docetaxel. a) Precursor 10-diacetylbaccatin-III is extracted from the needles of Taxus baccata, followed 
by preparation of b) Paclitaxel and docetaxel via esterification of 10-diacetylbaccatin-III. 
As demonstrated in Figure 4.1, docetaxel has a similar structure to paclitaxel with the only 
difference being the presence of the acetate group adjacent to the ketone on the 10-membered 
ring. Similar to paclitaxel, docetaxel functions as an anti-neoplastic agent by disrupting the 
microtubule networks which are responsible for mitotic and metabolic cell functions. 
Docetaxel’s anti-cancer activity occurs via the following multistep mechanism. Firstly 
docetaxel molecules bind, with high affinity, to free tubulin within the cell cytoplasm. 
Polymerisation via self-assembly of docetaxel-bound tubulin result in the formation of stable 
microtubules which are unable to undergo the disassembly processes. The formation of 
stabilised microtubule bundles render such biomaterials incapable of performing normal cell 
functions; failure of microtubules to disassemble prevent cellular replication processes. 
Selective delivery of docetaxel to cancerous cells can therefore promote apoptosis and thus 
provide effective anti-cancer treatment. The subtle differences in the chemical structures of 
docetaxel and paclitaxel have resulted in varied anti-tumour and toxicity activities. Docetaxel 
is considered the more potent cytotoxic anti-microtubule agent and has demonstrated to be 
five times more effective in promoting microtubule formation and subsequently inhibiting the 
disassembly processes when compared to paclitaxel during in vitro studies.21  
Despite the high potency of docetaxel as a chemotherapeutic, as well as the commercially 
viable semi-synthesis routes available for its production, the chemical properties of docetaxel 
have also hindered its translation to clinical applications. Docetaxel is a highly hydrophobic 
molecule which exhibits extremely low aqueous solubility.22,23 Furthermore, the high 
cytotoxicity, which makes docetaxel such a potent chemotherapeutic, produces negative side 
effects within healthy tissues when docetaxel is not taken up selectively by cancer cells.24,25 
To overcome these issues, research efforts have moved towards the development of drug 




4.1.2 Docetaxel Nanoformulation  
The concept of nanoformulation, and the many forms of drug nanocarriers currently receiving 
increased attention in nanomedicine research, have been discussed in Chapter 1, alongside the 
associated benefits of such formulation approaches. Here, a more detailed discussion of 
docetaxel-specific nanoformulation approaches which either form the basis of academic 
research or are currently under clinical application will be discussed. Beside the main 
nanomaterial platforms which have been developed to overcome issues of low aqueous 
solubility and high cytotoxicity, others include: docetaxel-polymer conjugates, dendrimers, 
inorganic nanoparticles and liposomes.30–37 Alternatively, a number of formulation strategies 
have been developed for the preparation of drug-polymer composites. In particular, this has 
involved the preparation of docetaxel-polymer composites using poly(lactic acid) and 
poly(lactic acid-co-glycolic acid) based (co)polymers via emulsification,38–43 
nanoprecipitation,44 thin film hydration,45 and ultrasonication.46 Whilst many of these 
techniques indeed form docetaxel-polymer composites with hydrodynamic diameters on the 
nanoscale, these synthetic approaches typically utilise low drug loadings, where relatively low 
weight fractions of drug are encapsulated during the nanoformulation process. In contrast, 
novel technology based strategies such as the particle replication in non-wetting templates 
(PRINT) process has enabled the preparation of docetaxel-polymer composites with average 
hydrodynamic diameters ca. 250 nm whilst containing high drug loadings (up to 40 wt %).47–
51 Furthermore, quantitative encapsulation efficiencies have been achieved using the PRINT 
process.  
BIND-01452,53 is one docetaxel-polymer composite which has recently undergone Phase 2 
clinical trials and showed mixed results depending on the specific clinical application;54 
BIND-014 gave positive outcomes for the treatment of prostate and non-small-cell lung 
cancers, whereas application of BIND-014 for the treatment of head and neck cancer was 
unsuccessful and clinical trials were terminated during Phase 2. Taxotere® is another 
commercially available docetaxel micelle formulation used for the treatment of a wide range 
of cancers. However, the continued pursuit for novel nanoformulation strategies for the 
preparation of DNCs which can produce optimal therapeutic effects will no doubt continue. 
Potential candidates for novel docetaxel nanocarriers must possess the following qualities: i) 
the ability to encapsulate high docetaxel payloads with near-quantitative encapsulation 
efficiency; ii) nanoparticles must retain colloidal stability following formulation; iii) 
encapsulated payloads must be maintained within the nanoparticle core until nanoparticles 
have accumulated at the target site; and iv) nanoparticles must be produced via facile and 





4.1.3 Chapter Aims 
The aims of this Chapter were to study the encapsulation and release of docetaxel from 
branched vinyl copolymer nanoparticles. Comprehensive co-nanoprecipitation studies were 
conducted to discover the maximum docetaxel loadings that can be encapsulated within 
branched vinyl copolymer nanoparticles without disrupting the formation process. This work 
aimed to build on the successful co-nanoprecipitations of p(HPMA), p(nBMA), p(nHMA), 
p(EHMA) and p(LMA) based copolymers discussed in Chapter 3. Radiometric analyses were 
utilised to quantify the efficiency of docetaxel encapsulation which allows the impact of 
copolymer functionality to be assessed.  
Docetaxel-loaded branched vinyl copolymer nanoparticles were subsequently studied to 
determine docetaxel release rates in vitro. The effect of the polarity and viscosity of each 
nanoparticle core on docetaxel release rates are presented. Detailed kinetic analyses were 
conducted to evaluate the temperature dependence of docetaxel release from branched vinyl 
copolymer nanoparticles; this was investigated with respect to the physical properties of the 
copolymers from which nanoparticles are constructed. Finally, factors which influence the 
potential of these nanoparticles, such as drug half-life, as prospective DNC systems for the 
site-specific delivery of docetaxel in vivo will be discussed.  
 
Figure 4.2 Schematic representation of the research aims of the work conducted in Chapter 4.                
a) Encapsulation of docetaxel within the core of branched vinyl copolymer nanoparticles during 
co-nanoprecipitation. b) Monitoring the rate of encapsulated docetaxel release from branched vinyl 







4.2 Docetaxel Encapsulation via Co-nanoprecipitation 
The use of branched vinyl copolymer nanoparticles as prospective docetaxel DNC systems 
required a series of preliminary experiments to determine whether docetaxel could be 
encapsulated during the co-nanoprecipitation process. It was important to understand whether 
stable, docetaxel-loaded aqueous nanoparticle dispersions could be prepared as well as the 
maximum docetaxel loading that could be encapsulated without having a negative impact on 
the co-nanoprecipitation process. As they had proven to be the most robust and reproducible 
co-nanoprecipitation processes, docetaxel encapsulation experiments were conducted 
involving the addition of docetaxel into the co-nanoprecipitations of p(HPMA), p(nBMA), 
p(nHMA), p(EHMA) and p(LMA) based copolymers.  
In order to generate comparable data, given the large number of co-nanoprecipitations being 
studied, it was important to determine standard conditions under which all docetaxel 
encapsulation experiments could be conducted. All co-nanoprecipitations were therefore 
performed from THF (1 mL, 5 mg mL-1) into DI H2O (1 mL, DR = 5). It was important to 
ensure that all encapsulation experiments involved co-nanoprecipitation of the same total solid 
mass therefore, in all cases, a constant total solid mass of 5 mg was present within the initial 
THF solution. The total solid mass consisted of varying ratios of docetaxel and the copolymers 
used in co-nanoprecipitation, in order to achieve target drug loadings ranging from 0 – 50 wt % 
of the total solid mass. This involved systematic variation of the weight fractions of the total 
polymer mass from 1.0 to 0.5 whilst simultaneously increasing the docetaxel weight fraction 
from 0.0 to 0.5 within the initial THF solution (Table 4.1). All co-nanoprecipitations were 
conducted using equal weight fractions of AB block and branched copolymers (ωi = 0.5). A 
general overview of the docetaxel encapsulation experiments is presented in Figure 4.3.  
 
Figure 4.3 Schematic representation of the encapsulation of docetaxel at varied target drug 
loadings via co-nanoprecipitation of amphiphilic AB and branched copolymers. Co-nanoprecipitations 
conducted at varied target drug loadings can form a) macroscopic aggregation or b) Docetaxel-loaded 




Table 4.1 DLS analyses of docetaxel-loaded branched vinyl copolymer nanoparticle dispersions 
formed via co-nanoprecipitation. Co-nanoprecipitations conducted at target weight loadings ranging 


















1.000 0.000 0.0 N 76 61 0.030 181444 
0.990 0.010 1.0 N 79 64 0.021 244478 
0.975 0.025 2.5 N 79 63 0.029 248334 
0.950 0.050 5.0 N 77 60 0.048 225962 
0.900 0.100 10.0 N 77 63 0.015 222840 
0.850 0.150 15.0 N 82 66 0.022 238247 
0.800 0.200 20.0 N 79 64 0.029 224827 
0.750 0.250 25.0 N 77 61 0.026 215901 
0.700 0.300 30.0 Y* - - - - 
0.600 0.400 40.0 Y* - - - - 
0.500 0.500 50.0 Y* - - - - 
p(nBMA) 
1.000 0.000 0.0 N 107 88 0.019 517987 
0.990 0.010 1.0 N 106 85 0.037 459493 
0.975 0.025 2.5 N 100 82 0.039 422213 
0.950 0.050 5.0 N 88 69 0.037 373594 
0.900 0.100 10.0 N 85 67 0.029 345979 
0.850 0.150 15.0 N 84 66 0.050 337393 
0.800 0.200 20.0 N 87 66 0.051 322274 
0.750 0.250 25.0 Y* - - - - 
0.700 0.300 30.0 Y* - - - - 
0.600 0.400 40.0 Y* - - - - 
0.500 0.500 50.0 Y* - - - - 
p(nHMA) 
1.000 0.000 0.0 N 106 87 0.033 495260 
0.990 0.010 1.0 N 109 89 0.019 536666 
0.975 0.025 2.5 N 103 86 0.014 512039 
0.950 0.050 5.0 N 97 79 0.025 479461 
0.900 0.100 10.0 N 86 69 0.023 358284 
0.850 0.150 15.0 N 89 74 0.018 379010 
0.800 0.200 20.0 N 92 72 0.049 382924 
0.750 0.250 25.0 Y* - - - - 
0.700 0.300 30.0 Y* - - - - 
0.600 0.400 40.0 Y* - - - - 
0.500 0.500 50.0 Y* - - - - 
p(EHMA) 
1.000 0.000 0.0 N 109 88 0.031 512757 
0.990 0.010 1.0 N 101 81 0.041 508852 
0.975 0.025 2.5 N 98 79 0.038 480232 
0.950 0.050 5.0 N 93 76 0.019 400514 
0.900 0.100 10.0 N 85 69 0.021 341935 
0.850 0.150 15.0 N 85 69 0.031 351118 
0.800 0.200 20.0 Y* - - - - 
0.750 0.250 25.0 Y* - - - - 
0.700 0.300 30.0 Y* - - - - 
0.600 0.400 40.0 Y* - - - - 
0.500 0.500 50.0 Y* - - - - 
p(LMA) 
1.000 0.000 0.0 N 140 119 0.021 819851 
0.990 0.010 1.0 N 109 89 0.022 548381 
0.975 0.025 2.5 N 127 107 0.018 550903 
0.950 0.050 5.0 N 107 88 0.031 494591 
0.900 0.100 10.0 N 94 75 0.033 426528 
0.850 0.150 15.0 N 98 80 0.029 443566 
0.800 0.200 20.0 N 100 84 0.016 483511 
0.750 0.250 25.0 Y* - - - - 
0.700 0.300 30.0 Y* - - - - 
0.600 0.400 40.0 Y* - - - - 
0.500 0.500 50.0 Y* - - - - 
aPolymer ωi = (total polymer mass / (total polymer mass + docetaxel mass)). bDocetaxel ωi = (docetaxel 
mass/(total polymer mass + docetaxel mass)) cTarget drug loading = (docetaxel mass/(docetaxel mass 
+ total polymer mass) x 100). dDetermined visually. eDetermined by DLS analysis at a concentration of 




For each copolymer system, docetaxel encapsulation experiments involved 11 
co-nanoprecipitations conducted at targeted drug loadings of: 0.0, 1.0, 2.5, 5.0, 7.5, 10, 15, 20, 
25, 30, 40 and 50 wt %. The success of co-nanoprecipitations were initially judged visually.  
In all cases, the addition of the drug/copolymer THF solution resulted in the formation of a 
turbid/translucent mixture and there was no evidence of sedimentation. However, following 
THF removal over 48 hours, only some formulations remained as almost clear 
nanodispersions, whilst others showed evidence of macroscopic precipitation. The success of 
such co-nanoprecipitations was clearly dependent on the drug loading targeted during the 
co-nanoprecipitation. In all cases, co-nanoprecipitations failed at high drug loadings 
(≥30 wt %) and this was evident from the appearance of large aggregates within the resultant 
aqueous nanoparticle dispersions (Appendix, Figure A4.1). In contrast, all 
co-nanoprecipitations conducted at target drug loadings ≤15 wt % were deemed successful. 
The drug loadings at which co-nanoprecipitations failed varied for each copolymer system. 
The maximum drug loadings at which stable aqueous nanoparticle dispersions were obtained, 
with the absence of larger aggregates, was at 25, 20, 20 15 and 20 wt % for p(HPMA), 
p(nBMA), p(nHMA), p(EHMA) and p(LMA) based co-nanoprecipitations respectively. The 
absence of large aggregates within aqueous nanoparticle dispersions produced via successful 
co-nanoprecipitation indicated that docetaxel undergoes rapid nucleation and growth 
following addition to DI H2O due to a state of supersaturation within the THF/DI H2O mixture.  
The impact of targeted drug loading on the success of nanoparticle formation during 
co-nanoprecipitation was initially assumed to occur due to the inherent reduction in the 
number of AB block copolymer chains present as a proportion of the total solid mass being 
co-nanoprecipitated, as target drug loadings were increased. In all co-nanoprecipitations, 
increases in target docetaxel loading from 0 % to 50 % therefore caused a reduction in the 
overall AB block copolymer weight fraction from 0.50 to 0.25. As a result, fewer AB block 
copolymer chains are available to provide steric stabilisation and cap nanoparticle growth 
during co-nanoprecipitation. The importance of AB block copolymer composition in the 
stabilisation of branched vinyl copolymer nanoparticles was discussed in Chapter 3, Section 
3.4.3.1 In the cases of p(nBMA), p(nHMA), p(EHMA) and p(LMA) based 
co-nanoprecipitations, AB block copolymer weight fractions ≤ 0.80 had a negative impact on 
the capping of nanoparticle growth and resulted in increases to the average hydrodynamic 
diameters of the resulting nanoparticles. It is therefore reasonable to suggest that the inherent 
decreases in AB block copolymer composition which accompanied co-nanoprecipitations 
conducted at higher target drug loadings were responsible for unsuccessful nanoparticle 




Aqueous nanoparticle dispersions which did not show any signs of sedimentation were 
assessed by DLS. One of the biggest concerns prior to docetaxel loading experiments was that 
docetaxel would not exhibit the similar levels of supersaturation as hydrophobic branched and 
amphiphilic AB block copolymers within the THF/DI H2O mixture and would therefore 
nucleate at a different rate during co-nanoprecipitation. However, in all cases, monomodal 
nanoparticle size distributions were obtained with low PDI values (<0.100) which 
demonstrated that docetaxel-loaded nanoparticles were near-monodisperse. These data further 
supported claims that docetaxel undergoes rapid nucleation and/or growth during 
co-nanoprecipitation as slow or even heterogeneous nucleation processes do not typically 
produce monodisperse nanoparticles. It is therefore reasonable to suggest that, despite the 
presence of up to 25 wt % docetaxel, nanoparticle formation proceeds via a diffusion-limited 
cluster-cluster aggregation growth mechanism.  
Nanoparticle sizes were relatively consistent and comparable to those produced in the absence 
of docetaxel with intensity-average diameters varying between 79 and 142 nm. Interestingly, 
for p(nBMA), p(nHMA), p(EHMA) and p(LMA) based co-nanoprecipitations, nanoparticle 
size decreased with the weight fraction of docetaxel. For example, in the case of p(nHMA) 
based co-nanoprecipitations, intensity-average hydrodynamic diameters decreased from 109 
to 92 nm as target drug loadings were increased from 1 to 20 wt %. This was somewhat 
surprising given that, as discussed above, increases in target drug loading resulted in lower 
amphiphilic AB block copolymer concentrations during co-nanoprecipitation; nanoparticle 
sizes were therefore expected to increase with target drug loading. The relationship between 
target drug loading and nanoparticle size can be explained by consideration of the role of 
docetaxel within the co-nanoprecipitation process. Smaller nanoparticles indicated an increase 
in the number of nuclei formed during the early stages of co-nanoprecipitation. Combined with 
the low PDI values, which suggest that docetaxel undergoes rapid nucleation, the size data 
indicated that docetaxel formed higher numbers of nuclei per unit mass than the copolymers 
with which they were co-nanoprecipitated. This is not surprising given their contrasting 
molecular weights and thus the relative number of molecules dissolved within the initial THF 
solution. Increases in the number of nuclei formed during co-nanoprecipitation typically result 
in higher nanoparticle concentrations and would be expected to cause increases in the DCR. 
However, DCRs obtained by DLS decreased with drug loading; this was likely due to the 
simultaneous decrease in nanoparticle size. It is possible, however, that the simultaneous 
increase in the number of nuclei formed and the reduction in the AB block copolymer weight 
fraction may have led co-nanoprecipitations to fail at high target drug loadings. It was 
proposed that fewer AB block copolymer chains were able to provide the level of steric 




higher numbers of nuclei.  Co-nanoprecipitations conducted using higher weight fractions of 
AB block copolymer may therefore allow the preparation of docetaxel-loaded aqueous 
nanoparticle dispersions at higher target drug loadings. 
The impact of targeted drug loading on the hydrodynamic size was explored further in order 
to understand the role of docetaxel in the co-nanoprecipitation process. This was achieved by 
studying the intensity-average hydrodynamic diameters of nanoparticles generated in 
co-nanoprecipitations conducted in the presence and absence of docetaxel (Figure 4.4). This 
involved amalgamation of data obtained in the docetaxel loading experiments presented here 
(Table 4.1) with that obtained during the study of the influence of copolymer concentration at 
which co-nanoprecipitations are conducted, discussed in Chapter 3, Table 3.5. In both cases 
co-nanoprecipitations were conducted at varying copolymer concentrations within the initial 
THF solution. However, drug loading experiments also included the addition of docetaxel. 
This allowed direct comparison between aqueous nanoparticle dispersions produced under 
identical conditions in the presence and the absence of docetaxel. 
Nanoparticles generated in the absence of docetaxel exhibited little difference in 
hydrodynamic diameter, regardless of the amount of copolymer within the initial THF 
solution, over the concentration range studied. For example, negligible differences were 
observed in the intensity-average hydrodynamic diameters obtained for p(EHMA) 
nanoparticles generated in co-nanoprecipitations conducted at copolymer concentrations 
ranging from of 4.99 and 4.25 mg mL-1. In contrast, p(EHMA) co-nanoprecipitations 
conducted over an identical concentration range of copolymer concentration, in the presence 
of docetaxel, showed intensity-average hydrodynamic diameters decreasing from 101 to 
85 nm. Interestingly, large decreases in nanoparticle diameter occurred as target docetaxel 
loadings were increased from 0 to 5 wt % with intensity-average hydrodynamic diameters 
becoming constant thereafter. Whilst this clearly supports the role of docetaxel in driving the 
nucleation process during co-nanoprecipitation, it is clear that changes in hydrodynamic 
diameter were not directly proportional to targeted drug loadings. Once again, this could be 
due to the trade-off between increasing numbers of nuclei formed during the initial stage of 
co-nanoprecipitation and the associated decreases in the AB block copolymer composition. It 
was hypothesised that low targeted drug loadings increased the number of nuclei present whilst 
having little effect on the AB block copolymer concentration; this allowed smaller 
nanoparticles to be formed as sufficient levels of AB block copolymer were present to cover 
the greater surface area generated by the presence of higher numbers of nuclei during 
co-nanoprecipitation. Further increases in the targeted drug loading, however, had a larger 
impact on the AB block copolymer concentration. Increases in the number of nuclei formed 




nanoparticle growth at lower hydrodynamic diameters and resulted in no further change in 
nanoparticle size. 
  
Figure 4.4 The impact of copolymer concentration on the hydrodynamic diameters of loaded 
nanoparticles formed via co-nanoprecipitation. Comparison of intensity-average hydrodynamic 
diameters obtained for docetaxcel loaded (solid circles) and unloaded (open squares) for a) p(HPMA), 





In contrast, negligible changes in nanoparticle size were observed for p(HPMA) based 
co-nanoprecipitations as target drug loading was increased from 0 to 25 wt %. This was likely 
due to the dominance of electrostatic repulsion capping nanoparticle growth during p(HPMA) 
based co-nanoprecipitations. This supported findings in Chapter 3, Section 3.4.3.1, where the 
hydrodynamic diameters of nanoparticles formed were independent of the AB block 
copolymer composition at AB block copolymer weight fractions ≤ 0.60. It is therefore evident 
that nanoparticle growth capping mechanisms are equally important in the preparation of 
docetaxel loaded aqueous nanoparticle dispersions via co-nanoprecipitation.  
The contrast in the maximum drug loadings at which stable aqueous nanoparticle dispersions 
could be achieved was initially thought to be due to increased copolymer hydrophobicity, 
which would generate favourable drug-copolymer association during co-nanoprecipitation. 
The maximum drug loading that could be tolerated was therefore expected to increase with 
polymer hydrophobicity. However, this was not the case as the highest targeted drug loadings 
were achieved in co-nanoprecipitations of p(HPMA) based co-polymers (25 wt %) which are 
considered the least hydrophobic copolymers. Furthermore co-nanoprecipitations of the 
remaining copolymers yielded broadly similar results, with stable aqueous nanoparticle 
dispersions formed at comparable maximum drug loadings which ranged between 15 and 
20 wt %. Broadly speaking, the maximum drug loadings achieved were comparable and 
implied that monomer chemistry had little impact on docetaxel encapsulation during 
co-nanoprecipitation. This indicates that the encapsulation of docetaxel is largely under kinetic 
control. This may be considered unsurprising given the rapid rate at which nanoparticles are 
formed during co-nanoprecipitation and suggests that optimisation of drug encapsulation may 
not be possible via manipulation of copolymer chemistry.  
The presence of strong non-covalent interactions between docetaxel and the copolymers which 
make up the nanoparticle core, as well as the physical properties of the core itself, are therefore 
more likely to play a role in controlling the rate at which docetaxel is released from branched 
vinyl copolymer nanoparticles. It may be possible, however, to achieve higher docetaxel drug 
loadings via manipulation of the experimental conditions under which co-nanoprecipitations 
are conducted. Under the conditions that co-nanoprecipitations were conducted in this study, 
successful nanoparticle formation at target docetaxel loadings of 15, 20 and 25 wt % allowed 
aqueous docetaxel concentrations, dispersed within branched vinyl copolymer nanoparticles, 
of 0.15, 0.20 and 0.25 mg mL-1 to be achieved. Previous reports have demonstrated an aqueous 
saturation concentration of 6.5 µg mL-1 for docetaxel at ambient temperature.22,23 
Encapsulation of docetaxel within stable branched vinyl copolymer nanoparticles at drug 
loadings of 15, 20 and 25 wt % therefore represent 23-, 31- and 39-fold increases in the 




nanoparticles relative to the aqueous saturation concentration. Co-nanoprecipitation also 
offers two formulation pathways through which the aqueous concentration of docetaxel could 
be increased further. Firstly, as discussed in Chapter 3, Section 3.4.3.1, co-nanoprecipitations 
could be conducted at higher concentrations with minimal impact on nanoparticle size and 
stability. Alternatively, multiple copolymer additions could be used to increase nanoparticle 
concentration with minimal impact on nanoparticle size or stability. Either of these approaches 
could be used to achieve higher aqueous docetaxel concentrations. However, given the 
preliminary stage of this research, and that docetaxel had successfully been encapsulated 
within the nanoparticles, obtaining the maximum aqueous concentration of docetaxel that 
could be achieved via co-nanoprecipitation was not investigated further at this point. 
Encapsulation of docetaxel within branched vinyl copolymer nanoparticles therefore offers a 
number of advantages over the conventional administration of docetaxel. Firstly, due to the 
ability to achieve higher aqueous docetaxel concentrations, nanoformulation could increase 
the concentration of docetaxel within systemic circulation and therefore reduce the IV dose 
required. Furthermore, nanoformulations offer a more homogeneous form of docetaxel 
administration as aggregation of free docetaxel can result in opsonisation and subsequent 
clearance via the mononuclear phagocyte system. Secondly, it is highly likely that docetaxel 
is encapsulated within the core of branched vinyl copolymer nanoparticles. As a result, 
providing nanoparticles remain chemically inert, docetaxel would be protected from chemical 
degradation whether via opsonisation, enzymatic degradation or changes in the external 
environment such as pH. Encapsulation may therefore reduce the amount of docetaxel being 
removed from systemic circulation via physiological defence mechanisms. Finally, docetaxel 
is a relatively low molecular weight compound (808 g mol-1); unencapsulated docetaxel 
molecules are therefore susceptible to size-dependent physiological filtration mechanisms 
within systemic circulation. It is therefore likely that encapsulation of docetaxel within 
nanoparticles with hydrodynamic diameters of ~100 nm would greatly reduce the clearance of 
docetaxel from systemic circulation via renal filtration pathways. Furthermore, due to 
prolonged circulation times, such nanoparticles would likely benefit from the enhanced 
permeation and retention effect, discussed in Chapter 1, Section 1.2.2.3. As a result, 
encapsulation of docetaxel within branched vinyl copolymer nanoparticles would likely 
greatly increase the accumulation of drug at a tumour site and, therefore, increase the efficacy 
of such chemotherapy treatments, whilst minimising toxic side effects which have a significant 





Whilst preliminary drug loading co-nanoprecipitations showed that aqueous nanoparticle 
dispersions could be formed in the presence of increasing concentrations of docetaxel, they 
provided no quantitative evidence of docetaxel encapsulation within the core of branched vinyl 
copolymer nanoparticles. Although the absence of sedimentation at docetaxel concentrations 
in excess of the aqueous saturation limit suggests docetaxel encapsulation, further quantitative 
analyses were required to determine whether, and what proportion of, docetaxel had been 
encapsulated during co-nanoprecipitation. Studies were therefore required to understand the 
relationship between the chemical structure of the hydrophobic nanoparticle cores and the rate 
at which docetaxel was released from branched vinyl copolymer nanoparticles.  
4.3 Quantitative Analysis of Docetaxel Encapsulation and Release from Branched Vinyl 
Copolymer Nanoparticles formed via Co-Nanoprecipitations 
The ability to encapsulate docetaxel within the core of branched vinyl copolymer nanoparticles 
during co-nanoprecipitation offered the opportunity for docetaxel release over prolonged time 
periods, and perhaps in a controlled manner. In order to demonstrate this potential, quantitative 
analyses were required to demonstrate that: i) docetaxel was in fact encapsulated within the 
core of branched vinyl copolymer nanoparticles; and ii) encapsulation within branched vinyl 
copolymer nanoparticles could be used to modulate docetaxel release. The research focus, 
therefore, moved towards the development of techniques which would provide facile and 
reproducible quantification of drug encapsulation and release rates. 
4.3.1 Quantification of Docetaxel Encapsulation Efficiency and Drug Loading achieved 
during Nanoparticle Formation via Co-Nanoprecipitation  
There are several possible fates for docetaxel molecules employed in co-nanoprecipitation. 
Perhaps the most obvious fate would be that docetaxel is encapsulated during the 
co-nanoprecipitation process and would therefore be located within the core of branched vinyl 
copolymer nanoparticles. Alternatively, docetaxel, likely accompanied by hydrophobic 
copolymers, can sediment from the aqueous nanoparticle dispersion. Sedimentation occurs 
when co-nanoprecipitation processes fail to encapsulate docetaxel within nanoparticles which 
would be capable of maintaining their colloidal stability both during and after the 
co-nanoprecipitation process. Finally, small amounts of docetaxel, ≤6.5 µg mL-1, is likely to 
be dissolved within the DI H2O in which branched vinyl copolymer nanoparticles were formed 
and dispersed. In order to gain an insight into the efficiency of docetaxel encapsulation, 
quantitative techniques were required to determine the amount of docetaxel within each of 
these environments. 
Encapsulation efficiency (EE) and total drug loading (DL) are two key factors which must be 
considered when evaluating the efficiency of any drug encapsulation process. EE and DL are 




fraction of drug that has been encapsulated during nanoparticle formation (Dencap), as a 
proportion of the total amount used during the formulation process. The total docetaxel mass 
(Dtotal) consists of encapsulated docetaxel (Dencap) and free docetaxel (Dfree) in aqueous solution 
(Dtotal = Dencap + Dfree). Alternatively, the DL gives an indication of the nanoparticle 
composition and quantitatively represents the amount of encapsulated drug (mED) as a 
proportion of the total mass of the nanocarrier (mtotal = mpolymer + mED). EE and DL are therefore 
both important factors required in order to provide a true representation of the efficiency of 
drug encapsulation process.  
     𝐸𝐸 =
𝐷𝑒𝑛𝑐𝑎𝑝
𝐷𝑡𝑜𝑡𝑎𝑙
                  Equation 4.1
  
                 𝐷𝐿 =  
𝑚𝐸𝐷
𝑚𝑝𝑜𝑙𝑦𝑚𝑒𝑟+ 𝑚𝐸𝐷
 × 100           Equation 4.2
  
4.3.1.1 Quantifying the EE and DL of 3H -labelled Docetaxel during Co-Nanoprecipitation 
Initial research involved attempts to develop techniques which could be used for the 
quantification of the docetaxel EE and DL achieved during co-nanoprecipitation. Due to 
docetaxel’s extremely low aqueous saturation solubility, quantification of aqueous docetaxel 
concentrations is a challenging task. A maximum solubility of 6.5 µg mL-1 meant that accurate 
analysis of aqueous nanoparticle dispersions could not be achieved using 1H NMR 
spectroscopy. Similarly, reliable calibration curves could not be obtained for docetaxel in DI 
H2O using ultraviolet-visible spectroscopy (UV-Vis). As a result, direct analysis of aqueous 
nanoparticle dispersions was not possible using either 1H NMR or UV-Vis spectroscopy. 
Alternatively, following removal of DI H2O via freeze-drying and subsequent full dissolution 
in CDCl3 and THF, docetaxel quantification was achieved by 1H NMR and UV-Vis 
respectively. However, whilst this allowed the amount of docetaxel present to be quantified, 
this approach was labour-intensive and was generally incompatible with the low solid masses 
employed in co-nanoprecipitations and the high sensitivity required caused inconsistencies in 
results obtained using 1H NMR and UV-Vis spectroscopy. As a result, this approach was not 
taken forward and radiometric analysis was explored as an alternative for the quantification 
and comparison of the EE and DL achieved during co-nanoprecipitations. 
Tritium (3H) radio-labelling of docetaxel and subsequent liquid scintillation counting (LSC) 
was used as the quantitative analytical technique to determine EE and DL achieved during 
co-nanoprecipitations. 3H is a low energy (0.0186 MeV) beta (β) emitting radio nuclide with 
a half-life of more than 12 years; negligible radio-decay would therefore be expected over the 
time scales that docetaxel encapsulation and release studies were conducted during the course 




penetration distances in air (6 mm) from emitted electrons and an inability to penetrate through 
the top layer of any exposed skin. Nonetheless, experiments conducted using 3H-labelled 
molecules required basic radiation protection training at the University of Liverpool and all 
experiments were conducted within the Rannard Group Radio Materials Laboratory under the 
supervision of an accredited radiation protection supervisor, Dr. Helen Cauldbeck.  
Co-nanoprecipitations were conducted using 3H-labelled docetaxel containing specific 
activities ranging from 6.61 - 6.65 µCi mg-1. Specific activity (SA) refers to the intensity of 
β-emissions from 3H nuclei per unit mass of docetaxel. The relationship between total 
radioactivity (TR), SA and docetaxel mass (mDocetaxel) is presented in Equation 4.3. It is 
important to clarify, however, that not every docetaxel molecule contained radioactive 3H 
nuclei. Nevertheless, accurate quantification of the SA of a sample of 3H-labelled docetaxel 
allows the total docetaxel mass to be calculated from the intensity of the β-emission observed 
during LSC analysis. The radio-purity of 3H-labelled docetaxel was confirmed using radio-
thin layer chromatography; this showed the presence of just one 3H-labelled species which 
gave an identical Rf value to that obtained from regular thin-layer chromatography of non-
labelled docetaxel using the same eluent system. This allowed quantification of the amount of 
docetaxel present within aqueous nanoparticle dispersions via LSC analysis and was essential 
for the calculation of the EE and DL achieved during co-nanoprecipitation.  
𝑚𝐷𝑜𝑐𝑒𝑡𝑎𝑥𝑒𝑙(mg) = TR(µ𝐶𝑖)/𝑆𝐴 (µ𝐶𝑖 𝑚𝑔
−1)       Equation 4.3   
An overview of the encapsulation of 3H-labelled docetaxel during the co-nanoprecipitation 
process is given in Figure 4.5. Co-nanoprecipitations were conducted using equal weight 
fractions of amphiphilic AB block and branched copolymers (ωi = 0.5) from THF (1 mL), at 
a total solids concentration of 5 mg mL-1, into DI H2O (5 mL, DR = 5). In order to generate 
comparable drug release data, all co-nanoprecipitations were conducted at target drug loadings 
of 15 wt % as this was the maximum target drug loading at which stable docetaxel-loaded 
aqueous nanoparticle dispersions were produced from all copolymer co-nanoprecipitations. 
Co-nanoprecipitations were left for 48 hours to allow complete THF removal via evaporation 





Figure 4.5 Schematic representation of the encapsulation of 3H-labelled docetaxel within the 
core of branched vinyl copolymer nanoparticles via co-nanoprecipitation.  
In all cases, co-nanoprecipitations resulted in the formation of turbid and translucent 
3H-docetaxel-loaded aqueous nanoparticle dispersions which showed no sedimentation. This 
was consistent with the observations made for the analogous co-nanoprecipitations conducted 
using unlabelled docetaxel, described in Section 4.2. 3H-docetaxel-loaded nanoparticle 
dispersions were assessed by DLS, and in all cases had monomodal size distributions with 
intensity-average hydrodynamic diameters consistent with those generated previously (Table 
4.2). Aqueous nanoparticle dispersions also showed low PDI values which, once again, 
confirmed the success of co-nanoprecipitations in the presence of 15 wt % targeted docetaxel 
loadings.  
Table 4.2 Radiometric and DLS analyses of 3H-docetaxel-loaded aqueous nanoparticle 












p(HPMA) 14.3 0.769 11.0 86 58 0.111 
p(nBMA) 13.6 0.954 13.0 88 57 0.126 
p(nHMA) 13.5 0.955 12.9 109 75 0.098 
p(EHMA) 13.0 0.974 12.7 81 54 0.095 
p(LMA) 12.4 0.836 10.4 99 73 0.071 
aDetermined by radiometric analysis of aqueous nanoparticle dispersion prior to centrifugation.                  
bCalculated using masses of encapsulated and free docetaxel determined using radiometric analyses 
following ultracentrifugation. cDL = Target loading x EE. dDetermined by DLS at a concentration of 
1 mg mL-1.  
Quantification of the EE and DL achieved during co-nanoprecipitation first required a process 




nanoparticle dispersions through a 3.5 kDa membrane, allowing free docetaxel dissolved 
within the aqueous medium to be separated from the branched vinyl copolymer nanoparticles 
in which the remainder of the initial docetaxel loading was encapsulated. The purification 
process is presented in Figure 4.6. Briefly, LSC analysis was conducted on the initial aqueous 
nanoparticle dispersion (ctotal = 1 mg mL-1) in order to determine the total amount of docetaxel 
present (Dtotal) This allowed accurate quantification of the actual docetaxel concentration 
within the aqueous nanoparticle dispersion (i.e. the experimental target drug loading). 0.5 mL 
of the aqueous nanoparticle dispersion was then placed in the top of a centrifuge tube 
containing a 3.5 kDa filter. The sample was then centrifuged, which allowed the vast majority 
of the water, along with any free docetaxel to pass into the lower chamber of the centrifuge 
tube. The amount of free docetaxel (Dfree) was then determined via LSC analysis of the liquid 
collected in the lower chamber of the centrifuge tube. EE was then calculated in accordance 
with Equation 4.1.  
 
Figure 4.6 Schematic representation of nanoparticle purification via centrifugation. a) Aqueous 
nanoparticle dispersions consisting of both encapsulated and free docetaxel and b) Purification of 
aqueous nanoparticle dispersions by separation of encapsulated (top) and free (bottom) docetaxel. 
Data obtained from LSC analyses were used to determine the EE and DL achieved during all 
co-nanoprecipitations (Table 4.2). In all cases, the experimental targeted drug loadings were 
slightly below the theoretical 15 wt %, possibly due to loss of initial solution of 3H- docetaxel/ 
copolymer-THF solution on the pipette tip during co-nanoprecipitation or affinity of the drug 
for glass. In all cases, high docetaxel encapsulation efficiencies were observed during 
co-nanoprecipitation; this was evident by LSC analyses which showed ≥76.9 % docetaxel 
remained within branched vinyl copolymer nanoparticles following centrifugation. 
Exceptionally high encapsulation efficiencies were observed during co-nanoprecipitations of 
p(nBMA), p(nHMA) and p(EHMA) based copolymers (EE ≥0.954). As was observed during 
initial docetaxel encapsulation studies, no correlation was observed between EE and the 
chemical structure of the copolymers used during co-nanoprecipitation. For example, the 
lowest EE values were observed for p(HPMA) and p(LMA) based copolymers. These 




study. This once again indicated that copolymer structure had little impact on docetaxel 
encapsulation during the co-nanoprecipitation process. This supports earlier indications that 
docetaxel encapsulation is a kinetically-driven process due to the high levels of supersaturation 
during co-nanoprecipitation and that, although copolymers are essential for successful 
nanoparticle formation, they have little impact on the level of small molecules encapsulated 
during co-nanoprecipitation.  
The ability to determine both the experimental targeted drug loading and the EE of docetaxel 
using radiometric analyses allowed the actual docetaxel DL achieved during 
co-nanoprecipitation to be calculated. In all cases, the amount of docetaxel encapsulated was 
lower than the theoretical target, but DLs ranging between 10.4 and 13.0 % of the total 
nanoparticle mass were achieved during co-nanoprecipitation. Given the higher EE achieved 
during co-nanoprecipitation, the highest drug loadings, which ranged from 12.7 to 13.0 %, 
were achieved for p(nBMA), p(nHMA) and p(EHMA) based nanoparticles. In contrast, lower 
docetaxel DLs of 11.0 and 10.4 % were achieved during co-nanoprecipitations of p(HPMA) 
and p(LMA) based copolymers. Although accurate quantification of docetaxel encapsulation 
could be achieved using radiometric analyses, it was clear that manipulation of copolymer 
structure could not be used as a tool to increase docetaxel encapsulation or EE during 
co-nanoprecipitation.  
The 3H-docetaxel encapsulation experiments were conducted at a fixed target drug loading of 
15 wt %. It is therefore possible that studying the EE across the full range of targeted drug 
loadings attempted in Section 4.2 could impact the EE and DLs achieved during 
co-nanoprecipitation. For example, 15 wt % was the highest targeted drug loading at which a 
suitable aqueous nanoparticle dispersion was generated during p(EHMA) based 
co-nanoprecipitations. It is therefore feasible that higher EE values could be achieved during 
co-nanoprecipitations conducted at lower targeted DL. The trade-off between target DL and 
EE may allow for the preparation of aqueous nanoparticle dispersions which have reduced 
amounts/no free drug present within the aqueous phase; and achieve higher overall DL due to 
increased EE. Such studies are outside the scope of this thesis.   
The data obtained here further demonstrated the ability to encapsulate hydrophobic guest 
molecules within the core of branched vinyl copolymer nanoparticles during the 
co-nanoprecipitation process. Although the docetaxel encapsulation experiments yielded 
stable aqueous nanoparticle dispersions, with desirable size characteristics, it was evident that 
the co-nanoprecipitation failed to ensure complete docetaxel encapsulation at higher targeted 
drug loadings. Despite this, the encapsulation of relatively high loadings of docetaxel would 




experiments compared with administration of the free drug. The impact of docetaxel 
encapsulation, as well as that of the presence of free docetaxel, required further studies to 
monitor the release of docetaxel from branched vinyl copolymer nanoparticles. Fortunately, 
the presence of 3H-docetaxel within the core of branched vinyl copolymer nanoparticles 
allowed this release to be studied using further radiometric analyses.  
4.3.2 Monitoring Docetaxel Release via 3H Radio-dialysis 
The encapsulation of docetaxel during co-nanoprecipitation was expected to modulate the 
rates of docetaxel release from branched vinyl copolymer nanoparticles. The high sensitivity 
of radio experiments and LSC allows the detection and accurate quantification of the low 
docetaxel concentrations expected to be released following high dilution. A series of radio-
dialysis experiments were therefore conducted to determine whether docetaxel was released 
from branched vinyl copolymer nanoparticles and, in particular, to understand whether the 
chemical nature of the nanoparticle core affected docetaxel release rates. Docetaxel release 
experiments were conducted using the 3H-docetaxel-loaded aqueous nanoparticle dispersions 
generated in Section 4.3.1 and experiments to evaluate the impact of copolymer structure and 
temperature on the rate of docetaxel release from branched vinyl copolymer nanoparticles 
were undertaken.  
An overview of the radio-dialysis procedure is presented in Figure 4.7. Briefly, 1 mL of 
docetaxel-loaded branched vinyl copolymer nanoparticles was added to a double-sided 
bio-dialyser and sealed with a 3.5 kDa molecular weight cut-off (MWCO) membrane. A 
bio-dialyser was considered more suitable for radio-dialysis experiments as its rigid structure 
provided more secure containment of 3H-labelled compounds compared with conventional 
dialysis tubing. A bio-dialyser also provides conditions which are easily replicated which 
reduces inter-experiment variability with respect to surface area of nanoparticle dispersion 
exposed to the dialysis membrane. To ensure that sink conditions were achieved, the 
bio-dialyser was placed in a reservoir containing 100 mL of DI H2O. Initial radio-dialyses 
were conducted over 24 hours at ambient temperature during which time the external reservoir 
was replaced at regular intervals of: 0.5, 1, 2, 3, 4, 5, 6, 7, 8 and 24 hours. LSC analysis 
conducted on samples of the external reservoir allowed quantification of the amount of 





Figure 4.7 Schematic representation of the radio-dialysis experiments through which the rates of 
docetaxel release from branched vinyl copolymer nanoparticles were determined. Docetaxel loaded 
aqueous nanoparticle dispersions were loaded into a bio-dialyser (3.5 kDa MWCO) and placed in DI 
H2O under sink conditions, allowing docetaxel diffusion into the external reservoir.  
4.3.2.1 The Impact of Copolymer Structure on Docetaxel Release from Branched Vinyl 
Copolymer Nanoparticles 
Initial radio-release studies sought to determine the impact of nanoparticle core chemistry on 
the rate of docetaxel release from branched vinyl copolymer nanoparticles. This was achieved 
by conducting identical radio-release experiments using aqueous nanoparticle dispersions 
consisting of p(HPMA), p(nBMA), p(nHMA), p(EHMA) and p(LMA) based copolymers. To 
remove any possible impact of temperature on docetaxel release rates, initial radio-dialyses 
were conducted at 20 ℃ over 24 hours.  
 
Figure 4.8 Cumulative 3H-labelled docetaxel release data obtained over 24 hour via 
radio-dialyses of: p(HPMA) (red open circles), p(nBMA) (blue open squares), p(nHMA) (green open 
triangles), p(EHMA) (teal open hexagons) and p(LMA) (purple open diamonds) based branched vinyl 




Clear differences were observed between the docetaxel release rates obtained for branched 
vinyl copolymers consisting of various hydrophobic copolymers. For example, after 8 hours 
43, 18, 15, 11 and 26 % of the initial docetaxel loading had been released from branched vinyl 
copolymer nanoparticles consisting of p(HPMA), p(nBMA), p(nHMA), p(EHMA) and 
p(LMA), respectively. The 3H-labelled release curves, obtained from radio-dialysis of all 
docetaxel loaded aqueous nanoparticle dispersions at ambient temperature, are presented in 
Figure 4.8. Interestingly, DLS studies of branched vinyl copolymer nanoparticles before and 
after radio-dialyses indicated negligible impact on nanoparticle size or stability (Appendix, 
Table A4.1). This was somewhat surprising given that nanoparticles had lost a significant 
proportion of their original mass. This, however, supported earlier claims that, due to 
nanoparticle stability to dilution, docetaxel release most likely occurred via diffusion from the 
nanoparticle cores rather than as a result of complete disassembly of nanoparticle structure.  
It is important to state that the total amount of docetaxel used in each radio-dialysis experiment 
(ca. 0.15 mg) was significantly below the docetaxel aqueous saturation limit within the 
100 mL external reservoir (Cmax = 0.65 mg, 6.5 µg mL-1).22,23 This suggests that under 
homogeneous conditions and rapid equilibration, that >99 % of docetaxel release could 
theoretically be achieved within 0.5 hours. It must be noted, however, that this would require 
complete equilibration of the concentration gradient within the first 30 minutes of 
radio-dialysis. Radio-dialysis of free docetaxel was attempted by addition of a docetaxel-EtOH 
solution directly into the bio-dialyser. This, however, did not show the expected burst release 
profile typically obtained for dialysis of free drugs. Instead, free docetaxel showed a 
comparable release profile to that obtained for p(HPMA) based nanoparticles (Appendix 
Figure A4.2). This likely occurred due to the formation of large aggregates within the 
bio-dialyser as the docetaxel concentration exceeded its aqueous saturation limit. As a result, 
docetaxel release was dependent upon the rate at which such aggregates dissolved, which was, 
in turn, limited by the aqueous docetaxel saturation limit. It was therefore not possible to obtain 
comparable release data for free docetaxel under the experimental conditions that 
radio-dialyses were conducted. 
The highest docetaxel release rates were observed for branched vinyl copolymer nanoparticles 
consisting of p(HPMA) and p(LMA) based copolymers. This was somewhat unsurprising 
given the lower encapsulation efficiencies achieved during co-nanoprecipitation (0.769 and 
0.836 respectively). It is therefore likely that high concentrations of free docetaxel within the 
aqueous nanoparticle dispersion were immediately able to permeate through the dialysis 
membrane into the external reservoir. In contrast, p(nBMA), p(nHMA) and p(EHMA) based 
nanoparticles, which showed higher encapsulation efficiencies (≥0.954) showed slower 




rates from branched vinyl copolymer nanoparticles formed via co-nanoprecipitation. 
Interestingly, comparison between docetaxel release from p(nBMA), p(nHMA) and p(EHMA) 
based nanoparticles, which achieved comparable encapsulation efficiencies during 
co-nanoprecipitation, generally showed a strong correlation with the hydrophobicity of the 
copolymers from which nanoparticles were constructed. Release rates obtained at 20 ℃ 
decreased in the order of p(nBMA) > p(nHMA) > p(EHMA). This strongly suggested that the 
nanoparticle core chemistry had a significant influence on the rate at which docetaxel was 
released, at least within this series of materials. Furthermore, this implied that hydrophobic 
interactions between the aliphatic side chains of copolymer repeat units and encapsulated 
docetaxel were responsible for an aspect of drug release modulation.    
In all cases, docetaxel release kinetics demonstrated first-order release. This indicated that 
release rates were proportional to the docetaxel concentration within the nanoparticle cores. 
Given that the initial concentration of docetaxel was known and that the amount of docetaxel 
released at each time point had been quantified, this allowed the concentration of encapsulated 
docetaxel ([Docetaxel]) to be calculated at each time point during the radio-dialysis. This data 
was used to determine the docetaxel release constants (k) for each of the branched vinyl 
copolymer nanoparticles studied. This was achieved using the integrated rate law for first order 
reactions to construct plots of ln[Docetaxel] vs. time (Equation 4.4). In order to eliminate any 
effects of varied concentration gradients, semi-logarithmic plots were constructed using data 
obtained between hours 1 and 8 of radio-dialysis experiments during which time the external 
reservoir was replaced at regular intervals. In all cases, this generated reliable data (R2 ≥ 0.95) 
which allowed determination of docetaxel release rate constants for each of the radio-dialyses. 
In ascending order, these rate constants of 47.9, 67.7, 82.4, 125.6 and 256.3 s-1 were obtained 
for p(EHMA), p(nHMA), p(nBMA), p(LMA) and p(HPMA) based nanoparticles respectively. 
[𝐷𝑜𝑐𝑒𝑡𝑎𝑥𝑒𝑙]𝑡 =  [𝐷𝑜𝑐𝑒𝑡𝑎𝑥𝑒𝑙]0 𝑒
−𝑘𝑡            Equation 4.4  
The release rate constants obtained were used to determine the half-life (t1/2) of docetaxel 
within the core of branched vinyl copolymer nanoparticles. In this sense, t1/2 refers to the time 
taken for 50 % of the initial docetaxel loading to be released into the external reservoir. This 
is not to be confused with the plasma half-life, which refers to the time taken for the 
concentration of an active pharmaceutical ingredient to be reduced to 50 % of its initial value 
within systemic circulation. Given that, t1/2 is proportional to k for processes that obey 
first-order kinetics (Equation 4.5), release rate constants could easily be converted into 
docetaxel half-lives. At ambient temperature, half-lives of 52.1, 36.9, 30.3, 19.9 and 9.7 hours 
were obtained for docetaxel release from p(EHMA), p(nHMA), p(nBMA), p(LMA) and 
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Equation 4.5 Calculation of the half-life (t1/2) of docetaxel which remained in the core of branched 
vinyl copolymer nanoparticles. 
The calculation of docetaxel half-lives provided context for the impact of nanoparticle core 
chemistry on the rate at which encapsulated payloads are released from branched vinyl 
copolymer nanoparticles. The calculated docetaxel half-lives indicated that branched vinyl 
copolymers are capable of retaining encapsulated payloads for prolonged time periods. For 
example, more than 50 % of encapsulated docetaxel  would remain within the p(EHMA) 
nanoparticle cores for two days after dilution. In all cases, branched vinyl copolymer 
nanoparticles retained  more than 50 % of their encapsulated payloads long after the time 
typically required for significant nanoparticle accumulation within tumour tissue as a result of 
the enhanced permeation and retention effect in vivo (6 hrs).55 Initial radio-dialyses therefore 
demonstrated that docetaxel-loaded branched vinyl copolymer nanoparticles have the potential 
to modulate drug release in vivo. Whilst initial studies sought to understand the relationship 
between nanoparticle chemistry and docetaxel release rates, applications of drug nanocarriers 
within a clinical setting require nanoparticles to be able to modulate drug release at 
physiological temperatures. Further studies were therefore required to understand the impact 
of temperature on docetaxel release from branched vinyl copolymer nanoparticles. 
4.3.2.2 The Impact of Temperature on Docetaxel Release Rates  
It was predicted that temperature would have a significant impact on the rate of docetaxel 
release from branched vinyl copolymer nanoparticles. Increases in temperature were expected 
to produce (i) an increase in the aqueous solubility limit of docetaxel and (ii) higher rates of 
docetaxel diffusion from the nanoparticle cores. A series of radio-dialyses were conducted to 
evaluate the extent, if any, to which increases in temperature impacted docetaxel release rates. 
Further radio-dialyses were conducted at 37 ℃ and 50 ℃ under otherwise identical conditions 
to those discussed in Section 4.3.3, allowing comparison with the release data generated above 
and therefore enabling docetaxel release rates to be studied at temperatures ranging from 20 ℃ 
to 50 ℃. In all cases, faster docetaxel release rates were observed at higher temperature. For 
example, p(nBMA)-based nanoparticles released 18, 30 and 39 % of  their encapsulated 
docetaxel payloads over 8 hours during radio-dialyses conducted at 20, 37 and 50 ℃ 
respectively. Overlaid docetaxel release curves obtained for each nanoparticle type at various 





Figure 4.9 The effect of temperature on the rate of docetaxel release from branched vinyl 
copolymer nanoparticles. Overlaid docetaxel release curves obtained from radio-dialyses of                              
a) p(HPMA), b) p(nBMA), c) p(nHMA), d) p(EHMA) and e) p(LMA) based branched vinyl copolymer 
nanoparticles at 20 ℃ (open circles, short dashed lines), 37 ℃ (open squares, medium dashed lines) 
and 50 ℃ (open triangles, solid lines) over 24 hours. 
Release data demonstrated that, regardless of the chemical nature of the nanoparticle core, 
temperature had a profound effect on docetaxel release rates. Interestingly, nanoparticles for 
which high encapsulation efficiencies were achieved during co-nanoprecipitation saw 
docetaxel release rates increase at higher temperature. In contrast, p(HPMA) and p(LMA) 




increased from 20 to 37 ℃ than a similar increase from 37 to 50 ℃. As suggested above, it is 
possible that the higher release rates are observed due to a higher proportion of free drug within 
the aqueous nanoparticle dispersions; initial increases in temperature may therefore have a 
disproportionate impact on aqueous nanoparticle dispersions containing higher concentrations 
of free drug. These data suggest that faster release rates likely occurred due to a combination 
of higher rates of docetaxel diffusion through the nanoparticle cores to the nanoparticle-water 
interface, and increased docetaxel solubility within the aqueous phase.   
Docetaxel release rates obtained for nanoparticles comprising various core chemistries 
generally remained constant across the temperature range that radio-dialyses were conducted. 
This is demonstrated in Figure 4.10; release data have been replotted to show overlaid 
docetaxel release plots obtained for different nanoparticles consisting at each of the 
temperatures studied.   
 
Figure 4.10 The effect of nanoparticle core chemistry on the rate of docetaxel release from 
branched vinyl copolymer nanoparticles at various temperatures. Overlaid docetaxel release curves 
obtained for p(HPMA) (red, open circles), p(nBMA) (blue, open squares), p(nHMA) (green, open 
triangles), p(EHMA) (teal, open hexagons) and p(LMA) (purple, open diamonds) during radio dialyses 




Radio-dialyses conducted at 37 ℃, Figure 4.10b, provided an indication of the docetaxel 
release rates that may be achieved at physiological temperature. The release rates observed at 
37 ℃ increased in the order of p(EHMA), p(nHMA), p(nBMA), p(LMA) and p(HPMA), 
which was identical to the order observed at 20 ℃. However, significantly higher amounts of 
docetaxel were released after 8 hours at 37 ℃ compared to the amounts released from the 
same nanoparticles at 20 ℃. For example, cumulative docetaxel releases of 17, 24, 30, 40 and 
61 wt % were achieved following 8 hours of radio-dialysis at 37 ℃ for p(EHMA), p(nHMA), 
p(nBMA), p(LMA) and p(HPMA)-based nanoparticles respectively. These values were 
significantly higher than the 11, 15, 18, 26 and 43 wt % of encapsulated docetaxel payloads 
that were cumulatively released during radio-dialysis of the same nanoparticles at 20 ℃. 
A further increase in the temperature at which radio-dialyses were conducted generally 
resulted in further increases in the rate at which docetaxel was released from branched vinyl 
copolymer nanoparticles. Surprisingly, however, docetaxel release from p(LMA) 
nanoparticles at 50 ℃ was almost identical to that observed for the same nanoparticles at 
37 ℃. For example, the same batch of p(LMA) nanoparticles showed comparable cumulative 
docetaxel release of 39.6 and 39.1 wt% of the initial encapsulated docetaxel payload following 
radio-dialysis over 8 hours. The factors that affect docetaxel release from p(LMA)-based 
branched vinyl copolymer nanoparticles will be discussed in more detail later in this Chapter. 
With the exception of p(LMA)-based nanoparticles, the order of docetaxel release rates 
obtained at 50 ℃ followed the same trend observed at lower tempeatures. This once again 
demonstrated the temperature dependence of docetaxel release from branched vinyl copolymer 
nanoparticles.  
Detailed kinetic analyses were conducted using the data obtained from radio-dialysis of each 
of the branched vinyl copolymer nanoparticles at each of the temperatures studied. This 
analysis allowed further understanding of the effect of temperature on docetaxel release rates. 
Kinetic analysis first involved the construction of semi-logarithmic plots using release data 
obtained from radio-dialysis. This allowed determination of docetaxel release rate constants 
via calculation of the gradients obtained from plots of ln[Docetacel]t vs. time. Kinetic plots 
obtained from radio-dialysis of each nanoparticle type at different remperatures were overlaid 
in order to demonstrate the impact of temperature on docetaxel release rates (Figure 4.11). In 
all cases, docetaxel release constants increased with temperature. For example, docetaxel 
release rate constants of 256.3, 441.7 and 552.2 s-1 were obtained for p(HPMA) nanoparticles 
during radio dialyses conducted at 20, 37 and 50 ℃, respectively. In contrast to the general 
trends observed, comparable release rate constants of 200.9 and 211.0 s-1 were calculated from 
data obtained from radio-dialysis of p(LMA)-based nanoparticles at temperatures of 37 and 





Figure 4.11 Calculation of docetaxel release rate constants at various temperatures. 
Semi-logarithmic kinetic plots constructed using data obtained from radio-dialysis of: a) p(HPMA), b) 
p(nBMA), c) p(nHMA), d) p(EHMA) and e) p(LMA)-based docetaxel-loaded branched vinyl 
copolymer nanoparticles at 20 ℃ (open circles), 37 ℃ (open squares) and 50 ℃ (open triangles) over 
24 hours. 
Release rate constants were used to calculate docetaxel half-lives within branched vinyl 
copolymers during radio-dialyses conducted at various temperatures. All calculated docetaxel 




decreased with temperature, as docetaxel release rates increased. For example, docetaxel 
half-lives of 36.9, 22.4 and 17.7 hours were calculated for docetaxel within the core of 
p(nHMA)-based nanoparticles during radio-dialysis conducted at temperatures of 20, 37 and 
50 ℃, respectively. Docetaxel half-lives calculated at 37 ℃ were perhaps of most significance 
due to their relevance to the physiological conditions with which branched vinyl copolymer 
nanoparticles would be exposed during in vivo release studies. Branched vinyl copolymer 
nanoparticles consisting of p(EHMA), p(nHMA), p(nBMA), p(LMA) and p(HPMA) gave 
docetaxel half-lives of 35.4, 22.4, 17.0, 12.4 and 5.65 hours respectively at 37 ℃. With the 
exception of p(HPMA), all nanoparticles would be expected to release more than 50 % of their 
encapsulated payload after 12 hours dialysis at 37 ℃. This is particularly significant for DNC 
systems which target the enhanced permation and retention effect in order to achieve high 
levels of nanoparticle accumulation within tumour tissue in vivo. It is therefore highly likely, 
should docetaxel half-lives translate to in vivo release studies, that the vast majority of 
encapsulated docetaxel payloads would be released either within the tumour tissues or within 
cancer cells if passive accumulation had occurred. 
Table 4.3 Release rate constants and half-lives obtained from radio-dialysis of 3H-labelled 
docetaxel-loaded aqueous nanoparticle dispersions at varied temperature.  
Nanoparticle core 
















p(HPMA)  256.3 9.74  401.7 6.21  552.2 4.52 
p(nBMA)  82.4 30.3  146.9 17.0  208.4 12.0 
p(nHMA)  67.7 36.9  111.6 22.4  140.8 17.7 
p(EHMA)  47.9 52.1  70.6 35.4  123.1 20.3 
p(LMA)  125.6 19.9  200.9 12.4  211.0 11.8 
aCalculated from plots of ln[Docetaxel] vs. time. bCalculated using docetaxel release rate constants 
obtained from radio release data (t1/2 = ln2/k.). 
Whilst data obtained from radio-dialyses conducted at 50 ℃ may not have any clinical 
relevance to the application of branched vinyl copolymer nanoparticles as drug nanocarriers, 
such experiments were essential to understand the impact of temperature on docetaxel release 
from branched vinyl copolymer nanoparticles. Importantly, the avoidance of a “cold chain” in 
storage and supply is critical for the commercial viability of new drug delivery systems and 
storage temperatures can reach 50 ℃  in hot warehouse environments. It is noteworthy that 
branched vinyl copolymer nanoparticles were able to maintain their structural integrity 
following prolonged to temperatures up to 50 ℃. As with experiments conducted at 20 and 
37 ℃, this was demonstrated by the negligible differences observed in the branched vinyl 
copolymer nanoparticle size distributions and intensity-average hydrodynamic diameters 




Whilst docetaxel release rates from p(HPMA), p(nBMA), p(nHMA) and p(EHMA) based 
nanoparticles showed strong dependence upon the temperature at which radio-dialyses were 
conducted, the comparable docetaxel release rates obtained for p(LMA) based nanoparticles 
at temperatures ≥37 ℃ indicated that there may be a point at which docetaxel release rates 
become independent of temperature. Further analysis of release data and further copolymer 
analysis was therefore required in order to try to understand the factors governing docetaxel 
release rates from branched vinyl copolymer nanoparticles.  
4.3.2.3 Understanding the Temperature Dependence of Docetaxel Release from Branched 
Vinyl Copolymer Nanoparticles 
There are numerous chemical and physical factors which could have influenced docetaxel 
release rates from branched vinyl copolymer nanoparticles during radio-dialyses. 
Encapsulated docetaxel molecules must diffuse through the branched vinyl copolymer core in 
order to arrive at the polymer-water interface. The diffusion of small molecules through a 
polymer matrix is typically a temperature-dependent process; it is therefore likely that the rate 
of docetaxel release could be limited by the docetaxel diffusion to the polymer-water interface. 
Another factor which must be considered is the docetaxel solubility parameter within the 
nanoparticle core. In cases where favourable non-covalent interactions exist between 
docetaxel molecules and the hydrophobic domains of branched and amphiphilic AB block 
copolymers, which make up the nanoparticle core, high drug solubility within the copolymer 
matrix would be expected. High docetaxel-polymer compatibility would likely reduce the rate 
at which docetaxel molecules diffuse from the polymer phase into the surrounding aqueous 
environment. Furthermore, the docetaxel saturation limit within the surrounding aqueous 
environment would also likely influence the rate at which docetaxel molecules cross the 
polymer-water interface. Many of these factors are difficult to determine specifically for 
docetaxel encapsulated within different nanoparticle cores. Radio-release data was combined 
with copolymer characterisation, to develop a further understanding of the relationships 
between the physical properties of branched copolymers and docetaxel release rates from their 
ensuing branched vinyl copolymer nanoparticles.  
The docetaxel release rate constants acquired from radio-dialyses conducted at varied 
temperatures were used to further demonstrate the impact of temperature on docetaxel release 
rates. This was achieved using an Arrhenius analysis. The Arrhenius equation is presented in 
Equation 4.6, which shows the relationship between the rate constant, k, and the activation 
energy (Ea), the universal gas constant (R) and temperature (T). The Arrhenius equation also 
involves the pre-exponential factor A, which is related to the frequency of collisions within 









                            Equation 4.6  
Plots of ln k vs. 1/T were used to graphically demonstrate the relationship between the release 
rate constants and the temperature at which radio-dialyses were conducted. These plots were 
constructed using release data generated for all the branched vinyl copolymer nanoparticles 
studied (Figure 4.12). With the exception of data obtained from radio-dialyses of p(LMA) 
based nanoparticles, strong relationships were observed between temperature and the 
docetaxel release rates. The trend observed in data obtained from p(LMA)-based nanoparticles 
confirmed that the rate of docetaxel release became independent of temperature as it was 
increased from 37 to 50 ℃.  
 
Figure 4.12 Analysis on the temperature dependence of docetaxel release rate constants obtained 
from radio-dialyses. Linear Arrhenius plots of lnk vs. 1/T showing the clear dependence of docetaxel 
release rates on the temperature that radio-dialyses were conducted. Arrhenius analyses were conducted 
on data obtained from: p(HPMA) (red, open circles), p(nBMA) (blue, open squares), p(nHMA) (green, 
open triangles), p(EHMA) (teal, open hexagons) and p(LMA) (purple, open diamonds) radio-dialyses 
at temperatures varying from 20 to 50 ℃. 
Although the temperature-dependent docetaxel release rates were evident, the reason for such 
a relationship was less clear. It was hypothesised that an increase in temperature would 
promote docetaxel diffusion through the cores of the branched vinyl copolymer nanoparticles. 
Higher diffusion rates would therefore reduce the time taken for docetaxel molecules to 
permeate to the nanoparticle surface in order leave the nanoparticle and enter the aqueous 
surrounding environment. Interestingly, Arrhenius plots are also used to describe the 
temperature dependence of the rate of small molecule diffusion through polymer matrices.56–
58 The modified Arrhenius plot used to describe the temperature dependence of diffusion 
processes is described in Equation 4.7.  









This version of the Arrhenius plot demonstrates how small molecule diffusion rates increase 
with temperature. In particular, it shows that the diffusion rate (D) observed at temperature (T) 
is proportional to the exponential decay in the theoretical diffusion rate at infinite temperature 
(D∞), which occurs in proportion to the magnitude of the activation energy of diffusion (ΔEd) 
and the gas constant (R).59 Whilst the diffusion rates through the copolymer matrices were not 
quantified, the temperature dependence of both the diffusion and release rates are highly 
indicative that docetaxel diffusion through the nanoparticle core to the polymer-water interface 
is a key factor which drove the temperature dependence of the docetaxel release rates during 
radio-dialyses at varied temperatures.  
All nanoparticles used in this study were constructed from amorphous copolymers. It was 
therefore initially expected that copolymer glass transition temperatures (Tg) would be a key 
factor in influencing the rate of docetaxel diffusion and, by extension, release rates from 
branched vinyl copolymer nanoparticles. The branched copolymers were therefore assessed 
using differential scanning calorimetry (DSC). Tg values of 70, 27, -7 and -11℃ were obtained 
for p(HPMA63-co-EGDMA0.90), p(nBMA73-co-EGDMA1.12), p(nHMA68-co-EGDMA1.03) and 
p(EHMA69-co-EGDMA1.06) respectively. The Tg of p(LMA70-co-EGDMA1.04) could not be 
determined by DSC, however Tg values ranging from -65 to -53 ℃ have been reported in the 
literature.60 It was therefore expected that radio-dialysis at temperatures above the Tg of the 
copolymers from which nanoparticles were constructed would result in faster release rates due 
to greater docetaxel diffusion. However, no evidence of any correlation between copolymer 
Tg and docetaxel release rates were observed. For example, all radio-dialyses were conducted 
above the Tg of p(LMA), p(nHMA), and p(EHMA) based copolymers whereas all dialyses 
were conducted below the Tg of p(HPMA) based copolymers. Nevertheless, docetaxel release 
rates were highest for p(HPMA) nanoparticles which, in theory, possessed more solid 
glass-like cores which would be expected to limit docetaxel diffusion and the observed release 
rates. Furthermore, a Tg of 27 ℃ was obtained from DSC analysis of 
p(nBMA73-co-EGDMA1.12) but the relationship between docetaxel release rate constants and 
the temperature remained consistent regardless of whether radio-dialyses of p(nBMA) 
nanoparticles were conducted below or above the p(nBMA) glass transition.  
Another factor which was expected to impact docetaxel diffusion rates was the internal 
viscosity within the core of branched vinyl copolymer nanoparticles, especially at 
temperatures above their individual Tg values. Polymer viscosity typically decreases with 
temperature as polymer chains acquire more thermal energy to overcome the significant 
non-covalent interactions acting between large macromolecules. Although the glass transition 
defines the temperature at which polymer chains exhibit greater mobility, considerable 




the Tg, polymers typically behave as highly viscous liquids. It is therefore unsurprising that the 
onset of the glass transition has little impact on docetaxel release rates as diffusion of docetaxel 
molecules through a highly viscous liquid would still require high amounts of energy. 
Rheological analyses were therefore conducted in order to understand the impact of 
temperature on the complex viscosity of each of the branched copolymers from which 
nanoparticles were constructed.  
Rheological analyses involved performing reverse oscillatory temperature sweeps between 
temperatures of 150 to 25 ℃. The use of reverse temperature sweeps ensured that all polymers 
initially formed low viscosity liquids of which the complex viscosity could be determined. 
Copolymer complex viscosities were then measured at 5 ℃ steps until either the temperature 
reached 25 ℃ or the minimum temperature at which reliable complex viscosity data could be 
obtained. This allowed graphical demonstration of the relationships between temperature and 
the complex viscosities of the branched copolymers from which each of the nanoparticles were 
constructed (Figure 4.13). Unsurprisingly, in all cases, lower temperatures caused significant 
increases in branched copolymer viscosity. For example, the complex viscosity of 
p(nHMA68-co-EGDMA1.03) increased from to 319 to 92477  Pa s-1 on cooling from 130 to 
25 ℃. In the cases of p(nBMA73-co-EGDMA1.12) and p(HPMA63-co-EGDMA0.90), reliable 
complex viscosity data could not be obtained as temperatures were lowered below 55 and 135 
℃ respectively. The order of complex viscosities observed were consistent with the Tg of the 
branched copolymers and, in all cases, exponential increases in copolymer complex viscosities 
were observed shortly before measurements failed. Interestingly, rheological analyses 
demonstrated that, in all cases, lower complex viscosities occurred at temperatures 
significantly higher than the Tg of the branched copolymers studied. For example, the lowest 
temperature at which complex viscosity of p(nBMA73-co-EGDMA1.12) could be measured was 
at 55 ℃, which is 28 ℃ above the Tg recorded by DSC. Although bulk properties may not 
translate to copolymer behaviour at the nanoscale, these results clearly indicate that, although 
branched copolymers acquire greater chain mobility above their Tg, the significant reduction 
in copolymer viscosity required to increase docetaxel diffusion rates typically occurred at 





Figure 4.13 Rheological analysis of the branched copolymers which make up the core of branched 
vinyl copolymer nanoparticles. Change in the complex viscosity of branched vinyl copolymers using a 
reverse temperature sweep from 150 to 25 ℃ (or failure) at steps of 5 ℃. Complex viscosity data was 
plotted on both a) linear and b) log scales. Analysis was conducted on p(HPMA) (red, open circles), 
p(nBMA) (blue, open squares), p(nHMA) (green, open triangles), p(EHMA) (teal, open hexagons) and 
p(LMA) (purple, open diamonds).   
Analysis of the rheology data obtained for p(LMA70-co-EGDMA1.04) initially appeared to 
show that complex viscosity remained independent of temperature across the temperature 
range studied. However, a closer individual inspection of the p(LMA70-co-EGDMA1.04) 
complex viscosity data (Appendix, Figure A4.3) as well as replotting of complex viscosity 
data on a logarithmic scale (Figure 4.13b) showed, albeit still at extremely low complex 
viscosities (≤ 170 Pa s-1), exponential increases in complex viscosity in the temperature steps 
taken shortly before the reverse oscillatory temperature reached 25 ℃. The exponential 
increase observed indicated that the core viscosity of p(LMA70-co-EGDMA1.04) based 
nanoparticles would most likely be significantly more viscous at 20 ℃ than at 37 or 50 ℃. 
Furthermore, a negligible difference was observed between the complex viscosities of 
p(LMA70-co-EGDMA1.04) measured at 35 and 50 ℃ where, in both cases, complex viscosities 
were below 100 Pa s-1 and were indicative of low-viscosity liquids.  
The significant reduction in complex viscosity of p(LMA70-co-EGDMA1.04) at higher 
temperature could explain the trend observed in docetaxel release rates observed from p(LMA) 
nanoparticles at various temperatures. The temperature increase from 20 to 37 ℃ would be 
expected to have had a profound impact on the core viscosity of p(LMA) based nanoparticles. 
This would likely cause a significant increase in the rate of docetaxel diffusion through the 
cores of branched vinyl copolymer nanoparticles and could explain the faster docetaxel release 
rates observed at 37 ℃. The low viscosity of p(LMA70-co-EGDMA1.04) at 37 ℃ meant that 
further increases in temperature had a smaller impact on copolymer viscosity. As a result, 
comparable docetaxel diffusion rates would be expected at both 37 and 50 ℃. This may 
explain the comparable docetaxel release rates observed during radio-dialysis of p(LMA) 




The non-linear temperature dependence of docetaxel release rates could be attributed to the 
plateau in the complex viscosity of the copolymer from which p(LMA) nanoparticles were 
constructed. This would suggest that, above 37 ℃, the rate of docetaxel diffusion through the 
nanoparticle cores is dependent on both the viscosity within the nanoparticle core as well as 
the energy of individual docetaxel molecules. In the case of p(LMA), it appeared that core 
viscosity made the biggest contribution to docetaxel release rates. Radio-dialyses conducted 
above the temperature at which core viscosity appeared to reach a plateau demonstrated that 
docetaxel release rates became independent of temperature. In contrast, docetaxel release rates 
from nanoparticles consisting of branched copolymers which exhibited higher complex 
viscosities (>9400 Pa s-1) showed linear temperature dependence across the temperature range 
studied. Rheology data obtained for branched copolymers suggests that, at these temperatures, 
nanoparticle core viscosities would be almost 2 orders of magnitude higher than that of 
p(LMA) nanoparticles. In such cases, docetaxel release rates would be expected to increase 
with temperature due to a simultaneous increase in the kinetic energy of docetaxel molecules 
as nanoparticle core viscosity decreased.   
Another factor which may have influenced docetaxel release rates at higher temperature was 
the level of interaction between the hydrophobic domains within the core of branched vinyl 
copolymer nanoparticles. The reduction in core polarity observed in nanoparticles constructed 
from copolymers of greater hydrophobicity likely impacted the extent of host-guest interaction 
between aliphatic side-chains of copolymer repeat units and encapsulated docetaxel 
molecules. This would be expected to alter docetaxel release rates from branched vinyl 
copolymer nanoparticles. Evidence of this is clear upon comparison of the order of docetaxel 
release rates observed from p(HPMA), p(nBMA), p(nHMA) and p(EHMA) nanoparticles. The 
measurement of nanoparticle core polarities, conducted in Chapter 3, Section 3.4.2.2, showed 
that, with the exception of p(LMA) nanoparticles, docetaxel release rates correlated well with 
the nanoparticle core polarity. This implied that the rate at which docetaxel diffused to the 
polymer-water interface was affected by the chemical nature of the nanoparticle core. In cases 
where nanoparticle cores showed high polarity, docetaxel showed lower affinity for the 
polymer phase, which resulted in faster release rates. Alternatively, less polar cores provided 
a better environment for the hydrophobic chemotherapeutic, thus increasing its affinity for the 
polymer phase and reducing the rate at which it was released from branched vinyl copolymer 
nanoparticles. Higher temperature would therefore be expected to significantly reduce the 
prevalence of such host-guest interactions as docetaxel molecules acquire sufficient thermal 
energy to overcome non-covalent interactions with the copolymers which make up the 
nanoparticle core. Combined with the higher solubility within the aqueous phase, which 




polymer-water interface would likely increase and, therefore, increase docetaxel release rates 
from branched vinyl copolymer nanoparticles.  
The main exception to the trend observed between core polarity and docetaxel release rates is 
that of p(LMA) nanoparticles. There are three possible reasons for this exception. As discussed 
above, these include the low EE observed during co-nanoprecipitation and the faster diffusion 
rates due to the low viscosity shown by p(LMA70-co-EGDMA1.04). The factors which govern 
docetaxel release from branched vinyl copolymer nanoparticles are clearly complex. It is 
evident that both core polarity and core viscosity may be associated with the variation in 
docetaxel release rates observed for branched vinyl copolymer nanoparticles; a highly 
hydrophobic environment within the core of branched vinyl copolymer nanoparticles appears 
to retard drug release and copolymer viscosity correlates with variation in docetaxel diffusion 
rates within the nanoparticle core. However, further studies would be required to determine 
the extent to which the release of encapsulated docetaxel was influenced by either of these 
macroscopic properties since they are dependent upon the length and/or functionality of 
aliphatic side chains of copolymer repeat units.  
4.4 Conclusions 
This work aimed to explore the behaviour of encapsulated docetaxel within the core of 
branched vinyl copolymer nanoparticles during co-nanoprecipitation. This was achieved via a 
comprehensive co-nanoprecipitation study which demonstrated that docetaxel loadings up to 
25 wt % could be encapsulated without any impact on the stability and size distributions of 
the resultant nanoparticles. Furthermore, docetaxel loadings up to 15 wt % could be achieved 
regardless of the chemical nature of the copolymers used during co-nanoprecipitation. The 
ability to encapsulate up to 25 wt % drug makes co-nanoprecipitation an attractive approach 
for the preparation of DNC systems and allows the preparation of nanoparticle dispersions 
which contain more than a 20-fold increase in the aqueous docetaxel saturation limit to be 
formulated. Radiometric analyses determined the success of docetaxel encapsulation and 
demonstrated that not all of the initial docetaxel loading was encapsulated during 
co-nanoprecipitation. Simultaneous nanoparticle formation and drug encapsulation is a 
kinetically-driven process and, as a result, copolymer functionality has little impact on the 
encapsulation efficiency achieved during co-nanoprecipitation. Despite this, 
co-nanoprecipitation remains a robust and facile synthetic approach for the preparation of 
docetaxel-loaded aqueous nanoparticle dispersions.  
3H-labelled docetaxel loaded branched vinyl copolymers formed during co-nanoprecipitation 
studies were also used to determine docetaxel release rates in vitro. Radiometric analysis 




the need for additional extraction and/or purification. This enabled quantitative comparison 
between the drug release rates from branched vinyl copolymer nanoparticles consisting of 
various core chemistries. Enhanced docetaxel release rates observed for nanoparticles formed 
via co-nanoprecipitations which achieved low EE highlighted the importance of 
preventing/removing free drug in order to prevent burst release during radio-dialysis. The 
variation observed in docetaxel release rates demonstrated that the macroscopic behaviour of 
branched vinyl copolymer nanoparticles depends on their chemical structure. Furthermore, the 
temperature dependence of docetaxel release rates highlighted the importance of nanoparticle 
core viscosity in controlling drug release.  
Kinetic analysis of docetaxel release rates demonstrated that branched vinyl copolymer 
nanoparticles are able to modulate drug release over clinically-relevant time periods at 
physiological temperature. This highlighted the suitability of such materials for further 
application as DNC systems and indicated that they should be considered for in vivo analysis.  
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5.1 Conclusions  
The primary aim of this research was to expand the scope of co-nanoprecipitation in order to 
generate nanomaterials which have the potential to modulate the release of hydrophobic 
chemotherapeutics in vivo. In many ways this research has created more questions that it has 
answered. However, it has, without doubt, achieved its primary objective and has produced 5 
suitable candidates which can be now taken forward for in vitro and in vivo pharmacological 
evaluation. This research has provided fundamental understanding of the polymerisation and 
nanoprecipitation processes by which these polymers and nanoparticles were formed and 
allowed a number of factors which influence such processes to be identified.  
5.1.1 Chapter 2 
The research presented in Chapter 2 represents a significant advance in the expansion of the 
scope of Cu-RDRP of hydrophobic methacrylates in anhydrous alcohols. For the first time, 
successful Cu-RDRPs of EMA, nHMA, CHMA, BzMA and EHMA were achieved in 
anhydrous methanol at 60 ℃. Successful Cu-RDRP of MMA, tBMA, CHMA, LMA and SMA 
were also conducted in anhydrous IPA at 60 ℃. The successes of such Cu-RDRPs were 
attributed to the previously reported monomer co-solvency effect.1,2 The use of pyrene as a 
fluorescent probe allowed assessment of polymerisation mixture polarities via fluorescence 
spectroscopy. These assessments revealed that polymerisations of hydrophobic monomers in 
anhydrous alcohols had a significant impact on reaction mixture polarity. The extent of this 
impact was dependent upon the relative polarities of the reaction mixture i.e. monomers and 
solvents used in Cu-RDRP.  As a result, in cases where a contrast existed between the polarity 
of the monomer and solvent, large changes in the reaction mixture occurred as Cu-RDRPs 
proceeded. This research therefore reiterated the importance of monomer-co-solvency in 
facilitating Cu-RDRP of hydrophobic monomers in alcohols that their resulting polymers are 
typically insoluble in and, furthermore, highlighted the importance of conducting such 
polymerisations at high concentration (i.e. 50 wt %). Despite the co-solvency effect, many 
monomer-alcohol mixtures were unable to retain polymer solubility following monomer 
depletion and, as a result, many Cu-RDRPs underwent polymerisation-induced phase 
separation. This was particularly prevalent during Cu-RDRP of low polarity monomers due to 
the increased polymer sensitivity to increases in polymerisation mixture polarity. Furthermore, 
monomer polarity also influenced the point at which polymerisation-induced phase separation 
occurred. Remarkably, Cu-RDRP in anhydrous alcohols facilitated the synthesis of linear 
homopolymers of low dispersity with control over the molecular weight; Cu-RDRP in 
anhydrous alcohols was expanded further by the preparation of various copolymer 




preparation and subsequent use of a PEG macro-initiator permitted the preparation of 
amphiphilic block copolymers via Cu-RDRP.  
The preparation of a wide range of branched copolymers was achieved via RDRcP of 
hydrophobic methacrylates with EGDMA in anhydrous alcohols. This was somewhat 
remarkable given the apparent onset of polymerisation-induced phase separation during 
copolymerisations. TD-SEC proved to be an effective technique for the characterisation of 
branched copolymers. Refitting of conventional molecular weight data allowed the 
development of new TD-SEC analyses which illustrated the broad distribution of 
macromolecular architectures which make up branched copolymer molecular weight 
distributions. However, despite the high monomer conversions achieved during 
copolymerisations, contrasting levels of branching were observed during these 
copolymerisations. As a result, many copolymerisations were able to avoid the formation of a 
gelled network despite being conducted at experimental [B]0/[I]0 ratios in excess of the 
theoretical gel points. Furthermore, the extent of branching appeared to be highly dependent 
upon the nature of the monomer used. 
It is highly likely that these contrasting branching behaviours occurred as a result of variation 
in the relative levels of pendant group consumption via intermolecular and intramolecular 
cyclisation.  There are three possible reasons which could explain the contrasting branching 
behaviours observed during Cu-RDRcP. These are: i) an inherent decrease in the concentration 
of active chain-ends/ methacrylate groups as a result of the increased weight fraction of the 
monomer side chain; ii) increased steric hindrance around pendant methacrylate groups due to 
the increased size of monomer repeat units; and iii) the conformation of primary chains in the 
polymerisation mixture and therefore the accessibility of pendant methacrylate groups. All of 
these factors naturally arise when conducting branching copolymerisations of EGDMA with 
different comonomers and each of these factors likely influence the consumption of EGDMA 
pendant methacrylate groups during copolymerisation. Whilst many reports of the impact of 
concentration on the extent of branching observed in copolymerisations of monofunctional 
and BFMs, have appeared in the literature,3–5 they have typically studied the copolymerisation 
of EGDMA with only one monomer type. Studies are therefore required to understand how 
the size of the methacrylate side chain influences pendant methacrylate group consumption. 
However, given the nature of the copolymerisations presented in Chapter 2, it is not possible 
to determine which of these factors are responsible for the low levels of branching observed 
in some branching copolymerisations. Future research must therefore look to modify 





5.1.2 Chapter 3 
The research presented in Chapter 3 showed an expansion of the scope of branched and AB 
block copolymers that can be used to form branched vinyl copolymer nanoparticles via 
co-nanoprecipitation. In particular, co-nanoprecipitations of p(nBMA), p(nHMA), p(EHMA) 
and p(LMA) based copolymers formed stable highly monodisperse aqueous nanoparticle 
dispersions and showed a robustness to changes in experimental conditions. This allowed the 
preparation of branched vinyl copolymer nanoparticles which possessed nanoparticle cores of 
significantly contrasting polarities than had been reported previously.6 This is of particular 
significance given the desired application of such nanomaterials as nanocarriers of 
hydrophobic chemotherapeutics in vivo. This approach allows the macroscopic properties of 
branched vinyl copolymers to be designed at the initial stage of the production process and 
demonstrates how the advances in RDRP techniques have facilitated the bottom-up design of 
such nanomaterials. The encapsulation of low loadings of a hydrophobic guest molecule was 
achieved by simply adding small amounts of the compound to the initial THF solution from 
which copolymers were co-nanoprecipitated. The presence of small amounts of pyrene had 
minimal impact on nanoparticle formation via co-nanoprecipitation. This is particularly 
relevant as it offers a relatively facile synthetic approach for the encapsulation of hydrophobic 
chemotherapeutics during co-nanoprecipitation.  
Surprisingly, nanoprecipitations and co-nanoprecipitations of p(nBMA), p(nHMA), 
p(EHMA) and p(LMA) based (co)polymers did not show the architecture dependent 
nucleation typically exhibited by (co)nanoprecipitations of p(HPMA) based copolymers; this 
likely occurred as a result of enhanced levels of (co)polymer supersaturation during 
co-nanoprecipitation. These results indicate that high molecular weight branched copolymers 
are not essential to drive (co)polymer nucleation during such co-nanoprecipitations and, as a 
result, are not compulsory for the formation of stable and highly monodisperse aqueous 
nanoparticle dispersions. This allowed the first report of successful nanoparticle formation 
from co-nanoprecipitations of linear homopolymers with amphiphilic AB block copolymers 
as well as the nanoprecipitations of amphiphilic AB block copolymers. These results are of 
considerable importance as they remove the need for relatively complex branched copolymer 
syntheses during preparation of aqueous nanoparticle dispersions consisting of p(nBMA), 
p(nHMA), p(EHMA) and p(LMA). These results demonstrate that it is the extent of excipient 
supersaturation not (co)polymer molecular weight which governs the rate of nucleation and 
subsequent nanoparticle formation during co-nanoprecipitation. This is of particular clinical 
relevance and should be taken into account when selecting excipients, which contain low to 





As well as the expansion of the scope of co-nanoprecipitation, the work presented in Chapter 3 
provided a deeper understanding of the co-nanoprecipitation process and the factors which 
influence nanoparticle formation. In particular, this research showed the entrapment of 
amphiphilic AB block copolymers within the core of branched vinyl copolymers during 
co-nanoprecipitation. This is significant as previous studies had concluded that amphiphilic 
AB block copolymers led to the location of hydrophilic block segments solely at the surface 
of branched vinyl copolymer nanoparticles. However, the use of copolymers of increased 
hydrophobicity allowed the dependence of nanoparticle core polarity on AB block copolymer 
composition to be demonstrated and was highly indicative of polar PEG chains within the 
nanoparticle core. Co-nanoprecipitations conducted at varied branched to AB block copolymer 
ratios also showed the dependence of nanoparticle size on the concentration of amphiphilic 
block copolymers; this highlighted the importance of steric stabilisation in arresting 
nanoparticle growth during co-nanoprecipitation. This is of particular importance as it allows 
the composition of the initial THF solution to be used as a tool to control nanoparticle size, 
which is traditionally difficult to achieve through kinetically-controlled nanoprecipitation 
processes. Attempts to use copolymer concentration to control nanoparticle size were 
unsuccessful as steric stabilisation dominated the capping of nanoparticle growth during co-
nanoprecipitation. This, however, brings alternative benefits as it allows aqueous nanoparticle 
dispersions to be prepared at a range of concentrations with negligible impact on nanoparticle 
size. This could allow the preparation of highly concentrated aqueous nanoparticle dispersions 
without having to compromise nanoparticle stability and uniformity, and would likely be of 
relevance in the preparation of drug-loaded aqueous nanoparticle dispersions at therapeutically 
relevant concentrations.  
Finally, branched vinyl copolymer nanoparticles showed resistance to dilution and 
physiologically-relevant salt concentrations.  This indicated that nanoparticles are likely to 
retain their structural integrity during pharmacological evaluations conducted in buffered and 
physiological media. This is important as it suggests that future in vivo studies of the 
pharmacology and immunology profiles of branched vinyl copolymer nanoparticles could be 
most likely conducted on intact, homogeneous nanoparticle dispersions rather than their 
aggregated or dissociated copolymer components. Furthermore, the resistance of branched 
vinyl copolymer nanoparticles to dilution ensures that drug release must occur via diffusion of 
encapsulated drug molecules through the copolymer matrix, rather than as a result of 
nanoparticle disassembly and subsequent burst release. This implies that such materials have 





 5.1.3 Chapter 4 
The primary aim of the research conducted throughout this thesis was to achieve the 
encapsulation and modulate the release of a hydrophobic chemotherapeutic, docetaxel, from 
branched vinyl copolymer nanoparticles formed via co-nanoprecipitation. This was achieved 
using 5 different branched vinyl copolymer systems. Docetaxel encapsulation experiments 
showed that relatively high loadings (15-25 wt %) of docetaxel could be achieved during 
co-nanoprecipitations of branched and amphiphilic AB block copolymers, with negligible 
impact on the stability and dispersity of branched vinyl copolymer nanoparticles. This is 
particularly noteworthy as the drug loadings achieved through co-nanoprecipitation are 
significantly higher than those previously reported using alternative nanoformulation 
approaches.7–11 The ability to encapsulate high docetaxel payloads whilst maintaining 
nanoparticle size, monodispersity and stability is a promising sign for the use of branched 
vinyl copolymer nanoparticles as docetaxel nanocarriers. Interestingly, in many cases, 
increases in the weight fraction of docetaxel used in co-nanoprecipitation resulted in a 
reduction in nanoparticle hydrodynamic diameter. This was surprising given the reduced 
weight fraction of the AB block copolymer stabiliser and implied that docetaxel may 
participate in driving nucleation, or even arresting nanoparticle growth, during 
co-nanoprecipitation. This is particularly interesting for chemists conducting research on the 
formulation of water-insoluble chemotherapeutics. Drug encapsulation is often viewed as 
having negative impacts on nanoformulation approaches yet, in the case of 
co-nanoprecipitation, the presence of docetaxel appeared to aid nanoparticle formation.   
Radiometric analyses proved to be an effective tool for the assessment of docetaxel 
encapsulation and release from branched vinyl copolymer nanoparticles formed via co-
nanoprecipitation. Interestingly, significantly higher docetaxel encapsulation efficiencies 
(≥95.5 %) were achieved during co-nanoprecipitation of p(nBMA), p(nHMA) and p(EHMA)-
derived copolymers although encapsulation efficiencies showed no correlation with the 
hydrophobicity of the copolymers from which nanoparticles were constructed. However, in all 
cases, encapsulation efficiencies ≥76.9 % were achieved during co-nanoprecipitations 
conducted at target drug loadings of 15 wt %. Docetaxel encapsulation was independent of  
branched copolymer hydrophobicity and therefore implied that docetaxel encapsulation during 
co-nanoprecipitation is under kinetic control. This may seem somewhat unsurprising given 
that nanoprecipitation processes are typically under kinetic control.12 This poses real problems 
for the clinical translation of drug-loaded nanoformulations prepared by co-nanoprecipitation 
as the presence of free drugs within nanoformulations are often the main cause for sub-optimal 
burst release profiles observed both in vivo and within clinical settings.13 It is therefore likely 




alternatively further development of formulation processes to increase the encapsulation 
efficiencies achieved during nanocarrier formation.  
Radio-dialysis proved a simple and effective technique for measurement of docetaxel release 
rates from branched vinyl copolymer nanoparticles. Radio-dialyses clearly showed that the 
nanoparticle core hydrophobicity had a profound impact on docetaxel release rates. This was 
most apparent during comparisons of docetaxel release from p(nBMA), p(nHMA) and 
p(EHMA)-derived nanoparticles, which all achieved comparable encapsulation efficiencies, 
where release constants increased with repeat unit hydrophobicity. As would be expected, 
nanoparticles which achieved lower encapsulation efficiencies showed faster release rates, 
even in the case of p(LMA)-based nanoparticles which possessed the most hydrophobic repeat 
units. This highlighted the importance of ensuring high encapsulation efficiency during 
co-nanoprecipitation. Surprisingly, however, the strongest correlations were observed with 
copolymer viscosities. The rate of docetaxel release from branched vinyl copolymer 
nanoparticles was highly dependent on the temperature that radio-dialyses were conducted. 
This was linked to faster docetaxel diffusion rates caused by a reduction in the core viscosity 
of branched vinyl copolymer nanoparticles. The impact of copolymer viscosity is rarely 
mentioned in nanoparticle research papers. Although a more detailed study is required to 
further understand these relationships, it appears that this is an area of nanoparticle research 
that is not receiving significant attention. Given that polymer structure, architecture and 
molecular weight can all be manipulated without impacting the chemistry of the nanoparticle 
core, these polymer properties may offer a new tool which can be used to modulate 
hydrophobic payload release from polymer-based nanoparticles.   
Kinetic analyses were used to determine docetaxel release constants for each of the 
nanoparticles studied. Release constants were then used to calculate docetaxel half-lives within 
the core of branched vinyl copolymer nanoparticles during radio-dialyses; this provided 
context for the observed release rates by showing that, at physiological temperature, over 50 
% of docetaxel payloads remained encapsulated within branched vinyl copolymer 
nanoparticles after 12 hours. This demonstrated that significant amounts of docetaxel should 
remain within branched copolymer nanoparticles for sufficient time to allow nanoparticle 
accumulation within tumour tissues via the EPR effect. As a result significant increases in 
docetaxel internalisation within cancer cells would be expected when administered within 
branched vinyl copolymer nanoparticles. This may also reduce the associated toxicity due to 






5.2 Future Work 
There are many ways that the research conducted in this thesis could be taken forward, here 
two future directions are highlighted: i) additional research to further develop the fundamental 
understanding of the specific materials presented in this thesis; and ii) expansion of 
preliminary research which aims to explore alternative functional handles to control the 
macroscopic behaviour of branched vinyl copolymer nanoparticles formed via 
co-nanoprecipitation. A series of recommendations for future work, including some data from 
preliminary experiments, are presented herein.   
5.2.1 Further Development of the Research Conducted in this Thesis 
Recommendations for the future development of this research can be broken down into three 
categories, these are: polymer chemistry, nanoparticle formulation via (co)nanoprecipitation 
and drug loading and release.  
5.2.1.1 Chapter 2 – Polymer Chemistry 
The work presented in Chapter 2 could open up numerous new avenues of polymer chemistry 
research. One being determination of the reasons behind the variation in control observed 
between Cu-RDRPs of different hydrophobic methacrylates. It is likely that the control 
exhibited during Cu-RDRP is related to the solubility of the [Cu(bpy)2]Cl catalytic system. 
Research should therefore aim to determine catalyst solubility within each of the 
monomer-alcohol mixtures. Furthermore, the use of ligands such as 
4,4′-dinonyl-2,2′-bipyridine, could be used to prepare an alternative Cu-catalytic system which 
show higher solubility within low polarity monomer-alcohol mixtures. This would likely 
reduce the dispersity of polymers generated during Cu-RDRP of LMA and SMA. Kinetic 
studies of the Cu-RDRP of nHMA in anhydrous methanol showed that the onset of 
polymerisation-induced phase separation had negligible impact on polymerisation kinetics and 
the evolution of molecular weight. However, this was likely due to the onset of the phase 
separation occurring at high monomer conversion (92 %). Additional kinetic studies of the 
Cu-RDRP of all other hydrophobic methacrylates are therefore required to demonstrate the 
relationship between monomer polarity and the onset of polymerisation-induced phase 
separation. Furthermore, these studies can be used to understand the impact of phase 
separation on polymerisation kinetics and the evolution of molecular weight during Cu-RDRP 
in anhydrous alcohols.  
The preparation of amphiphilic block copolymers via Cu-RDRP of hydrophobic methacrylates 
in polar alcohols offers the exciting prospect of the in situ preparation of block copolymer 
nanoparticles via polymerisation-induced self-assembly (PISA). The high solubility of 




as well as that of LMA and SMA in IPA, combined with the low solubility of their resulting 
polymers would be expected to trigger PISA during Cu-RDRP. This research could be 
conducted using Cu-RDRP or alternatively via RAFT polymerisation using a MeOH-soluble 
macro-RAFT agent. This would allow the preparation of block copolymer nanoparticles 
consisting of hydrophobic domains which cannot be achieved via aqueous PISA.  
Perhaps the most significant finding presented in Chapter 2 was the contrasting levels of 
branching observed during Cu-RDRcP of hydrophobic methacrylates with EGDMA in 
anhydrous alcohols. Future research must therefore look to further understand branching 
reactions both in Cu-RDRcP in anhydrous alcohols and more generally during statistical 
copolymerisations of monofunctional and bifunctional monomers. In particular, research must 
explore the experimental gel points for each of the copolymerisations of EGDMA with 
hydrophobic methacrylates ranging from MMA to SMA. This would facilitate the 
achievement of ideal branching behaviour during copolymerisation and would therefore 
permit the preparation of highly branched, high molecular weight copolymers using all of the 
hydrophobic methacylates studied in this Chapter. Future research in this area must seek to 
understand the impact of the following three factors: i) lower vinyl group concentration due to 
higher monomer side chain mass, ii) steric hindrance around pendant methacrylate groups and 
iii) the impact of polymer conformation within the polymerisation mixture. This will require 
the use of detailed branched copolymer characterisation techniques, i.e. quantification of the 
prevalence of intermolecular branching and intramolecular cyclisation via NMR 
spectroscopy.14 Experimental conditions must be manipulated to allow each of these factors to 
be studied in isolation. Such experiments would therefore provide a detailed assessment of the 
impact of each of these factors on the nature of pendant methacrylate group consumption 
during copolymerisation.   
5.2.1.2 Chapter 3 – Nanoparticle Formation via (Co)nanoprecipitation  
The sole focus of the research presented in Chapter 3 was to develop branched vinyl copolymer 
nanoparticles via co-nanoprecipitation. As a result, alternative possibilities of 
(co)-nanoprecipitation research were not studied to the same level of detail as presented for 
branched vinyl copolymer nanoparticles. Future work should therefore look to explore such 
potential areas of nanoprecipitation research. The success of the nanoprecipitations of 
amphiphilic AB block copolymers is one area which should be studied further. This is 
especially relevant for amphiphilic AB block copolymers where hydrophobic domains 
consisted of p(nBMA), p(nHMA), p(EHMA) and p(LMA), which formed stable highly 
monodisperse aqueous nanoparticle dispersions with hydrodynamic diameters <100 nm. 




copolymer properties influence nanoparticle formation via nanoprecipitation. Given the 
success of AB block copolymer nanoprecipitation, these materials should be considered as 
prospective nanocarriers of docetaxel, as well as a series of other hydrophobic active 
pharmaceutical ingredients.   
Further research should also be conducted to improve the properties of nanoparticles formed 
via co-nanoprecipitation. Chapter 3 involved manipulation of experimental factors which 
impact nanoparticle formation. Future research should therefore look to understand the impact 
of polymer structure on the co-nanoprecipitation process. In particular, this should involve 
manipulation of the respective block lengths of the hydrophobic and hydrophilic domains of 
amphiphilic AB block copolymers. This should provide control over the size and density of 
the hydrophilic PEG shells which stabilise branched vinyl copolymer nanoparticles; 
furthermore, this may impact the nanoparticle formation process and could provide an 
enhanced level of control over nanoparticle size than was achieved via manipulation of 
experimental conditions. Further characterisation and imaging techniques are required to fully 
understand branched vinyl copolymer nanoparticles. Development of cryo-SEM techniques 
are ongoing and should be developed further to allow representative imaging of branched vinyl 
copolymer nanoparticles constructed from low Tg copolymers. Furthermore, analysis of 
nanoparticles in their aqueous state, for example using small-angle X-ray scattering,15 could 
provide further evidence of the spherical morphology of branched vinyl copolymer 
nanoparticles. 
Given the desire to use branched vinyl copolymer nanoparticles as docetaxel nanocarriers in 
vivo, pharmacological evaluation of such materials is an essential component of future 
research. Pharmacological evaluations must focus on assessing the safety and suitability of 
such nanomaterials to their application within physiological environments. This should 
involve determination of nanoparticle resistance to opsonisation and cytotoxicity to both 
healthy and cancerous cell lines. As they will likely be administered intravenously, the 
haematological behaviour of branched vinyl copolymer nanoparticles, such as their impact on 
blood coagulation, should also be assessed. It is important to determine the level of 
nanoparticle interaction with plasma proteins. Flow cytometry may therefore be used to 
determine the level of interaction between branched vinyl copolymer nanoparticles and 
proteins of the complement system.16 This will provide an evaluation of the possible 
immunogenic properties of such nanomaterials and in particular should provide evidence for 
the role of the PEG shell in preventing opsonisation by plasma proteins. Nanoparticle 
cytotoxicity must be assessed for both healthy endothelial cells as well as for cancerous cell 
lines, and will provide an indication of whether branched vinyl copolymer nanoparticles are 




5.2.1.3 Chapter 4 – Understanding Drug Encapsulation and Release 
The research presented in Chapter 4 showed that the use of 3H-labelled docetaxel in drug 
loading co-nanoprecipitations allowed docetaxel encapsulation efficiencies (EE) and drug 
loadings (DL) to be determined via liquid scintillation counting (LSC). Future research should 
look to use this technique to investigate how EE and, by extension, DL vary with the targeted 
drug loading used in co-nanoprecipitation. This should allow optimisation of drug 
encapsulation for each of the copolymer systems studied in Chapter 4. This may allow the 
preparation of branched vinyl copolymer nanoparticle dispersions containing minimal free 
docetaxel, which could prevent initial burst release and high cytotoxicity typically associated 
with low encapsulation efficiencies of chemotherapeutics. Further efforts should also be made 
to increase the docetaxel concentration within aqueous nanoparticle dispersions. This should 
involve increasing the concentration at which co-nanoprecipitations are conducted and/or 
conducting multiple additions of the THF-copolymer-docetaxel solutions.6 The potential to 
encapsulate hydrophobic chemotherapeutics during co-nanoprecipitation extends beyond 
docetaxel; studies should therefore be conducted using a range of other chemotherapeutics 
such as SN-38, paclitaxel and doxorubicin. 
Future experiments should aim to further understand the links between copolymer properties 
and drug release rates. In particular, focus should move away from the functionality of the 
copolymer repeat unit and should consider the physical properties of the polymer materials. In 
particular, research should seek to understand the impact of copolymer crystallinity, viscosity 
and polarity on the release of encapsulated payloads. This research should involve systematic 
variations in copolymer properties in order to isolate individual physical properties and aid the 
identification of trends with drug release rates; in particular, this could be achieved via 
copolymerisation of monomers which generally produce copolymers of varied physical and 
chemical properties. Where possible, this should be supported with physical and chemical 
characterisation techniques.  Preliminary work has been conducted in this area and is presented 
in Section 5.2.2.1.  
Finally, pharmacological evaluation should also be conducted for docetaxel-loaded branched 
vinyl copolymer nanoparticles. This would allow assessment of the cytotoxicity and the extent 
of cellular internalisation of nanoformulated docetaxel encapsulated within branched vinyl 
copolymer nanoparticles, in comparison to unformulated docetaxel. In vivo tumour models 
would also allow the impact of encapsulation on the accumulation of docetaxel within tumour 
tissues to be understood. Furthermore, this would allow comparison with similar experiments 
conducted using unloaded branched vinyl copolymer nanoparticles, recommended in 




5.2.2 Alternative Approaches to Manipulation of Nanoparticle Properties 
Whilst the work discussed in Chapters 2 – 4 focused on the manipulation of nanoparticle core 
chemistry using copolymers consisting of a sole type of hydrophobic monomer, alternative 
strategies were also studied to manipulate the properties of branched vinyl copolymer 
nanoparticles. These included: i) systematic variation of nanoparticle properties via 
co-nanoprecipitations of statistical copolymers; ii) using branched copolymer end-groups to 
modify the core of branched vinyl copolymer nanoparticles; and iii) preparation of branched 
vinyl copolymers containing varied hydrophilic shell functionality. Preliminary experiments 
were conducted in order to assess the feasibility of future research in each of these areas.    
5.2.2.1 Optimisation of Nanoparticle Properties using Bespoke Copolymers  
In Chapters 3 and 4, the hydrophobic repeat units of branched and AB block copolymers made 
up the vast majority of the mass of branched vinyl copolymer nanoparticles formed via 
co-nanoprecipitation. It was for this reason that the hydrophobic repeat unit functionality had 
such a significant impact on the macroscopic properties of the branched vinyl copolymers 
formed. For example, large contrasts were observed in nanoparticle formation, core polarity 
and docetaxel release rates between branched vinyl copolymer nanoparticles constructed from 
HPMA and EHMA. It is therefore possible that control over nanoparticle properties could be 
achieved by systematic variation of the structures and compositions of the copolymers from 
which they are constructed. Preliminary research was therefore conducted to see if this could 
be achieved via statistical copolymerisation of different hydrophobic monomers used in this 
thesis. Given that p(HPMA) and p(EHMA) based nanoparticles showed the fastest and slowest 
docetaxel release rates during radio-dialyses conducted in Chapter 4, preliminary research 
aimed to prepare statistical branched and AB block copolymers, constructed from HPMA and 
EHMA, across a range of monomer compositions.  
Given the success of Cu-RDRP of both HPMA and EHMA in anhydrous MeOH, presented in 
Chapter 2, this approach was used for the preparation of branched and AB block statistical 
copolymers. The synthetic approaches used to prepare branched and AB block copolymers are 
presented in Figure 5.1. Branching copolymerisations targeted a DPn of 60 monomer units 
([M]0/[I]0 = 60) and a nominal branching ratio of 0.90 molar equivalents of EGDMA per unit 
of the BzBiB initiator ([B]0 /[I]0) = 0.90). AB block copolymerisations were conducted using 
the PEG45-Br macro-initiator, synthesised in Chapter 2, and targeted a total number average 
degree of polymerisation of 120 monomer units ([M]0/[I]0 = 120). Branched and AB block 
copolymers were prepared containing varied molar ratios of HPMA and EHMA; this was 
achieved by conducting copolymerisations using mole fractions (Xf) of HPMA:EHMA of 





Figure 5.1 Schematic representation of the synthesis routes used for the preparation of 
a) branched and b) AB block statistical copolymers via Cu-RDRP at 50℃ in anhydrous MeOH.  
Interestingly, comonomer composition had a profound impact on the homogeneity of reaction 
mixtures observed during copolymerisations. In the preparation of both branched and AB 
block copolymers, copolymerisations conducted using HPMA Xf ≥0.10 remained 
homogeneous throughout the course of the copolymerisation, whereas polymerisation-induced 
phase separation occurred in copolymerisations conducted at HPMA Xf ≤0.10. This was 
somewhat unsurprising given the high EHMA content, especially as polymerisation-induced 
phase separation was observed during branching copolymerisations of EHMA conducted in 
Chapter 2. Despite the occurrence of polymerisation-induced phase separation, branching 
copolymerisations achieved high monomer conversion (≥97 %) in all cases. The purified 
branched copolymers were assessed by TD-SEC (Table 5.1). In all cases, the number-average 
molecular weights obtained were significantly higher than theoretical number-average 
molecular weights. This indicates the formation of branched macromolecular architectures by 
coupling of primary chains during copolymerisation, as supported by the low MHS exponents 
(α ≤ 0.50), representative of densely-packed structures, obtained from MHS plots. This 
demonstrated that branched statistical copolymer architectures containing more than one 





Table 5.1 Branched and AB block statistical copolymers prepared via RDRcP of HPMA and EHMA in anhydrous MeOH at 60 ℃.  























p(EHMA60-co-EGDMA0.90) 60 0.90 1.00 0.00 >99  698 200 33 300 20.96 0.378 
p(EHMA54-co-HPMA6-co-EGDMA0.90)  60 0.90 0.90 0.10 >99  794 500 42 500 18.69 0.378 
p(EHMA45-co-HPMA15-co-EGDMA0.90)  60 0.90 0.75 0.25 98  185 000 37 600 4.92 0.403 
p(EHMA30-co-HPMA30-co-EGDMA0.90) 60 0.91 0.50 0.50 97  155 000 38 300 4.05 0.406 
p(EHMA15-co-HPMA45-co-EGDMA0.90)  60 0.90 0.25 0.75 99  254 600 57 200 4.45 0.389 
p(EHMA6-co-HPMA54-co-EGDMA0.90) 61 0.90 0.10 0.90 >99  485 300 57 100 8.49 0.281 
p(HPMA60-co-EGDMA0.90) 60 0.90 0.00 1.00 98  302 500 28 000 10.82 0.349 
PEG45-b-p(EHMA)120  120 - 1.00 0.00 99  33 400 28 100 1.19 0.574 
PEG45-b-p(EHMA108-co-HPMA12) 120 - 0.90 0.10 97  40 800 31 200 1.31 0.460 
PEG45-b-p(EHMA90-co-HPMA30) 120 - 0.75 0.25 97  35 200 27 700 1.27 0.498 
PEG45-b-p(EHMA60-co-HPMA60) 120 - 0.50 0.50 97  37 300 26 300 1.41 0.466 
PEG45-b-p(EHMA30-co-HPMA90) 120 - 0.25 0.75 98  34 000 29 100 1.17 0.571 
PEG45-b-p(EHMA12-co-HPMA108) 120 - 0.10 0.90 99  35 300 30 600 1.15 0.582 
PEG45-b-p(HPMA)120 120 - 0.00 1.00 98  23 000 18 500 1.22 0.409 
aDetermined by 1H NMR studies of the polymerisation prior to addition of the CuCl. bDetermined by 1H NMR studies of the polymerisation mixture at tf. CObtained 








The preparation of AB block copolymers were conducted over 48 hours in order to 
accommodate the higher target DPn of 120 monomer units. As a result, copolymerisations 
achieved high monomer conversion (≥97 %) in all cases. Analysis of AB block copolymers 
by TD-SEC showed good agreement between experimental and theoretical number-average 
molecular weights. Furthermore, molecular weight distributions generally showed low 
dispersity, which is indicative of a controlled RDRP process. However, high molecular weight 
shoulders within the RI chromatograms were observed for all copolymerisations involving 
HPMA. Similar observations have been made during polymerisations of hydroxyl-functional 
methacrylates containing low amounts of BFM impurities.17 It is also possible that the 
formation of a high molecular weight fraction occurred as a result of small amounts of 
termination by combination due to prolonged exposure to monomer-starved conditions over 
the 48 hour reaction time. Nonetheless, these reactions showed that AB block copolymers 
containing hydrophobic blocks of varied monomer composition could be prepared with a 
degree of control over copolymer molecular weight via Cu-RDRcP in anhydrous MeOH.  
Statistical copolymerisations were conducted in order to manipulate the chemical and physical 
properties of branched vinyl copolymer nanoparticles. In particular, given the contrast in the 
core polarities and branched copolymer complex viscosities identified in Chapter 4, 
preliminary studies sought to demonstrate whether systematic variation in copolymer 
composition could be used to influence the macroscopic behaviour. Branched copolymers 
were therefore subjected to the same rheological analyses shown in Chapter 4 (Figure 5.2).  
 
Figure 5.2 The impact of monomer composition on the complex viscosity of branched statistical 
copolymers formed via Cu-RDRcP. Rheological analyses of branched statistical copolymers 
containing varied monomer compositions using an oscillatory reverse temperature sweep from 




Rheological analysis on cooling from 150 to 25 ℃ showed that copolymer complex viscosities 
were highly dependent upon branched copolymer composition. The temperature at which 
dramatic increases in complex viscosity were observed increased as the EHMA composition 
was decreased. This demonstrated that branched copolymer complex viscosity can be 
influenced by the composition and type of hydrophobic monomers distributed along the 
primary chain backbone. By extension, this indicated that it is possible to use monomer 
composition to manipulate the core viscosity of branched vinyl copolymer nanoparticles 
formed via co-nanoprecipitation. However, it must be noted that all branched copolymer 
complex viscosities recorded at 25 ℃ were significantly higher than that of the p(LMA70-co-
EGDMA1.22) studied in Chapter 4. As a result, it is unlikely that the changes in complex 
viscosity shown here would be sufficient to influence docetaxel release rates from branched 
vinyl copolymer nanoparticles. Future studies could therefore look to replace EHMA with a 
hydrophobic methacrylate monomer that would form branched copolymers containing lower 
complex viscosities than those observed for p(EHMA60-co-EGDMA0.90). 
Co-nanoprecipitation of the corresponding statistical branched and AB block copolymers were 
conducted in order to understand whether the variation in copolymer properties, which arise 
as a result of manipulation of monomer composition, translate to the macroscopic properties 
of branched vinyl copolymer nanoparticles. Co-nanoprecipitations were conducted using 
branched and AB block copolymers containing identical weight fractions of EHMA and 
HPMA. For example, the branched copolymer, p(EHMA30-co-HPMA30-co-EGDMA0.90), was 
co-nanoprecipitated with the AB block copolymer, PEG45-b-p(EHMA60-co-HPMA60). This 
allowed the overall hydrophobic Xf of each monomer within the core of the resulting branched 
vinyl copolymers to be known. Co-nanoprecipitations utilised equal weight fractions of 
branched and AB block copolymers (ωi = 0.5) and were conducted from THF (1 mL, [P]0 = 5 
mg mL-1) into DI H2O (5 mL, DR = 5) under magnetic stirring. In addition, pyrene (1 wt %) 
was added into the initial THF-copolymer solution in order to facilitate measurement of the 
core polarity of branched vinyl copolymer nanoparticles using fluorescence emission 
spectroscopy. In all cases, co-nanoprecipitations were successful and showed no sign of 
copolymer sedimentation. The resulting aqueous nanoparticle dispersions were assessed using 







Table 5.2 Analysis of aqueous nanoparticle dispersions formed through co-nanoprecipitations 
of branched and AB block statistical copolymers containing varied molar ratios of EHMA and HPMA 













1.00 0.00 131 116 0.014 -9.84 1.07 
0.90 0.10 112 95 0.019 -14.3 1.09 
0.75 0.25 103 85 0.037 -13.6 1.10 
0.50 0.50 91 69 0.071 -10.4 1.17 
0.25 0.75 89 65 0.083 -12.9 1.22 
0.10 0.90 84 69 0.023 -10.1 1.34 
0.00 1.00 77 59 0.055 -23.8 1.60 
aObtained by DLS analysis of aqueous nanoparticle dispersions at a concentration of 1 mg mL-1. bZeta 
potentials measured at a concentration of 0.01 M KCl. cObtained via fluorescence emission 
spectroscopy of encapsulated pyrene.  
In all cases, stable and highly monodisperse nanoparticles were produced from 
co-nanoprecipitations of branched and AB block copolymers across the whole monomer 
composition range studied. This showed that it is possible to manipulate nanoparticle core 
chemistry without having a negative impact on nanoparticle formation via 
co-nanoprecipitation. In all cases, highly monodisperse branched vinyl copolymer 
nanoparticles were formed. This indicated nanoparticle formation via homogeneous 
nucleation and subsequent diffusion-limited cluster-cluster aggregation (DLCA) growth 
mechanism. Interestingly, copolymer composition had a significant impact on the 
hydrodynamic diameter and the internal polarity of branched vinyl copolymer nanoparticles 
(Figure 5.3). Both intensity- and number-average hydrodynamic diameters showed a general 
increase with EHMA composition; for example, intensity-average hydrodynamic diameters of 
77, 91 and 131 nm were recorded for branched vinyl copolymer nanoparticles containing 
EHMA Xf of 0.0, 0.5 and 1.0 respectively. In contrast, nanoparticle core polarities decreased 
with increasing EHMA composition with obtained I1/I3 ratios showing a general decrease from 
1.60 to 1.07 over the range of copolymer compositions studied. This demonstrated that 
copolymer composition could be used to achieve a significant level of control over the 






Figure 5.3 Analysis of branched vinyl copolymer nanoparticles formed via co-nanoprecipitation 
of branched and AB block copolymers containing varied comonomer compositions. a) The impact of 
copolymer composition on nanoparticle size and dispersity. b) The impact of copolymer composition 
on the internal polarity of branched vinyl copolymer nanoparticles. 
Given that copolymer composition had a profound effect on nanoparticle properties, docetaxel 
encapsulation and release studies were conducted to determine whether these effects 
influenced their performance as potential docetaxel nanocarriers. Co-nanoprecipitations were 
conducted using equal weight fractions of branched and AB block copolymers (ωi = 0.425), a 
docetaxel weight fraction of 0.15 and were conducted from THF (1 mL, [P]0 = 5 mg mL-1) into 
DI H2O (5 mL, DR = 5) under magnetic stirring. Co-nanoprecipitations were conducted using 
3H labelled docetaxel (targeted specific activity = 6.5 µCi mg-1) in order to allow measurement 
of docetaxel EE, DL and release rates using radiometric analyses (Table 5.3).  
Table 5.3 Analysis of the encapsulation and release of 3H-labelled docetaxel from branched 
















1.00 0.00 81 54 0.095 0.974 12.7 70.6 35.3 
0.90 0.10 126 96 0.067 0.972 11.9 83.1 30.0 
0.75 0.25 104 70 0.111 0.807 11.0 152.3 16.4 
0.50 0.50 121 88 0.079 0.837 11.9 138.2 18.1 
0.25 0.75 102 83 0.045 0.889 11.7 137.5 18.1 
0.10 0.90 107 88 0.027 0.865 10.7 318.6 7.80 
0.00 1.00 86 58 0.111 0.769 11.0 401.7 6.21 
 aObtained by DLS analysis of aqueous nanoparticle dispersions at a concentration of 1 mg mL-1. 
bDetermined by radiometric analyses following purification via centrifugation. CObtained from 
radio-dialyses of 3H-docetaxel loaded branched vinyl copolymer nanoparticles at 37 ℃.  
The resulting 3H labelled aqueous nanoparticle dispersions were also assessed by DLS. The 
size trends observed in branched vinyl copolymer nanoparticles produced via 
co-nanoprecipitation in the absence of docetaxel were not observed during docetaxel loading 
co-nanoprecipitations. As was shown in Chapter 4, this indicated that the presence of docetaxel 
impacted nanoparticle formation during the co-nanoprecipitation process. Interestingly, the 




Chapter 4, indicated that the functionality of branched copolymer repeat units did impact the 
EE achieved during co-nanoprecipitation in this case.  
Radio-dialyses of 3H-docetaxel loaded branched vinyl copolymer nanoparticles were 
conducted at 37 ℃ over 24 hours in order to determine the impact of copolymer composition 
on the docetaxel release rates (Figure 5.4). Radio dialyses showed that copolymer composition 
had a profound impact on docetaxel release. Results generally showed that docetaxel release 
rates decreased as the EHMA Xf was increased. This reiterated findings in Chapter 4 which 
showed that the chemistry of copolymer repeat units had a significant impact on the release of 
docetaxel from branched vinyl copolymer nanoparticles. The order of docetaxel release rates 
were comparable for nanoparticles containing EHMA Xf from 0.25 to 0.75. This can be 
explained by the lower EE observed for nanoparticles containing EHMA Xf of 0.75. Docetaxel 
release rates can therefore be thought of as products of both the EE achieved during co-
nanoprecipitation and the rates at which encapsulated docetaxel is released from branched 
vinyl copolymer nanoparticles. This demonstrated that, although the nanoparticle core 
functionality is an important factor in docetaxel release rates, a high EE is essential to allow 
modulation of docetaxel release from branched vinyl copolymer nanoparticles. 
 
Figure 5.4 Release of 3H-labelled docetaxel from branched vinyl copolymer nanoparticles 
consisting of varied comonomer compositions during radio-dialysis over 24 hours.  
These preliminary results demonstrate that it is possible to influence the properties of branched 
vinyl copolymer nanoparticles via systematic variation of the composition of copolymers used 
in co-nanoprecipitation. As a result, this approach can be used to influence the EE achieved 
during co-nanoprecipitation and modulate docetaxel release profiles from branched vinyl 
copolymer nanoparticles. These results may inspire future research aiming to optimise the 
encapsulation and release of docetaxel, or other hydrophobic drugs, from branched vinyl 




alternative monomer pairings to influence specific nanoparticle properties (i.e. core polarity, 
viscosity or nanoparticle size); this approach could be used to manipulate each of these 
nanoparticle properties in isolation and may therefore allow their impact on drug encapsulation 
and release to be studied. Furthermore, this approach could be used to incorporate repeat units 
which, alone, are incapable of forming stable branched vinyl copolymer nanoparticles through 
co-nanoprecipitation. For example, statistical copolymerisation of EHMA with BzMA may 
allow aromatic character to be incorporated into the core of branched vinyl copolymer 
nanoparticles. This may have a further impact on influencing the encapsulation and release of 
hydrophobic chemotherapeutics. 
5.2.2.2 Copolymer End-Groups to Modulate Docetaxel Release  
The work presented in Chapters 2, 3 and 4 focused on the use of monomer functionality to 
influence the core chemistry of branched vinyl copolymer nanoparticles. Future research must 
therefore look to exploit alternative functional handles and assess their impact on influencing 
the macroscopic behaviour of branched vinyl copolymer nanoparticles. As identified in 
Chapter 1, polymer end-groups enable chemical functionality to be integrated into both 
polymers and the resultant nanomaterials that they are used to construct. Future research 
should therefore look to assess whether end-group chemistry can be used to influence the rate 
of docetaxel release from branched vinyl copolymer nanoparticles. This could be achieved by 
the selection of chemical functionalities which can promote host-guest interactions between 
branched copolymers and docetaxel, which make up the nanoparticle core, and encapsulated 
docetaxel molecules. There are many directions that this research could take. Hyper-branched 
polydendrons are an established macromolecular architecture designed to amplify chemical 
functionality at branched copolymer end-groups;18–22 this approach therefore offers one 
potential synthetic route to influence docetaxel release rates via control over the functionality 
of branched copolymer end-groups.  
The research presented in this thesis focused on modulating the docetaxel release. It was 
hypothesised that, in order to influence docetaxel release from branched vinyl copolymer 
nanoparticles, branched copolymer end-groups must possess a high affinity for docetaxel. 
Preliminary studies therefore aimed to incorporate docetaxel at the end-groups of branched 
copolymers formed via Cu-RDRcP. The synthetic route taken to prepare such docetaxel 





Figure 5.5 Schematic representation of the incorporation of docetaxel at the end-groups of 
branched copolymers prepared by Cu-RDRP. a) The preparation of a monofunctional docetaxel initiator 
via esterification of docetaxel with α–bromoisobutyryl bromide.  b) The preparation of 
docetaxel-polymers conjugates containing i) linear homopolymer and ii) branched copolymer 
architectures. 
Briefly, this involved preparation of a docetaxel functional alkyl bromide initiator, which was 
subsequently employed for both the homopolymerisation of nHMA and its copolymerisation 
with EGDMA. The docetaxel-based initiator was prepared via esterification of docetaxel with 
α-bromoisobutyryl bromide, using a similar approach to those described for the preparation of 
benzyl- and PEG-based initiators in Chapter 2. The presence of multiple docetaxel hydroxyl 
groups meant that a mixture of products were isolated from the reaction. Purification via 
column chromatography confirmed the formation of monofunctional, bifunctional and 
trifunctional docetaxel initiators, which were characterised via electrospray ionisation mass 
spectrometry, 1H and 13C NMR spectroscopy (Appendix, Figures A5.1 – A5.3). 1H and 13C 
NMR of the monofunctional adduct showed that the initiating moiety was exclusively located 
at the hydroxyl β to the amide group, as shown in Figure 5.5. This was consistent with the 
order of hydroxyl reactivity identified during previously reported functionalisation of 
docetaxel and other taxanes.23–25 
The monofunctional docetaxel initiator was later employed in the Cu-RDRP of nHMA at 
60 ℃ in anhydrous MeOH (Table 5.4). Cu-RDRP was facilitated by a [Cu(bpy)2]Cl catalytic 
system and targeted a DPn of 50 monomer units. As had been observed for Cu-RDRP of nHMA 
in anhydrous MeOH using a benzyl-based initiator, polymerisation-induced phase separation 
occurred during polymerisation and resulted in the formation of a biphasic reaction mixture. 
Despite the onset of polymerisation-induced phase separation, the polymerisation achieved 
high monomer conversion (> 99 %) and subsequent analysis of the purified polymer by 




TD-SEC analysis showed that docetaxel initiators achieved high initiation efficiency 
(IE(TD-SEC) = 93 %). This was higher than had been achieved during Cu-RDRP conducted using 
BzBiB in Chapter 2 (77 %). This highlighted that the docetaxel-based macro-initiator was able 
to facilitate polymerisation of nHMA without hindering the RDRP process. Branching 
copolymerisations were also conducted by addition of small amounts of EGDMA under 
identical polymerisation conditions and showed identical phase behaviour to linear 
homopolymerisations.  
Table 5.4 Characterisation of (co)polymers produced from linear polymerisation and branched 
statistical copolymerisation of nHMA using a monofunctional docetaxel initiator.  















dctx-p(nHMA)55 51 - >99 93 11 900 10 400 1.14 0.676 
dctx-p(nHMA54-co-EGDMA0.97) 50 0.90 >99 - 185 200 32 000 6.59 0.384 
aObtained from 1H NMR spectroscopy of the polymerisation mixture prior to initiation. bObtained from 1H NMR spectroscopy 
of polymerisation mixture following deactivation of the Cu-catalyst. cObtained by comparison of theoretical and experimental Mn 
values determined by 1H NMR and TD-SEC respectively. dDetermined via TD-SEC in THF/TEA at a flow rate of 1 mL min-1.  
In contrast to the linear homopolymer, the branched copolymer exhibited a broad molecular 
weight distribution (Đ = 6.59, Figure 5.6) and had a significantly higher molecular weight 
(Mw = 185 200 g mol-1). This demonstrated that the onset of phase separation had not 
prevented the formation of branched copolymers during Cu-RDRcP of nHMA with EGDMA. 
The branched copolymer architecture was further confirmed by the lower MHS exponents. 
However, the overlap between the RI output signals obtained for dctx-p(nHMA)55 and the low 
molecular weight fraction of dctx-p(nHMA54-co-EGDMA0.97) highlight the presence of linear 
primary chains within the molecular weight distribution. This indicated that further work is 
required to manipulate reaction conditions in order to promote optimal branching reactions 
during copolymerisation.   
 
Figure 5.6 TD-SEC analysis of linear and branched (co)polymers generated via Cu-RDRP from 
a docetaxel-based macro-initiator. Overlaid a) RI and b) LALS chromatograms obtained for p(nHMA)55 




Co-nanoprecipitation studies were conducted to investigate whether docetaxel-functional 
branched copolymers could be successfully incorporated into the core of branched vinyl 
copolymer nanoparticles (Figure 5.7). This involved co-nanoprecipitation of 
dctx-p(nHMA54-co-EGDMA0.97) with the amphiphilic AB block copolymer, 
PEG45-b-p(nHMA)127, prepared in Chapter 2. The co-nanoprecipitation was conducted using 
equal weight fractions of dctx-p(nHMA54-co-EGDMA0.97) and PEG45-b-p(nHMA)127. 
Co-nanoprecipitations were conducted from THF (1 mL, [P]0 = 5 mg mL-1) into DI H2O (5 mL, 
DR = 5). The co-nanoprecipitation of dctx-p(nHMA54-co-EGDMA0.97) and 
PEG45-b-p(nHMA)127 yielded a turbid, translucent aqueous nanoparticle dispersion. Analysis 
by DLS showed that the nanoparticles formed were highly monodisperse (PDI = 0.028) and 
possessed intensity- and number-average hydrodynamic diameters of 97 and 78 nm 
respectively. This showed that the presence of docetaxel end-group functionality had little 
impact on nanoparticle formation. Furthermore, the size distributions and hydrodynamic 
diameters were comparable to that obtained from the co-nanoprecipitation of 
PEG45-b-p(nHMA)127 with the branched copolymer, p(nHMA68-co-EGDMA1.03), which 
contained benzyl end-group functionality (Figure 5.7b).  
 
Figure 5.7 Incorporation of dctx-p(nHMA54-co-EGDMA0.97) into branched vinyl copolymer 
nanoparticles via co-nanoprecipitation. a) Schematic representation of the co-nanoprecipitation process 
through which nanoparticles are formed and b) overlaid nanoparticle size distributions obtained from 
DLS analysis of aqueous nanoparticle dispersions constructed from branched copolymers containing 
docetaxel and benzyl end-group functionalities.  
The preliminary results demonstrate that docetaxel can be incorporated into the core of 
branched vinyl copolymer nanoparticles via covalent attachment at branched copolymer 
end-groups. Interestingly, at a primary chain DPn of 54 monomer units, docetaxel occupied 
9.4 wt % of the branched copolymer mass. As a result, branched copolymer nanoparticles were 
formed containing a dctx-p(nHMA54-co-EGDMA0.97) weight fraction of 0.5, and a docetaxel 





The preliminary results presented here demonstrate that covalent conjugation of docetaxel at 
the end-groups of branched copolymers can be used to incorporate this drug within the core of 
branched vinyl copolymer nanoparticles formed via co-nanoprecipitation. This approach can 
therefore be used to drive future research. In particular, research should look to understand 
whether i) the presence of docetaxel moieties at branched copolymer end-groups affects the 
encapsulation efficiency of unbound docetaxel during co-nanoprecipitation; and ii) the 
presence of docetaxel end-groups impact the release of unbound docetaxel from branched 
vinyl copolymer nanoparticles during radio-dialysis. Furthermore, research should look to 
understand whether the ester linkages between docetaxel and α-terminus of primary chains 
can be cleaved in the presence of esterase enzymes. This research also suggests that it may be 
possible to incorporate docetaxel at alternative points on different macromolecular 
architectures. For example, the reaction of docetaxel with methacryloyl chloride should 
produce a docetaxel monomer which would place docetaxel units along the polymer 
(co)backbone. Research should also look to increase the composition of docetaxel within 
branched vinyl copolymer nanoparticles. This could be achieved in two ways: i) decreasing 
the primary chain DPn or ii) increasing the weight fraction of dctx-p(nHMA54-co-EGDMA0.97) 
used during co-nanoprecipitation.  
5.2.2.3 Alternative Block Copolymers to Modify Nanoparticle Shell Functionality 
The work presented in this thesis demonstrated that it is possible to encapsulate and modulate 
the release of docetaxel from branched vinyl copolymers formed through 
co-nanoprecipitation. Future research should begin to explore how such nanoparticles behave 
in biological and physiological environments; in particular, how nanoparticles interact with 
plasma proteins, cell membranes and over-expressed receptors on cell surfaces. The 
hydrophilic shell which surrounds the hydrophobic core of branched vinyl copolymer 
nanoparticles is the component which has the highest level of interaction with the external 
environment.  Future research could therefore look to explore the significance of the chemical 
functionality of the hydrophilic components that make up the nanoparticle shell, and should 
look to understand how they influence the macroscopic behaviour of such nanoparticles.  
Preliminary research has been conducted to assess the feasibility of varying the shell 
functionality of branched vinyl copolymer nanoparticles. This involved the preparation of a 
series of amphiphilic AB block copolymers which contain varied hydrophilic functionalities. 
These materials were then used as stabilisers in co-nanoprecipitations with the hydrophobic 
branched copolymer, p(nHMA68-co-EGDMA1.03). The synthetic approach employed in the 





Figure 5.8 Schematic representation of the preparation of AB block copolymers via RAFT 
polymerisation. i) Preparation of a p(nHMA) macro-RAFT agent via polymerisation of nHMA using 
RAFT. ii) A series of separate chain extensions of the p(nHMA) macro-RAFT agent using a range of 
different methacrylate monomers.   
The preparation of a p(nHMA) based macro-RAFT agent was achieved via RAFT 
polymerisation of nHMA in toluene at 80 ℃ for 16 hours. 1H NMR analysis of the purified 
macro-CTA showed a DPn of 122 and, more importantly, high retention of the dithiobenzoate 
end-group. Further characterisation by TD-SEC showed a narrow molecular weight 
distribution (Đ = 1.12) which was indicative of a controlled polymerisation (Table 5.5). The 
purified macro-RAFT agent was then used in the preparation of AB block copolymerisation 
via separate chain extensions with oligo(ethylene glycol) monomethacrylate (OEGMA, Mn = 
300 g mol-1), 2-(dimethylamino) ethyl methacrylate (DMAEMA), 2-hydroxyethyl 
methacrylate (HEMA) and tBMA. The decision to chain-extend with tBMA was made as it 
was hypothesised that if co-nanoprecipitations involving p(nHMA122-b-tBMA16) fail, the 
importance of conducting chain extensions with a hydrophilic monomer would be highlighted; 
this would therefore reiterate the importance of hydrophilic domains of AB block copolymers 
in stabilising branched vinyl copolymer nanoparticles during co-nanoprecipitation. Short 
chain lengths were targeted for the second copolymer block in order to retain sufficient overall 
hydrophobicity and therefore to ensure that AB block copolymers experience a state of 
supersaturation during co-nanoprecipitation. Chain extensions were conducted in toluene at 
80 ℃ and were stopped after 4 hours, following which AB block copolymers were purified 
and characterised by TD-SEC. In all cases, an increase in molecular weight was observed in 




exhibited low dispersities (Đ = ≤1.22) which again showed that RAFT polymerisations had 
proceeded in a controlled manner. In all cases, AB block copolymers showed negligible 
solubility in DI H2O which indicated that all AB block copolymers should experience a state 
of supersaturation during co-nanoprecipitation.  
Table 5.5 Characterisation of the p(nHMA) macro-RAFT agent and AB block copolymers 
formed during subsequent chain extension using a number of methacrylate monomers.  














p(nHMA)122 125 95 122 16 17 000 15 200 1.12 
p(nHMA122-b-OEGMA11) 20 57 122, 11 4 24 700 21 100 1.18 
p(nHMA122-b-tBMA16) 20 82 122, 16 4 21 200 18 800 1.13 
p(nHMA122-b-HEMA14) 20 70 122, 14  4 23 750 19 400 1.22 
p(nHMA122-b-DMAEMA19) 20 97 122, 19 4 22 850 19 350 1.18 
a Calculated through 1H NMR analysis of the polymerisation mixture prior to initiation. b Calculated through 1H NMR analysis 
of the polymerisation mixture after the polymerisation had been stopped. C Macro-RAFT agent DPn calculated from 
1H NMR of 
the purified polymer. DPn of second block calculated as DPn = ([M]0/[CTA]0 x conv.)/100. Dd Obtained from TD-SEC analysis 
in THF/TEA (98/2 v/v %) conducted at 35 ℃ at a flow rate of 1 mL min-1.  
The AB block copolymers prepared by RAFT polymerisation were studied as stabilisers in 
co-nanoprecipitation with the hydrophobic branched copolymer p(nHMA68-co-EGDMA1.03). 
An overview of the co-nanoprecipitations conducted is presented in Figure 5.9. Briefly, 
co-nanoprecipitations involved equal weight fractions of p(nHMA68-co-EGDMA1.03) and the 
respective AB block copolymer (ωi = 0.5) and were conducted from THF 
(1 mL, [P]0 = 5 mg mL-1) into DI H2O (5 mL, DR = 5, [P]f = 1 mg mL-1) under magnetic 
stirring and were left for 48 hours to ensure complete THF removal via evaporation. In addition 
to the AB block copolymers produced using RAFT polymerisation, separate 
co-nanoprecipitations were also conducted using PEG45-b-p(nHMA)127 and the p(nHMA)122 
macro-RAFT agent. 
 
Figure 5.9 A general overview of the co-nanoprecipitations of p(nHMA68-co-EGDMA1.03) with 
a range of AB block copolymer stabilisers to produce branched vinyl copolymer nanoparticles 




With the exception of those conducted using p(nHMA122-b-tBMA16) and the p(nHMA)122 
macro-RAFT agent as the stabiliser blocks, all co-nanoprecipitations were successful and 
created turbid, translucent aqueous nanoparticle dispersions with no signs of sedimentation. In 
contrast, co-nanoprecipitations conducted using p(nHMA122-b-tBMA16) and the p(nHMA)122 
macro-RAFT agent as stabilisers resulted in (co)polymer sedimentation and were deemed to 
have failed. This reiterated the importance of the hydrophilic components of amphiphilic AB 
block copolymers in the stabilisation of growing nanoparticles during co-nanoprecipitation 
with hydrophobic branched polymers. All aqueous nanoparticle dispersions generated from 
successful co-nanoprecipitations were assessed using DLS. Interestingly, little size difference 
was observed between nanoparticles generated using different AB block copolymer stabilisers, 
which were comparable to that of the aqueous nanoparticle dispersion of PEG45-b-p(nHMA)127 
and p(nHMA68-co-EGDMA1.03), also discussed in Chapter 3. DLS studies showed that all 
aqueous nanoparticle dispersions were highly monodisperse (PDI ≤0.090 ), which indicated 
growth via a DLCA growth mechanism.  
Sole nanoprecipitations were conducted to investigate the role of AB block copolymers during 
co-nanoprecipitation. Despite the absence of p(nHMA68-co-EGDMA1.03), sole 
nanoprecipitations were performed using identical conditions to those used for the 
co-nanoprecipitations described above. As would be expected for an AB block copolymer that 
does not contain a hydrophilic block, the nanoprecipitation of p(nHMA122-b-tBMA16) was 
unsuccessful and resulted in macroscopic aggregation and subsequent copolymer 
sedimentation. This reiterated claims, made in Chapter 3, that the success of the sole 
nanoprecipitation of an AB block copolymer is highly indicative of its ability to stabilise 
growing nanoparticles during co-nanoprecipitation. In contrast, nanoprecipitations of 
p(nHMA122-b-OEGMA11), p(nHMA122-b-HEMA14) and p(nHMA122-b-DMAEMA19) 
produced translucent/turbid and colloidally stable aqueous nanoparticle dispersions and 
showed no sign of copolymer sedimentation. Nanoparticles were assessed using DLS (see 
Table 5.6) and showed slightly reduced hydrodynamic diameters to their corresponding 
branched vinyl copolymer nanoparticles produced via co-nanoprecipitation with p(nHMA68-
co-EGDMA1.03). This indicated that the inherent increase in stabiliser concentration, which 
accompanied the increase in the AB block copolymer weight fraction from 0.5 to 1.0, produced 
smaller nanoparticles. Interestingly, aqueous nanoparticle dispersions formed via the sole 
nanoprecipitation of p(nHMA122-b-OEGMA11) and p(nHMA122-b-HEMA14) exhibited higher 
PDI  values compared to those formed from co-nanoprecipitation with p(nHMA68-co-
EGDMA1.03). This indicated that these AB block copolymers underwent slower nucleation in 
the absence of p(nHMA68-co-EGDMA1.03). It is possible that the use of alternative hydrophilic 




solubility in DI H2O, could influence the state of supersaturation achieved during 
co-nanoprecipitation.  
Table 5.6 DLS analysis of aqueous nanoparticle dispersions produced via co-nanoprecipitation 
of p(nHMA68-co-EGDMA1.03) with polymeric stabilisers and sole nanoprecipitations of AB block 
copolymers.  








a -a -a 
p(nHMA68-co-EGDMA1.03) p(nHMA122-b-OEGMA11) 100 79 0.049 
p(nHMA68-co-EGDMA1.03) p(nHMA122-b-HEMA14) 110 78 0.090 
p(nHMA68-co-EGDMA1.03) p(nHMA122-b-DMAEMA19) 104 86 0.036 
p(nHMA68-co-EGDMA1.03) PEG45-b-p(nHMA)127 99 78 0.035 
p(nHMA68-co-EGDMA1.03) p(nHMA122-b-tBMA16) -
 a - a -a 
Sole nanoprecipitation 
-b p(nHMA122-b-OEGMA11) 90 50 0.196 
-b p(nHMA122-b-HEMA14) 98 67 0.107 
-b p(nHMA122-b-DMAEMA19) 78 63 0.034 
-b p(nHMA122-b-tBMA16) -
a -a -a 
aCo-nanoprecipitation failed – sedimentation observed. Reliable DLS analysis could not be obtained. bSole 
nanoprecipitation of AB block copolymer - no branched copolymer used.  
The work presented here demonstrates that it is possible to prepare branched vinyl copolymer 
nanoparticles containing shell functionalities beyond the PEG45 used throughout this thesis. 
This approach could therefore be used to control the surface functionality of branched vinyl 
copolymer nanoparticles and hence allow their interactions with biological and physiological 
components to be influenced. Synthetic polymer chemistry should be used to vary the 
functionality, density and length of the hydrophilic blocks that make up the shell of branched 
vinyl copolymer nanoparticles. Future research should involve pharmacological evaluation of 
the impact of shell functionality on nanoparticle behaviour in both biological and physiological 
environments. In particular, research should seek to understand the impact of shell 
functionality on the cytotoxicity, cellular uptake and opsonisation of branched vinyl 
copolymer nanoparticles in vitro.  
5.3 References  
1 A. B. Dwyer, P. Chambon, A. Town, T. He, A. Owen and S. P. Rannard, Polym. 
Chem., 2014, 5, 3608–3616. 
2 A. B. Dwyer, P. Chambon, A. Town, F. L. Hatton, J. Ford and S. P. Rannard, Polym. 
Chem., 2015, 6, 7286–7296. 
3 H.-J. Yang, B.-B. Jiang, W.-Y. Huang, D.-L. Zhang, L.-Z. Kong, J.-H. Chen, C.-L. 
Liu, F.-H. Gong, Q. Yu and Y. Yang, Macromolecules, 2009, 42, 5976–5982. 
4 P. Polanowski, J. K. Jeszka, W. Li and K. Matyjaszewski, Polymer., 2011, 52, 5092–
5101. 
5 J. Rosselgong, S. P. Armes, W. R. S. Barton and D. Price, Macromolecules, 2010, 43, 
2145–2156. 
6 J. Ford, P. Chambon, J. North, F. L. Hatton, M. Giardiello, A. Owen and S. P. 




7 J. M. Benito, M. Gómez-García, C. Ortiz Mellet, I. Baussanne, J. Defaye and J. M. 
García Fernández, J. Am. Chem. Soc., 2004, 126, 10355–10363. 
8 U. Boas and P. M. H. Heegaard, Chem. Soc. Rev., 2004, 33, 43–63. 
9 P. K. Jain, I. H. El-Sayed and M. A. El-Sayed, Nano Today, 2007, 2, 18–29. 
10 A. S. Mikhail and C. Allen, Biomacromolecules, 2010, 11, 1273–1280. 
11 S.-S. Feng, L. Mei, P. Anitha, C. W. Gan and W. Zhou, Biomaterials, 2009, 30, 
3297–3306. 
12 W. S. Saad and R. K. Prud’Homme, Nano Today, 2016, 11, 212–227. 
13 B. Sharma, R. M. Crist and P. P. Adiseshaiah, AAPS J., 2017, 19, 1632–1642. 
14 J. Rosselgong and S. P. Armes, Macromolecules, 2012, 45, 2731–2737. 
15 E. E. Brotherton, F. L. Hatton, A. A. Cockram, M. J. Derry, A. Czajka, E. J. Cornel, 
P. D. Topham, O. O. Mykhaylyk and S. P. Armes, J. Am. Chem. Soc., 2019, 141, 
13664–13675. 
16 N. J. Liptrott, M. Giardiello, J. W. Hunter, L. Tatham, L. R. Tidbury, M. Siccardi, S. 
Rannard and A. Owen, Nanomedicine, 2014, 10, 1407–1421. 
17 L. Ratcliffe, A. Blanazs, C. N. Williams, S. L. Brown and S. Armes, Polym. Chem., 
2014, 5, 3643–3655. 
18 F. L. Hatton, L. M. Tatham, L. R. Tidbury, P. Chambon, T. He, A. Owen and S. P. 
Rannard, Chem. Sci., 2015, 6, 326–334. 
19 F. L. Hatton, P. Chambon, A. C. Savage and S. P. Rannard, Chem. Commun., 2016, 
52, 3915–3918. 
20 F. L. Hatton, P. Chambon, T. O. McDonald, A. Owen and S. P. Rannard, Chem. Sci., 
2014, 5, 1844–1853. 
21 F. Y. Hern, A. Hill, A. Owen and S. P. Rannard, Polym. Chem., 2018, 9, 1767–1771. 
22 H. E. Rogers, P. Chambon, S. E. R. Auty, F. Y. Hern, A. Owen and S. P. Rannard, 
Soft Matter, 2015, 11, 7005–7015. 
23 Y. Bao, E. Guégain, J. Mougin and J. Nicolas, Polym. Chem., 2018, 9, 687–698. 
24 B. Louage, M. J. van Steenbergen, L. Nuhn, M. D. P. Risseeuw, I. Karalic, J. Winne, 
S. Van Calenbergh, W. E. Hennink and B. G. De Geest, ACS Macro Lett., 2017, 6, 
272–276. 

































6.1 Materials  
Methyl methacrylate (MMA, 99 %) ethyl methacrylate (EMA, 99%), n-butyl methacrylate 
(nBMA 99 %), t-butyl methacrylate (tBMA 99 %), n-hexyl methacrylate (nHMA, 99 %), 
cyclohexyl methacrylate (CHMA, 99 %), benzyl methacrylate (BzMA, 96 %), 2-ethyl hexyl 
methacrylate (EHMA, 99 %), lauryl methacrylate (LMA, 99 %), stearyl methacrylate (SMA, 
99 %), copper (I) chloride (Cu(I)Cl, 99 %), deuterated chloroform (CDCl3, 98.8 atom % D), 
pyrene (99 %), α-bromo isobutyryl bromide (99 %), benzyl alcohol (99 %), anhydrous 
tetrahydrofuran (a. THF, 99.8 %) anhydrous triethyl amine (TEA, 99 %), dimethyl amino 
pyridine (DMAP, 99 %), 2,2’ – bipyridine (bpy, 99%), anhydrous methanol (a. MeOH, 
99.8 %), anhydrous propan-2-ol (a. IPA, 99.8 %) and aluminium oxide (activated, neutral) 
were purchased from Sigma Aldrich. Tetrahydrofuran (THF, reagent grade), chloroform 
(CHCl3, reagent grade), methanol (MeOH, reagent grade), acetone (reagent grade), ethyl 
acetate (reagent grade), ethanol (reagent grade), toluene (reagent grade), hexane (reagent 
grade) and petroleum ether (40 - 60 ° C, reagent grade) were purchased from Fisher Scientific. 
Docetaxel was purchased from Chemleader Biochemical. ProSafe+ scintillation cocktail 
(Meridian Biotechnologies Ltd.). All materials were used as received. Tritiated docetaxel was 
purchased from American Radiolabelled Chemical, Inc.in an ethanol solution. Ethanol was 
removed before experiments conducted.   
6.2 Characterisation  
1H and 13C nuclear magnetic resonance (NMR) spectra were recorded in CDCl3 using a Bruker 
Avance spectrometer operating at 400 and 100 MHz respectively. Chemical shifts (δ) are 
reported in parts per million (ppm) and TMS was used as an internal standard for both 1H and 
13C NMR spectra. Triple detection size exclusion chromatography (SEC) was conducted using 
a Malvern Viscotek instrument equipped with a GPCmax VE2001 auto-sampler, two viscotek 
T6000 columns (and a guard column), a refractive index (RI) detector VE3580 and a dual 270 
detector (light scattering and viscometer). SEC was performed at a flow rate of 1 mL min-1 
using THF (containing 2 v/v % of TEA) as the mobile phase. Fluorescence spectra were 
obtained using a Shimadzu RF-5301PC spectrofluorophotometer. Emission spectra for pyrene 
were recorded between 350 and 500 nm. An excitation wavelength of λex = 335 nm was used 
for all studies as well as an excitation slit width of 2.5 nm and an emission slit width of 2.5 nm 
with a scan rate of 60 nm min-1. Electrospray (ESI) mass spectrometry data were recorded in 
the Mass Spectrometry Laboratory at the University of Liverpool using a MicroMass LCT 
mass spectrometer using electron ionisation and direct infusion syringe pump sampling. All 
materials were diluted with methanol. Elemental analyses were obtained from a Thermo 




Dynamic light scattering (DLS) and zeta potential measurements were performed at 25 °C 
using a Malvern Zetasizer Nano ZS instrument (laser wavelength = 630 nm) at a nanoparticle 
concentration, unless otherwise stated, of 1 mg mL-1. Scanning electron microscopy (SEM) 
images were obtained using a Hitachi S-4800 FE-SEM. Sample preparation involved dropping 
the aqueous samples on to silicon wafers mounted on an aluminium stub with a carbon tab. 
Samples were dropped directly onto SEM stubs and left to dry overnight. Samples were then 
subjected to gold sputter coating at 20 mA for 2 minutes prior to imaging. All radiation 
measurements were carried out using a liquid scintillation counter (Packard Tri-Carb 3100TR; 
Isotech) and radio-TLC analysed on an AR-2000 radio-TLC imaging scanner (Bioscan Inc.) 
6.3 Methods  
6.3.1 Chapter 2 
6.3.1.1 Monomer-Alcohol Miscibility Studies   
Monomer-solvent miscibility studies were conducted at a monomer concentration of 50 weight 
percent (50 wt %) with respect to the total mass of the monomer-solvent mixture. Solvent 
miscibility was assessed visually at both ambient and elevated (60 ℃) temperatures. In a 
typical experiment, MMA (1.00 g, 9.99 mmol) and anhydrous methanol (1.00 g, 1.26 mL) 
were added to a glass vial and sealed. The vial was agitated gently in order to give ample 
opportunity for mixing, after which monomer-solvent miscibility at ambient temperature was 
assessed visually. A magnetic stirrer bar was then added, the vial was re-sealed with a rubber 
septum and placed in an oil bath at 60 ℃ under magnetic stirring. After 10 minutes, the vial 
was withdrawn from the oil bath and monomer-alcohol miscibility at an elevated temperature 
was assessed visually. 
6.3.1.2 Pyrene Fluorescence Emission Spectroscopy of Monomer, Solvent and 
Monomer-Alcohol Solutions 
Pyrene emission fluorescence spectroscopy was conducted at a pyrene concentration of 
10 nM. Solutions were prepared with pyrene dissolved in: neat methacrylic monomers, 
common organic solvents, monomer-MeOH mixtures or monomer-IPA mixtures. As in the 
miscibility studies described in Section 6.3.1.1, monomer-alcohol mixtures were prepared at 
a monomer concentration of 50 wt %. In a typical experiment, an acetone stock solution of 
pyrene was added to a glass vial (300 µL, 0.1 mg mL-1). The vial was left in a low velocity 
fumehood overnight, allowing complete evaporation of acetone, to give a known quantity of 
solid pyrene (0.03 mg, 1.48 x 10-4 mmol). Following addition of the MMA-MeOH mixture 
(14.8 mL, 50 wt %), the vial was sealed and placed on an orbital mixer to ensure full 
dissolution of pyrene. The solution (ca. 1.00 mL) was added to a quartz cuvette and placed in 




recorded between 350 nm and 500 nm following excitation at 335 nm. The polarity of all 
pyrene solutions were determined using the I1/I3 ratio, by comparison of the relative intensities 
of the first (I1, ca. 373 nm) and third (I3, ca. 384 nm) vibrational bands of the pyrene 
fluorescence emission (Appendix, Figure A6.1). 
6.3.1.3 Synthesis of Benzyl Initiator  
Benzyl alcohol (5.00 g, 46.2 mmol), anhydrous TEA (7.02 g, 69.4 mmol) and DMAP (0.565g, 
4.62 mmol) were added to an oven dried round bottomed flask containing a magnetic stirrer 
bar and was equipped with a pressure equalising dropping funnel. The round bottom flask was 
purged with nitrogen followed by addition of anhydrous THF (100 mL), the solution was 
cooled to 0 ℃ in an ice bath. α-bromo isobutyryl bromide (13.8 g, 7.43 mL, 60.1 mmol) and 
anhydrous THF (25.0 mL) were added dropwise over 30 minutes via the pressure equalising 
dropping funnel and the reaction could be observed to occur immediately by the formation of 
the of a white precipitate. After one hour the ice bath was removed and the reaction was 
allowed to proceed for a further 23 hours. The precipitate was removed by filtration and the 
THF from the filtrate was removed in vacuo. The product was then extracted using diethyl 
ether and dried in vacuo to give a colourless oil. The pure product was isolated by silica gel 
column chromatography using a hexane/ethyl acetate mobile phase (95/5 volume %), 
Rf = 0.44, giving a colourless oil (71 %). 1H NMR (400 MHz, CDCl3) δ ppm 7.40 – 7.30 (m, 
5H), 5.21 (s, 2H), 1.95 (s, 6H). 13C NMR (100 MHz, CDCl3) δ ppm 171.5, 135.4, 128.6, 128.4, 
127.9, 67.6, 55.7, 30.8. m/z (ES MS)  274.0 [M+NH4]+ m/z required 256.01 [M]+. C11H13BrO2 
requires C, 51.38; H, 5.98; Br, 18.96; O, 15.19 %. Found C, 51.62; H, 5.75 % 
6.3.1.4 Synthesis of Poly(Ethylene Glycol) Macro-Initiator (PEG45-Br) 
This synthesis was conducted in accordance with the method previously reported.1–3 
Poly(ethylene glycol) methyl ether  (20.5 g, 10.3 mmol), anhydrous TEA (3.14 mL, 
22.5 mmol) and DMAP (158 mg, 1.30 mmol) were added to an oven dried round bottomed 
flask containing a magnetic stirrer bar and was equipped with a pressure equalising dropping 
funnel. The round bottom flask was purged with nitrogen followed by addition of anhydrous 
DCM (100 mL) and the solution was cooled to 0 ℃ in an ice bath. α-bromo isobutyryl bromide 
(3.69 g, 2.78 mL, 22.5 mmol) and anhydrous DCM (25.0 mL) were added dropwise over 30 
minutes via the pressure equalising dropping and the reaction could be observed immediately 
by the formation of the of a white precipitate. After one hour the ice bath was removed and 
the reaction was allowed to proceed at ambient temperature for a further 23 hours. The 
precipitate was removed by filtration and the resulting solution was diluted in DCM and passed 
over a basic alumina column. The product was dried in vacuo, re-dissolved in a minimum 




(B.P. = 40 - 60 ℃). The resulting white solid was dried in vacuo at 40 ℃ for 72 hours to give 
poly(ethylene glycol)45 2-bromo-2-methyl propanoate (PEG45-Br). Purified PEG45-Br was 
assessed by 1H NMR in order to determine the number average degree of polymerisation (DPn) 
and molecular weight (Mn). DPn (NMR) = 45, Mn (NMR) = 2130 (Appendix, Figure A6.2). 
1H NMR (400 MHz, D2O) δ ppm: 4.40 (t, 2H), 3.90 – 3.60 (s, 182 H), 3.40 (s, 3H), 1.98 (s, 
6H).  
6.3.1.5 General Procedure for the Synthesis of Linear Homopolymers by Cu-RDRP (MMA, 
EMA, nBMA, tBMA, nHMA, CHMA, BzMA, EHMA, LMA and SMA)  
Prior to use, all monomers and initiators were deoxygenated via gentle bubbling with N2 for 
60 minutes. In a typical synthesis of a methacrylic linear homopolymer targeting DPn = 60 
monomer units, nHMA (5.00 g, 29.4 mmol), bpy (153 mg, 0.979 mmol) and BzBiB (126 mg, 
0.489 mmol) were added to an oven dried round bottom flask (25 mL) equipped with a 
magnetic stirrer bar. The reaction solvent, either anhydrous MeOH (6.73 mL, 50 wt %) or 
anhydrous IPA (6.74 mL, 50 wt %), was added and the resulting solution was purged with N2 
for a further 15 minutes. At this point a sample was withdrawn (ca. 100 µL) and diluted in 
CDCl3 allowing quantification of [M]0/[I]0 by 1H NMR (Figure 6.1).  
 
Figure 6.1 Quantification of [M]0/[I]0 for the polymerisation of nHMA by analysis of the 
reaction mixture, prior to initiation, using 1H NMR spectroscopy (CDCl3, 400 MHz).  
Cu(I)Cl (48.5 mg, 0.489 mmol) was added rapidly to the flask, and instantly formed a brown 
solution. The reaction was then purged with N2 for a further 60 seconds, sealed and swiftly 




reaction mixture remained homogeneous throughout the reaction and phase separation only 
occurred on cooling following removal from the oil bath at 60 ℃. In all other cases (nHMA, 
CHMA, EHMA, LMA and SMA) phase separation occurred during polymerisation and the 
reaction proceeded as a biphasic mixture. The reaction was stopped after 24 hours by dilution 
with CDCl3 until a homogeneous blue/green solution was obtained, at this point a sample (ca. 
500 μL) was taken for quantification of monomer conversion by 1H NMR (Figure 6.2).  
 
Figure 6.2 Quantification of the monomer conversion achieved during Cu-RDRP of nHMA by 
1H NMR analysis of the reaction mixture after 18 hours (CDCl3, 400 MHz).  
The solution was further diluted in CHCl3, passed over a neutral alumina column to remove 
the copper catalyst and dried in vacuo. The polymer was re-dissolved in a minimum amount 
of THF and precipitated twice from THF into cold methanol, or another suitable anti-solvent 
(Appendix, Table A6.1) to give p(nHMA) as a clear viscous oil. The polymer was then dried 
in vacuo at 40 ° C for 48 hours and characterised via 1H NMR in CDCl3 (Figure 6.3) and triple 






Figure 6.3 Quantification of the number average degree of polymerisation of p(nHMA) using 
1H NMR spectroscopy (CDCl3, 400 MHz). 
6.3.1.6 Kinetic Studies of the Cu-RDRP of nHMA at 60 ℃ in MeOH 
Kinetic studies were conducted largely in accordance with the procedure outlined above 
(Section 6.3.1.5). Prior to use, all monomers and initiators were deoxygenated via gentle 
bubbling with N2 for 60 minutes. Kinetic studies of the Cu-RDRP of nHMA targeted a 
DPn = 60 monomer units. nHMA (25.0 g, 147 mmol), bpy (765 mg, 2.45 mmol) and BzBiB 
(630 mg, 2.45 mmol) were added to an oven dried round bottom flask (100 mL) equipped with 
a magnetic stirrer bar. The reaction solvent, either anhydrous MeOH or anhydrous IPA 
(33.7 mL, 50 wt %), was added and the resulting solution was purged with N2 for a further 15 
minutes. A sample was withdrawn (ca. 100 µL) and diluted in CDCl3 allowing quantification 
of [M]0/[I]0 by 1H NMR. Cu(I)Cl (48.5 mg, 0.489 mmol) was added rapidly to the flask, and 
instantly formed a brown solution. The reaction was purged with N2 for a further 60 seconds; 
the Cu-RDRP was then rapidly transferred to 15 individual 10 mL RBFs, via a syringe under 
N2, which were each sealed and quickly submerged into an oil bath preheated at 60 ℃. At 
pre-determined time points individual Cu-RDRP were removed from the oil bath and stopped 
via simultaneous dilution with CDCl3 and exposure of oxygen, following which a sample (ca. 
500 μL) was taken for quantification of monomer conversion by 1H NMR. Solutions were then 
passed over a neutral alumina column and dried in vacuo. The molecular weights of p(HMA), 




6.3.1.7 General Procedure for the Synthesis of AB Block Copolymers by Cu-RDRP (MMA, 
EMA, nBMA, tBMA, nHMA, CHMA, BzMA, EHMA, LMA and SMA)  
In a typical synthesis, targeting DPn = 120 monomer units and using PEG45–Br as the 
macro-initiator, PEG45-Br (526 mg, 0.245 mmol), nHMA (5.00 g, 29.4 mmol) and bpy 
(76.5 mg, 0.489 mmol) were added to a 25 mL single-neck round bottom flask equipped with 
a magnetic stirrer bar. Anhydrous MeOH (7.07 mL, 50 wt % wrt. monomer) was added and 
the resulting solution was sparged with N2 for a further 15 minutes. At this point a sample was 
withdrawn (ca. 100 µL) and diluted in CDCl3 allowing quantification of [M]0/[I]0 by 1H NMR, 
as described in Figure 6.1. Cu(I)Cl (24.3 mg, 0.245 mmol) was rapidly added to the flask, and 
a brown solution instantly formed. The reaction was then purged with N2 for a further 60 
seconds, sealed and quickly submerged into an oil bath preheated at 60 ℃. Cu-RDRPs were 
then allowed to proceed for 48 hours. The polymerisation was stopped by cooling the flask to 
room temperature, exposing its contents to air and diluting the reaction medium with CDCl3. 
The polymer solution was passed through a neutral alumina column to remove the catalyst 
using DCM as the mobile phase and the resulting solution was concentrated under reduced 
pressure. The AB block copolymer was purified via precipitation from THF into cold MeOH 
and subsequently dried in vacuo at 40 ℃ over 48 hours. The pure AB block copolymer was 
then characterised via 1H NMR (CDCl3) and TD-SEC (THF/TEA), in accordance with the 
procedures outlined above, to determine DPn and molecular weights. 
6.3.1.8 General Procedure for the Synthesis of Branched Statistical Copolymers by Cu-RDRP 
(MMA, EMA, nBMA, tBMA, nHMA, CHMA, BzMA, EHMA, LMA and SMA)  
In a typical branching statistical copolymerisation of nHMA and EGDMA targeting a primary 
chain DPn of 60 monomer units and a branching ratio ([B]0/[I]0) of 0.90, nHMA (5.00 g, 
29.4 mmol), EGDMA (87.3 mg, 0.441 mmol), bpy (153 mg, 0.978 mmol) and BzBiB (126 mg, 
0.489 mmol) were added to a round bottom flask (25 mL) equipped with a magnetic stirrer 
bar. The reaction solvent, either anhydrous MeOH (6.84 mL, 50 wt %) or anhydrous IPA 
(6.86 mL, 50 wt %) was added and the resulting solution purged with N2 for a further 15 
minutes. A sample was withdrawn (ca. 100 µL) and diluted in CDCl3 allowing quantification 





Figure 6.4 Quantification of [B]0/[I]0 for the polymerisation of nHMA via analysis of the reaction 
mixture at t0 using 1H NMR spectroscopy (CDCl3, 400 MHz).  
Cu(I)Cl (48.5 mg, 0.978 mmol) was rapidly added to the flask, instantly forming a brown 
coloured solution. The reaction was purged with N2 for a further 60 seconds and submerged 
into a preheated oil bath at 60 ° C. The reaction was stopped after 24 hours by dilution with 
CDCl3 until a homogeneous blue/green solution was obtained, at this point a sample (ca. 
500 μL) was taken for quantification of monomer conversion by 1H NMR. The solution was 
further diluted in CHCl3, passed over a neutral alumina column to remove the copper catalyst 
and dried in vacuo. The branched copolymer was then dissolved in a minimum amount of THF 
and precipitated twice from THF into cold methanol to give p(nHMA65-co-EGDMA0.95) as a 
viscous clear liquid. p(nHMA65-co-EGDMA0.95) was then dried in vacuo at 40 ℃ for 48 hours 
and characterised by 1H NMR in CDCl3 (Figure 6.5) and triple detection SEC using a 





Figure 6.5 Quantification of the DPn of the primary chains of which branched statistical 
copolymers, in this case p(nHMA65-co-EGDMA0.98), are constructed. Analyses were conducted via 
1H NMR spectroscopy of branched copolymers following purification (CDCl3, 400 MHz).  
6.3.1.9 Analysis of Branched Copolymer Architecture by TD-SEC  
Plots of cumulative weight fraction (cum. ωf) vs. number of primary chains per macromolecule 
were constructed by modification of the original cum. ωf vs. molecular weight plots generated 
via TD-SEC. the absolute molecular weights (M) obtained were divided by the Mn of their 
linear homologues, generated in the absence of EGDMA under identical polymerisation 
conditions, which provided suitable representation of the primary chains from which the 
branched copolymers were constructed (Equation 6.1). For example, the modification of the 
cum. ωf vs. M plot obtained for p(MMA70-co-EGDMA0.94), calculation of the number of 
primary chains per macromolecule was achieved by dividing each incremental increase in M 
by the Mn of p(MMA)67 obtained from the homopolymerisation of MMA in anhydrous IPA 
(Mn = 6 700 g mol-1). Similar modifications were made to generate plots of cumulative mole 
fraction (Xf) vs. number of primary chains per macromolecule (Appendix, Figure A2.8).   




Equation 6.1 Calculation of the number of primary chains per macromolecule where M = absolute 
molecular weight of the species contributing towards the cum. ωf and Mn (LH) = the number average 






6.3.2 Chapter 3 
6.3.2.1 Polymer Solubility Studies  
Polymer solubility studies were conducted in acetone and THF with the branched statistical 
copolymers used in Chapter 3. In a typical solubility study, p(EHMA68-co-EGDMA0.93) 
(50 mg) was added to a glass vial followed by THF (5 mL). The glass vial was then sealed and 
placed on a roller mixer at ambient temperature for 48 hours. The homogeneity of the THF/ 
p(EHMA68-co-EGDMA0.93) solution ([P] = 10 mg mL-1) was inspected visually. In cases 
where the polymers had not dissolved the sample was disregarded. 
THF/ p(EHMA68-co-EGDMA0.93) solution which appeared to have dissolved were passed over 
a 0.25 µm PTFE filter to test for the presence of small aggregates. In any samples which caused 
resistance on the syringe filter, the polymer/solvent mixture was deemed incompatible. 
6.3.2.2 Initial Nanoprecipitation Studies 
Initial nanoprecipitations were conducted from THF (1 mL) into DI H2O (5 mL) (dilution 
ratio = 5). (Co)polymers were nanoprecipitated from an initial concentration of 5 mg mL-1 in 
THF ([P]0 = 5 mg mL-1) which, following solvent removal, gave a final (co)polymer 
concentration of 1 mg mL-1 in DI H2O ([P]f = 1 mg mL-1). In a typical nanoprecipitation 
p(HPMA63-co-EGDMA0.90) (25 mg) and THF (5 mL) were added to a glass vial and sealed. 
The vial was placed on a roller mixer and the polymer allowed to dissolve over 48 hours at 
ambient temperature to give a p(HPMA63-co-EGDMA0.90)/ THF solution at a concentration of 
5 mg mL-1. The p(HPMA63-co-EGDMA0.90)/ THF solution (1 mL, 5 mg mL-1) was added to a 
glass vial containing DI H2O (5 mL) under magnetic stirring. The sample was then left for 48 
hours at ambient temperature to allow solvent removal via evaporation resulting in an aqueous 
nanoparticle dispersion at a concentration of 1 mg mL-1. Aqueous nanoparticle dispersions 
were assessed visually for signs of polymer sedimentation following which, nanoparticles 
were assessed via DLS, zeta potential measurements taken and SEM. This method was 
employed for: sole nanoprecipitations of linear homopolymers, branched statistical 
copolymers and AB block copolymers.  
6.3.2.3 Initial Co-Nanoprecipitation Studies 
Initial co-nanoprecipitations were conducted from THF (1 mL) into DI H2O (5 mL) (dilution 
ratio = 5). Equal weight fractions of each of the two components (ωi = 0.5) were used during 
co-nanoprecipitations. (Co)Polymers were nanoprecipitated from an initial concentration of 
5 mg mL-1 in THF ([P]0 = 5 mg mL-1) which, following solvent removal, gave a final 
(co)polymer concentration of 1 mg mL-1 in DI H2O ([P]f = 1 mg mL-1). In a typical 




PEG45-b-p(nBMA)125 and p(nBMA73-co-EGDMA1.12) (50 mg) were added into separate glass 
vials followed by THF (10 mL). Each of the vials were then sealed and placed on a roller mixer 
for 48 hours at ambient temperature. The resulting THF/ copolymer solutions (3 mL, 
5 mg mL-1) were added to a separate glass vial; this was then sealed and placed on an orbital 
mixer for 1 minute at ambient temperature to ensure complete homogenisation. The resulting 
copolymer/ THF solution contained AB block and branched copolymer weight fractions of 
0.50 and a total copolymer concentration of 5 mg mL-1 ([P]0 = 5 mg mL-1). The copolymer/ 
THF solution (1 mL, 5 mg mL-1, branched copolymer ωi = 0.50) was then rapidly added to DI 
H2O (5 mL) under magnetic stirring. The co-nanoprecipitation was then stirred at ambient 
temperature for 48 hours in order to allow complete THF removal via evaporation, to give an 
aqueous nanoparticle dispersion at a concentration of 1 mg mL-1 ([P]f = 1 mg mL-1). Aqueous 
nanoparticle dispersions were visually evaluated for signs of polymer sedimentation following 
which, nanoparticles were assessed via DLS, zeta potential measurements and SEM. This 
approach was used for the co-nanoprecipitations of linear homopolymers and branched 
copolymers, linear homopolymers and AB block copolymers and branched copolymers and 
AB block copolymers. 
6.3.2.4 Nanoparticle Imaging via Scanning Electron Microscopy  
SEM images of branched vinyl copolymer nanoparticles were prepared from a solution with 
initial nanoparticle concentration of 0.1 mg mL-1. In a typical preparation of a sample for SEM 
analysis, a p(nBMA) based aqueous nanoparticle dispersion (1 mL, 1 mg mL-1) was added to 
a glass vial containing DI H2O (9 mL) to give a diluted aqueous nanoparticle dispersion at a 
concentration of 0.1 mg mL-1. The sample was agitated gently on a roller mixer for 
approximately 5 minutes following which the aqueous nanoparticle dispersion (0.1 mg mL-1) 
was dropped on to a glass cover slide mounted on an aluminium stub with a carbon tab and 
left to dry overnight. Dried samples were gold sputter coated at 20 mA for 2 minutes prior to 
imaging. 
6.3.2.5 Pyrene Encapsulation Studies 
Pyrene encapsulation studies were conducted using standard co-nanoprecipitations of AB 
block and branched copolymers outlined in Section 6.3.2.3. Co-nanoprecipitations were 
conducted using a target pyrene loading of 1 wt % with respect to the total copolymer mass. 
In a typical pyrene encapsulation experiment, a stock solution of pyrene in acetone (250 µL, 
1 mg mL-1) was added to a glass vial and left at ambient temperature for 48 hours to allow 
complete acetone removal via evaporation resulting in a solid pyrene mass of 0.25 mg. THF 
stock solutions of PEG45-b-p(nBMA)125 (2.5 mL, 5 mg mL-1) and p(nBMA73-co-EGDMA1.12) 




mixer for 2 hours to allow complete homogenisation. The resulting THF/ copolymer/ pyrene 
solution (1 mL, [P]0 = 5 mg mL-1, [pyrene]0 = 0.05 mg mL-1) was rapidly added to DI H2O 
(5 mL, DR = 5) under magnetic stirring. The co-nanoprecipitation was then stirred at ambient 
temperature for 48 hours to allow complete THF removal via evaporation, resulting in an 
aqueous nanoparticle dispersion at a concentration of 1 mg mL-1 ([P]f = 1 mg mL-1). Aqueous 
nanoparticle dispersions were assessed visually for signs of polymer sedimentation; 
nanoparticles were assessed via DLS and fluorescence emission spectroscopy (λex = 335 nm).  
6.3.2.6 Nanoparticle Composition Co-Nanoprecipitation Studies 
Nanoparticle composition studies were conducted using standard co-nanoprecipitations of AB 
block and branched copolymers, outlined in Section 6.3.2.3. Co-nanoprecipitation studies 
were conducted using AB block and branched copolymer weight fractions of: 1.0:0.0, 0.9:0.1, 
0.8:0.2, 0.7:0.3, 0.6:0.4, 0.5:0.5, 0.4:0.6, 0.3:0.7, 0.2:0.8, 0.1: 0.9 and 0.0:1.0. A typical 
co-nanoprecipitation of PEG45-b-p(nBMA)125 and p(nBMA73-co-EGDMA1.12), targeting AB 
block and branched copolymer weight fractions of 0.4 and 0.6 respectively was conducted as 
follows. Stock solutions of PEG45-b-p(nBMA)125 and p(nBMA73-co-EGDMA1.12) were 
prepared at a copolymer concentration of 5 mg mL-1 in THF. The PEG45-b-p(nBMA)125 
(1.2 mL, 5 mg mL-1) and p(nBMA73-co-EGDMA1.12)  (1.8 mL, 5 mg mL-1) stock solutions 
were added to a glass vial containing pyrene (0.15 mg). The vial was then sealed and placed 
on a roller mixer for 24 hours to ensure complete homogenisation. The resulting THF solution 
contained a total copolymer concentration of 5 mg mL-1 with a PEG45-b-p(nBMA)125 ωi of 0.4 
and a  p(nBMA73-co-EGDMA1.12) ωi of 0.6. The THF solution (1 mL) was then added to DI 
H2O (5 mL, DR = 5) under magnetic stirring and left at ambient temperature for 48 hours, to 
allow complete THF removal via evaporation. The resultant aqueous nanoparticle dispersion 
was at a concentration of 1 mg mL-1 ([P]f = 1 mg mL-1). Aqueous nanoparticle dispersions 
were assessed visually for signs of polymer sedimentation; nanoparticles were assessed via 
DLS, zeta potential measurements and fluorescence emission spectroscopy (λex = 335 nm).  
6.3.2.7 Co-Nanoprecipitation Concentration Studies 
Co-nanoprecipitation concentration studies were conducted using co-nanoprecipitations of AB 
block and branched copolymers, outlined in Section 6.3.2.3. Co-nanoprecipitations were 
conducted using stock solutions containing varied copolymer concentrations ranging from 5.0 
to 0.5 mg mL-1 in THF. All co-nanoprecipitations were conducted using equal weight fractions 
of AB block and branched copolymers (ωi = 0.5). A typical co-nanoprecipitation of 
PEG45-b-p(nBMA)125 and p(nBMA73-co-EGDMA1.12) from a [P]0 of 1 mg mL-1 was conducted 
as follows. Separate stock solutions of PEG45-b-p(nBMA)125 and p(nBMA73-co-EGDMA1.12) 




5 mg mL-1) were added to a glass vial and homogenised using an orbital mixer for 1 minute at 
ambient temperature. The stock solution (1 mL, 5 mg mL-1) was then added to a separate glass 
vial followed by THF (4 mL); the vial was then sealed and placed on an orbital mixer for 1 
minute to give a copolymer concentration of 1 mg mL-1. The stock solution (1 mL, 1 mg mL -1) 
was then added to DI H2O (5 mL, DR = 5) under magnetic stirring and was left at ambient 
temperature for 48 hours, in order to allow complete THF removal via evaporation. An 
aqueous nanoparticle dispersion at a concentration of 1 mg mL-1 ([P]f = 0.20 mg mL-1) resulted. 
Aqueous nanoparticle dispersions were assessed visually for signs of polymer sedimentation 
following which, nanoparticles were assessed via DLS. 
6.3.2.8 Nanoparticle Stability to Dilution Studies  
Nanoparticle dilution studies were conducted using aqueous nanoparticle dispersions                    
(1 mg mL-1) prepared by co-nanoprecipitations of AB block and branched copolymers. 
Co-nanoprecipitations were conducted from THF (1 mL) into DI H2O (5 mL) (dilution 
ratio = 5). Equal weight fractions of each of the two components (ωi = 0.5) were used during 
co-nanoprecipitation. In a typical co-nanoprecipitation of p(nBMA) based AB block and 
branched copolymers, PEG45-b-p(nBMA)125 and p(nBMA73-co-EGDMA1.12) (50 mg) were 
added into separate glass vials followed by THF (10 mL). Each of the glass vials were then 
sealed and placed on a roller mixer for 48 hours at ambient temperature. The resulting THF/ 
copolymer solutions (2 mL, 5 mg mL-1) were added to a separate glass vial; this was sealed 
and placed on an orbital mixer for 1 minute at ambient temperature to ensure complete 
homogenisation. The resulting copolymer THF solution contained AB block and branched 
copolymer weight fractions of 0.5 and a total copolymer concentration of 5 mg mL-1 
([P]0 = 5 mg mL-1). The copolymer/ THF solution (1 mL, 5 mg mL-1, branched copolymer 
ωi = 0.5) was then rapidly added to DI H2O (5 mL) under magnetic stirring. The co-
nanoprecipitation was stirred at ambient temperature for 48 hours in order to allow complete 
THF removal via evaporation, resulting in an aqueous nanoparticle dispersion at a 
concentration of 1 mg mL-1 ([P]f = 1 mg mL-1).  
Aqueous nanoparticle dispersions were then diluted in DI H2O using a serial dilution method 
over a dilution factor of 1000. For example, to achieve a 100 fold dilution, an aqueous 
p(nBMA) nanoparticle dispersion (1 mL, [P]f = 1 mg mL-1) was added to a glass vial along 
with 9 mL of DI H2O, the diluted sampled was then placed on a roller mixer for approximately 
30 minutes. The resulting diluted aqueous nanoparticle dispersion (1 mL, 
[P]H2O = 0.1 mg mL-1) was added to a glass vial along with 9 mL DI H2O. The vial was sealed 




([P]H2O = 0.01 mg mL-1). The diluted aqueous nanoparticle dispersion was then assessed using 
DLS.  
6.3.2.9 Nanoparticle Salt Stability Studies  
Nanoparticle dilution studies were conducted using aqueous nanoparticle dispersions                    
(1 mg mL-1) prepared by co-nanoprecipitations of AB block and branched copolymers. 
Co-nanoprecipitations were conducted from THF (1 mL) into DI H2O (5 mL) (dilution 
ratio = 5). Equal weight fractions of each of the two components (ωi = 0.5) were used during 
co-nanoprecipitations. In a typical co-nanoprecipitation, PEG45-b-p(LMA)121 and 
p(LMA70-co-EGDMA1.04) (50 mg) were added into separate glass vials followed by THF 
(10 mL). Each of the glass vials were then sealed and placed on a roller mixer for 48 hours at 
ambient temperature. The resulting THF/ copolymer solutions (2 mL, 5 mg mL-1) were added 
to a separate glass vial, this was then sealed and placed on an orbital mixer for 1 minute at 
ambient temperature to ensure complete homogenisation. The resulting copolymer THF 
solution contained AB block and branched copolymer weight fractions of 0.5 and a total 
copolymer concentration of 5 mg mL-1 ([P]0 = 5 mg mL-1). The copolymer/ THF solution 
(1 mL, 5 mg mL-1, branched copolymer ωi = 0.5) was then rapidly added to DI H2O (5 mL) 
under magnetic stirring. The co-nanoprecipitation was stirred at ambient temperature for 48 
hours in order to allow complete THF removal via evaporation, to give an aqueous 
nanoparticle dispersion at a concentration of 1 mg mL-1 ([P]f = 1 mg mL-1).  
Nanoparticle dispersions were diluted in NaCl solutions of varied concentration whilst 
maintaining a constant nanoparticle concentration of 0.5 mg mL-1. For example, to achieve a 
salt concentration of 0.5 mol dm-3, an aqueous p(LMA) nanoparticle dispersion (1 mL, 
[P]0 =  1 mg mL-1) and an aqueous solution of NaCl (1 mL, 1.0 mol dm-3) were added a glass 
vial. The vial was sealed and placed on a roller mixer for 24 hours to give an aqueous 
nanoparticle dispersion with a [P]H2O = 0.5 mg mL-1 and a [NaCl] = 0.5 mol dm-3. The stability 
of the aqueous nanoparticle dispersion was first assessed visually and, where there were no 
signs of copolymer sedimentation, this was followed by DLS analysis.  
6.3.3 Chapter 4 
6.3.3.1 Initial Docetaxel Encapsulation Study 
Initial docetaxel loading experiments were conducted using a constant fixed total mass during 
co-nanoprecipitation. The total solid mass consisted of branched and AB block copolymers, 
which contained equal weight fractions (ωi = 0.50), and docetaxel. Co-nanoprecipitations were 
conducted using a constant dilution ratio of 5 (VH2O/VTHF = 5) from an initial total solid 




25.0, 30.0, 40.0 and 50.0 wt % with respect to the total solid mass were attempted during initial 
docetaxel encapsulation studies. A typical co-nanoprecipitation, targeting a docetaxel loading 
of 25 wt % was conducted as follows. Docetaxel (50 mg) and dichloromethane (DCM) were 
added to a glass vial. The vial was sealed and placed on a roller mixer at ambient temperature 
overnight. The resulting docetaxel stock solution (375 µL, 10 mg mL-1) was added to a 
separate glass vial and left at ambient temperature for 24 hours to allow complete DCM 
removal via evaporation, leaving a solid docetaxel mass of 0.375 mg. Stock solutions of 
p(HPMA63-co-EGDMA0.90) and PEG45-b-p(HPMA)124 (1.5 mL, 3.75 mg mL-1) were added to 
the vial which was then sealed and placed on a roller mixer for 24 hours. The stock solution 
(1 mL, 5 mg mL-1 docetaxel ωi = 0.25) was then rapidly added to DI H2O (5 mL) under 
magnetic stirring. The co-nanoprecipitation was left at ambient temperature for 48 hours to 
allow complete THF removal via evaporation to give an aqueous docetaxel loaded 
nanoparticle dispersion at a concentration of 1 mg mL-1. Aqueous nanoparticle dispersions 
were initially assessed visually for signs of copolymer/ drug sedimentation. 
Co-nanoprecipitations were deemed to have failed in any cases where sedimentation was 
observed. Aqueous nanoparticle dispersions that showed no evidence of sedimentation were 
assessed using DLS.  
6.3.3.2 Calculation of Drug Loading via 1H NMR Spectroscopy 
Analysis of docetaxel encapsulation by 1H NMR spectroscopy required co-nanoprecipitations 
to be conducted on a larger scale to those reported above. In a typical large-scale 
co-nanoprecipitation, PEG45-b-p(nBMA)125 and p(nBMA73-co-EGDMA1.12) (45 mg) were 
added to separate glass vials followed by THF (10 mL). The glass vials were sealed and placed 
on a roller mixer for 48 hours to ensure complete copolymer dissolution. The resulting 
copolymer-THF stock solutions (6 mL, 4.5 mg mL-1) were added to a separate glass vial 
containing docetaxel (3 mg); the vial was sealed and placed on a roller mixer for a further 24 
hours. The resulting stock solution (5 mL, total solid mass = 5 mg mL-1, docetaxel ωi = 0.1) 
was added to DI H2O (25 mL, DR = 5) under magnetic stirring and was left for 72 hours at 
ambient temperature to allow complete THF removal. The resulting aqueous nanoparticle 
dispersion (25 mL, 1 mg mL-1, docetaxel ωi = 0.1) was inspected visually for signs of 
sedimentation and was subsequently assessed using DLS.  
In a typical drug loading analysis by 1H NMR spectroscopy, an aqueous nanoparticle 
dispersion (5 mL, 1 mg mL-1) was added to a glass vial and cooled under liquid N2 for 
5 minutes and freeze-dried over 72 hours. A separate sample of the same aqueous nanoparticle 
dispersion (5 mL, 1 mg mL-1) was added to a Amicon® Ultra-15 Centrifugal filter unit and 




nanoparticle dispersion remaining at the top of the centrifuge chamber was transferred to a 
glass vial, rapidly cooled in liquid N2 and was also freeze-dried for 72 hours. Following freeze 
drying, both samples were assessed using 1H NMR spectroscopy (400 MHz, CDCl3). The 
molar ratio of copolymer to docetaxel was determined by comparison of the relative intensities 
of chemical shifts of the: docetaxel allylic unit, the PEG methyl end-group and the ethylene 
protons of methacrylate repeat units (Figure 6.6).  
 
Figure 6.6 An exemplary 1H NMR spectrum obtained for docetaxel loaded p(nBMA) 
nanoparticles following water removal via freeze drying.  
Molar ratios were converted into mass ratio using the molecular weights of: docetaxel 
(808 g mol-1), the PEG45-Br macro initiator (2150 g mol-1) and that of the repeat unit 
(142.2 g mol-1) respectively. Drug loading was calculated by comparison of the mass of 
docetaxel in proportion with that of the overall mass, in accordance with Equation 6.2, where 
mD = docetaxel mass, mRU = the mass of the methacrylate repeat unit and mPEG = the mass of 
the PEG domains of amphiphilic block copolymers.  
𝐷𝐿 (%) =  (
𝑚𝐷
𝑚𝐷+ 𝑚𝑅𝑈+ 𝑚𝑃𝐸𝐺
)  × 100             
Equation 6.2 Calculation of drug loading of docetaxel with respct to overall mass where mD = docetaxel 
mass, mRU = the mass of the methacrylate repeat unit and mPEG = the mass of the PEG domains of 




Encapsulation efficiencies were calculated via comparison of the of docetaxel weight fractions 
in freeze dried samples obtained before and after nanoparticle purification via centrifugation. 




              
Equation 6.3 Calculation of encapsulation efficiency as a fraction of docetaxel weight in freeze dried 
samples before and after filtration. 
6.3.3.3 Calculation of Drug Loading via Ultraviolet-Visible Spectroscopy  
Analysis of docetaxel encapsulation by 1H NMR spectroscopy required co-nanoprecipitations 
to be conducted on a larger scale to those reported above. In a typical large-scale 
co-nanoprecipitation, PEG45-b-p(nBMA)125 and p(nBMA73-co-EGDMA1.12) (45 mg) were 
added to separate glass vials followed by THF (10 mL). The glass vials were sealed and placed 
on a roller mixer for 48 hours to ensure complete copolymer dissolution. The resulting 
copolymer-THF stock solutions (6 mL, 4.5 mg mL-1) were added to a separate glass vial 
containing docetaxel (3 mg); the vial was sealed and placed on a roller mixer for a further 24 
hours. The resulting stock solution (5 mL, total solid mass = 5 mg mL-1, docetaxel ωi = 0.1) 
was added to DI H2O (25 mL, DR = 5) under magnetic stirring and was left for 72 hours at 
ambient temperature to allow complete THF removal. The resulting aqueous nanoparticle 
dispersion (25 mL, 1 mg mL-1, docetaxel ωi = 0.10) was inspected visually for signs of 
sedimentation and was subsequently assessed using DLS.  
UV-Vis measurements were conducted in THF. Docetaxel concentrations were calculated 
using an extinction coefficient (ε) obtained from a calibration curve for docetaxel in THF. In 
a typical drug loading analysis by UV-Vis spectroscopy, an aqueous nanoparticle dispersion 
(5 mL, 1 mg mL-1) was added to a glass vial and cooled under liquid N2 for 5 minutes and 
freeze-dried over 72 hours. A separate sample of the same aqueous nanoparticle dispersion 
(5 mL, 1 mg mL-1) was added to a Amicon® Ultra-15 Centrifugal filter unit and placed under 
high centrifugation (4000 xg, swing bucket rotor) for 60 minutes. The filtrate, located in the 
lower compartment of the centrifugal filter unit transferred to a glass vial, rapidly cooled in 
liquid N2 and was also freeze-dried for 72 hours. Following freeze-drying, both the unfiltered 
nanoparticle-drug and the filtrate were dissolved in a known volume of THF and the docetaxel 
mass concentration was calculated from the UV-vis absorption at 244 nm. The drug loading 
was determined using Equations 6.4 and 6.5, where mDencap is the mass of encapsulated 
docetaxel, mDtotal is the total mass of docetaxel in the aqueous nanoparticle dispersion and 





        𝑚𝐷𝑒𝑛𝑐𝑎𝑝 = 𝑚𝐷𝑡𝑜𝑡𝑎𝑙 − 𝑚𝐷𝑓𝑟𝑒𝑒              
Equation 6.4 Calculation of mass of encapsulated docetaxel within aqueous nanoparticle dispersion 
where mDtotal is the total mass of docetaxel in the aqueous nanoparticle dispersion and mDfree is the mass 
of free docetaxel which was not encapsulated during co-nanoprecipitation.  
𝐷𝐿 (%) =  (
𝑚𝐷𝑒𝑛𝑐𝑎𝑝
𝑚𝐷𝑡𝑜𝑡𝑎𝑙+𝑚𝑝𝑜𝑙𝑦𝑚𝑒𝑟
) × 100              
Equation 6.5 Calculation of drug loading as a percentage of mass of docetaxel encapsulated compared 
to total mass of docetaxel and polymer within the aqueous nanoparticle dispersion. 
Encapsulation efficiencies (EE) were calculated via comparison of the docetaxel 
concentrations in freeze dried samples obtained before and after nanoparticle purification via 
ultracentrifugation. Docetaxel concentrations, determined by UV-Vis spectroscopy, within the 
filtrate ([D]free) were compared to the total docetaxel concentration within the unfiltered 
sample ([D]total). This allowed encapsulation efficiencies to be determined in accordance with 
Equation 6.6.  
𝐸𝐸 =  (
[𝐷]𝑡𝑜𝑡𝑎𝑙− [𝐷]𝑓𝑟𝑒𝑒
[𝐷]𝑡𝑜𝑡𝑎𝑙
)           
Equation 6.6 Calculation of encapsulation efficiency of docetaxel within aqueous nanoparticle 
dispersion via freeze-drying samples before and after ultracentrifugation to determine [D]free (amount 
of docetaxel in filtrate, unencapsulated) compared to [D]total (the total docetaxel concentration within 
the unfiltered sample) measured by UV-Vis spectroscopy. 
6.3.3.4 Assessment of 3H-Labelled Radio Purity via Radio Thin-Layer Chromatography 
Thin-layer chromatography (TLC) analysis was conducted of unlabelled docetaxel in order to 
establish a suitable eluent system and Rf value; these were determined to be 
ethyl acetate/ hexane (30/70 v/v %) and Rf = 0.40. Radio-TLC was then conducted using the 
same mobile phase to define radio-purity of tritiated docetaxel. TLC of tritiated docetaxel was 
analysed in parallel to analogous unlabelled docetaxel. Once the TLC plate had been exposed 
to the eluent system for a sufficient amount of time it was dried and placed on a radio-TLC 
imaging scanner. The scanner contained a gas-filled proportional counter which provided a 
direct digital counting of tritium and a corresponding Rf value of the radioisotope. The Rf 
value obtained for tritiated docetaxel concurred with that of the unlabelled analogue, therefore 
the tritiated docetaxel was deemed pure. 
6.3.3.5 Preparation of 3H-Docetaxel Loaded Branched Vinyl Copolymer Nanoparticles via 
Co-Nanoprecipitation  
All 3H-docetaxel co-nanoprecipitations were conducted using equal weight fractions of AB 




respect to the total solid mass. Co-nanoprecipitations were conducted from THF into DI H2O 
using a dilution ratio of 5. 
A typical preparation of 3H-docetaxel loaded p(nHMA) branched vinyl copolymer 
nanoparticles was conducted as follows. A stock solution of docetaxel (5 mg, 6.189 µmol) and 
3H labelled docetaxel (33 µCi, 6.6 µCi/mg-1) was prepared in EtOH. This stock solution (225 
µL, 1.125 mg, 6.6 µCi/mg-1) was added to a glass vial and left at ambient temperature 
overnight to allow complete EtOH via evaporation. Stock solutions of 
p(nHMA68-co-EGDMA1.03) (0.75 mL, 4.25 mg mL-1) and PEG45-b-p(nHMA)127 (0.75 mL, 
4.25 mg mL-1) in THF were added to the glass vial containing dried docetaxel (1.125 mg, 
6.6 µCi/mg-1); the vial was then sealed and homogenised by placing the vial on an vortex mixer 
for 1 minute. This solution (1 mL) was then added to DI H2O (5 mL) under magnetic stirring 
and was left at ambient temperature for 48 hours to allow complete THF removal via 
evaporation to give an aqueous nanoparticle dispersion at a solids concentration of 1 mg mL-1. 
Aqueous nanoparticle dispersions were assessed by DLS at a concentration of 1 mg mL-1 at 
25 ℃.    
6.3.3.6 Measurement of Encapsulation Efficiency and Drug Loading of 3H-Labelled 
Docetaxel Using Radiometric Analysis 
Docetaxel drug loadings were determined via liquid scintillation counting (LSC) analysis of 
known volumes of aqueous nanoparticle dispersions prior to centrifugation and the resulting 
filtrate. In a typical analysis of docetaxel loading and encapsulation efficiency, an aqueous 
nanoparticle dispersion (1 mL, 1.000 g) was analysed using LSC in order to determine the 
total mass of docetaxel present. A separate sample of the same aqueous nanoparticle dispersion 
(0.500 mL, 1 mg mL-1) was added to a centrifugal filter unit and was placed under high 
centrifugation (14,000 rpm) for 60 minutes. Analysis of untreated aqueous nanoparticle 
dispersions allowed the total docetaxel concentration ([D]total) and therefore the total docetaxel 
mass (mDtotal) to be determined by LSC analysis. Alternatively, LSC analysis of the filtrate, 
collected at the bottom of the centrifuge tube, allowed the concentration [D]free and thus the 
mass (mDfree) of free docetaxel to be determined. Docetaxel encapsulation efficiencies were 
calculated in accordance with Equation 6.7.  
𝐸𝐸 =  
𝑚𝐷𝑡𝑜𝑡𝑎𝑙 − 𝑚𝐷𝑓𝑟𝑒𝑒
𝑚𝐷𝑡𝑜𝑡𝑎𝑙
            
Equation 6.7 Calculation of encapsulation efficiency of docetaxel within aqueous nanoparticle 
dispersion via radiometric analysis before and after ultracentrifugation to determine mDfree (amount of 
docetaxel in filtrate, unencapsulated) compared to mDtotal (the total docetaxel concentration within the 




Given that the aqueous nanoparticle dispersion mass and the copolymer concentrations were 
known and that the concentration of docetaxel could be determined via LSC analysis, 
docetaxel drug loadings were be calculated using Equation 6.8, where mPtotal is the total mass 
of branched and AB block copolymers. mPtotal was based on a copolymer concentration of 0.85 
mg mL-1   
𝐷𝐿 =  
𝑚𝐷𝑡𝑜𝑡𝑎𝑙 − 𝑚𝐷𝑓𝑟𝑒𝑒
𝑚𝐷𝑡𝑜𝑡𝑎𝑙+ 𝑚𝑃𝑡𝑜𝑡𝑎𝑙
            
Equation 6.8 Calculation of drug loading of mass of docetaxel encapsulated compared to total mass of 
docetaxel and polymer within the aqueous nanoparticle dispersion. 
6.3.3.7 Monitoring Release of 3H-Labelled Docetaxel from Branched Vinyl Copolymer 
Nanoparticles during Radio-Dialyses  
Radio-dialysis of aqueous nanoparticle dispersions was conducted using a nanoparticle 
concentration of 1 mg mL-1, at a docetaxel loading of 15 wt %. Radio-dialyses were conducted 
using a 1:100 dilution. Dialyses were conducted at ambient temperature (20 ℃), 37 ℃ and 
50 ℃. Docetaxel release was monitored at set time points of: 0.5, 1, 2, 3, 4, 5, 6, 7, 8 and 24 
hours. In a typical radio-dialysis, a 3H labelled aqueous nanoparticle dispersion (1 mL) was 
added to a double sided bio-dialyser fitted with 3.5 kDa MWCO membranes. The bio-dialyser 
was placed in DI H2O 100 mL and stirred at 100 rpm; the reservoir was placed in an oil bath 
at the desired temperature. At regular time intervals, the bio-dialyser was transferred to a fresh 
reservoir (100 mL). A sample was then taken from the previous external reservoir (1 mL) to 
determine docetaxel release using LSC.  
6.3.3.8 Determination of Branched Copolymer Complex Viscosities Using Rheological 
Analysis  
Branched copolymer complex viscosities were determined using a reverse oscillatory 
temperature sweep from 150 ℃ to 25 ℃. All samples were tested using a 40 mm cross-hatched 
stainless steel parallel plate and were subjected to the same conditions during reverse 
oscillatory temperature sweeps, these included: i) a time sweep to probe the stability of each 
sample at 150 ℃ during which measurements were taken at 5 second intervals over a time 
period of 180 seconds using an oscillatory frequency of 1 Hz. ii) A temperature sweep from a 
start temperature of 150 ℃ to an end temperature of 25 ℃ which included measurement of 







6.3.4 Chapter 5 
6.3.4.1 Preparation of Branched Statistical Copolymers of HPMA, EHMA and EGDMA via 
Cu-RDRP at 60 ℃ in Anhydrous Methanol 
In a typical branching statistical copolymerisation of HPMA, EHMA and EGDMA targeting 
a primary chain DPn = 60 monomer unit, a branching ratio ([B]0/[I]0) of 0.9 and a HPMA Xf 
of 0.5, HPMA (2.12 g, 14.7 mmol), EHMA (2.92 g, 14.7 mmol), EGDMA (87.3 mg, 
0.441 mmol), bpy (153 mg, 0.978 mmol) and BzBiB (126 mg, 0.489 mmol) were added to a 
round bottom flask (25 mL) equipped with a magnetic stirrer bar. The reaction solvent, 
anhydrous MeOH (5.40 g, 6.83 mL, 50 wt %), was then added and the resulting solution was 
purged with N2 for a further 15 minutes. A sample was withdrawn (ca. 100 µL) and diluted in 
CDCl3 allowing quantification of [M]0/[I]0 and [B]0/[I]0 by 1H NMR spectroscopy. Cu(I)Cl 
(48.5 mg, 0.978 mmol) was rapidly added to the flask, and a brown coloured solution instantly 
formed. The reaction was purged with N2 for a further 60 seconds and submerged into a 
preheated oil bath at 60 °C. After 24 hours, a sample (ca. 500 μL) was taken for quantification 
of monomer conversion by 1H NMR and the polymerisation was then stopped by dilution with 
THF until a homogeneous blue/green solution was obtained. The solution was then further 
diluted in THF, passed over a neutral alumina column to remove the copper catalyst and dried 
in vacuo. The branched copolymer was then re-dissolved in a minimum amount of THF and 
precipitated twice from THF into cold petroleum ether to give p(EHMA30-co-HPMA30-co-
EGDMA0.90). The branched copolymer was then dried in vacuo at 40 ℃ for 48 hours and 
characterised by triple detection SEC using a THF/TEA eluent (98/2 v/v %) using narrow and 
broad poly(styrene) standard calibrations. 
6.3.4.2 Preparation of Statistical AB Block Copolymers of PEG45 EHMA and HPMA via 
Cu-RDRP at 60 ℃ in Anhydrous Methanol  
In a typical synthesis, targeting DPn = 120 monomer units and a HPMA Xf of 0.5, using 
PEG45-Br as the macro-initiator; PEG45-Br (526 mg, 0.245 mmol), HPMA (2.12 g, 
14.7 mmol),  EHMA (2.92 g, 29.4 mmol) and bpy (76.5 mg, 0.489 mmol) were added to a 
25 mL single-neck round bottom flask equipped with a magnetic stirrer bar. Anhydrous MeOH 
(5.67 g, 7.16 mL, 50 wt % w.r.t. monomer) was added and the resulting solution was sparged 
with N2 for a further 15 minutes. At this point a sample was withdrawn (ca. 100 µL) and diluted 
in CDCl3 allowing quantification of [M]0/[I]0 by 1H NMR. Cu(I)Cl (24.3 mg, 0.245 mmol) 
was rapidly added to the flask, and a brown solution instantly formed. The reaction was then 
purged with N2 for a further 60 seconds, sealed and quickly submerged into an oil bath 
preheated at 60 ℃. The polymerisation was then allowed to proceed for 48 hours. After 48 




and the polymerisation was then stopped by dilution with THF and exposure to air until a 
homogeneous blue/green solution was obtained. The polymer solution was passed through a 
neutral alumina column to remove the catalyst using THF as the mobile phase and the resulting 
solution was concentrated under reduced pressure. The AB block copolymer was purified via 
precipitation from THF into cold petroleum ether and subsequently dried in vacuo at 40 ℃ 
over 48 hours. The pure AB block copolymer was then characterised via TD-SEC using 
THF/TEA eluent (98/2 v/v %) and a narrow poly(styrene) standard calibration. 
6.3.4.3 Rheological Analyses of Branched Statistical Copolymers  
Branched copolymer complex viscosities were determined using a reverse oscillatory 
temperature sweep from 150 ℃ to 25 ℃. All samples were tested using a 40 mm cross-hatched 
stainless steel parallel plate and were subjected to the same conditions during reverse 
oscillatory temperature sweeps, these included: i) a time sweep to probe the stability of each 
sample at 150 ℃ during which measurements were taken at 5 second intervals over a time 
period of 180 seconds using an oscillatory frequency of 1 Hz. ii) A temperature sweep from a 
start temperature of 150 ℃ to an end temperature of 25 ℃ which included measurement of 
complex viscosities at an oscillatory frequency of 1 Hz at 5 ℃ steps across the temperature 
range.  
6.3.4.4 Co-nanoprecipitations of Statistical Branched and AB Block Copolymers  
All co-nanoprecipitations were conducted from THF (1 mL) into DI H2O (5 mL) (dilution 
ratio = 5). Equal weight fractions of each of the hydrophobic branched and amphiphilic AB 
block copolymers (ωi = 0.5) were used during co-nanoprecipitations. Copolymers were 
nanoprecipitated from an initial concentration of 5 mg mL-1 in THF ([P]0 = 5 mg mL-1) which, 
following solvent removal, gave a final copolymer concentration of 1 mg mL-1 in DI H2O 
([P]f = 1 mg mL-1). In a typical co-nanoprecipitation of statistical branched and AB block 
copolymers, PEG45-b-p(EHMA60-co-HPMA60)125 and p(EHMA30-co-HPMA30-co-
EGDMA1.12) (50 mg) were added into separate glass vials followed by THF (10 mL). Each of 
the vials were then sealed and placed on a roller mixer for 48 hours at ambient temperature. 
The resulting THF/ copolymer solutions (3 mL, 5 mg mL-1) were added to a separate glass 
vial; this was then sealed and placed on an orbital mixer for 1 minute at ambient temperature 
to ensure complete homogenisation. The resulting copolymer/ THF solution contained AB 
block and branched copolymer weight fractions of 0.5 and a total copolymer concentration of 
5 mg mL-1 ([P]0 = 5 mg mL-1). The copolymer/ THF solution (1 mL, 5 mg mL-1, branched 
copolymer ωi = 0.5) was then rapidly added to DI H2O (5 mL) under magnetic stirring. The 
co-nanoprecipitation was then stirred at ambient temperature for 48 hours in order to allow 




concentration of 1 mg mL-1 ([P]f = 1 mg mL-1). Aqueous nanoparticle dispersions were 
visually evaluated for signs of polymer sedimentation following which, nanoparticles were 
assessed via DLS. 
6.3.4.5 Monitoring 3H-Docetaxel Release from Branched Vinyl Copolymer Nanoparticles 
during Radio-Dialyses   
The preparation of p(HPMA-co-EHMA) based 3H-docetaxel loaded branched vinyl 
copolymer nanoparticles were conducted in accordance with the procedures outlined in 
Chapter 6, Section 6.3.3.5. Docetaxel encapsulation efficiencies and total drug loadings were 
determined in accordance with the procedures and calculations outlined in Chapter 6, Section 
6.3.3.6.  Radio-dialyses, docetaxel release, determination of release constants and docetaxel 
half-lives were conducted in accordance with the procedures and outlined in Chapter 6, Section 
6.3.3.7. 
6.3.4.6 Preparation of a Docetaxel Based Macro-Initiator   
Docetaxel (1.00 g, 1.24 mmol, 1 equiv.), anhydrous TEA (187 mg, 1.86 mmol, 1.5 equiv.) and 
DMAP (30 mg, 0.248 mmol, 0.2 equiv.) were added to an oven dried 25 mL round bottom 
flask containing a magnetic stirrer bar. The round bottom flask was purged with N2 followed 
by addition of anhydrous DCM (10 mL), the solution was cooled to 0 ℃ in an ice bath. A 
solution of α-bromo isobutyryl bromide (285 mg, 1.86 mL, 1.24 mmol, 1.00 equiv.) in 
anhydrous DCM (2.5 mL) were added dropwise, using a syringe under N2, over 30 minutes. 
After one hour the ice bath was removed and the reaction was allowed to proceed for a further 
23 hours. After a total of 24 hours, the reaction was quenched by addition of DI H2O (0.5 mL). 
The crude reaction mixture was dried in vacuo and the pure product was isolated using silica 
gel column chromatography using a hexane/ethyl acetate mobile phase (50/50 volume %), 
Rf = 0.27, giving docetaxel 2-bromo methyl propanoate (Doc-BiB) as a solid white powder. 
m/z (ES MS)  980.3 [MNa]+ m/z required 980.3 [MNa]+. 1H NMR (400 MHz, CDCl3) δ(ppm) 
8.11, 8.09, 7.62, 7.50, 7.38, 7.26, 6.21, 5.68, 5.66, 5.47, 5.27, 5.21, 4.95, 4.93, 4.62, 3.91, 3.89, 
3.47, 2.57, 2.37, 2.27, 2.25, 1.85, 1.75, 1.71, 1.34, 1.23, 1.13. 13C NMR (101 MHz, CDCl3) 
δ(ppm) 211.33, 172.74, 170.34, 167.02, 155.36, 138.47, 138.33, 135.89, 133.73, 130.17, 
129.11, 128.84, 128.72, 128.06, 126.74, 84.14, 81.05, 80.23, 78.78, 74.79, 74.52, 73.66, 72.42, 
71.99, 57.63, 56.17, 46.46, 43.06, 36.96, 35.68, 28.19, 26.43, 22.57, 20.64, 14.39, 9.86. 
6.3.4.7 Linear Polymerisation of nHMA via Cu-RDRP at 60 °C in Anhydrous Methanol using 
a Docetaxel Based Macro-Initiator 
Prior to use, all monomers and initiators were deoxygenated via gentle bubbling with N2 for 




units, nHMA (1.00 g, 5.87 mmol), bpy (37 mg, 0.235 mmol) and Doc-BiB (112 mg, 
0.117 mmol) were added to an oven dried round bottom flask (5 mL) equipped with a magnetic 
stirrer bar. Anhydrous MeOH (1.186 g, 1.50 mL, 50 wt %) was added and the resulting solution 
was purged with N2 for a further 15 minutes. At this point a sample was withdrawn (ca. 
100 µL) and diluted in CDCl3 allowing quantification of [M]0/[I]0 by 1H NMR. Cu(I)Cl 
(11.5 mg, 0.117 mmol) was added rapidly to the flask, and instantly formed a brown solution. 
The reaction was then purged with N2 for a further 60 seconds, sealed and swiftly submerged 
into an oil bath preheated at 60 ℃. The reaction was stopped after 24 hours by dilution with 
CDCl3 and exposure to air until a homogeneous blue/green solution was obtained, at this point 
a sample (ca. 500 μL) was taken for quantification of monomer conversion by 1H NMR. The 
solution was further diluted in CHCl3, passed over a neutral alumina column to remove the 
copper catalyst and dried in vacuo. The polymer was re-dissolved in a minimum amount of 
THF and precipitated twice from THF into cold MeOH, to give Doc-p(nHMA)50 as a clear 
viscous oil. The polymer was then dried in vacuo at 40 °C for 48 hours and characterised via 
1H NMR in CDCl3 and triple detection SEC using a THF/TEA eluent (98/2 v/v %) and a 
narrow poly(styrene) standard calibration. 
6.3.4.8 Branched Copolymerisation of nHMA and EGDMA via Cu-RDRP at 60 °C in 
Anhydrous Methanol using a Docetaxel Based Macro-Initiator 
In a typical branching statistical copolymerisation of nHMA and EGDMA targeting a primary 
chain DPn = 60 monomer units and a branching ratio ([B]0/[I]0) of 0.9, nHMA (1.00g, 
5.87 mmol), bpy (37 mg, 0.235 mmol) EGDMA (21 mg, 0.105 mg) and Doc-BiB 
(112 mg, 0.117 mmol) were added to an oven dried round bottom flask (5 mL) equipped with 
a magnetic stirrer bar. Anhydrous MeOH (1.186 g, 1.50 mL, 50 wt %) was added and the 
resulting solution was purged with N2 for a further 15 minutes. At this point a sample was 
withdrawn (ca. 100 µL) and diluted in CDCl3 allowing quantification of [M]0/[I]0 by 1H NMR. 
Cu(I)Cl (11.5 mg, 0.117 mmol) was added rapidly to the flask, and instantly formed a brown 
solution. The reaction was then purged with N2 for a further 60 seconds, sealed and swiftly 
submerged into an oil bath preheated at 60 ℃. The reaction was stopped after 24 hours by 
dilution with CDCl3 and exposure to air until a homogeneous blue/green solution was 
obtained, at this point a sample (ca. 500 μL) was taken for quantification of monomer 
conversion by 1H NMR. The solution was further diluted in CHCl3, passed over a neutral 
alumina column to remove the copper catalyst and dried in vacuo. The polymer was 
re-dissolved in a minimum amount of THF and precipitated twice from THF into cold 
methanol, to give Doc-p(nHMA50-co-EGDMA0.90) as a clear viscous oil. The polymer was 




detection SEC using a THF/TEA eluent (98/2 v/v %) and a narrow poly(styrene) standard 
calibration. 
6.3.4.9 Co-Nanoprecipitation of Branched Docetaxel Copolymer Conjugates and 
Amphiphilic AB Block Copolymers 
Co-nanoprecipitations were conducted from THF (1 mL) into DI H2O (5 mL) (dilution 
ratio = 5). Equal weight fractions of Doc-p(nHMA50-co-EGDMA0.90) and 
PEG45-b-p(nHMA)127 (ωi = 0.5) were used during co-nanoprecipitations. Copolymers were 
nanoprecipitated from an initial concentration of 5 mg mL-1 in THF ([P]0 = 5 mg mL-1) which, 
following solvent removal, gave a final copolymer concentration of 1 mg mL-1 in DI H2O ([P]f 
= 1 mg mL-1). In a typical co-nanoprecipitation, Doc-p(nHMA50-co-EGDMA0.90) and PEG45-
b-p(nHMA)127 (50 mg) were added into separate glass vials followed by THF (10 mL). Each 
of the vials were then sealed and placed on a roller mixer for 48 hours at ambient temperature. 
The resulting THF/ copolymer solutions (3 mL, 5 mg mL-1) were added to a separate glass 
vial; this was then sealed and placed on an orbital mixer for 1 minute at ambient temperature 
to ensure complete homogenisation. The resulting copolymer/ THF solution contained AB 
block and branched copolymer weight fractions of 0.5 and a total copolymer concentration of 
5 mg mL-1 ([P]0 = 5 mg mL-1). The copolymer/ THF solution (1 mL, 5 mg mL-1, branched 
copolymer ωi = 0.5) was then rapidly added to DI H2O (5 mL) under magnetic stirring. The 
co-nanoprecipitation was then stirred at ambient temperature for 48 hours in order to allow 
complete THF removal via evaporation, to give an aqueous nanoparticle dispersion at a 
concentration of 1 mg mL-1 ([P]f = 1 mg mL-1). Aqueous nanoparticle dispersions were visually 
evaluated for signs of polymer sedimentation following which nanoparticles were assessed via 
DLS. 
6.3.4.10 Preparation of a p(nHMA) Based Macro-RAFT Agent  
Prior to polymerisation nHMA and anhydrous toluene were deoxygenated via gentle N2 
bubbling for 60 minutes. AIBN (32 mg, 0.196 mmol, 0.2 equiv.), CPBD (217 mg, 0.979 mmol, 
1 equiv.), nHMA (20.0g, 0.117 mol, 120 equiv.) and anhydrous toluene (20.25 g, 23.4 mL, 
50 wt %) were added to a round bottom flask (50 mL). The reaction was deoxygenated via 
gentle nitrogen bubbling for a further 30 minutes following which an aliquot of the reaction 
mixture was taken for determination of [M]0 / [CTA]0 by 1H NMR in CDCl3. This was 
achieved by comparison of the integrals from CPBD aromatic resonances (7.90ppm, 2H) with 
those of the O-CH2 adjacent to the ester of the nHMA monomer (4.20ppm, 2H). The flask was 
placed in an oil bath at 80 °C for 16 hours, after which the reaction was stopped rapidly via 
placement in an ice bath; an aliquot was taken for analysis of monomer conversion by 1H NMR 




acetone and precipitated three times from cold methanol giving a pale pink viscous oil. The 
polymer was dried in vacuo at 40 ° C for 48 hours and was characterised by TD-SEC 
(THF/TEA) and 1H NMR (CDCl3). DPn (NMR) was determined by comparison of the aromatic 
resonances from the RAFT end-group (7.90 ppm, 2H) with those from the O-CH2 group 
adjacent to the ester of the p(nHMA) repeat unit (4.00 ppm, 2H). 
6.3.4.11 Chain Extension of a p(nHMA)122 Macro-RAFT Agent 
All monomers and solvents were deoxygenated via gentle N2 bubbling for 60 minutes prior to 
synthesis. In a typical chain extension of a p(nHMA)122 macro-RAFT agent with OEGMA, 
OEGMA (0.50 g, Mn = 300 g mol-1, 1.67 mmol, 20 equiv.), p(nHMA)122 (1.75 g, 
Mn(NMR) = 21 000 g mol-1, 0.083 mmol, 1 equiv.) and AIBN (2.74 mg, 0.0167 mmol, 
0.2 equiv.) and anhydrous toluene (3.41 g, 3.93 mL, 60 wt %) were added to a round bottom 
flask (5 mL). The mixture was deoxygenated via gentle nitrogen bubbling for a further 30 
minutes following which an aliquot of the reaction mixture was taken for determination of 
[M]0 / [CTA]0 by 1H NMR in CDCl3. This was achieved by comparison of the integrals from 
aromatic resonances of the macro-RAFT agent (7.90 ppm, 2H) with those of the vinyl protons 
of the OEGMA monomer (6.05 ppm, 2H). The flask was placed in an oil bath at 80 °C for 4 
hours, after which the reaction was stopped rapidly by placement of the reaction flask in an 
ice bath; an aliquot was taken for analysis of monomer conversion by 1H NMR. The reaction 
mixture was concentrated in vacuo, diluted in acetone and precipitated three times from cold 
methanol which gave a pale pink viscous oil. The polymer was dried in vacuo at 40 °C for 48 
hours and was characterised using a THF/TEA eluent (98/2 v/v %) and a narrow poly(styrene) 
standard calibration. 
6.3.4.12 Sole Nanoprecipitations of Amphiphilic AB Block Copolymers  
Nanoprecipitations of amphiphilic AB block copolymers were conducted from THF (1 mL) 
into DI H2O (5 mL) (dilution ratio = 5). Copolymers were nanoprecipitated from an initial 
concentration of 5 mg mL-1 in THF ([P]0 = 5 mg mL-1) which, following solvent removal, gave 
a final copolymer concentration of 1 mg mL-1 in DI H2O ([P]f = 1 mg mL-1). In a typical 
nanoprecipitation p(nHMA)122-b-p(OEGMA)11 (25 mg) and THF (5 mL) were added to a glass 
vial and sealed. The vial was placed on a roller mixer and the polymer allowed to dissolve 
over 48 hours at ambient temperature to give a p(nHMA)122-b-p(OEGMA)11/ THF solution at 
a concentration of 5 mg mL-1. The p(nHMA)122-b-p(OEGMA)11/ THF solution (1 mL, 5 mg 
mL-1) was added to a glass vial containing DI H2O (5 mL) under magnetic stirring. The sample 
was then left for 48 hours at ambient temperature to allow solvent removal via evaporation 




nanoparticle dispersions were assessed visually for signs of polymer sedimentation following 
which, nanoparticles were assessed via DLS.  
6.3.4.13 Co-nanoprecipitations of p(nHMA68-co-EGDMA1.03) with Amphiphilic AB Block 
Copolymers 
Co-nanoprecipitations were conducted from THF (1 mL) into DI H2O (5 mL) (dilution 
ratio = 5). Equal weight fractions of each of the two components (ωi = 0.5) were used during 
co-nanoprecipitations. Copolymers were nanoprecipitated from an initial concentration of 
5 mg mL-1 in THF ([P]0 = 5 mg mL-1) which, following solvent removal, gave a final 
(co)polymer concentration of 1 mg mL-1 in DI H2O ([P]f = 1 mg mL-1). In a typical 
co-nanoprecipitation p(nHMA68-co-EGDMA1.03) and p(nHMA)122-b-p(OEGMA)11 (50 mg) 
were added into separate glass vials followed by THF (10 mL). Each of the vials were then 
sealed and placed on a roller mixer for 48 hours at ambient temperature. The resulting THF/ 
copolymer solutions (3 mL, 5 mg mL-1) were added to a separate glass vial; this was then 
sealed and placed on an orbital mixer for 1 minute at ambient temperature to ensure complete 
homogenisation. The resulting copolymer/ THF solution contained 
p(nHMA68-co-EGDMA1.03) and p(nHMA)122-b-p(OEGMA)11 weight fractions of 0.5 and a 
total copolymer concentration of 5 mg mL-1 ([P]0 = 5 mg mL-1). The copolymer/ THF solution 
(1 mL, 5 mg mL-1) was then rapidly added to DI H2O (5 mL) under magnetic stirring. The 
co-nanoprecipitation was then stirred at ambient temperature for 48 hours in order to allow 
complete THF removal via evaporation, resulting in an aqueous nanoparticle dispersion at a 
concentration of 1 mg mL-1 ([P]f = 1 mg mL-1). Aqueous nanoparticle dispersions were 
visually evaluated for signs of polymer sedimentation following which, nanoparticles were 
assessed via DLS. 
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Figure A2.1 Monomer SMA in anhydrous methanol miscibility studies at ambient and elevated 
temperatures. a) SMA-MeOH (50 wt %) at i) 20 ℃ and ii) 60 ℃. b) SMA-IPA mixtures (50 wt %) at 
i) 20 ℃ and ii) 60 ℃. 
 
Figure A2.2 Overlaid 13C NMR spectra (D2O, 100 MHz) of (a) PEG45-Br and (b) PEG45-OH. 
 
 
Figure A2.3 1H NMR spectra (CDCl3, 400 MHz) of p(nHMA) to quantify the degree of 





Figure A2.4 Comparison of molecular weight distributions obtained by TD-SEC. Overlaid 
refractive index (RI; solid lines) and right-angle light scattering (RALS; dotted lines) 
chromatograms obtained for linear homopolymers (red) and the highest molecular weight 
branched statistical copolymers (blue) obtained for the following monomer-alcohol systems: 
a) MMA-IPA, b) EMA-MeOH, c) nBMA-MeOH, d) tBMA-MeOH, e) nHMA-MeOH, 






Figure A2.5 Overlaid Mark-Houwink-Sakurada (MHS) plots obtained for linear 
homopolymers and branched statistical copolymers consisting of a) p(MMA) b) p(EMA), 
c) p(nBMA), d) p(tBMA), e) p(nHMA), f) p(CHMA), g) p(BzMA), h) p(EHMA), i) p(LMA), 






Figure A2.6 Deconvolution of MHS plots obtained for branched statistical copolymers 
consisting of a) p(MMA66-co-EGDMA0.90), b) p(EMA66-co-EGDMA0.90), 
c) p(nBMA66-co-EGDMA0.90), d) p(tBMA66-co-EGDMA0.90), e) p(nHMA66-co-EGDMA0.90), 
f) p(CHMA66-co-EGDMA0.90), g) p(BzMA66-co-EGDMA0.90), h) p(EHMA66-co-EGDMA0.90), 






Figure A2.7 Overlaid (i) RI and (ii) RALS chromatograms for branched copolymers 
obtained from statistical copolymerisations of EGDMA with (a) MMA, (b) EMA, (c) nBMA. 
(d) tBMA, (e) nHMA, (f) CHMA, (g) BzMA, (h) EHMA, (i) LMA, (j) SMA produced via 







Figure A2.8 Plots of primary chains per macromolecule vs. cumulative mol fraction (cum. x f) 
for branched statistical copolymers: a) p(MMA66-co-EGDMA0.90), 
b) p(EMA66-co--EGDMA0.90), c) p(nBMA66-co-EGDMA0.90), d) p(tBMA66-co-EGDMA0.90), 
e) p(nHMA66-co-EGDMA0.90), f) p(CHMA66-co-EGDMA0.90), g) p(BzMA66-co-EGDMA0.90), 
h) p(EHMA66-co-EGDMA0.90), i) p(LMA66-co-EGDMA0.90), j) p(SMA66-co-EGDMA0.90) 
produced via Cu-catalysed RDRP. 
Figure A2.9 Spartan simulations of pendant group and repeat unit protrusion distances in 
p(MMA) and p(LMA) oligomers (DP = 10) containing one EGDMA unit per chain. Distances 
were measured between the polymer backbone and the: a) pendant methacrylate group in 
p(MMA10-co-EGDMA1), b) pendant CH3 of a p(MMA) repeat unit, c) pendant methacrylate 








Table A2.1 I1/I3 ratios obtained by fluorescence emission spectroscopy of pyrene dissolved within: neat 




Table A2.2 Calculation of the differences in initiator ([I]0) and methacrylate group ([M]0) 
concentrations which arises as a result of the increased contribution of the pendant side group to the 










Table A2.3 Calculation of the differences in initiator ([I]0) and methacrylate group ([M]0) 
concentrations which arises as a result of the increased contribution of the pendant side group to the 
overall monomer mass. 
 
 
Table A2.4 Calculated pendant group and repeat unit protrusion distances from the methacrylic polymer 
backbone using Spartan molecular modelling software.  
 
 
Figure A3.1 TD-SEC analysis of p(HPMA) based: linear homopolymer, amphiphilic branched 
copolymer prepared via methanolic Cu-RDRP.  
 
 
Figure A3.2 Scanning electron microscopy images of nanoparticles constructed of low Tg polymers 






Figure A3.3 Graphical representation of the relationship between I1/I3 ratios and the weight fraction of 
the aliphatic side chain of the monomers from which the polymers used during co-nanoprecipitation are 
constructed. 
 
Figure A3.4 DLS analysis of the sole nanoprecipitation of p(HPMA63-co-EGDMA0.90) at 
[P]0 =100 mg mL-1 in THF.  
 
Figure A3.5 Aqueous nanoparticle dispersion without the PEG-based amphiphilic AB block 
copolymers which have been exposed to a low concentration of NaCl. 
Table A3.1 Characterisation of p(HPMA) based: linear homopolymer, amphiphilic branched 













p(HPMA)65 60 - 98 65 26 000 20 700 1.26 0.490 
p(HPMA63-co-EGDMA0.90) 60 0.90 99 63 704 300 55 000 12.80 0.345 




Table A3.2 DLS analysis to show the impact of a serial dilution on aqueous nanoparticle dispersions 















1 1.000 64 50 0.041 92823 
2 0.500 64 50 0.044 48697 
5 0.200 64 50 0.041 16885 
10 0.100 64 50 0.045 9208 
20 0.050 63 49 0.040 4844 
50 0.020 62 49 0.046 1382 
100 0.010 66 46 0.109 744 
200 0.005 62 48 0.082 321 
500 0.002 64 48 0.055 139 
1000 0.001 79 51 0.135 82 
p(nBMA) 
1 1.000 83 59 0.086 274752 
2 0.500 83 59 0.083 101591 
5 0.200 83 58 0.089 47517 
10 0.100 85 65 0.052 20559 
20 0.050 84 63 0.084 11107 
50 0.020 83 59 0.089 5255 
100 0.010 113 48 0.231 4052 
200 0.005 85 64 0.077 1156 
500 0.002 87 60 0.106 490 
1000 0.001 84 64 0.148 220 
p(nHMA) 
1 1.000 92 75 0.028 424110 
2 0.500 94 77 0.007 276294 
5 0.200 93 76 0.016 82576 
10 0.100 93 77 0.026 44437 
20 0.050 92 75 0.029 19635 
50 0.020 93 77 0.013 9362 
100 0.010 95 78 0.025 5137 
200 0.005 94 77 0.007 1938 
500 0.002 115 97 0.190 1035 
1000 0.001 99 81 0.146 470 
p(EHMA) 
1 1.000 76 60 0.036 299966 
2 0.500 77 62 0.036 110756 
5 0.200 76 61 0.035 48299 
10 0.100 77 62 0.029 21175 
20 0.050 77 62 0.034 11423 
50 0.020 78 60 0.069 5498 
100 0.010 79 64 0.032 2195 
200 0.005 77 58 0.057 1016 
500 0.002 77 62 0.030 478 
1000 0.001 90 75 0.088 264 
p(LMA) 
1 1.000 137 118 0.015 589909 
2 0.500 137 118 0.012 441019 
5 0.200 138 118 0.007 253568 
10 0.100 138 119 0.014 94073 
20 0.050 137 118 0.020 50593 
50 0.020 138 119 0.012 17694 
100 0.010 138 119 0.008 10990 
200 0.005 138 119 0.011 5811 
500 0.002 139 120 0.013 1792 






Figure A4.1 Failed docetaxel-loaded branched vinyl copolymer nanoparticle dispersions formed via 
co-nanoprecipitation at drug loadings ≥ 30 wt % of a) p(HPMA), b) p(nBMA), c) p(nHMA), 
d) p(EHMA) and p(LMA). 
 






Figure A4.3 A closer individual inspection of the p(LMA70-co-EGDMA1.04) complex viscosity data 
showing an exponential increase in copolymer viscosity between 50 – 25 ℃. 
Table A4.1 DLS analysis of 3H-docetaxel loaded aqueous nanoparticle dispersions produced via 












20 0 81 55 0.101 
20 24 82 57 0.100 
37 24 82 55 0.099 
50 24 81 58 0.100 
 
Figure A5.1 Electrospray ionisation mass spectrometry of monofunctional, bi-functional and 







Figure A5.2 13C NMR (CDCl3, 100 MHz) analysis of monofunctional, bi-functional and trifunctional 
docetaxel initiators which have been isolated from the reaction via column chromatography. 
 
Figure A5.3 13C NMR (CDCl3, 100 MHz) analysis of monofunctional, bi-functional and trifunctional 





Figure A6.1 Determination of the polarity of pyrene solutions using the I1/I3 ratio; comparison of the 
relative intensities of the first (I1, ca. 373 nm) and third (I3, ca. 384 nm) vibrational bands of the 
pyrene fluorescence emission. 
 
Figure A6.2 1H NMR (CDCl3, 400 MHz) analysis to determine the number average degree of 
polymerisation (DPn) and molecular weight (Mn) of purified PEG45-Br. 
Table 6.1 Good and bad solvents identified for purification of linear homopolymers and branched 
statistical copolymers. 
 
